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Abstract 
Macroautophagy, hereafter called autophagy, is an intracellular degradation 
pathway that functions to degrade bulk material and recycle macromolecules to 
maintain cell homeostasis. Autophagy has a protective role and is also implicated 
in disease processes such as cancer, neurodegeneration and pathogen clearance. 
Autophagy is characterised by the formation of a double-membrane structure in 
response to stress insults such as amino acid starvation, which encapsulates cargo 
to form an enlarged vesicle called an autophagosome. The autophagosome fuses 
with the lysosome for degradation of the contents. Although the core protein 
machinery of autophagy has been known for some time, the regulation of this 
process is not fully understood.  
WAC was previously identified as a novel positive regulator of starvation-
induced autophagy. However the mechanism by which WAC regulates autophagy 
is completely unknown. It is known that WAC performs functions both in the 
nucleus and on the Golgi. In order to elucidate the function of WAC in autophagy, I 
performed a study of WAC function by a combination of microarray transcriptomic 
analysis and immunoprecipitation coupled with mass spectrometry to identify genes 
regulated by WAC and novel WAC interaction partners, respectively. WAC is not a 
potent regulator of autophagy gene expression. However, I identified GM130, a 
negative regulator of autophagy, as a novel WAC interaction partner. I show here 
that WAC promotes ULK1 activation whereas GM130 inhibits the early autophagy 
stages. GM130 is the receptor for WAC on the Golgi and binds WAC directly. This 
interaction is mediated by the C-terminal regions of both proteins which contain 
predicted coiled-coil domains. WAC and GM130 both interact with the autophagy 
protein GABARAP, indirectly and directly respectively. WAC regulates a novel 
centrosomally-localised pool of GABARAP, GABARAP binding to GM130 and 
GABARAP localisation to the Golgi. This centrosomal pool of GABARAP, is able to 
translocate to autophagic structures during starvation. In addition I describe a 
GABARAP mediated activation of the ULK1 complex. Through the WAC-GM130-
GABARAP interplay, I propose that WAC promotes a centrosome to 
autophagosome GABARAP trafficking step that may in addition maintain ULK1 
activation during starvation-induced autophagy.
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Chapter 1. Introduction 
1.1 Autophagy introduction 
1.1.1 The three forms of autophagy 
Autophagy is an evolutionarily conserved membrane trafficking pathway that 
functions as an intracellular recycling pathway. Autophagy can be divided into three 
forms known as macroautophagy, microautophagy and chaperone-mediated 
autophagy (Mizushima and Komatsu, 2011) (Figure 1.1). This thesis focuses on the 
regulation of macroautophagy. These three forms of autophagy have in common 
the delivery of cargo to the lysosome for degradation. Microautophagy involves the 
invagination of the lysosomal membrane to capture cytoplasmic cargo in a non-
selective manner. This results in the formation of an intralumenal vesicle in the 
lysosome. The resultant vesicle and its contents are degraded by lysosomal 
proteases. There are other, selective forms of microautophagy such as piecemeal 
microautophagy of the nucleus in yeast, where invaginations of the vacuole take a 
part of the nucleus for degradation (Krick et al., 2009). During chaperone-mediated 
autophagy (Cuervo and Wong, 2014), proteins containing a pentapeptide motif 
related to the KFERQ sequence are selectively targeted to the lysosome via 
binding to the chaperone heat shock cognate protein of 70 kDa (hsc70), and 
delivery to the lysosomal membrane by binding to lysosome-associated membrane 
protein type 2A (LAMP-2A) on the outer membrane. This promotes the 
oligomerisation of LAMP-2A monomers. The targeted protein is unfolded and this is 
likely mediated by hsc70 at the lysosomal membrane. Multimeric LAMP-2A then 
functions to translocate the unfolded peptide chain into the lysosomal lumen for 
degradation. 
Macroautophagy involves the de novo formation of a large vesicle that 
sequesters cargo, known as an autophagosome, followed by terminal fusion of the 
vesicle to the lysosome for content degradation. Macroautophagy, hereafter called 
autophagy, can be a non-selective process or a selective one and this has been 
reviewed extensively (Behrends and Fulda, 2012, Johansen and Lamark, 2011, 
Okamoto, 2014, Stolz et al., 2014, Svenning and Johansen, 2013, Rogov et al., 
2014). During selective autophagy, cargoes are specifically targeted for 
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encapsulation into the autophagosome by autophagy receptors, which bind to both 
the cargo and to proteins attached to the autophagosome membrane. Thus 
autophagy receptors function to bridge the autophagosome to the cargo. Such 
cargo could be bacterial pathogens, protein aggregates, mitochondria and the 
endoplasmic reticulum (ER) (Khaminets et al., 2015) as well as others. The focus 
of my study has been on non-selective autophagy and from now on I use the term 
autophagy to refer to non-selective macroautophagy. It should be mentioned 
though that the discovery of increasing numbers of autophagy receptors on a wide 
range of cargo, has led some to believe that non-selective autophagy does not 
exist and rather that autophagy is a highly specific process. However for the 
purposes of my discussion, I use the term non-selective autophagy to refer to the 
common autophagy pathway that employs the basic core machinery, not biased to 
any one particular cargo. 
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Figure 1.1 All roads lead to the lysosome - the three major forms of autophagy 
All three forms of the autophagy result in the degradation of cargo in the lysosome 
and the recycling of macromolecule products, which can be used for biosynthetic 
and metabolic pathways. 
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1.1.2 Proteasomal and lysosomal degradation 
There are two main forms of intracellular protein degradation in the cell, 
namely the proteasomal and the lysosomal pathways. In the proteasomal pathway 
(Finley, 2009), individual proteins are targeted to the proteasome, a large (>2.5 
MDa) multi-subunit protein complex that assumes a barrel-like structure. The core 
of the proteasome is a 28-subunit particle (also known as the 20S particle) that has 
protease activity. The core particle consists of four rings of seven subunits that are 
stacked on top of each other. Unfolded peptide chains are threaded into the barrel 
core of the proteasome where they are accessed by proteases, resulting in the 
degradation of the protein and the release of peptides but not free amino acids. 
These peptides can be used for antigen presentation in the adaptive immune 
response. The unfolding and translocation of the protein requires ATP hydrolysis. 
The targeting of proteins to the proteasome is tightly regulated by the attachment of 
a small 8.5 kDa protein called Ubiquitin, to lysine residues on the target protein. 
Ubiquitin is attached to the target protein through its C-terminus. Ubiquitin 
molecules themselves can be attached together to form polyubiquitin chains. These 
chains can have different linkages, dictated by the positions of the lysines on the 
ubiquitin molecule itself. Together this system of tagging, targeting and degradation 
is called the ubiquitin-proteasome system (UPS). Molecules known as E1 
(ubiquitin-activating enzymes), E2 (ubiquitin-conjugating enzymes) and E3 
(ubiquitin ligases) act to ubiquitinate the target protein. The specificity of the system 
is directed by the E3 ligases, which is a much more diverse family than the E1 and 
E2 proteins. The ubiquitinated substrate docks onto the proteasome at the 19-
subunit regulatory particle (also known as the 19S particle) that controls substrate 
entry into the proteasome, through a variety of ubiquitin receptors. The 19S 
regulatory particle sits on the entrance of the 20S core particle. Ubiquitinated 
substrates can also be recognised by proteasome-associated subunits that are not 
integral to the proteasome, but contain ubiquitin-associated domains. The substrate 
is then threaded into the core particle, driven by a set of six ATPases that form a 
ring complex in the regulatory particle. Covalently attached ubiquitin moieties can 
be removed by the action of deubiquitinases (DUBs). Proteins can also be targeted 
to the proteasome for degradation independently of ubiquitin, although most known 
cases of proteasomal degradation involve ubiquitination. Although a well-known 
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function of ubiquitin post-translational modifications is in protein turnover and 
stability, monoubiquitination and different chain linkages of polyubiquitin can direct 
different functions. For example, ubiquitination can direct protein sorting in 
membrane trafficking pathways, kinase activation and is used as an epigenetic 
modification (Komander and Rape, 2012). Although the UPS directs specificity, the 
problem remains that only one protein molecule can be processed by a 
proteasome at any one time. Autophagy, on the other hand, functions to efficiently 
dispatch much larger substrates, such as a malfunctioning mitochondrion for 
example.  
Proteins are also delivered to the lysosome for degradation by various 
autophagic mechanisms as discussed above. In addition, the endocytic pathway 
can function to degrade extracellular molecules and cell surface receptors via 
membrane trafficking from the plasma membrane to the lysosome. Autophagy 
solves the problem of the degradation of large structures, such as organelles or 
protein aggregates. In addition autophagy tends to degrade long-lived proteins, 
whereas shorter lived proteins are degraded by the proteasome (Finley, 2009). 
Autophagy is conserved in eukaryotes, from yeast to human. In the presence of an 
adequate nutrient supply there is a low level of continuous autophagy, which I refer 
to as basal autophagy. However, autophagy is in general considered a stress 
response, as withdrawal of nutrients is a potent inducer of autophagosome 
formation. In yeast nitrogen starvation and in mammalian cells amino acid 
starvation are potent inducers of autophagosome formation (Mizushima, 2007). In 
the Tooze lab we use amino acid starvation of HEK293A cells to study autophagy. 
This is achieved by washing cells from growth medium into EBSS medium, which is 
devoid of amino acids but also of serum. Withdrawal of amino acids is thought to 
be a more potent inducer of autophagy than withdrawal of serum in vitro 
(Mizushima et al., 2010). HEK293A cells provide a useful model for studying 
autophagy, as autophagy can be switched readily from an off to an on position by 
starvation, whereas some cell lines have high levels of basal autophagy to start 
with, making interpretation of autophagic flux sometimes difficult (Klionsky et al., 
2012). In addition, HEK293A cells grow rapidly and are easy to transfect for DNA 
overexpression or siRNA knockdown studies. It is worth noting that amino acid 
withdrawal is not the only inducer of autophagy, but hypoxia, glucose starvation, 
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serum starvation, ammonia, pathogen invasion and mitochondrial dysfunction, as 
well as other signals, induce autophagy (Kroemer et al., 2010).  
Autophagy is implicated in a range of pathogenic and physiological process, 
such as neurodegeneration, immunity, cancer and exercise, as has been reviewed 
in (Cuervo and Wong, 2014). For example autophagy is involved in the removal of 
α-Synuclein (Webb et al., 2003) and mutant huntingtin protein aggregates (Martin 
et al., 2015), which are implicated in Parkinson’s disease and Huntingtin’s disease 
respectively. In cancer, autophagy provides a dual role. Autophagy is thought to 
protect from tumourigenesis perhaps by maintaining mitochondrial function and 
reducing the formation of reactive oxygen species (Takamura et al., 2011). The 
autophagy gene Beclin 1 is also a tumour suppressor gene (Liang et al., 1999, Yue 
et al., 2003). However, autophagy is also used by cancer cells to survive and 
autophagy may allow cancer cells to overcome insults such as nutrient deprivation 
or chemotoxicity. 
 
1.1.3 Autophagy is a membrane remodelling process 
The initiation of autophagy results in the de novo formation of an organelle 
called an autophagosome. The autophagosome is a large double membrane 
vesicle that can be between 0.5-1.5 µm in diameter in mammalian cells (Mizushima 
et al., 2002). Thus is it much larger than other membrane trafficking vesicles, such 
as COPI coated vesicles which are typically around 50-70 nm (excluding coat) in 
diameter (Bednarek et al., 1995). The contents of an autophagosome are identical 
to the surrounding cytoplasm, and autophagosomal membranes stain heavily with 
osmium and thus can be distinguished from other organelles by electron 
microscopy (Lamb et al., 2013). Indeed, autophagy was originally discovered more 
than half a century ago by transmission electron microscopy, and for some time 
this was the only method to study autophagosome biogenesis (Eskelinen et al., 
2011). Autophagosomes form within minutes of starvation (Kochl et al., 2006) and 
in mammalian cells multiple autophagosomes form and are seen throughout the 
cytoplasm. The formation of the autophagosome takes place through the 
elongation of unclosed membranes which finally fuse to form the closed 
autophagosome. The unclosed autophagosomal membrane is known as the 
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isolation membrane or the phagophore. Clearly the formation of this organelle, the 
autophagosome, represents a significant and dynamic membrane remodelling step 
that the cell has to rapidly undergo in response to stress stimuli. The 
autophagosome is thought to acquire its membrane from pre-existing membrane 
compartments or by lipid synthesis activity localised to other compartments. Many 
membranes have been proposed to contribute to the forming autophagosome 
(Figure 1.3), such as the ER-Golgi intermediate compartment (ERGIC) (Ge et al., 
2014, Ge et al., 2013), the nuclear envelope (English et al., 2009), the ER 
(Hayashi-Nishino et al., 2009, Yla-Anttila et al., 2009), mitochondria (Hailey et al., 
2010), ER-mitochondria contact sites (Hamasaki et al., 2013), the plasma 
membrane (Ravikumar et al., 2010), recycling endosomes (Longatti et al., 2012, 
Knaevelsrud et al., 2013), Golgi (Geng et al., 2010, Yamamoto et al., 1990, Ohashi 
and Munro, 2010, van der Vaart et al., 2010, Biazik et al., 2015) and the Atg9 
compartment (Orsi et al., 2012, Mari et al., 2010, Yamamoto et al., 2012). This has 
recently been reviewed (Lamb et al., 2013). It could be that the source of the 
membrane contributing to the forming autophagosome varies according to cell type 
or nutrient stimulus, however this remains to be demonstrated.  
Perhaps the best characterised proposed source of autophagosome 
membrane is the ER. Autophagosomes can form at phosphatidylinositol-3-
phosphate (PI3P) enriched, Ω-shaped subdomains of the endoplasmic reticulum 
(ER) known as omegasomes (Axe et al., 2008) (Figure 1.2). The PI3P-binding 
protein Double FYVE Containing Protein 1 (DFCP1) is used to mark omegasomes. 
DFCP1 also colocalises with early autophagy proteins such as WIPI2 (Polson et 
al., 2010). Direct connections between the ER and the phagophore have been 
observed (Hayashi-Nishino et al., 2009, Yla-Anttila et al., 2009) and the 
phagophore is often in close proximity to the ER membrane, at a distance that may 
allow lipid transfer (Biazik et al., 2015). The ER is the membrane compartment that 
makes the most frequent contacts with phagophores. These conclusions have 
been reached by the use of electron microscopy and tomography. The phagophore 
has been observed cradled between two sheets of ER, in a structure that 
resembles, or is identical to, the omegasome. Conceptually, it would make sense if 
the ER was the primary membrane source of the forming autophagosome, as it has 
a much larger surface area then the plasma membrane of the cell (Alberts, 2002). 
In addition to a possible role in membrane supply, proteins involved in autophagy 
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such as Atg14L, VMP1 and ULK1 are resident on the ER (Matsunaga et al., 2010, 
Itakura and Mizushima, 2010). Moreover, the localisation of Atg14L to the ER is 
required for autophagy. In addition to being present at the ER, the ULK complex 
also associates with omegasomes and appears to dissociate prior to closure of the 
autophagosome (Karanasios et al., 2013). A summary of the autophagy proteins 
and their functions will be provided later. 
 
 
Figure 1.2 The omegasome model of the phagophore assembly site (PAS) in 
mammalian cells 
In yeast autophagosomal proteins are recruited to a single site for autophagosome 
biogenesis, known as the phagophore assembly site (PAS). In contrast, in 
mammals autophagosomes form throughout the cytoplasm. The current best 
candidate for an analogous PAS in mammalian cells is the omegasome. 
 
Membrane contact sites have also been observed between the phagophore 
and other organelles such as the Golgi and mitochondria (Biazik et al., 2015) 
(Figure 1.3). Markers of the outer mitochondrial membrane have been observed on 
autophagosomes too, suggesting that the mitochondrial membrane can contribute 
to autophagosome biogenesis (Hailey et al., 2010). The mitochondria could be a 
site of autophagy regulation, as autophagy regulating proteins such as Ambra1, 
BCL-2 and Beclin 1 localise to mitochondria (Pattingre et al., 2005, Strappazzon et 
al., 2011). The contribution of the ER or mitochondria as membrane sources for the 
autophagosome could be linked rather than competing models for organelle 
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biogenesis. This is because ER-mitochondria contact sites are also thought to be 
sites of autophagosome formation (Hamasaki et al., 2013). ER-mitochondria 
contact sites are the best characterised organelle contact sites, and they provide 
functions such as lipid synthesis and Ca2+ transfer (Rowland and Voeltz, 2012). 
These contact sites are characterised by apposition of two membranes that are in 
close proximity to one-another (10-30 nm apart) but are not fused, suggesting 
tethering of two organelles together. The contact sites also appear to be stable 
structures. Atg14L and Atg5, proteins that mark the early stages of autophagosome 
formation, were shown to localise to the ER-mitochondria contact site upon 
starvation. Furthermore, disruption of ER-mitochondria contact sites impairs 
starvation-induced autophagy (Hailey et al., 2010, Hamasaki et al., 2013). 
The Golgi complex is also likely involved in autophagy modulation through 
the regulation of autophagy proteins and by direct membrane contribution to the 
autophagosome. A minority of phagophores or autophagosomes were found to 
make contacts with the Golgi complex, defined as membranes within 20 nm 
distance of each other (Biazik et al., 2015). The Golgi also acts as a hub for 
autophagy proteins under basal conditions, such as Beclin 1, GATE-16, Atg9, 
Atg16, GABARAP and LC3 (Sagiv et al., 2000, Guo et al., 2012, Itoh et al., 2008, 
Shoji-Kawata et al., 2013, Kittler et al., 2001, Young et al., 2006). For example, 
Beclin 1 is tethered to the Golgi via binding to GAPR-1/GLIPR2 (Shoji-Kawata et al., 
2013). Introduction of a peptide from Beclin 1 that binds to GAPR-1, or knockdown 
of GAPR-1, results in the relocalisation of Beclin 1 to autophagosomes and induces 
autophagy. In addition, Golgi localised Rab proteins are known to control 
autophagy. Rabs are a family of small GTPases that regulate membrane trafficking 
steps and are thought to confer membrane compartment identity. Rab1 is localised 
to the Golgi and is involved in secretion (Moyer et al., 2001). However, Rab1 is also 
required for omegasome (Huang et al., 2011) (Mochizuki et al., 2013) and 
autophagosome formation (Zoppino et al., 2010). Rab33b, a Golgi localised protein 
thought to be involved in retrograde trafficking (Zheng et al., 1998) (Valsdottir et al., 
2001), is also involved in autophagy. Rab33b interacts with Atg16L1 (Itoh et al., 
2008) and expression of a piece of Atg16L1 that binds Rab33b inhibits 
autophagosome formation, suggesting that this interaction regulates autophagy. In 
addition, Rab33b is also thought to be involved in autophagosome maturation 
mediated by its proposed regulator OATL1 (Itoh et al., 2011). Coiled-coil Golgi 
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tethering proteins, known as golgins, have also been implicated in autophagy. 
GM130/GOLGA2, a cis-Golgi protein (Nakamura et al., 1995), is thought to be a 
negative regulator of autophagosome formation (Chang et al., 2012). In addition, 
the trans-Golgi protein p230/golgin-245 is a positive regulator of autophagosome 
formation (Sohda et al., 2015). The role of the plasma membrane, recycling 
endosomes and plasma membrane will not be discussed here for brevity, and has 
been recently reviewed in (Lamb et al., 2013). 
 Under starvation conditions the forming autophagosomes capture cargo in 
a non-specific fashion, which could include for example cytosol, Golgi stacks, 
mitochondria and ER. The enclosed autophagosome then undergoes a maturation 
process whereby it fuses with endosomes forming an amphisome. Proteins 
involved in the secretory pathway, such as the COPI coatomer, which are also 
involved in maintaining endosome function, are also involved in autophagosome 
maturation (Razi et al., 2009). The amphisome can terminally fuse with the 
lysosome forming the autolysosome. Additionally the autophagosome can fuse with 
lysosomes without fusing to endosomes beforehand. These fusion events are 
regulated by soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
(SNARE) proteins. For example syntaxin 17 (Stx17) is found on the outer surface 
of fully formed but not immature autophagosomes, and interacts with SNAP-29 and 
VAMP8 on the endosome/lysosome to mediate fusion (Itakura et al., 2012). 
SNAREs can also function in autophagosome formation, for example VAMP3 is 
thought to mediate the fusion of the autophagosome precursor membranes (Puri et 
al., 2013). Other membrane trafficking proteins direct the vesicle tethering and 
fusion events of maturation, such as Rab7 (Gutierrez et al., 2004) and the HOPS 
complex (McEwan et al., 2015). As my project has focused on the regulation of 
autophagosome formation, an exhaustive description of the players in 
autophagosome maturation will not be provided here. After fusion with the 
lysosome, the contents of the autophagosome are degraded by proteases and this 
includes the degradation of the inner autophagosomal membrane but not the outer 
membrane. The resultant macromolecules exit the lysosome via membrane 
permeases. These macromolecules are then available for use in biosynthetic and 
metabolic pathways. Thus, in its most basic (non-selective) physiological function, 
autophagy functions as a recycling process. 
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Figure 1.3 Membrane sources for autophagosome biogenesis 
There is extensive cross-talk between the secretory pathway and endosomal 
system and the autophagosome formation pathway. In addition, and not depicted 
here, autophagy functions in the non-conventional secretion of cytosolic proteins 
(Ponpuak et al., 2015). Early endosomes (EE) are marked by Rab5. Recycling 
endosomes (RE) are marked by Rab11. Atg9 may traffic to forming 
autophagosomes from the highly tubulovesicular Atg9 compartment and/or Atg9 
may be endocytosed from the plasma membrane into clathrin coated vesicles 
(CCVs), in a pathway that forms Atg16L1 and Atg9 positive autophagosome 
precursor membranes. COPII coat is thought to be involved in the budding of 
ERGIC membranes as an autophagic membrane source.  
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1.2 Autophagy machinery and signalling 
The core genes involved in autophagy were discovered in genetic screens 
in yeast in the early 1990s (Tsukada and Ohsumi, 1993, Thumm et al., 1994, 
Harding et al., 1995). These genes are known as autophagy-related (Atg) genes in 
yeast. Their mammalian homologues often, but not always, have alternative 
names. These Atg genes encode for the core protein machinery that drives 
formation of the autophagosome. Since the discovery of the Atg genes, there has 
been an increase in our knowledge of how this machinery is regulated through the 
discovery of binding partners, a variety of post-translational modifications and other 
processes that direct the activity of the core autophagy machinery (Boya et al., 
2013). This increase in our knowledge has been facilitated by the development of 
tools to study autophagy, such as marker proteins that can be used to study 
autophagosome formation by western blot or immunofluorescence in mammalian 
cells (Kabeya et al., 2000). A PubMed search for publications (Figure 1.4) focusing 
on autophagy shows the striking progression of the field, especially in the last 
decade, and highlights the growing interest in autophagy research. My work 
investigates the regulation of autophagy in human cells and thus I will focus on the 
mammalian autophagy system. Although some of the mammalian autophagy 
genes have sequence and/or functional orthologues in yeast, some of the critical 
mammalian autophagy proteins do not have identified equivalents in yeast. 
 
 
Figure 1.4 Autophagy publications per year, PubMed  
In the past decade there has been a greater than 10-fold increase in the number of 
autophagy papers. 
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1.2.1 mTORC1 
In mammals, under nutrient replete conditions autophagy is kept in the off 
state by the kinase, mechanistic target of rapamycin complex 1 (mTORC1). 
mTORC1 is a master regulator of cell growth and of autophagy and integrates 
multiple input signals; for example from growth factor and amino acid availability 
(Laplante and Sabatini, 2012). In the presence of nutrients mTORC1 functions to 
drive cell growth by promoting biosynthetic pathways such as protein synthesis and 
repress the catabolic autophagy pathway. mTORC1 is a serine/threonine kinase 
complex containing: mTOR, Raptor, mLST8 (GβL), Pras40, Deptor and Tti1/Tel2 
(Laplante and Sabatini, 2012). The Raptor subunit functions to regulate substrate 
binding to mTORC1. mTOR also exists in a separate complex known as mTORC2, 
which also contains the Deptor, mLST8 (GβL) and Tti1/Tel2 subunits in addition to 
the mTORC2 unique subunits of mSin1, protor1/2 and Rictor. The Rictor subunit 
regulates the substrate binding of mTORC2. mTORC1 is thought to be more critical 
for the regulation of macroautophagy and will be discussed here, however 
mTORC2 has been implicated in chaperone-mediated autophagy (Arias et al., 
2015). The presence of amino acids maintains mTORC1 in the active state and 
amino acids are especially important for mTORC1 activity, as re-feeding starved 
cells with growth factors in the absence of amino acids fails to activate the kinase 
(Wang et al., 1998, Hara et al., 1998). The current view, reviewed by (Jewell et al., 
2013), of how amino acids activate mTORC1 begins with a signal to the vacuolar 
H+-ATPase (v-ATPase) on the lysosome (Figure 1.5). The v-ATPase controls the 
guanine nucleotide exchange factor (GEF) activity of the Ragulator complex, which 
functions as a GEF for the RAG small GTPase complex. The presence of amino 
acids results in the formation of an active RAG complex. mTORC1 binds to the 
RAG complex and is recruited to the lysosome, where it is possibly kept in an 
active state by the action of the RHEB GTPase. Other signals, such as growth 
factor signalling and energy status, signal to mTORC1 via different routes. 
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Figure 1.5 ‘Inside-out’ signalling of amino acids from the lysosomal lumen to 
activate mTORC1 
The Ragulator complex is a pentameric complex of p18, p14, MP1, C7orf59 and 
HBXIP. p18 is tethered to the membrane by myristoylation and palmitoylation, 
mediating the lysosomal localisation of the Ragulator complex and the RAG 
GTPases. There are four RAG GTPase proteins in humans and the RAGs form 
heterodimers, RAGA or RAGB dimerises with RAGC or RAGD, with four possible 
complexes being formed. 
 
1.2.2 The ULK complex 
Active mTORC1 binds, phosphorylates and inhibits the action of the 
uncoordinated 51-like kinase (ULK) complex and therefore autophagy (Ganley et 
al., 2009, Hosokawa et al., 2009a, Jung et al., 2009) (Figure 1.6). mTORC1 also 
inhibits autophagy in an indirect fashion, through the phosphorylation of the 
transcription factor TFEB, to repress the expression of lysosomal biogenesis genes 
(Martina et al., 2012, Roczniak-Ferguson et al., 2012, Settembre et al., 2012). The 
ULK complex can be considered the autophagy initiating kinase and is a 
serine/threonine kinase. The ULK complex consists of the proteins ULK1 or ULK2, 
FIP200, Atg13 and Atg101, and the complex is thought to be stable under basal or 
starvation conditions (Mercer et al., 2009, Hara et al., 2008, Chan et al., 2009, 
Ganley et al., 2009, Hosokawa et al., 2009b, Hosokawa et al., 2009a, Jung et al., 
2009). Moreover, members of the complex appear to stabilise one another. In the 
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presence of nutrients mTORC1 phosphorylates ULK1 and Atg13. The 
phosphorylation of ULK1 by mTORC1 on Ser757 antagonises the pro-autophagic 
interaction between ULK1 and AMPK (Kim et al., 2011). The yeast orthologue of 
ULK is Atg1 and in humans there are 5 proteins orthologous to Atg1, known as 
ULK1-4 and STK36/fused (Chan and Tooze, 2009). Of these orthologues ULK1 
and ULK2 are the most similar to yeast Atg1. ULK1 was the first human Atg1 
homologue to be characterised and it was shown in HEK293A cells and cerebellar 
granule neurons that ULK1 alone but not ULK2 is required for autophagy (Chan et 
al., 2007, Lee and Tournier, 2011). However ULK1 and ULK2 have a redundant 
pro-autophagy function in MEFs (Lee and Tournier, 2011, McAlpine et al., 2013). 
Out of the five Atg1 homologues in humans, ULK1 is the best characterised. Upon 
starvation, mTORC1 is deactivated, ULK1 is released from Raptor, and the 
inhibitory phosphorylation on ULK1 is reduced and ULK1 relocalises to autophagic 
membranes (Chan et al., 2009). The PP2A-B55α phosphatase complex 
dephosphorylates ULK1 upon starvation (Wong et al., 2015). Active ULK1 is 
autophosphorylated and phosphorylates its complex members Atg13 and FIP200. 
Atg13 purified from E. coli was able to bind to the lipids phosphatidic acid, PI3P 
and PI4P, via a short motif near its N-terminus (Karanasios et al., 2013). Mutation 
of this lipid association motif reduced the number of starvation-induced puncta that 
GFP-Atg13 was able to form. Thus it is plausible that Atg13 could promote 
targeting of the ULK complex to membranes. Another nutrient sensing kinase, 
AMP-activated kinase (AMPK), also regulates (activates) ULK1 in response to 
glucose starvation (Kim et al., 2011). Aspects of regulation of and by the ULK 
complex have been reviewed in more detail (Wirth et al., 2013, Wong et al., 2013). 
Active ULK1 is thought to exert its function by phosphorylating substrates such as 
Ambra1 (Di Bartolomeo et al., 2010) and Beclin 1 (Russell et al., 2013). Upon 
starvation ULK1 phosphorylates Ser14 on Beclin 1 to promote the lipid kinase 
activity of the Vps34-containing Beclin1 complex, which catalyses the next 
signalling stage in autophagosome formation. 
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Figure 1.6 Aspects of regulation of and by the ULK1 complex 
The mTORC1 complex is depicted with only the mTOR and Raptor subunits, for 
clarity. In addition to the mechanisms discussed in the text, ULK1 is also activated 
upon serum starvation through acetylation (Ac) by Tip60 (Lin et al., 2012). mTOR 
also phosphorylates and inhibits the Beclin 1 regulator Ambra1, whereas Ambra1 
promotes the TRAF6-mediated activating K63-linked ubiquitination of ULK1 (Nazio 
et al., 2013). ZIPK promotes autophagy and is phosphorylated upon ULK1 
overexpression and interacts with ULK1 (Tang et al., 2011). Other aspects of ULK 
regulation are discussed in section 1.2.5 and also reviewed in (Wong et al., 2013). 
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1.2.3 The Beclin 1 complex 
The Beclin 1 complex performs the next major signalling function in the 
stages of autophagy initiation (Figure 1.7). The core Beclin 1 complex consists of 
the members Beclin1, p150 and Vps34, and there are additional more transient or 
unstable interactors such as the positive autophagy regulator Ambra1 and the 
negative regulator Rubicon (Funderburk et al., 2010, Simonsen and Tooze, 2009, 
Kang et al., 2011, Wirth et al., 2013). Vps34 is the class III lipid kinase that 
catalyses the conversion of phosphatidylinositol (PI) to phosphatidylinositol 3-
phosphate (PI3P) on membranes, and thus the Beclin 1 complex functions to 
create a pool of PI3P at the omegasome and phagophore. The p150 subunit is N-
terminally myristoylated and anchors the complex to membranes. The core Beclin 1 
complex can associate with different proteins to form mutually exclusive and 
functionally different complexes with Atg14L (also known as Barkor) and UVRAG 
(Liang et al., 2006, Itakura et al., 2008, Sun et al., 2008, Zhong et al., 2009, 
Matsunaga et al., 2009). The Atg14L-containing Beclin 1 complex is required for 
autophagosome formation and Atg14L targets the Beclin 1 complex to the ER and 
the Omegasome (Matsunaga et al., 2010). The C-terminal region of Atg14L 
contains an amphipathic ɑ-helix within its BATS (Barkor autophagosome targeting 
sequence) domain that targets the protein to autophagosomes (Fan et al., 2011). 
Moreover, through this region Atg14L can preferentially bind directly to highly 
curved membranes (possibly equivalent to early autophagic structures) enriched for 
PI3P, and it is thought that Atg14L can sense and maintain membrane curvature. 
Thus, the Atg14L-containing Beclin 1 complex may function in a reinforcing 
manner, to create and maintain PI3P enriched curved membranes. In addition to 
Atg14L, Beclin 1 can interact with membranes via the evolutionarily conserved 
domain (ECD) of Beclin 1, which contains an aromatic finger (a surface loop with 
aromatic residues at the tip) required for the function of Beclin 1 autophagosome 
biogenesis (Huang et al., 2012).  
The Beclin 1 core complex can also interact with UVRAG, exclusive of the 
Beclin 1-Atg14L complex, and UVRAG promotes the activity of the Beclin 1 
complex. Both UVRAG and Atg14L have coiled-coil domains and compete for 
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Beclin 1 binding to the coiled-coil domain of Beclin 1. The UVRAG-containing 
Beclin 1 complex has been implicated in both autophagosome formation and 
maturation (Liang et al., 2006, Itakura et al., 2008, Sun et al., 2008, Matsunaga et 
al., 2009, Zhong et al., 2009). However the role of UVRAG in autophagosome 
formation is controversial, as knockdown of UVRAG did not reduce 
autophagosome formation in a study by (Itakura et al., 2008). In addition, UVRAG 
localises to the ER and binds PI3P and the localisation of UVRAG to the ER is 
dependent on PI3P (He et al., 2013). This ER-localised UVRAG regulates COPI 
retrograde trafficking to the ER, and Golgi maintenance, through an interaction with 
an ER-tethering complex containing RINT-1. However, the UVRAG-RINT-1 
complex dissociates upon autophagy induction and UVRAG interacts with the Bif-1 
containing Beclin 1 complex to mobilise the Atg9 compartment and promote 
autophagosome formation. Thus, this demonstrates another intersection between 
the secretory pathway and autophagy. The Beclin 1 complex is regulated by 
interactions with other proteins, post-translational modifications and transcriptional 
and translational control mechanisms, see reviews (Wirth et al., 2013, Kang et al., 
2011, Wirawan et al., 2012). 
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Figure 1.7 The Beclin 1 complex and subcomplexes 
The core complex is shown in yellow. Stable interactors with the core complex are 
shown in the semi-circle and more transient or unstable interactors are shown 
outside of the circle. Positive regulators are shown in green and negative regulators 
shown in red. UVRAG directly interacts with the BAR domain-containing protein Bif-
1, which can bind membranes and induce curvature (Takahashi et al., 2007). This 
interaction is thought may be important in starvation-induced Atg9 trafficking 
(Takahashi et al., 2011). Bcl-2 binds to the BH3 domain of Beclin 1 to inhibit 
binding of Beclin 1 to Vps34 and autophagy (Pattingre et al., 2005). Bcl-2 binding to 
Beclin 1 can be disrupted by binding to the transmembrane protein VMP1 (Molejon 
et al., 2013). Figure adapted from Wirth et al. (Wirth et al., 2013). 
 
1.2.4 PI3P effectors, Atg9 and the ubiquitin-like conjugation systems 
The spatially and temporally restricted pool of PI3P formed at 
autophagosome formation sites by the Beclin 1 complex upon starvation functions 
to recruit PI3P binding proteins that act as autophagy effectors. Such proteins 
include DFCP1 (Axe et al., 2008) and the WIPI proteins (Proikas-Cezanne et al., 
2004, Polson et al., 2010, Dooley et al., 2014). DFCP1 localises to the ER and 
Golgi and upon amino acid starvation relocalises to PI3P-positive omegasomes but 
is not incorporated into the autophagosome. However, the exact function of DFCP1 
in autophagy is unknown, as siRNA depletion of DFCP1 does not inhibit autophagy 
(Axe et al., 2008). WIPI2 also binds to the autophagosomal pool of PI3P formed 
upon starvation and depletion of WIPI2 results in reduced autophagosome 
formation (as assessed by LC3 lipidation and spot formation) and an accumulation 
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of DFCP1-positive omegasomes. Thus WIPI2 functions in the progression of 
omegasomes to autophagosomes. The function of WIPI2 is to recruit a complex of 
Atg12–5-16L1 to drive LC3 lipidation. The pool of autophagosomal PI3P is 
removed by PI3P phosphatases such as MTMR14 (Jumpy) (Vergne et al., 2009) 
and MTMR3 (Taguchi-Atarashi et al., 2010), which negatively regulate autophagy. 
The transmembrane protein Atg9 has an important function in the very early 
stages of autophagosome formation and promotes the formation of DFCP1-positive 
structures and autophagosomes (Orsi et al., 2012). Atg9-positive structures have 
been observed making dynamic contacts with forming autophagosomes but it is 
thought that mammalian Atg9 itself does not become incorporated into the 
autophagosomal membrane. It is likely that Atg9 functions in the expansion of the 
phagophore. Atg9 resides on endosomes and recycling endosomes but also on a 
morphologically distinct membrane compartment comprised of tubulated and 
vesicular membranes radiating from vacuolar structures. This compartment exists 
under basal and starvation conditions. Atg9 is also found on the trans-Golgi 
network (TGN) under basal conditions and redistributes to peripheral endosomal 
membranes upon autophagy induction (Young et al., 2006). This trafficking of Atg9 
requires ULK1 and PI3 kinase activity. Atg9 also resides on the plasma membrane 
(Puri et al., 2013, Popovic and Dikic, 2014), and the endocytosis of Atg9 is thought 
to contribute to the formation of autophagosome precursor membranes. The 
mobilisation of Atg9-positive membranes is hypothesised to function in the delivery 
of lipids or regulators to the forming autophagosome upon starvation, however the 
precise molecular role of mammalian Atg9 in autophagosome biogenesis remains 
to be elucidated. 
There are two ubiquitin-like conjugation systems involved in the closure of 
the autophagosome (Figure 1.8), reviewed in (Mizushima et al., 2011). The first 
system of reactions results in the formation of the constitutive Atg12–Atg5-Atg16L1 
complex. The second system results in the formation of lipidated Atg8. Atg12 is a 
small ubiquitin-like protein that becomes covalently attached to the Atg5 protein. 
The protein Atg10 acts as the E2-like enzyme in this reaction and Atg7 acts as the 
E1-like enzyme. Atg12 is activated by Atg7 and transferred to Atg10 prior to 
conjugation to Atg5, to form the Atg12–Atg5 conjugate (Mizushima et al., 1998). 
Atg7 is also the E1-like enzyme for the generation of lipidated Atg8. Atg16L1 non-
covalently associates non-covalently with Atg5 forming the Atg12–Atg5-Atg16L1 
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complex (Mizushima et al., 2003). The Atg12–5-16L1 complex resides (mostly) on 
the outer surface of the phagophore and dissociates from the membrane soon after 
autophagosome completion or just before (Mizushima et al., 2001).  
 
 
Figure 1.8 The two ubiquitin-like conjugation systems operating in autophagy 
Illustrated here is the yeast conjugation system, as was originally elucidated. 
However Atg8 could be substituted with LC3s or GABARAPs and Atg16 and be 
substituted with Atg16L1 for the analogous mammalian system. Atg10 can mediate 
the formation of the Atg12-5 conjugate without an E3-like enzyme (Yamaguchi et 
al., 2012). 
 
The Atg12–5-16L1 complex acts as an E3-like enzyme for the generation of 
lipidated Atg8, with Atg3 providing the E2-like function in the Atg8 conjugation 
system (Hanada et al., 2007). Atg3 promotes the lipidation of Atg8 proteins at 
highly curved membranes and this function, mediated by an N-terminal 
amphipathic helix, may have evolved to sense the highly curved cup-shaped 
structure of the phagophore (Nath et al., 2014). The ubiquitin-like protein Atg8 is 
translated as a pro-protein that becomes cleaved by Atg4 at the C-terminus to 
expose a glycine residue (Kirisako et al., 2000). Unlike yeast which has only one 
Atg8 protein in mammals there are multiple Atg8 homologues that have different 
names, which are discussed later, however the mechanism of their processing and 
subsequent conjugation is thought to be the same (Kabeya et al., 2004). This 
cleaved form of the Atg8 protein is cytosolic and is known as the “I” form. The C-
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terminal glycine of the cleaved Atg8 protein is attached to the lipid 
phosphatidylethanolamine (PE) to anchor the Atg8s to the phagophore membrane. 
This lipidated form is known as the “II” form. LC3B is the best known Atg8 
homologue in mammalian cells and is routinely used as a marker for autophagy. 
LC3B is often abbreviated simply to LC3. The LC3-II form (lipidated) migrates 
faster by SDS-PAGE than the LC3-I (cytosolic) form and thus the initiation of 
autophagy by starvation can be monitored by western blotting (Klionsky et al., 
2012).  
When autophagy is initiated, LC3 becomes lipidated, but also becomes 
degraded in the lysosome. This is because LC3 is attached to both the concave 
and convex surfaces of the phagophore membrane (unlike the Atg12–5-16L1 
complex) and is also on fully formed autophagosomes (Kirisako et al., 1999) 
(Figure 1.9). Thus the LC3 on the inner (concave) membrane is terminally delivered 
to the lysosomal lumen. Atg4 acts as a deconjugating enzyme to cleave and 
release LC3 from PE on the autophagosome membrane after formation. One 
function of the Atg8s is to promote the elongation and final closure of the 
autophagosomes (Weidberg et al., 2010), likely mediated through the activity of the 
Atg8s in membrane tethering and fusion (Weidberg et al., 2011). It has been shown 
with purified yeast proteins that the Atg12–5-16 complex along with Atg8-PE forms 
a scaffold structure on the outer (convex) surface of the phagophore and that Atg8 
interacts with Atg12 to facilitate this cage-like structure (Kaufmann et al., 2014). 
Formation of this scaffold is important for progression of autophagy, however on 
the concave surface Atg8 functions to bind cargo receptor proteins for capturing 
cargo (Behrends and Fulda, 2012, Johansen and Lamark, 2011, Okamoto, 2014, 
Stolz et al., 2014, Svenning and Johansen, 2013, Rogov et al., 2014). Thus it 
appears that Atg8 could have distinct spatially controlled functions on the same 
membrane structure, in phagophore expansion and cargo capture. Whether this 
scaffold occurs in mammalian cells remains to be elucidated. 
As mentioned the Atg8s function in binding cargo receptors to recruit 
substrates for degradation. One such cargo receptor that binds the Atg8s directly is 
p62 (Pankiv et al., 2007, Bjorkoy et al., 2005), which is also known as 
sequestosome-1. p62 contains an LC3-interacting region (LIR), which is a short 
motif that facilitates the direct interaction with Atg8s. In addition to binding Atg8s, 
p62 functions to bind ubiquitinated protein aggregates and thus facilitates the 
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clearance of protein aggregates by autophagy (aggrephagy). Because p62 is 
bound to and encapsulated by the autophagosome, it is also degraded upon 
starvation. Because of this, degradation of p62 is routinely monitored by western 
blotting as a late stage readout of autophagic flux (Klionsky et al., 2012).  
 
 
Figure 1.9 The mammalian machinery of autophagosome formation 
Autophagosome formation can be divided into 3 stages: initiation, nucleation and 
expansion. Initiation is the transmission of the nutrient status signal to the 
membrane where phagophore membranes are generated (nucleation). The 
membranes must grow in size (expansion) to form the cargo-capturing 
autophagosome.  
 
1.2.5 Non-hierarchical autophagy 
Autophagy is usually described as a hierarchical sequence of signal 
transduction and protein recruitment events, as I have done above. However in 
recent years this view has been modified somewhat, as it is apparent now that 
autophagy is a complicated network of protein interactions and feedback/forward 
mechanisms (Behrends et al., 2010). The autophagy proteins I have described 
here are involved in the starvation-induced autophagy pathway, however 
autophagy can occur in certain settings without these core proteins, this form of 
autophagy is known as non-canonical autophagy (Codogno et al., 2012). For 
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example ammonia induces autophagy in ULK1 and ULK2 double knockout MEFs, 
suggesting that the canonical initiating signals of autophagy can be bypassed in 
some way (Cheong et al., 2011).  
I will highlight some examples of how autophagy is not a simple hierarchical 
pathway. The non-hierarchical autophagy I describe here is canonical in the sense 
that it requires the core autophagy components. ULK1 promotes the 
phosphorylation of the Raptor subunit of the mTORC1 complex and reduces the 
binding of substrates to Raptor (Dunlop et al., 2011) and inhibits mTOR function 
(Jung et al., 2011) (Figure 1.6). In addition ULK1 can also phosphorylate and inhibit 
AMPK (Loffler et al., 2011). Thus ULK1 can feedback to two major upstream 
regulators of its function. The ULK complex is thought of as the autophagy initiating 
kinase that acts at very early stages. However, it is also known that maximal and 
stable recruitment of the ULK complex requires PI3P (Karanasios et al., 2013), 
which is formed downstream of ULK1 activation. Thus PI3P functions as a signal to 
enforce ULK maintenance at the phagophore. Atg14L, which is part of the early 
acting Beclin 1 lipid kinase complex, binds to the SNARE syntaxin 17 and promotes 
tethering and fusion of autophagosome membranes to later compartments (Diao et 
al., 2015). In addition, the Atg12–5 conjugate is also implicated in later maturation 
stages. The Atg12–5 conjugate forms a complex with TECPR1, which is separate 
from the Atg12–5-16L1 complex, that promotes the fusion of autophagosomes with 
lysosomes (Chen et al., 2012). Thus, an emerging theme is that an individual 
autophagy protein may regulate the pathway at different points and indeed provide 
different functions at different stages. An additional worthwhile consideration is that 
autophagy proteins have functions outside of autophagy; for example Atg7 binds 
the tumour suppressor protein p53 to regulate the transcription of the p21 cell cycle 
arrest gene (Lee et al., 2012). The non-autophagic functions of the Atg proteins 
have been recently reviewed (Subramani and Malhotra, 2013). Conceptually this 
makes sense as the autophagy proteins are already translated and at adequate 
supply to facilitate the rapid formation of autophagosomes upon starvation. Thus 
during basal conditions when autophagy levels are low, it would be sensible to 
have dual functions of the autophagy proteins. However, I think the question 
remains as to what these proteins are doing in the basal state. For example, the 
majority of the WIPI2 and ULK1 proteins are not on membranes by subcellular 
fractionation (Chan et al., 2009) (Polson et al., 2010), and there is no significant 
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recruitment to a crude membrane extract during starvation. Presumably the 
membrane localised populations of the proteins are involved in autophagy, so one 
may ask what is the function of the remaining population? 
Since the discovery of the autophagy machinery proteins, there has been a 
great increase in our understanding of the regulation of these proteins. The 
literature on autophagy regulation is vast and autophagy proteins can be regulated 
by: protein binding partners, control of subcellular localisation, stabilisation from 
proteasomal degradation, post-translational modifications such as acetylation, 
ubiquitination and phosphorylation (Kroemer et al., 2010) (Xie et al., 2015). The 
expression of autophagy genes is also regulated by transcription factors, epigenetic 
control and translational control through miRNAs (Fullgrabe et al., 2014). However, 
our understanding of the regulation of autophagy is still in its growing stages. 
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1.3 WAC 
WW domain-containing adapter protein with coiled-coil (WAC) is a recently 
discovered positive regulator of starvation-induced autophagy (McKnight et al., 
2012). As described, the core protein machinery of autophagosome formation has 
been known for some time, however how this process is regulated is still to be 
uncovered. To this end a previous PhD student in the lab, Nicole McKnight, carried 
out a genome-wide screen (McKnight et al., 2012) to uncover novel regulators of 
amino acid starvation-induced autophagy. WAC was a main candidate for a novel 
positive regulator of autophagy whose function in autophagy was unknown. It has 
been shown that WAC is a positive regulator of autophagy in HEK293A cells and in 
HeLa cells (McKnight et al., 2012) and Nicole McKnight, (“A Genome-wide Screen 
for Starvation-induced Autophagy Identifies New Modulators of Autophagy”, 2010). 
In HEK293 cells stably expressing GFP-LC3B, WAC was required for maximal 
puncta (autophagosome) formation under conditions of EBSS starvation and 
leupeptin treatment to block lysosomal protein degradation. In HEK293A cells, 
WAC is required for efficient endogenous LC3 lipidation as determined by depleting 
WAC, EBSS starving cells and simultaneously treating with the vacuolar ATPase 
inhibitor bafilomycin A1 (BafA) (Yamamoto et al., 1998). BafA and leupeptin 
prevent the degradation of LC3 covalently linked to the inner autophagosomal 
membrane. Thus, during treatment with BafA or leupeptin it is possible to assay 
solely for the formation of LC3-II (lipidated LC3) and exclude degradation of LC3 
(Klionsky et al., 2012). This phenotype was observed with multiple siRNA 
sequences targeting WAC, suggesting that it was not an off-target effect of any one 
siRNA. In addition, in basal and starvation conditions, knockdown of WAC results in 
the accumulation of the autophagy substrate p62, suggesting a defect in p62 
degradation by autophagy. These data suggest that basal autophagy, as well as 
starvation-induced autophagy, is regulated by WAC. Upon starvation in EBSS, 
some p62 degradation was observed in WAC knockdown cells. This suggests that 
WAC is not absolutely required for autophagy, but is rather a regulatory protein. It 
is also possible that a WAC knockout, such as generation of a CRISPR cell line, 
would exhibit a more enhanced phenotype. WAC depletion also attenuated LC3 
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lipidation in HeLa cells, this was evidenced by an observed decrease in the LC3-
II/LC3-I ratio (Nicole McKnight, “A Genome-wide Screen for Starvation-induced 
Autophagy Identifies New Modulators of Autophagy”, 2010). As HeLa cells have a 
high level of basal LC3-II in our hands (data not shown), it may be more informative 
to measure changes in LC3-I in addition to LC3-II rather than LC3-II/Actin (Nicole 
McKnight, “A Genome-wide Screen for Starvation-induced Autophagy Identifies 
New Modulators of Autophagy”, 2010). Myc-WAC was also shown to interact with 
GFP-Beclin 1 (McKnight et al., 2012) and was found as a low confidence interactor 
of FLAG-HA-Beclin 1 in the autophagy network (Behrends et al., 2010). In addition 
to WAC’s role in promoting autophagy, WAC may negatively regulate proteasomal 
degradation (McKnight et al., 2012). Using UbG76V-YFP, a reporter of proteasomal 
degradation (Dantuma et al., 2000), after depletion of WAC less UbG76V-YFP was 
found, and this was rescued with the proteasomal inhibitor MG132, suggesting that 
the UPS was enhanced upon WAC depletion.  
WAC is implicated in pathologies and is expressed in a wide range of tissues 
(Totsukawa et al., 2011). For example, WAC is mutated in acute myeloid 
leukaemia after relapse but not in the primary cancer (Ding et al., 2012), mutations 
in WAC could be involved in intellectual disability (Hamdan et al., 2014) and WAC 
nonsense or frameshift mutations are thought to result in neurocognitive 
phenotypes and facial dysmorphism (DeSanto et al., 2015). WAC was first cloned 
and expressed over a decade ago and in humans there are four WAC isoforms that 
are generated by alternative splicing (Xu and Arnaout, 2002). Isoform 1 of WAC is 
the best characterised and the longest WAC isoform of 647 amino acids, encoded 
by 14 exons on chromosome 10 (Ensembl). WAC contains a predicted WW domain 
towards its N-terminus, and a predicted coiled-coil (CC) domain at its C-terminus. 
See Figure 4.9c for the primary structure of WAC human isoform 1, discussed in 
greater detail in Chapter 4. Both of these WAC domains mediate protein-protein 
interactions (Zhang and Yu, 2011). There are no other known domains in the 
protein. The WW and CC domains of WAC are conserved to Drosophila, however 
there is no known WAC homologue in yeast. The rest of the WAC protein is not 
well conserved, although between mouse and human WAC there is 95% similarity 
at the amino acid level of the full length protein (Xu and Arnaout, 2002). In flies, the 
homologous sequences of the WW and CC domains of WAC are encoded by a 
polypeptide chain (protein name CG8949) that also contains sequences 
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homologous to SNRP70, a component of the spliceosome. However in mammals, 
WAC orthologues exist as separate peptide chains to SNRP70. This suggests that 
evolutionarily, WAC may have functioned in splicing but has since diverged in 
function. The WW domain of WAC comprises of 2 tryptophan (W) residues 
separated by 23 amino acids (inclusive). WW domains are protein interaction 
domains, which usually bind to proline rich regions (PPXY, PPLP and PGM motifs) 
(Chen and Sudol, 1995) (Bedford et al., 1998) (Chan et al., 1996) or to 
phosphorylated serine or threonine residues (Lu et al., 1999). The WW domain of 
WAC has been shown to bind proline motifs directly, suggesting that it is a 
functional WW domain (Kato et al., 2004). The WW domain in WAC is 
characterised by the presence of a triple tyrosine (YYY) motif, which is an element 
found in the WW domains of some spliceosomal proteins. When WAC was first 
expressed (Xu and Arnaout, 2002), immunofluorescence showed that the tagged 
form of the protein formed nuclear speckles that colocalised with the splicing factor 
SC35. Thus it was hypothesised that WAC functioned in splicing. However, to date 
there has been no functional evidence of this. In my hands overexpressed WAC 
does form structures that resemble nuclear speckles, however this only occurs in 
cells expressing high levels of WAC, and does not reflect the localisation of the 
endogenous protein (data not shown). The earliest paper on WAC (Xu and 
Arnaout, 2002) also provided evidence that WAC is phosphorylated on tyrosine 
residues. Indeed, numerous phosphorylation sites have since been discovered on 
WAC by mass spectrometry (www.phosphosite.org). 
WAC was later shown to perform a function in the nucleus (Zhang and Yu, 
2011) (Figure 1.10). WAC promotes monoubiquitination of histone 2B (H2B) at 
lysine 120. This epigenetic mark is associated with regions of active transcription 
and is enriched downstream of the transcription start site (Bonnet et al., 2014). 
WAC, via its WW domain, binds to RNA polymerase II (RNAP) and binds to the 
phosphorylated C-terminal domain (CTD) of RNAP when phosphorylated at the 
serine 2 position of the heptads in the CTD. This modification is associated with the 
coding regions of genes and is promoted by CDK9 (Komarnitsky et al., 2000, 
Pirngruber et al., 2009). At the same time as binding RNAP, WAC is thought to act 
as an adaptor by binding to and activating, an E3 ligase complex of RNF20/40. 
This interaction occurs through the CC domain of WAC, with the CC domains of 
RNF20/40. WAC also indirectly interacts with the E2 enzyme RAD6. Thus WAC 
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recruits the RNF20/40 E3 ligase complex to RNAP, to promote the ubiquitination of 
histones in front of the processing polymerase. Through this mechanism of H2B 
ubiquitination, WAC promotes the expression of p53 target genes such as p21.This 
mechanism was shown to be important for the protective response of cell cycle 
arrest after DNA damage. Normally this checkpoint would ensure arrest of DNA 
replication to allow DNA repair. However in WAC knockdown cells exposed to 
ionising radiation, the expression of p21 was impaired leading to the continuation of 
DNA replication instead of arrest. The complex of WAC/RNF20/40 was shown to 
exist in nuclear extracts and the interactions are direct. Moreover this complex 
remains associated during size-exclusion chromatography and is predicted to occur 
as a heterohexameric complex with a 2:2:2 stoichiometry. In addition to WAC’s role 
in the DNA damage response, WAC and H2B monoubiquitination are involved in 
the differentiation of human mesenchymal stem cells into osteoblast or adipocyte 
lineages (Karpiuk et al., 2012). 
 
 
Figure 1.10 The function of WAC in the nucleus 
See main text for details. Transcription start site, TSS. 
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WAC was also found in purified rat liver Golgi membranes, where it was 
stably associated after 1M KCl washes (Totsukawa et al., 2011). This is similar to 
the Golgi matrix protein GM130 (Nakamura et al., 1995) and WAC also colocalises 
with GM130 in HeLa cells (Totsukawa et al., 2011). On the Golgi, WAC interacts 
directly with the deubiquitinase (DUB) VCIP135 and stimulates its DUB activity 
(Figure 1.11). VCIP135 interacts with valosin-containing protein (VCP) also known 
as p97 and Cdc48 in yeast, and through VCIP135, WAC and VCP interact 
indirectly. This interaction of WAC with VCIP135 and its stimulation of VCIP135 
DUB activity function in the reformation of Golgi cisternae post-mitosis. During 
mitosis the Golgi vesiculates, through the phosphorylation-mediated inhibition of 
factors such as GM130 by cell cycle regulated kinases, and the disassembly of 
tethering complexes (Nakamura et al., 1997, Lowe et al., 1998, Wang et al., 2003, 
Corda et al., 2012). Knockdown of WAC resulted in the fragmentation of the Golgi 
complex by immunofluorescence and by electron microscopy, where there was a 
reduction in cisternal structures and an increase in tubules and vesicles around the 
Golgi. Although WAC may anchor VCIP135 to the Golgi, the factor that anchors 
WAC to the Golgi is unknown. Thus WAC appears to have at least 2 functions, one 
in the nucleus in epigenetic regulation and one on the Golgi in membrane 
biogenesis, and WAC interacts with both E3 ligases and deubiquitinases.  
 
 
Figure 1.11 The function of WAC on the Golgi complex 
See main text for details. Golgi membrane fusion is facilitated by ATPases such as 
NSF and p97. p97 forms distinct complexes with p37 or p47 (shown here). The 
p97/47 mechanism of membrane fusion is thought to be specific for Golgi 
reformation at mitosis and mediated by the syntaxin 5 SNARE but not by the p115 
or GM130 tethers. 
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1.4 GM130 
GM130 was first characterised around two decades ago and was shown to be 
a Golgi matrix protein localised mostly to the cis-Golgi with a predicted extended 
rod-like structure and extensive coiled-coil regions (Nakamura et al., 1995). GM130 
can also cycle between the Golgi complex and the ERGIC and is part of a family of 
extended coiled-coil Golgi proteins known as golgins (Wong and Munro, 2014, 
Marra et al., 2001). GM130 may be involved in disease; for example GM130 is 
downregulated in breast and colorectal cancer and depletion of GM130 in breast 
cancer cells increases their migration speeds and invasiveness (Baschieri et al., 
2015, Baschieri et al., 2014). In addition the bacterial toxin EspG, found in 
pathogenic strains of E. coli, binds to GM130 and induces the fragmentation of the 
Golgi (Clements et al., 2011). GM130 was isolated from rat liver Golgi extracts and 
remained associated with Golgi matrix after 1 M KCl washes and is 130 kDa in size 
(Nakamura et al., 1995). GM130 has a homologue in Drosophila and a functional 
homologue in yeast, Bug1 (Behnia et al., 2007). GM130 has 4 or 6 major coiled-coil 
domains, depending on the bioinformatic prediction tool used, and forms a parallel 
homotetramer (Ishida et al., 2015). GM130 has also been observed as a hexamer 
(Hu et al., 2015). A schematic of the primary structure of GM130 is provided in 
Figure 4.11c. GM130 also contains a functional nuclear localisation signal towards 
its N-terminus (Wei et al., 2015). At its N-terminus GM130 binds to the coiled-coil 
tethering factor p115 and during mitosis GM130 is phosphorylated on Ser25 by the 
kinase CDK1/Cdc2 (Nakamura et al., 1997, Lowe et al., 1998). The 
phosphorylation of GM130 is associated with the dissociation of the p115 and 
GM130 interaction and this is thought to facilitate the COPI mediated disassembly 
of the Golgi complex at mitosis (Nakamura et al., 1997, Lowe et al., 1998). 
However, Ser25 phosphorylation of GM130 may not be the only mechanism for 
mitotic Golgi fragmentation (Sundaramoorthy et al., 2010). In addition N-terminal 
arginine residues in GM130 are targeted for methylation by the methyltransferase 
PRMT5 (Zhou et al., 2010), and this appears important for the integrity of the Golgi. 
p115 is thought to bridge the interaction between GM130 on the Golgi and Giantin, 
a large ~400 kDa protein enriched on COPI vesicles (Lesa et al., 2000, Seemann 
et al., 2000, Sonnichsen et al., 1998). However, this view has been challenged by 
the observation that p115 binds GM130 or Giantin individually but not 
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simultaneously (Linstedt et al., 2000). The GM130-p115 interaction can be 
disrupted by microinjection of a GM130 peptide corresponding to the interaction 
region (Seemann et al., 2000), this results in vesiculation around the Golgi complex 
suggesting that the GM130-p115 interaction promotes vesicle tethering and fusion 
with Golgi membranes (Figure 1.12b). However, the role of the GM130-p115 
interaction in maintaining Golgi structure is controversial, as it was reported that 
inhibition of GM130-p115 binding, by microinjection of anti-GM130 antibodies, has 
no detectable effect on Golgi structure (Puthenveedu and Linstedt, 2001). In 
addition, it was reported that the GM130-GRASP65 interaction (Figure 1.12d), and 
the GM130 mediated regulation of ER-to-Golgi carriers (Figure 1.12c) are important 
in regulating Golgi ribbon formation (Puthenveedu et al., 2006) (Marra et al., 2007). 
The complicated nature of GM130’s role in the maintenance of the Golgi is 
highlighted by the use of hamster cells (ldlG) with no detectable GM130, where the 
role of GM130 in Golgi morphology is apparent only at certain temperatures (Vasile 
et al., 2003). In addition to its proposed role in maintaining Golgi structure, GM130 
also regulates anterograde ER-Golgi traffic (Alvarez et al., 2001) although may not 
be absolutely required for forward secretion (Marra et al., 2007) (Puthenveedu et 
al., 2006). This likely because of redundancy between the golgins, and GM130 has 
recently been shown to function in a redundant manner with the golgin GMAP-210 
in ER to Golgi trafficking (Roboti et al., 2015). The role of GM130 in regulating 
protein glycosylation is also controversial (Marra et al., 2007) (Puthenveedu et al., 
2006). In support of GM130’s role in forward trafficking, GM130 interacts with 
Rab1b-GTP independently of p115 forming an effector complex that is thought to 
promote COPII vesicle tethering and fusion at the cis-Golgi (Weide et al., 2001, 
Moyer et al., 2001). In addition, mitochondrially targeted GM130 has been shown to 
capture ER-derived carriers (Wong and Munro, 2014). GM130 also interacts with 
another small Rab GTPase Rab33b in its active (GTP bound) state, although the 
exact function of this interaction is unknown (Valsdottir et al., 2001). Interestingly, 
as discussed earlier, Rab1 and Rab33b are both implicated in the regulation of 
autophagosome formation. At its C-terminus GM130 binds to the Golgi protein 
GRASP65 and this interaction is required for the localisation of both proteins to the 
Golgi (Barr et al., 1998) (Figure 1.12b). The anchoring of GM130 to the Golgi 
complex is thought to be mediated by N-myristoylation of GRASP65 (Barr et al., 
1997). The zinc finger integral membrane protein ZFPL1 and the SNARE protein 
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syntaxin 5 also interact with the C-terminal region of GM130 (Chiu et al., 2008, 
Diao et al., 2008) (Figure 1.12a). The interaction of GM130-syntaxin 5 is inhibited 
by the binding of p115 to the N-terminus of GM130. It is thought that GM130 may 
function to spatiotemporally coordinate vesicle tethering and subsequent SNARE-
mediated fusion events. 
 
 
Figure 1.12 Functions of GM130 in Golgi biogenesis and membrane trafficking 
(a) GM130 has a role in anterograde trafficking. p115 can bind Rab1b and could 
allow the capture of vesicles by GM130, possibly inducing a conformational change 
in GM130 to allow SNARE mediated fusions to occur after the release of syntaxin 5 
(Diao et al., 2008). For explanation of the other models see main text. 
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In addition to its role in membrane dynamics GM130 performs multiple other 
functions that have been discovered more recently. For example GM130 regulates 
signalling by maintaining the activity of the Rho family GTPase Cdc42. GM130 
interacts with Tuba, a GEF for Cdc42, and promotes Cdc42 activation at the Golgi 
(Kodani et al., 2009). This axis of Cdc42 and GM130 is thought to function in 
centrosomal organisation and function in interphase cells (Kodani and Sutterlin, 
2008b, Kodani et al., 2009). Furthermore, GM130 binds to an inhibitor of Cdc42, 
RasGRF (Baschieri et al., 2014). Depletion of GM130 releases RasGRF resulting 
in the inhibition of the Golgi pool of Cdc42 and dysregulation of cell polarity. GM130 
also regulates signalling by binding to and activating the YSK1 kinase, whose 
function is required for Golgi organisation, cell migration and invasion (Preisinger et 
al., 2004). 
GM130 is also connected with microtubule dynamics. GM130 interacts with 
AKAP450, a centrosomal gamma-tubulin interacting protein, and both GM130 and 
AKAP450 are involved in nucleating microtubules from the cis-face of the Golgi 
(Rivero et al., 2009, Hurtado et al., 2011). As mentioned GM130 regulates 
centrosome organisation but GM130 also controls mitotic and meiotic spindle 
formation and the localisation of spindle pole proteins (Kodani and Sutterlin, 2008b, 
Zhang et al., 2011, Wei et al., 2015). Upon mitosis, the phosphorylation of GM130 
by CDK1 to remove p115 binding is thought to allow importin α binding to the NLS 
of GM130, this then releases the microtubule nucleating factor TPX2 from importin 
α and TPX2 can then nucleate microtubules (Wei et al., 2015). GM130 additionally 
captures the nascent microtubules directly (Wei et al., 2015). This mechanism is 
thought to function in accurate Golgi segregation during mitosis. Finally, GM130 
appears to be a negative regulator of autophagy (Chang et al., 2012). This will be 
discussed in more depth in Chapter 5. 
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1.5 GABARAP and the Atg8 family 
In yeast there is only one Atg8 protein, however in humans Atg8 has diverged 
into different orthologues (Shpilka et al., 2011). There are also multiple Atg4 genes 
in mammals, perhaps to direct specified processing of the different mammalian 
Atg8s. These mammalian Atg8s (mAtg8s) are split into three subfamilies based on 
their sequence similarity to one another. The Atg8 family of proteins are structurally 
similar ubiquitin-like proteins (Ubiquitin-like by structure not sequence), consisting 
of 2 N-terminal α-helices and a ubiquitin-like core. However, the family members 
vary at their N-terminus. There is the LC3 subfamily, comprised of LC3A (2 
isoforms by alternative splicing), LC3B, LC3B2 and LC3C, the GABARAP 
subfamily comprised of GABARAP and GABARAPL1, and the GATE-16 subfamily 
containing GABARAPL2 only, which is also known as GATE-16. Sometimes the 
three GABARAP genes from two subfamilies are grouped together and called the 
GABARAPs. LC3B is usually used as a readout of autophagy, because of the 
development of tools to study this particular mAtg8 (Kabeya et al., 2000). The 
mAtg8s can make protein-protein interactions that are LIR independent or LIR 
dependent (e.g. p62). The LIR motif has the core sequence (W/F/Y)XX(L/I/V), and 
often has acidic residues preceding the first hydrophobic residue (Alemu et al., 
2012). As mentioned earlier, the mAtg8s may also have a direct role in membrane 
tethering or fusion events, in addition to binding LIR-containing cargo receptors. In 
recent years there has been a great increase in the number of proteins known to 
bind the mAtg8s, many of which bind several different family members (Wild et al., 
2014). Moreover, some of the mAtg8s interact with one another. A few questions 
arise from this. What are the roles of the individual family members and what is the 
extent of redundancy versus specialism? Why are there so many mAtg8-interacting 
proteins and how is this selectivity regulated?  
There are examples of specific regulation/function of the mAtg8s and also of 
redundancy. The different mAtg8s have some difference in tissue expression 
(reviewed in (Shpilka et al., 2011)), which could be indicative of specialised 
functions. Moreover there are differences in expression levels of the mAtg8s, with 
GABARAP being the most abundantly expressed in the LNCaP prostate cancer cell 
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line (Szalai et al., 2015). Depletion of individual mAtg8 family members only has a 
partial inhibitory effect on autophagy, which could suggest redundancy of the family 
members (Weidberg et al., 2010). However, knockdown of the GABARAP proteins 
together, resulted in the accumulation of large unclosed phagophore membranes 
by electron microscopy (Weidberg et al., 2010). In contrast depletion of the LC3 
proteins together resulted in the accumulation of small phagophore structures. 
Depletion of the GABARAPs or the LC3s resulted in the accumulation of Atg5 and 
Atg12 puncta, suggesting a stalling of autophagosome biogenesis after recruitment 
of the Atg12-5-16L1 complex. These data suggest that the GABARAPs could 
function in the final elongation and closure stages of the phagophore whereas the 
LC3 subfamily may have a role in early phagophore elongation. Other examples of 
specific function include LC3C, which is involved in antibacterial autophagy of 
Salmonella via binding the LIR-containing adaptor protein NDP52 (von Muhlinen et 
al., 2013). In addition, LC3B appears to be more crucial for the incorporation of p62 
into the autophagosome than the GABARAPs (Maruyama et al., 2014, Shvets et 
al., 2011). One study concluded that the GABARAP proteins were crucial for bulk 
(non-selective) autophagy but the LC3s were dispensable (Szalai et al., 2015). 
However, despite evidence of specificity, the specific functions of the mAtg8s is 
largely unknown. 
I shall focus on an introduction of the GABARAP member of the Atg8 family, 
as this been a significant portion of my work. GABAA receptor associated protein 
(GABARAP) was identified as a 17 kDa interactor with GABAA receptors, which are 
receptors that mediate inhibitory neurotransmission (Wang et al., 1999). GABARAP 
facilitates the trafficking of GABAA receptors to the plasma membrane (Leil et al., 
2004) and also ER-to-Golgi trafficking of N-cadherin/β-catenin complexes 
(Nakamura et al., 2008). Another indication that GABARAP could be involved in 
membrane trafficking events, is that GABARAP was found enriched on the Golgi 
and to interact with N-ethylmaleimide-sensitive factor (NSF), which is an ATPase 
that mediates membrane fusion events (Kittler et al., 2001). In addition, GABARAP 
binds directly to tubulin and this is mediated by the N-terminal region of GABARAP 
through ionic interactions (Wang and Olsen, 2000). The crystal structure of 
GABARAP shows that it can oligomerise with itself in a head-to-tail manner and 
can adopt different conformations (Coyle et al., 2002). The role of GABARAP in 
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membrane trafficking events is incompletely understood and recent work has been 
focused more on the role of GABARAP in autophagy. 
In addition to the function of GABARAP in phagophore closure and binding 
cargo receptors, GABARAP also interacts with the ULK complex (Okazaki et al., 
2000, Alemu et al., 2012, Kraft et al., 2012). ULK complex members, ULK1, ULK2, 
Atg13 and FIP200, all have LIR motifs and bind GABARAP preferentially over 
LC3B (Alemu et al., 2012). The implication of this binding preference is currently 
unknown. ULK1 with its LIR mutated, formed fewer punctate structures upon 
starvation than wild-type ULK1. Hence, the presence of LIR motifs in the ULK 
complex is thought to facilitate the recruitment of ULK to the phagophore. In 
addition, overexpression of LIR mutant ULK1 causes the accumulation of WIPI2 
puncta, compared with wild-type ULK1. This suggests that immature autophagic 
structures accumulate in the absence of a functional ULK1 LIR. Thus it was 
hypothesised that the ULK1 complex somehow aids the function of the Atg8s in 
autophagosome formation. It could also be possible that GABARAP may regulate 
ULK1 activity through its interaction, although this remains to be demonstrated.  
GABARAP may also regulate autophagy, or be regulated, by binding to 
positive regulators such as MAPK15/ERK8 (Colecchia et al., 2012) and folliculin 
(FLCN) (Dunlop et al., 2014) or the negative regulator Bcl-2 (Ma et al., 2013). In 
addition GABARAP can function as a signalling scaffold. The interaction of 
GABARAP with an E3 ligase complex continuing CUL3, KBTBD6 and KBTBD7 
was required for substrate ubiquitination (Genau et al., 2015). GABARAP likely 
mediates selective cargo recognition for autophagy. For example, the LIR-
containing protein ALFY, which interacts with p62 and is involved in aggrephagy, 
selectively binds GABARAPs (and also LC3C) and this allows the clearance of a 
subset of p62 structures by autophagy (Lystad et al., 2014). Also, the interaction of 
GABARAP with the LIR-containing mitochondrial E3 ligase Mulan may be involved 
in mitophagy (Ambivero et al., 2014). Recently GABARAPs have been implicated in 
the later stages of autophagosome maturation. Both LC3s and GABARAPs interact 
directly with PLEKHM1, which forms a complex with the HOPs complex to regulate 
autophagosome-lysosome fusion (McEwan et al., 2015). Additionally, GABARAPs 
recruit the PI4 kinase PI4KIIα to autophagosomes from the Golgi region, in order to 
generate a pool of PI4P which promotes autophagosome-lysosome fusion (Wang 
et al., 2015). 
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1.6 Aims 
WAC is a positive regulator of autophagosome formation as judged by different 
readouts in HEK293A and HeLa cells: LC3 lipidation, GFP-LC3 spot formation and 
p62 degradation. This suggests that WAC affects autophagy at the stage of LC3 
attachment to the phagophore or even earlier. However the mechanism of WAC’s 
effect on autophagy is completely unknown. One clue is a proposed interaction of 
overexpressed WAC with Beclin 1 although this will have to be further investigated. 
There are two known functions of WAC, one in the nucleus and one centred on the 
Golgi. As the Golgi may act as a direct membrane source for phagophore 
formation/expansion and harbours autophagy regulatory proteins, WAC’s function 
at the Golgi is a good candidate for its role in autophagy. On the other hand, 
nuclear regulation of autophagy has been become more apparent recently, and the 
communication between the nucleus and cytoplasm certainly has a role in 
autophagy regulation. I aim to elucidate the mechanism by which WAC promotes 
autophagosome formation, by conducting an investigation into the novel functions 
of WAC in the nucleus and cytoplasm, exploring gene regulation and the 
identification of novel WAC binding partners. 
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Chapter 2. Materials & Methods 
2.1 Cell culture and transfection 
2.1.1 Cell culture 
Dishes, flasks and multiwell plates for cell culture were procured from 
Corning, and Dulbecco’s Modified Eagle Medium (DMEM) and fetal bovine serum 
(FBS) from Sigma. The following solutions were produced by Cell Services at the 
Francis Crick Institute, London: Earle’s Balanced Salt Solution (EBSS) (5.56 mM D-
glucose, 123.08 mM NaCl, 5.37 mM KCl, 1.82 mM CaCl2, 0.81 mM MgSO4, 0.99 
mM Na2HPO4, 13.10 mM NaHCO3), Phosphate buffered saline (PBSA) (137 mM 
NaCl, 3.4 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.2), trypsin (0.25% 
trypsin, 137 mM NaCl, 0.7 mM Na2HPO4, 5.6 mM D-glucose, 25 mM Tris-HCl pH 
7.7, 5.1 mM KCl, 42 µM Phenol Red, 0.25 mM penicillin, 172 µM streptomycin) and 
versene (0.02% (w/v) EDTA in PBSA). 
HEK293A cells were obtained from Cell Services, the Francis Crick Institute. 
MEFs used were from (McAlpine et al., 2013). RPE-1 cells were from Laurent 
Sansregret, the Francis Crick Institute. HeLa cells were obtained from Eeva-Liisa 
Eskelinen University of Helsinki, Helsinki, Finland. HCT116 and U2OS cells were a 
kind gift from Kevin Ryan, The Beatson Institute, Cancer Research UK, Glasgow. 
HEK293 Flp-In T-Rex GFP-GABARAP cells were a kind gift from Anne Simonsen, 
(University of Oslo, Norway). All cell lines in were maintained in DMEM 
supplemented with 10% FBS and 4.8 mM L-glutamine (full medium) under 
humidified conditions at 37 ºC in 10% CO2, unless otherwise specified here. Stably 
expressing WAC-FLAP HeLa cell line is maintained under 400 µg/mL geneticin 
(Life Technologies). HEK293 Flp-In T-Rex GFP-GABARAP cells were maintained 
in full medium + 200 µg/ml Hygromycin B + 5 µg/ml Blasticidin and induced for 24 
hr with 1 µg/ml tetracycline in full medium to express GFP-GABARAP after which 
cells were processed for immunofluorescence (Chapter 2.4.1). 
Cells were grown to 80-90% confluency and were passaged by washing 
once in versene before incubation in trypsin to detach cells. For maintenance, 
detached cells were split in a 1:10 dilution. Cells were maintained until a passage 
number of 20, after which they were discarded. Cells were frozen in a mixture of 
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90% FBS with 10% DMSO. For freezing, trypsinised cells from a confluent T150 
flask were centrifuged (1000 rpm, 3 minutes, room temperature) and resuspended 
in 4 mL of 90% FBS with 10% DMSO mixture. Aliquots of 1 mL were frozen in 
liquid nitrogen. When thawing, aliquots were resuspended in T75 flasks.  
To induce autophagy by starvation, cells were washed 3 times with Earle’s 
balanced salt solution (EBSS) and incubated in EBSS for two hours, unless 
otherwise stated. ‘Basal’ or ‘fed’ cells were maintained in growth medium as above. 
Where indicated, cells were treated with: 100 nM Bafilomycin A1 (Calbiochem), 100 
nM Wortmannin (Calbiochem), 10 µg/ml Brefeldin A (Sigma), 100 nM Torin1 
(Cayman Chemical), 50 µM Nocodazole (Sigma), 10 µM MG132 (Calbiochem), 100 
nM MitoTracker Red CMXRos (Thermo Fisher), 50 µM 5,6-Dichlorobenzimidazole 
1-β-D-ribofuranoside (DRB, Calbiochem) for 4 hours, or 20 ng/ml Leptomycin B 
(Sigma) for the specified time. To minimise detachment of HEK293A cells, 0.1 
mg/mL poly-D-lysine (Sigma) was used to coat the wells of multiwell plates or glass 
coverslips when cells were cultured in/on these. Poly-D-lysine coating was not 
required for other cell lines, or for HEK293A cells in dishes or flasks. 
 
2.1.2 Transfection 
All siRNA was used at a final concentration of 37.5 nM or at a combined 
concentration of 37.5 nM when multiple siRNAs were pooled together. However for 
knockdown of GABARAP for immunofluorescence (see Chapter 2.1.2.4) 
concentrations were different. 
Note that in transfection protocols ‘forward’ transfection refers to transfection 
the day after cells have been seeded, whereas ‘reverse’ transfection refers to a cell 
suspension that is added to pre-plated transfection complexes. 
 
2.1.2.1 siRNA and plasmid DNA transfection 
Lipofectamine 2000 (Life Technologies) was used for plasmid transfections 
of cells that were plated to be 80% confluent on the day of transfection. For 
transfection of plasmid DNA; for example for immunoprecipitation studies, 10 cm 
plates were seeded with 2 X 106 cells the day before Lipofectamine 2000 
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transfection. Cell numbers for smaller dish sizes were scaled according to the ratio 
of the surface area. The following was the reaction mixture for transfecting a 10 cm 
dish. Mixes for differently sized dishes were scaled according to surface area ratios. 
Mix ‘A’ was formed of 12 µL of Lipofectamine 2000 in 500 µL OptiMem. Mix ‘B’ is 
formed of 1 µg of plasmid DNA in 500 µL of Optimem. Mixes A and B were 
incubated separately at room temperature for 5 minutes before mixing and further 
incubating for 20 minutes at room temperature. Cells were incubated in the 
transfection mixture for at least 4 hours after aspirating the full medium they were 
grown in, adding 4 mL of OptiMem, and adding the 1 mL transfection mixture 
dropwise on top, (but not longer than 8 hours) before replacing the mix with fresh 
full medium. Cells were analysed 24 hours after plasmid DNA transfection. Where 
indicated pcDNA 3.1 (+) was used as an empty vector control. 
For siRNA knockdown studies, cells were transfected by a reverse 
transfection protocol using Lipofectamine 2000, usually in 24-well plates as follows. 
For one well in a 24-well plate: Mix ‘A’ was formed of 1.25 µL of Lipofectamine 
2000 in 50 µL OptiMem. Mix ‘B’ is formed of 0.93 µL of siRNA (20 µM stock) in 50 
µL of Optimem. Mixes A and B were incubated separately at room temperature for 
5 minutes before mixing and further incubating for 20 minutes at room temperature. 
The combined mix of 100 µL volume was added on to the poly-D-lysine coated well 
and 400 µL of a single-cell suspension (1.75 X 105 cells / mL in full medium or for 
HeLa cells, 3.5 X 105 cells / mL in full medium) was added on top and mixed. This 
mixture was incubated for 48 hr before changing the medium with fresh full medium 
and incubation for another 24 hr. Cells were analysed after 78 hr total knockdown. 
For siRNA transfections in other plates or dishes, the mixes and cell numbers were 
scaled according to surface area. 
 
2.1.2.2 Generation of HeLa WAC-FLAP stable cell line 
HeLa cell line stably expressing WAC-FLAP was established by transient 
transfection with a BAC (CTD-2309l17) containing the human WAC gene, obtained 
from Life Technologies. The WAC BAC was modified by homologous 
recombination to contain a C-terminal FLAP tag (Poser et al., 2008). Please refer to 
Chapter 4.2.2 for a more detailed explanation of the procedure. Transfection of 
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HeLa cells was carried out with Effectene (Qiagen) according to the method in 
(Poser et al., 2008). After transfection cells were selected with Geneticin (Life 
Technologies) at 800 µg/ml and surviving pools cloned by single-cell FACs sorting 
into 96-well plates for EGFP expression before being maintained in the presence of 
Geneticin (Life Technologies) at 400 µg/ml in full medium after colonies had grown.  
FACS sorting was performed by Andy Filby at the Francis Crick Institute. 
Geneticin stable pools of transfected HeLa cells were trypsinised and passed 
through a cell strainer cap into a 5 mL falcon tube to reduce clogging of the FACS 
sorter, into full medium containing 1% FBS only. Polystyrene tubes were used for 
sample intake but polypropylene tubes were used for collection to reduce static 
effects. Collection medium was full medium supplemented with penicillin and 
streptomycin. Please refer to Chapter 4.2.2 for more details. 
 
2.1.2.3 Rescue experiments 
Knockdown and rescue experiments for Immunofluorescence were 
performed by transfection with siRNA on day 1 as above. On day 2, the 
transfection medium was changed for fresh full medium and incubated for around 1 
hr before splitting the cells onto poly-D-lysine glass coverslips. The cells were left 
to adhere and on day 3 they were transfected with siRNA-resistant plasmid DNA. 
Rescue assay was carried out 24 hr after DNA transfection. 
For rescue of autophagy with GFP-WAC and analysis by immunoblot, 
siRNA reverse transfection with Lipofectamine 2000 was performed on day 1 and 
on day 3 plasmid siRNA-resistant plasmid DNA transfection was carried out with 
Lipofectamine 3000 (Life Technologies) according to the manufacturer’s 
instructions. 
 
2.1.2.4 GABARAP knockdown and RNAi for immunoprecipitation studies 
For RNAi of GABARAP for immunofluorescence, cells were transfected with 
siRNA reverse transfection on day 1 and with siRNA forward transfection on day 2 
of the procedure with two different siRNA duplexes with a combined concentration 
of 75 nM. For RNAi studies for immunoprecipitation. Cells were transfected in 10 
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cm dishes by siRNA reverse transfection on day 1 and by siRNA forward 
transfection on day 3 of the procedure, using 37.5 nM siRNA each time.  
 
2.1.2.5 siRNA duplexes 
siRNA was reconstituted in 1X siRNA buffer (Thermo Scientific) (60 mM KCl, 6 mM 
HEPES pH 7.5, 0.2 mM MgCl2). 
 
Table 2.1 siRNAs used in this thesis 
 
Target Gene siRNA Target sequence Supplier 
(RISC-free 
control) 
D-001220-01 
 
N/A 
 
Dharmacon 
 
ULK1 D-005049-04 
 
UGUAGGUGUUUAAGAAUUG 
 
Dharmacon 
WAC D-013325-02 
(for MEFs) 
UAAGCACACCUCAAACUAA Dharmacon 
WAC D-013325-03 GAGACAAACCCGUAUCACA Dharmacon 
WAC D-013325-04 CGAUCCACGUGUUCAUUAA Dharmacon 
GM130 D-017282-01 GGACAAUGCUGCUACUCUA Dharmacon 
GM130 D-017282-03 GAAUAUCAGCAGAGGAAUA Dharmacon 
RNF40 D-006913-01 GAGAUGCGCCACCUGAUUA Dharmacon 
RNF40 D-006913-02 GAUGCCAACUUUAAGCUAA Dharmacon 
RNF40 D-006913-03 GAUCAAGGCCAACCAGAUU Dharmacon 
RNF40 D-006913-04 CAACGAGUCUCUGCAAGUG Dharmacon 
RNF20 D-007027-01 CCAAUGAAAUCAAGUCUAA Dharmacon 
RNF20 D-007027-02 UAAGGAAACUCCAGAAUAU Dharmacon 
RNF20 D-007027-03 GCAAAUGUCCCAAGUGUAA Dharmacon 
RNF20 D-007027-04 AGAAGAAGCUACAUGAUUU Dharmacon 
GABARAP D-012368-02 GGUCAGUUCUACUUCUUGA Dharmacon 
GABARAP D-012368-03 GAAGCGAAUUCAUCUCCGA Dharmacon 
LC3B D-012846-01  Dharmacon 
GABARAPL1 D-014715-02  Dharmacon 
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Target Gene siRNA Target sequence Supplier 
GATE-16 D-006853-03 GUACUUGGUUCCAUCUGAU Dharmacon 
 
Unless otherwise specified, the siRNAs used for WAC, GM130 and GABARAP 
were -03, -01 and -02 respectively. 
2.2 Microarray and qRT-PCR 
2.2.1 Microarray 
Whole-genome gene expression analysis was performed by the Genome 
Centre at Barts and the London School of Medicine and Dentistry, Queen Mary 
University of London (London, UK) using the Illumina human HT-12 v4 beadchip. 
All gene expression data will be available through the GEO repository 
(http://www.ncbi.nlm.nih.gov/geo/) via accession number GSE66475. 
HEK293A cells were treated with RISC free, WAC, RNF40 or RNF20 siRNA 
pools (WAC-03 and 04; RNF40-01 and 02; RNF20-01, 02, 03 and 04) in triplicate 
and maintained in full medium, as described above. RNA was extracted using the 
RNeasy kit (Qiagen) and purity was assessed by NanoDrop spectrophotometer.  
The RNA was then sent on dry ice to the Genome centre (see above) where 
RNA integrity was confirmed by Agilent Bioanalyser. At this point I no longer 
processed the samples. RNA labelling was performed using the Ambion Total Prep 
Kit (Life Technologies). Briefly, total RNA is converted to double-stranded cDNA by 
reverse transcription followed by an in vitro transcription reaction to create biotin 
labelled cRNA. The cRNA is then hybridised to the bead array which consists of 
immobilised beads conjugated to 50-mer gene specific probes. The Bead chip is 
washed and blocked and streptavidin-Cy3 is added to bind to the biotin labelled 
cRNA and the chip is visualised and a fluorescence intensities quantified. 
The resultant data was analysed by Probir Chakravarty in the bioinformatics 
and statistics service (Francis Crick Institute). The following is a protocol provided 
by Probir. Gene expression data was analysed using Bioconductor 2.2 
(http://bioconductor.org) running on R2.7.1 (http://www.R-project.org). Normalised 
probe set expression measures were calculated using log2 transformation and 
quantile normalization using the Lumi package (Du et al., 2008). All groups 
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contained three independent samples except for RNF40, which had two 
independent samples after removal of one replicate for quality control. 
To determine significant differences of expression in the three groups: siWAC, 
siRNF20 and siRNF40 relative to RISC free, a moderated Student's t-test was 
computed on a gene-by-gene basis using the empirical Bayes statistics in the 
Limma package (Ritchie et al., 2015). The resultant p-values were adjusted for 
multiple testing using the False Discovery Rate (FDR) Benjamini and Hochberg 
method, where any probe sets that exhibited a FDR of less than 0.05 were called 
differentially expressed. No fold change thresholds were applied.  
Differential genes from three comparisons were intersected to identify common 
genes (Figure 3.8 and Table 7.3). The common genes (319) were further 
subdivided into two groups: those whose FC difference relative to RISC free were 
down regulated in all comparisons (183) and those whose FC difference relative to 
RISC free were up regulated in all comparisons (118). 18 genes were differentially 
regulated between knockdown of the 3 proteins and subtracted from our analysis. 
Differentially expressed genes (301) were analysed for enrichment of pathways, 
biological processes and transcription factor targets using gene sets from Metacore 
Pathway analysis tool (Thomson Reuters) using a hypergeometric distribution to 
determine enriched gene set using all genes on the Illumina array as the 
background. Pathways or processes that showed a FDR of less than 0.05 were 
called as enriched. 
2.2.2 qRT-PCR 
HEK293A cells were treated with the indicated siRNA and maintained in full 
medium. Total RNA was isolated using the RNeasy kit (Qiagen), the RNA was 
eluted in 30µL RNAase-free water and the RNA concentration was measured using 
a NanoDrop spectrophotometer (Thermo Scientific). All RNA was stored at -80ºC. 
cDNA synthesis was performed on 1 µg of RNA per sample with SuperScript II 
reverse transcriptase and Oligo dT (Life Technologies). qRT-PCR was performed 
using the Fast SYBR Green Master Mix (Applied Biosystems, 4385612) in a 20 µL 
reaction (2.5 µL cDNA, 10 µL Fast SYBR Green master mix and 2.4 µL of 2.5 µM 
forward and reverse primer mix, made to 20 µL with dH2O). PCR products were 
detected by the 7500 FAST Real-Time PCR System (Applied Biosystems). The 
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cycle threshold (CT) values corresponding to target mRNA were normalised to that 
of GAPDH mRNA. 
 
Table 2.2 qRT-PCR primers used in this thesis 
All primers were purchased from Sigma. 
Target name Forward primer (5' - 3') Reverse primer (5' - 3') 
BEX2 AATGTTGTTTTTGACCCAGTTTG CATCTTTCCATGCAATAGGTAAAAC 
C12ORF5 GGAAGAGTGCCCTGTGTTTA TCCGCTTCTTTCAGGATTAGTT 
CARD10 ACTACCCCGAACACTTCACG GTCATCAAGAATTGGGTCAGG 
DENND5B CCAAAAACCTCCTCGAAATG TCGTGACCAATCTGAACAGTG 
DUSP3 CTTCATTGACCAGGCTTTGG GGGGAGCGGCTATAACCTT 
FAM69A GGTTTTTGTTGGAAGCTGGAT CAATAACTCCAGTCTTGTACTTGTCAC 
FHL1 GAAGTGTGCTGGATGCAAGA AGCAGTAGTCGTGCCAGGAT 
GABARAP GCG AGA AGA TCC GAA AGA AA  GAT CAG AAG GCA CCA GGT ATT T  
GABARAPL1 TGG GCC AAC TGT ATG AGG A  CTA CCC CCA AGT CCA GGT G 
GAPDH GAC CAC TTT GTC AAG CTC ATT TC CTC TCT TCC TCT TGT GCT CTT G 
GATE-16 CCG TCG TTG TTG TTG TGC T CTC CAC GCA TCT GTG TTC C  
HLA-E CTGGGATCATGGTAGATGGAAC GGACACGGAAGTGTGGAAATA 
HSPA1A CCACCATTGAGGAGGTAGATTAG CAGGAAATTGAGAACTGACAAACA 
LC3B GAG GAT CTT TAG GCC TGA G  TTC TCA CAC AGC CCG TTT AC  
LITAF GGCATGAATCCTCCTTCGTATTA AGGACAACACATTTGGATAGGG 
MBTPS1 GCTACAAGCCACAGGCAAGT GCCACATGTAGGGACACTCA 
NFKB1 CTGGCAGCTCTTCTCAAAGC TCCAGGTCATAGAGAGGCTCA 
p53 TTGCACCTACCTCACAGAGTGCAT AGAAACTACCAACCCACCGACCAA 
RAPGEF5 CCAGTATGCAGAAGAGGATCTG CGAGGGATTTGGAGATGACTAAG 
RCAN3 GTGATCTGCCTACCTCACTTT TGGTCATCATAGATGGTGAAGAG 
RNF20 CAGTTGAAAGCACACTTGGATG GACTAACCTCATCTCGCTCAATAA 
RNF40 AAC AAC GGC AGG CTT GTG AAG ATG ATC GGA GAA GGG CTT CCA CAG TTT 
SAMD9 ATCACACATGGACCAGCTATT TTACTGGGCTTTCCCATCTTAG 
Sestrin-2 ACAAGTGTTGTGGCCTTCCTGAAC ATGGGTGAATGGCAAGTAGGAGGT 
SH3PXD2A AACCCCTCCAAGCACTACG TGCTGTACCTCCGGTAGATAGTC 
SLC30A7 CAAGATCTCGGGCTGGTTTAG TCCAGATGCCGTAGAGTAGTT 
SYK ATGTGGGAAGCATTCTCCTATG CATCCGCTCTCCTTTCTCTAAC 
TMEM237 TCCACCTTTACACACCTTCTTC CACCACGAGATTCACCACAA 
UFC1 CAGCGACTGAAGGAGGAATATC CACCGAGTTCCTTCCTTGTT 
VAMP2 CTGCTATGCAATAGTCCCTCTC GAGTGAGGAGGAAAGAGGAAAG 
VAMP3 TGTGGGCAATCGGGATTACTGTT GAACAGCAGTTTTGAGTTCCGC 
WAC CCTCAAACTAACACAGTCCCTATC TGACACTGGTCCTTGCTTAAC 
ZSWIM5 CACAGCCCAGACTCCTTATC TTATTCGCTGTAGGTGGCTATC 
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2.3 Biochemical methods 
2.3.1 Antibodies 
Table 2.3 Primary antibodies used in this thesis 
Antigen 
 
Species 
 
Antibody 
 
Supplier 
 
Dilution 
 
Notes 
 Actin 
 
Rabbit 
 
ab8227 
 
Abcam 
 
WB 1:1000 
 
 
Atg13 Rabbit STO281 CRUK WB 1:500 (Chan et al., 2009) 
Atg13 pSer318 Rabbit 600-401-C49 Rockland WB 1:500 Run gel in MOPS 
Atg9 
 
Rabbit 
 
STO218 
 
CRUK 
 
WB 1:1000* 
 
Heat samples to 65oC 
Atg9 
 
Hamster 
 
14F2 
 
 
IF 1:1000 
 
(Young et al., 2006) 
Heat samples to 65oC 
Beta COP Mouse M3A5, G2279 Sigma IF 1:500 
Saponin method 
overnight 
Beta Tubulin Rabbit ab6046 Abcam IF 1:1000 Methanol method 
Beta’ COP Rabbit  F. Wieland WB 1:1000  
Centrin3 Mouse ab54531 Abcam IF 1:500 Methanol method 
ERGIC-53 Mouse 
ALX-804-602-
C100 
Enzo Life 
Sciences 
IF 1:100 
Triton method 
Sapnonin method for 
only juxtanuclear 
FLAG 
 
Mouse 
 
M2 
 
Sigma 
 
WB 1:2000 
 
 
GABARAP 
 
 
Sheep Ab62114 Abcam IF 1:500 
Methanol method, 
Stained centrosomal 
GABARAP but not 
autophagosomal 
GABARAP Rabbit AP1821a Abgent 
WB 1:250 
IF 1:250 
Methanol method, 
Good spots after 
starvation 
Gamma-tubulin Mouse GTU-88, T6557 Sigma IF 1:5000 Methanol method 
GFP Mouse 11814460001 Roche WB 1:1000 
Only antibody that 
detects WAC-FLAP in 
lysate as low levels 
GFP 
 
Mouse 
 
3E1 
CRUK 
 
WB 1:4000- 
1:20,000 
IF 1:250-1:1000 
Saponin method for 
WAC-FLAP on Golgi 
GFP Rabbit sc-8334 Santa Cruz WB 1:100  
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Antigen 
 
Species 
 
Antibody 
 
Supplier 
 
Dilution 
 
Notes 
 
GM130 Mouse 610822 BD 
IF 1:250 
WB 1:200 
Methanol or saponin 
method 
GM130 Rabbit 
 
ab52649 Abcam WB 1:1000 Monoclonal 
 
H2B Mouse ab52484 Abcam WB 1µg/ml final  
HA 
 
Mouse 
 
HA.11 
 
Covance 
 
WB 1:1000 
 
 
HA Rat 
3F10, 
11867423001 
Roche IF 1:1000 Methanol method 
HA Rabbit PRB-101P Covance WB 1:1000  
Lamin B Mouse LN43 CRUK WB 1:500  
LC3B 
 
Rabbit 
 
ab48394 
 
Abcam 
 
IF 1:2000 
WB 1:1000 
 
Methanol method 
 
Myc 
 
Mouse 
 
9E10 
 
CRUK 
 
WB 1:500 
IF: 1:200 
 
Methanol method 
p230/ 
GOLGA4 
Mouse 611280 BD IF 1:500 Saponin method 
p53 Mouse SC-126 Santa Cruz WB 1:1000  
p62 
 
Mouse 
 
H00008878-
M01 
Abnova 
 
WB 1:250 
 
Incubate overnight 
Detects murine p62 
 p62 
 
Mouse 
 
610832 BD 
 
WB 1:500 
 
Incubate overnight 
 p62 C-terminus 
 
Guinea Pig 
 
GP62-C 
 
Progen 
 
IF 1:300 
 
Methanol method 
RNF40 Rabbit A300-718A Bethyl Labs WB 1:500  
S6 Rabbit 2217 Cell signalling WB 1:1000 Monoclonal 
S6 pSer240/244 Rabbit 2215 Cell Signalling WB 1:4000 
Dilute according to 
datasheet instructions 
SOD1 Rabbit Ab16831 Abcam WB 1:2000 Overnight incubation 
TGN46 Sheep AHP500G Serotec IF 1:500 
Methanol or saponin 
methods 
Ubiquitin 
 
Mouse 
 
FK2 D058-3 
 
MBL 
 
IF 1:500 
 
Methanol method 
Ubiquityl-Histone 
H2B 
Mouse Clone 56 Millipore WB 1:4000  
ULK1 Rabbit sc-33182 Santa Cruz WB 1:250 Incubate overnight 
ULK1 pSer757 Rabbit 6888 Cell signalling WB 1:1000 
Dilute according to 
datasheet instructions, 
TBS not PBS 
VAMP3 Rabbit V31 & V32 Andrew Peden WB 1:200  
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Antigen 
 
Species 
 
Antibody 
 
Supplier 
 
Dilution 
 
Notes 
 
WAC Rabbit  Hisao Kondo 
WB 1:1000* 
IF 1:500 
(Totsukawa et al., 
2011) 
Saponin method, 
detects nuclear and 
Golgi WAC 
WAC Rabbit 
STO296 
 
CRUK 
Tooze Lab 
WB 1:1000* 
IF 1:3000 
Affinity purified at 1.8 
mg/ml, triton method 
detects nuclear WAC 
WIPI2 Rabbit STO280 CRUK 
IF 1:250* 
WB 1:250 
(Polson et al., 2010) 
Use whole serum for 
western blot 
 WIPI2 
 
Mouse 
 
2A2 
 
Dundee Cell 
Products 
 
IF 1:4000 
WB 1:1000 
 
 
 
*, affinity purified antibody 
 
Table 2.4 Secondary antibodies used in this thesis 
Antigen 
 
Conjugated to 
 
Supplier 
 
Dilution 
 Rabbit IgG 
TrueBlot 
HRP Rockland WB 1:2000 
Rabbit IgG 
 
HRP 
 
GE Healthcare 
 
WB 1:4000 
 Mouse IgG 
 
HRP 
 
GE Healthcare 
 
WB 1:4000 
 Hamster IgG 
 
HRP 
 
GE Healthcare 
 
WB 1:4000 
 Rabbit IgG 
 
Alexa Fluor 488 
 
Life Technologies 
 
IF 1:1000 
 Rabbit IgG 
 
Alexa Fluor 555 
 
Life Technologies 
 
IF 1:1000 
 Rabbit IgG 
 
Alexa Fluor 647 
 
Life Technologies 
 
IF 1:1000 
 Mouse IgG 
 
Alexa Fluor 350 
 
Life Technologies 
 
IF 1:1000 
 Mouse IgG 
 
Alexa Fluor 488 
 
Life Technologies 
 
IF 1:1000 
 Mouse IgG 
 
Alexa Fluor 555 
 
Life Technologies 
 
IF 1:1000 
 Mouse IgG 
 
Alexa Fluor 647 
 
Life Technologies 
 
IF 1:1000 
 Guinea pig IgG 
 
Alexa Fluor 555 
 
Life Technologies 
 
IF 1:1000 
 Guinea pig IgG 
 
FITC 
 
Santa Cruz 
 
IF 1:1000 
 Rat IgG 
 
Alexa Fluor 488 
 
Life Technologies 
 
IF 1:1000 
 Rat IgG 
 
Alexa Fluor 633 
 
Life Technologies 
 
IF 1:1000 
 Sheep IgG 
 
Alexa Fluor 488 
 
Life Technologies 
 
IF 1:1000 
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Antigen 
 
Conjugated to 
 
Supplier 
 
Dilution 
 Sheep IgG 
 
Alexa Fluor 647 
 
Life Technologies 
 
IF 1:1000 
 
Hamster Cy3 
Jackson 
ImmunoResearch 
IF 1:1000 
 
2.3.2 Cell lysis for western blot 
For cell lysis before immunoprecipitation see Chapter 2.3.6. For analysis of 
knockdown, expression, or autophagic readouts such as LC3 lipidation, cells were 
washed 3 x PBSA, liquid aspirated and then cells lysed in ice cold TNTE buffer (20 
mM Tris, pH 7.4, 150 mM NaCl, 0.5% w/v Triton X-100, 5 mM EDTA) containing 1 
X EDTA-free Complete Protease Inhibitor cocktail (Roche) and 1x PhosSTOP 
(Roche) on ice. Cells that were incubated in EBSS prior to lysis were not washed in 
PBSA before lysis, to reduce detachment (HEK293A cells only). 80 µL of lysis 
buffer was used for a single well of a 24-well plate, and volumes were adjusted for 
other sized plates or dishes based on the ratio of their surface areas. Cells were 
washed multiple times with the lysis buffer by pipetting up and down whilst scraping 
with the pipette tip. The lysis buffer from each well was then transferred to a clean 
1.5 mL Eppendorf tube and centrifuged at maximum speed (13,200 rpm) for 15 
minutes to pellet the nuclei. The clarified lysate was transferred to clean 1.5 mL 
Eppendorf tubes and 5X SDS sample buffer (15% SDS (w/v), 213.5 mM Tris-HCl 
pH 6.8, 50% glycerol (w/v), 16% β-mercaptoethanol, bromophenol blue) was added 
to a final concentration of 1X. Samples were heated at 100 ºC for 10 minutes (or 
65oC for detection of Atg9) before loading onto SDS-PAGE gels for electrophoresis 
and protein transfer (see below).  
For investigating histone modifications, 5X SDS sample buffer was added to 
1X to the insoluble pellet, which was then subjected to sonication and benzonase 
nuclease treatment (100U/ml added to sample in SDS sample buffer for 5 minutes 
at room temperature) to solubilise the sample, followed by boiling as above. 
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2.3.3 SDS-PAGE and protein transfer 
SDS-PAGE was carried out with precast NuPAGE 4-12% Bis-Tris mini or 
midi protein gels from Life Technologies. SDS-PAGE Gels were electrophoresed at 
200 V in MOPS (Life technologies, 20 X stock: 50 mM MOPS, 50 mM Tris Base, 
0.1% SDS, 1 mM EDTA, pH 7.7) or MES (Life technologies, 20 X stock: 50 mM 
MES, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.3) until the blue dye front 
reached the bottom of the gel (the time taken was approximately 50 minutes). 
MOPs was generally used for the running buffer, however for the analysis of LC3 
lipidation, or for analysis of Atg13 phosphorylation at Ser318, samples were run in 
MES buffer. This is to improve the separation of the LC3-I and –II forms and to 
improve the separation of p-Atg13 Ser318 from a non-specific band. 
Proteins were transferred to PDVF (polyvinylidene fluoride) membrane 
(Millipore) using wet transfer (GENIE® electrophoretic transfer, Idea Scientific 
Company). PDVF membrane was soaked in methanol before washing in transfer 
buffer (0.2% methanol, 150 mM glycine, 20 mM tris base). Thick blot paper (Sigma), 
transfer sponges and SDS-PAGE gels were also soaked in transfer buffer, prior to 
assembly of the transfer unit. Proteins were transferred at 27 V for 1 hour 30 min. 
Protein transfer to the PVDF membrane was visualised and assessed using 
Ponceau S stain (Sigma). The PVDF membrane was incubated in Ponceau S stain 
for ≥ 10 minutes with rocking at room temperature. Surplus dye was removed by 
repeated washes with water. The Ponceau S stained membrane was scanned and 
either dried by washes into Methanol and air drying for processing later, or 
processed for continuation of the Western blot protocol as below. 
 
2.3.4 Western blotting and detection 
If dried, PDVF membranes were soaked in methanol followed by washing in 
PBSA. The following incubation times are all at room temperature with rocking 
(unless otherwise declared). PVDF membranes were incubated in 5% powdered 
milk (w/v) (Marvel) in PBSA for 30 min, for blocking. Following blocking, 
membranes were incubated for 1-2 hours in primary antibodies diluted (as 
indicated in Table 2.3) in 5% milk (w/v) in PBSA for polyclonal antibodies or diluted 
in PBSA for monoclonal antibodies, unless otherwise specified in Table 2.3. Where 
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noted that an antibody was used overnight, this incubation was at 4 ºC. For western 
blotting of co-immunoprecipitated GM130 after immunoprecipitating WAC for 
example, GM130 primary antibody was diluted with SignalBoost Immunoreaction 
Enhancer Kit (Merck Millipore, 407207) and blots were developed with Luminata 
Crescendo Western HRP substrate (Merck Millipore). This technique was used to 
amplify weak signals in general. After incubation in primary antibody, the 
membrane was washed 5 times quickly in 0.05% Tween 20 in PBSA (PBST), 
followed by 3 x 5 minute washes in PBST. Membranes were then incubated in 
HRP-conjugated secondary antibodies (see Table 2.4) for 1-2 hours in 5% milk 
(w/v) in PBSA before washing in PBST as before, but with an additional 5 minute 
wash. Following washing, membranes were transferred to a clean glass plate and 
covered in ECL (Amersham, GE healthcare) for 1 min before exposing to film 
(Amersham Hyperfilm ECL, GE healthcare). For difficult to detect signals, 
membranes were covered with Luminata Crescendo Western HRP substrate 
(Merck Millipore) for between 2-5 minutes. Exposure times varied between western 
blots.  
For re-probing the same membrane, membranes were incubated in RestoreTM 
Plus Western Blot Stripping Buffer (Thermo Scientific) for 15 minutes. Membranes 
were subsequently washed in PBSA 7 times quickly and three times for 5 minutes 
before blocking in 5% milk (w/v) in PBSA for 30 minutes and then continuing with 
primary and secondary antibody incubations and washes as above. 
To reduce cross reactivity of secondary antibodies with denatured 
immunoglobulin chains in immunoprecipitation experiments, TrueBlot® from 
Rockland was used as a secondary antibody at 1:2000, to detect native 
conformations of immunoglobulins only. This was used when proteins of interest 
ran close to the immunoglobulin heavy chain. TrueBlot antibodies cross-react with 
protein G and A, and to counter this, when proteins ran close to protein G the 
TrueBlot secondary was diluted in EasyBlocker (GeneTex) following the 
manufacturer’s instructions. 
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2.3.5 Crude subcellular fractionation 
9 x 106 HEK293A cells were plated in a 15cm dish per sample the day prior 
to the extraction for assessing endogenous proteins. For overexpressed proteins 
1.5 x 106 cells were plated in a 10cm dish per sample for DNA transfection the next 
day and extraction 24 hours following transfection (see Chapter 2.1.2). On the day 
of extraction, for 10cm dishes (scaled accordingly for surface area in different sized 
dishes) cells were washed 1 x with 5 mL HB buffer (20 mM HEPES-KOH pH 7.5, 
10 mM KCl, 2.5 mM MgOAc, 1mM EDTA) and then scraped into 10 mL HB buffer. 
Cell suspensions were pelleted by centrifugation at 1,000 rpm for 5 min at 4oC in 15 
mL falcon tubes. The supernatant was discarded and the cell pellet was 
resuspended in 500 µL HB2 buffer (20 mM HEPES-KOH pH 7.5, 10 mM KCl, 2.5 
mM MgOAc, 1mM EDTA, 250 mM sucrose, 1mM DTT, 1 X PhosSTOP (Roche) 
and 1 X complete protease inhibitors (Roche)). Cell suspension was left for 20 
minutes on ice with occasional gentle mixing and then cells were homogenised by 
passing through a 27 gauge ½ inch needle (Becton, Dickinson and Company) 12-
14 times using a 1 mL syringe. Cell breakage was monitored with a light 
microscope and Trypan Blue staining. The nuclear pellet and intact whole cells 
were pelleted by centrifugation at 5,000 rpm for 5 minutes at 4oC in a microfuge. 
The post-nuclear supernatant (PNS1) was taken and pellet kept aside. The 
centrifugation was repeated with PNS1 to yield PNS2. The pellet after this spin was 
discarded. A sample of PNS2 was set aside for analysis and the remainder was 
taken for a second spin in a 1.5 mL Beckman Coulter ultracentrifuge tube at 
112,500 x g for 1 hour at 4oC in a benchtop ultracentrifuge. The resultant 
supernatant produces the true cytosol and the crude membrane fraction is 
contained in the pellet fraction. 5 X SDS sample buffer (15% SDS (w/v), 213.5 mM 
Tris-HCl pH 6.8, 50% glycerol (w/v), 16% β-mercaptoethanol, bromophenol blue) 
was added to the membrane pellet at a final of 2 X in 50 µL volume, to produce a 
10 X concentrated membrane sample relative to the cytosol and nuclear fractions. 
5 X SDS sample buffer was added to 1 X to the cytosolic fraction. To solubilise the 
nuclear pellet, 500 µL of 1 X SDS sample buffer was added to the pellet and the 
pellet was passed through a needle and syringe followed by sonication and 
benzonase nuclease treatment to digest the DNA (100U/ml benzonase added to 
sample in SDS sample buffer for 5 minutes at room temperature). The samples 
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were heated to 65oC for 10 mins to denature proteins and processed by Western 
blotting as above. 
 
2.3.6 Immunoprecipitation 
For immunoprecipitation of endogenous proteins, 4 x 106 cells were seeded 
in 10 cm dishes for immunoprecipitation the next day and for immunoprecipitation 
of overexpressed proteins, cells were transfected as described in Chapter 2.1.2.1 
prior to immunoprecipitation the next day. For extraction, cells were washed twice 
in PBSA (unless cells were staved in EBSS) and then lysed in 1mL ice cold TNTE 
buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 0.5% w/v Triton X-100, 5 mM EDTA) 
containing 1 X EDTA-free Complete Protease Inhibitor cocktail (Roche) and 1x 
PhosSTOP (Roche) on ice. Once lysed, cells were centrifuged at 13,200 rpm for 10 
minutes at 4ºC to pellet insoluble material. 
For each immunoprecipitation, 60 µL of a 50% slurry of protein G sepharose 
beads (Sigma) was washed four times in 1 mL of PBSA in a 1.5 mL Eppendorf tube 
with pelleting by centrifugation, aspirated and resuspended in PBSA to restore a 
50% slurry. The clarified lysate was incubated with 30 µL of the washed beads with 
rotation at 4oC for 1 hour to pre-clear the lysate. After pre-clear 40 µL of pre-cleared 
lysate was taken for the ‘input’ lysate sample. The remaining 30 µL of beads were 
subsequently resuspended in 700 µL of PBSA with 0.1% Triton X-100 and 
incubated with 5 µg of the relevant antibody for 45 minutes with rotation at 4oC, 
followed by washing twice in 1 mL of PBS before the pre-cleared clarified cell 
lysate was added. Immunoprecipitation mixes were rotated for 1 hr 30 min at 4 ºC 
and were subsequently washed three times in 1 mL of TNTE buffer without 
PhosSTOP (Roche). After removal of the final wash, beads were resuspended and 
boiled in 30 µL of 2 X SDS sample buffer before analysis by western blot. 
For GFP-Trap (ChromoTek) immunoprecipitation, 5 µL of GFP-Trap beads 
were washed 2 x PBSA with 0.1% Triton X-100. Cells were lysed as for protein G 
immunoprecipitations above. Cleared lysates were pre-cleared with rotation at 4oC 
for 1 hour with 5 µL blocked agarose beads (ChromoTek). Blocked agarose beads 
were washed as per GFP-Trap beads prior to the addition of clarified lysate for pre-
clear. After pre-clear 40 µL of pre-cleared lysate was taken for the ‘input’ lysate 
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sample. The remaining lysate was added to the 5 µL of GFP-Trap beads, which 
were used for each immunoprecipitation. GFP-tagged proteins were 
immunoprecipitated 1 hr 30 min by rotating at 4 ºC.  
For the immunoprecipitation of FLAG-tagged proteins, 20 µL agarose slurry 
of FLAG M2 Affinity Gel (Sigma) was used for each immunoprecipitation. The slurry 
was washed the same way as the GFP-Trap beads before adding the FLAG-
tagged clarified cell lysates (with no pre-clear) and rotating at 4 ºC for one hour 30 
minutes. GFP-Trap and FLAG M2 immunoprecipitations were all washed three 
times in TNTE lysis buffer without PhosSTOP (Roche) before adding 30 µL of 2 X 
SDS buffer and boiling at 100ºC for 10 minutes. 
 
2.3.7 Immunoprecipitation from mixed lysates 
This method refers to Figure 4.11b. I found that the expression levels of 
tagged proteins could be very variable, after co-transfection of multiple plasmids. 
Therefore, in experiments involving co-immunoprecipitation of overexpressed 
proteins, proteins were expressed in separate 10 cm dishes before mixing cell 
lysates to try and even out protein levels. Briefly, cells were lysed as detailed for 
immunoprecipitations (Chapter 2.3.6) and clarified lysate was obtained. HA-GM130 
pieces were expressed in separate dishes to GFP-WAC full length or GFP-WAC 
ΔCC Figure 4.11b. Each dish was lysed in 500 µL TNTE buffer. After clearing the 
lysates, ~500 µL of lysate containing GFP-WAC was mixed with ~500 µL of lysate 
containing HA-GM130 pieces. The clarified lysates were then used for pre-clearing 
and 40 µL of ‘input’ sample was taken after pre-clear. Pre-cleared cell lysates were 
then used for immunoprecipitation.  
 
2.3.8 Normalising variable levels of overexpressed proteins for 
immunoprecipitation 
Some constructs expressed at variable levels to others, making 
experimental interpretation difficult. For example, EGFP expresses much more 
readily then EGFP-WAC, even though they are both from the same base vector 
pEGFP C2. In these instances one of two methods was used. This was done on an 
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empirical basis after a working knowledge of the relative expression levels of 
different constructs was gained. During the transfection procedure, the amount of 
plasmid transfected would be reduced or increased relative to the others. However 
all samples would be transfected with the same total amount of DNA, with the 
remaining portion made up of empty vector DNA (pcDNA 3.1 (+)). In other cases 
the DNA ratios were not altered. Instead, after immunoprecipitation a small sample 
of the immunoprecipitation would be assessed by SDS-PAGE to judge the relative 
levels of the immunoprecipitated overexpressed proteins. Then a second final gel 
would be ran with different amounts of each sample to normalise for the amount of 
immunoprecipitated protein. The inputs were not altered in this procedure and a 
background binding control is always included, enabling interpretation of the 
experiment. 
 
2.3.9 Mass spectrometry to identify novel WAC interactors 
HEK293A or HeLa WAC-FLAP cells, maintained in full medium, were washed 
3 times in PBSA and lysed in TNTE buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 
5 mM EDTA, 0.5 % Triton X-100, 1x Complete protease inhibitor (Roche), 1x 
PhosSTOP (Roche)) and the lysate clarified by centrifugation (16,100 x g, 15 min). 
Lysates from HeLa WAC-FLAP cells were incubated with GFP-TRAP® beads at 
4oC for 2 hr. Lysates from HEK293A cells were incubated with Rabbit anti-WAC (5 
µg) bound to protein G sepharose (Sigma) at 4oC for 2 hr. Pelleted beads were 
washed 3 times with TNTE buffer and eluted with 2x SDS sample buffer at 100oC 
for 10 min. Care was taken to use fresh tips, tubes and sample buffer and to 
regularly change gloves and wear a clean lab coat, to prevent contamination of the 
immunoprecipitation samples. 
Eluted proteins were separated by SDS-PAGE. SDS-PAGE was performed 
using a clean gel tank (under a laminar-flow hood) and sterile MOPS running buffer 
made up in Milli-Q deionised water. The SDS-PAGE gel was run as usual, until the 
dye front exited the gel, and the gel was stained using GelCode Blue Stain 
Reagent (Thermo Scientific), a colloidal Coomassie based dye. 8 bands covering 
the entire lane were excised for each sample lane. Each of the 8 bands was cut 
into ~1mm3 pieces and placed into a 96-well plate with 100 µL HPLC-grade water, 
before being sent to the proteomics facility at the Francis Crick Institute. 
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The following is a protocol provided by the Proteomics facility at the Francis 
Crick Institute, for processing samples by mass spectrometry. This work was 
performed by Bram Snijders and David Frith. In-gel trypsin digestion was 
performed using a Perkin Elmer Janus liquid handling system. Lyophilized peptide 
samples were dissolved in 15 µL of 0.1 % Trifluoroacetic acid (TFA) and subjected 
to LC-MS analysis using a LTQ-Orbitrap instrument for data acquisition. Raw 
spectra were processed using the MaxQuant/Andromeda bioinformatics suite (Cox 
and Mann, 2008) and further analyzed in Perseus software. Data was searched 
against a UniProt fasta database containing human sequences and intensity based 
absolute quantification (iBAQ) (Schwanhausser et al., 2011) was used for label free 
quantification. WAC, WAC-FLAP and control IPs (beads and lysate) were analyzed 
to screen for novel WAC interactors and filtered as follows. Only proteins that 
received iBAQ values in both experiments and not in the control IPs were 
considered candidates. The original dataset contained 1536 protein identifications 
and using the filter criteria the list was reduced to 20 candidates that were enriched 
in the WAC & WAC-FLAP pull-downs vs control conditions. 
 
2.3.10 Recombinant protein expression, purification and in vitro binding 
Human GST-WAC fusion proteins were cloned into pGEX-4T-2 and 
expressed in E. coli BL21-CodonPlus(DE3)-RIL (Agilent) cells in LB medium. 
Human GST-GABARAP pGEX-5X-1 was a gift from Zvulun Elazar (Weizmann 
Institute of Science, Israel). Expression was induced by addition of 1 mM IPTG at 
OD600 = 0.6 and cells were incubated at 37°C for 4 hr. For analytical purposes, cells 
were pelleted and lysed directly in 5X SDS sample buffer (15% SDS (w/v), 213.5 
mM Tris-HCl pH 6.8, 50% glycerol (w/v), 16% β-mercaptoethanol, bromophenol 
blue) diluted to 1X, by sonication followed by boiling at 100oC for 10 minutes. 
Alternatively, harvested cells were lysed using sonication on ice in a lysis buffer 
(PBSA + 1 % Triton X-100, supplemented with 1 x Complete protease inhibitor 
(Roche)) and the clarified supernatant after centrifugation was subsequently 
applied to Glutathione Sepharose 4B beads (GE Healthcare). The pellet after 
sonication was sometimes kept to analyse protein solubility. The beads were 
incubated with the lysate for 1 hour at 4oC with rotation. After 5 washes with (PBSA 
Chapter 2 Materials and Methods 
 
75 
 
+ 1 % Triton X-100 + 500 mM NaCl supplemented with 1 x Complete protease 
inhibitor (Roche)), fusion protein-bound beads were used directly in GST pulldown 
assays or GST proteins were eluted and concentrations measured as described 
below.  
 Purified untagged human GABARAP was a gift from Stephane Mouilleron, 
Francis Crick Institute, London, UK. GST-GABARAP purification was performed by 
Harold Jefferies, Tooze Lab, Francis Crick Institute. 
Strep-Tag II-GM130 (Rat) was cloned into pcDNA 3.1(+) and co-expressed 
in HEK293A cells with the Ebola virus protein HA-VP35 to boost protein expression 
(Gantke et al., 2013). Cells were lysed in TNTE buffer (20 mM Tris-HCl pH 7.4, 150 
mM NaCl, 5 mM EDTA, 0.5 % Triton X-100, 1x Complete protease inhibitor 
(Roche), 1x PhosSTOP (Roche)). After clarification of lysates, lysates were 
incubated with magnetic Strep-Tactin beads (Qiagen) for 1 hr before 5x washes in 
stringent conditions (20 mM Tris-HCl pH 7.4, 1 M NaCl, 5 mM EDTA, 1 % Triton X-
100, 1x Complete protease inhibitor (Roche), 1x PhosSTOP (Roche)). Beads were 
incubated with elution buffer (TNTE + 10mM Biotin) for 15 mins on ice to elute 
Strep-Tag II-GM130. Purity of eluted protein was assessed by SDS-PAGE and 
colloidal coomassie staining. The yield of purified Strep-Tag II-GM130 was low and 
not directly measured, instead amounts were added by volume rather than µg for 
binding experiments.  
 For in vitro binding, soluble Strep-Tag II-GM130 was incubated with 
immobilized GST (20 µg), GST-GABARAP (20 µg), GST-WAC or GST-WAC ΔCC 
on glutathione beads for 2 hr at 4oC in TNTE buffer (GST-WAC) or 1.5 hr at 4oC in 
TNTE buffer supplemented with 10% (v/v) glycerol and 0.1% (w/v) BSA (GST and 
GST-GABARAP). Beads were then washed 3 x with TNTE before SDS-PAGE and 
western blotting.  
 
2.3.11 Measuring GST fusion protein concentration 
To measure the protein amounts (for GST and GST-GABARAP, performed 
by Harold Jefferies), GST-proteins were eluted off glutathione beads using elution 
buffer (10 mM reduced glutathione, 50 mM Tris-HCl pH 8, 0.1% Triton X-100, 150 
mM NaCl) at 4oC, by gravity flow of beads packed in a column. The eluate was 
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then dialysed overnight into PBSA using Slide-A-LyzerTM dialysis cassettes 
(Thermo Fisher). The dialysed eluted GST protein was measured using Bio-Rad 
protein assay dye solution (Bio-Rad). Serial dilutions of an IgG standard (Bio-rad) 
in same buffer as sample were made up to 800 µL with dH2O and added to 200 µL 
of dye solution for the production of a standard curve. The protein content of 
samples was determined by making up small volume of the sample to 800 µL with 
dH2O, as for the standard IgG, and adding 200 µL of dye solution. Both the protein 
sample mixes and the standard mixes were vortexed and incubated at room 
temperature for 15-60 minutes before measuring the absorbance at 595 nm using a 
spectrometer. 
 
2.4 Imaging methods 
2.4.1 Immunofluorescence labeling and confocal and epifluorescence 
microscopy 
8 X 104 cells were plated onto glass coverslips (The Francis Crick Institute) 
in 12-well plates (these were coated in poly-D-lysine for HEK293A cells) for 
immunofluorescence (IF), the day before fixation. If cells were plated onto 
coverslips for DNA transfection the next day, 1 X 105 cells were used because of 
Lipofectamine 2000 toxicity. All subsequent steps and solutions are at room 
temperature, unless otherwise stated. Cells were fixed in 3% paraformaldehyde 
(Agar Scientific) in PBS supplemented with 0.01 mM MgCl2 and 0.01 mM CaCl2 for 
20 minutes. Typically, cells were then washed twice in PBSA before 
permeabilisation with either 0.1 % saponin in PBS for 20 min (WAC & βCOP), 
0.2 % Triton X-100 in PBS for 3 min (ERGIC-53) or room temperature methanol for 
5 min (WIPI2 & GABARAP & other antibodies, see Table 2.3). Coverslips were 
then washed twice in PBSA and blocked for 20 minutes in 5 % BSA fraction V in 
PBS (Roche) after methanol permeabilisation, with 0.2 % gelatin in PBS after Triton 
X-100 permeabilisation or with 0.1 % saponin + 1 % BSA + 0.2 % gelatin in PBS for 
20 min after saponin permeabilisation. Coverslips were incubated with primary 
antibody diluted as indicated in Table 2.3, in 1 % BSA in PBS or 0.2 % gelatin in 
PBS for 1 hr at room temperature. For WAC and βCOP staining, coverslips were 
incubated with primary antibody + 0.1 % saponin, 1 % BSA and 0.2 % gelatin in 
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PBS overnight at 4oC. Coverslips were inverted onto 100 µL drops of primary 
antibody mix and incubated in a humidified chamber for 1 hour. Coverslips were 
washed once in the same solution as the primary antibody was diluted in and 
incubated with secondary antibody diluted (see Table 2.4) in the same buffer as 
primary for between 30 minutes to 1 hour. If used, Hoechst (Sigma) was added to 
the diluted secondary antibody solution at 5 µg/ml final concentration. Finally, 
coverslips were washed twice with PBSA and once with water. Coverslips were 
then mounted onto glass microscope slides (Thermo Scientific) with 10 µL of 
Mowiol 4-88 (CalBiochem). LC3 and WIPI2 puncta formation and centrosomal 
GABARAP intensity was quantified by Imaris image analysis software (Chapter 
2.6.1).  
Confocal images were taken with a Zeiss LSM510 laser-scanning 
microscope with a 63X, 1.4 NA, oil-immersion objective (Carl Zeiss MicroImaging, 
Inc). Epifluorescence images were taken on a Nikon epifluorescence microscope 
(Nikon Eclipse E1000), using either a 60X or 100X oil-immersion objective both 1.4 
NA. Separate fluorescence channels on the epifluorescence microscope are 
displayed as grayscale images. To obtain colour images, the separate channels 
were false-coloured in Adobe Photoshop and superimposed on each other to 
create a merge channel. Confocal images were taken with a slice thickness of 1 µm 
(normally for spot counting) or 2 µm (Atg9 staining). Laser settings were kept 
constant for imaging each condition of an experiment for comparison (e.g. spot 
counting, centrosomal signal intensity). Images were processed using Zeiss LSM 
510 software V4.2 and to obtain scale bars and to perform line scans. 
 
2.4.2 Live cell imaging and photoconversion 
Live cell imaging was performed on HEK293A cells transiently expressing 
EosFP-GABARAP. Alternatively, cells were treated with WAC siRNA for 48 hr prior 
to transfection with EosFP-GABARAP and imaging 24 hr later. Cells were plated 
onto poly-D-lysine coated glass bottom gridded 35 mm MatTek dishes. 1.7 x 105 
cells were plated the day prior to an imaging experiment. Cells were washed 3 
times into EBSS and maintained at 37oC with 10% CO2 during imaging with a 
Nikon Eclipse Ti microscope swept field confocal system. The imaging chamber 
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was brought to temperature overnight before each experiment. Photoconversion 
was performed with pulses of 405 nm light. Images were processed, and data 
analyzed, using the Fiji distribution of ImageJ. Where indicated, cells were 
pretreated with 50 µM Nocodazole (Sigma) in full medium for 2 hr before incubation 
with EBSS + 50 µM Nocodazole followed by imaging. During each experiment day 
the photoactivation laser would be tested on a few cells expressing EosFP-
GABARAP as I found the same laser setting couldn’t be used between sessions. 
This was to ensure I was able to photoconvert only a small area of choice, but also 
to have enough laser power to get a strong red signal after photoconversion. When 
I found a cell of choice to film (usually exhibiting an enlarged ring-like GABARAP 
structure), the position on the glass bottom grid was noted, the medium was 
changed into EBSS with washing 3 times with EBSS. This required me to remove 
the dish. The cell was located again and image acquisition was commenced. After 
a few seconds to minutes, photoactivation was performed. Usually 5-12 minutes 
had passed from the beginning of starvation to the moment of photoactivation. 
After time-lapse microscopy (usually 25 minutes filming), cells were 
immediately fixed in 3% paraformaldehyde and processed for confocal microscopy 
as detailed in Chapter 2.4.1. Photoconverted cells were located using gridded 
MatTek dishes. During 4-colour imaging (Figure 5.18c), 405 nm illumination was 
carried out only after acquisition of the other fluorophore signals, in order to prevent 
artefactual photoconversion. Note: caution must be taken as even fixed samples 
can be photoconverted (data not shown). 
 
2.5 Molecular biology methods 
2.5.1 PCR 
Polymerase chain reaction (PCR) was typically performed using the KOD hot start 
DNA polymerase kit (Novagen). 
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PCR mix: 
10X Buffer for KOD Hot Start DNA Polymerase - 5 µL  
10X PCRx enhancer solution (Life Technologies, not included in kit) - 5 µL  
25 mM MgSO4  - 3 µL  
dNTPs (2 mM each) - 5 µL  
Forward primer (10 µM from Sigma) - 1.5 µL  
Reverse primer (10 µM from Sigma) - 1.5 µL  
Template plasmid - 10 ng  
KOD Hot Start Polymerase 1 µL  
dH2O to 50 µL 
 
 
PCR cycle: 
Segment 
 
Cycles 
 
Temperature (ºC) 
 
Time 
 1 
 
1 
 
95 
 
2 min 
 2 
 
30 
 
95 
 
20 sec 
 55 
 
10 sec 
 70 
 
25 s/kb 
 3 
 
1 
 
4 
 
∞ 
  
A small amount of the complete PCR reaction was assayed by DNA 
agarose gel electrophoresis (Chapter 2.5.2). PCR products were purified using the 
QIAquick PCR purification Kit (Qiagen) (spin column purification) according to the 
manufacturer’s instructions, if a single PCR product was yielded. PCR products 
were purified by DNA agarose gel electrophoresis (Chapter 2.3.2) using the 
QIAquick Gel Extraction Kit if there were multiple PCR products produced in the 
reaction, according to the manufacturer’s instructions. When spin column purifying, 
PCR products were eluted in 30 µL elution buffer (Qiagen). 
When performing the PCR SOEing (splicing by overlap extension) method 
(Ho et al., 1989). The product of the two separate PCR reactions were mixed in 
equimolar ratios and used as both the template and primer for a second PCR 
reaction to generate a single PCR product containing both original sequences 
fused together. This was enabled by designing PCR primers/products with 
overhangs homologous to one another. Please see Chapter 4.4.3 for a further 
explanation. 
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2.5.2 DNA agarose gel electrophoresis 
Usually 0.8% agarose (w/v) (Invitrogen) was dissolved in 1 X Tris-borate-
EDTA (TBE) buffer (Cell services, The Francis Crick Institute) by heating using a 
microwave. For analysis of smaller DNA fragments (<500 bp) 2% agarose (w/v) 
gels were used. One drop of 0.625 mg/mL ethidium bromide (Amresco) was added 
per 50-100 mL of molten agarose and the mixture was poured into a mould with 
well comb to set. DNA was added to 5X DNA loading buffer (Qiagen) to a final of 1 
X, mixed, and loaded into wells. HyperLadderTM1kb (Bioline) was used as a size 
ladder marker. For smaller DNA fragments <500 kb HyperLadderTM 100bp marker 
(Bioline) was used as a size ladder. DNA bands were imaged using a UV irradiator 
(GeneFlash, SynGene BioImaging). If required, DNA bands were excised quickly 
using a clean scalpel, while visualised using a UV lamp, and purified using 
QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer’s instructions. 
DNA was eluted from the column using 30 µL elution buffer (Qiagen) and 
incubating at room temperature for 4 minutes before eluting. 
 
2.5.3 DNA digestion with restriction enzymes 
Plasmid DNA and PCR products were digested using the required restriction 
enzymes from New England Biolabs (NEB) according to the manufacturer’s 
instructions. 
 
Generally, the following mix was used in a 1.5 mL Eppendorf: 
DNA (µg as required) 
10X NEB buffer (1 µL) 
BSA 100 µg/ml final (if required) 
Restriction enzyme (0.5 µL) 
Nuclease-free water to 50 µL 
 
Restriction digest reactions were incubated for at least 30 minutes at 37oC 
in a water bath. If double digestions were required, the best compromise was 
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chosen in terms of NEBuffer. Double digestions were used to prevent re-ligation of 
the cut empty vector during DNA ligation. 
 
2.5.4 Ligation 
DNA fragments were ligated using T4 DNA Ligase (NEB) according to the 
manufacturer’s instructions. 
 
Ligation mix: 
 
10X T4 DNA Ligase Buffer 1 µL 
Vector DNA 10 ng 
Insert DNA 60 ng 
T4 DNA Ligase 1 µL 
Nuclease-free water to 10 µL 
 
Ligations were incubated at 16 ºC overnight in a 1.5mL Eppendorf in a water 
bath. A vector to insert ratio of 1:6 is shown above. 10ng of vector was used per 
ligation reaction, with the amount (ng) of insert determined by the formula: 6(insert 
length bp/vector length bp) x ng of vector. If ligations were unsuccessful a higher 
insert-to-vector ratio was tried. 
2.5.5 In-Fusion cloning 
Alternatively to ‘cut and paste’ cloning above. Cloning was performed using 
the In-Fusion® HD Cloning Kit (Clontech), a ligation free cloning method, according 
to the manufacturer’s instructions. I found this yielded a higher efficiency than 
ligation cloning. In brief, this method utilises the propriety In-Fusion enzyme. 15bp 
overhangs are introduced to each end of the desired insert fragment (linear PCR 
product) by PCR. These overhangs are homologues to the cut ends of the 
linearised vector at both the 5’ and 3’ (sticky or blunt) ends. The PCR products and 
cut vectors are prepared as above, then they are mixed in an In-Fusion cloning 
reaction with the following components: 
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2 µL 5X In-Fusion HD Enzyme Premix 
X µL Linearised vector (as per kit instructions) 
X µL Purified PCR fragment (as per kit instructions) 
dH2O to 10 µL 
 
The reaction is incubated for 15 minutes at 50oC and then placed on ice. 2.5 
µL of the mixture is then transformed into Stellar Competent Cells provided with the 
kit, using the heat shock transformation method as detailed in Chapter 2.5.8 for 
DH5α E. coli. 
 
2.5.6 BAC recombineering 
Please refer to Chapter 4.2.1 for more details. The CFLAP tag was amplified 
from the R6Kamp-FLAP plasmid from Tony Hyman (Max Planck Institute or 
Molecular Cell Biology and Genetics, Dresden, Germany). 50bp overhangs at the 
5’ and 3’ ends of the PCR product were designed to straddle to the WAC STOP 
codon of human WAC isoform 1 contained in the WAC-BAC (CTD-2309l17 was 
purchased from Life Technologies). These homology arms were designed using 
the mitocheck BAC finder tool (http://www.mitocheck.org/cgi-bin/BACfinder). 
pSC101-BAD-gbaAtet (for Red/ET recombination) was purchased from Gene 
Bridges. The recombination of the CFLAP tag into the WAC-BAC was carried out 
using a previously described method (Poser et al., 2008) and the Quick & Easy 
BAC Modification Kit from Gene Bridges. This is as specified in the kit however 
there are some factors worth noting, which are different to handling plasmid DNA. 
The BAC is a very large DNA fragment prone to shearing and breaking. Thus when 
handling BACs especially, they should never be vortexed and freezing should be 
avoided. Storage at 4oC in a Tris-EDTA buffer is sufficient for stability in my 
experience. BAC DNA is also too large to purify using the Qiagen Spin Miniprep kit. 
Specialised kits for purifying BAC DNA are available commercially. However, for 
maxi prep of large amount of BAC DNA I used a phenol-chloroform extraction 
method as described in detail here (Ciotta et al., 2011). For mini prep of smaller 
amount of BAC DNA for screening, I also used the detailed method (Ciotta et al., 
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2011). Briefly this uses the buffers from the QIAprep spin miniprep kit (Qiagen) to 
resuspend and lyse the bacteria and for neutralisation, followed by clarification and 
isopropanol precipitation of the BAC DNA. The BAC DNA is pelleted by 
centrifugation without using any columns. Insertion of the CFLAP TAG into the 
WAC-BAC was verified by sequencing, not by restriction digest. Sequencing 
directly from the BAC was problematic and unsuccessful for me. Therefore, I had to 
PCR amplify the region of the CFLAP tag insertion and sequenced the linear PCR 
product (see Chapter 2.5.12). Electroporation of the recombination plasmid or the 
linear PCR product (FLAP tag) into E. coli was performed according to the Quick & 
Easy BAC Modification Kit from Gene Bridges using a Bio-Rad E. coli Pulser, in 
chilled 1 mm cuvettes at 1350 V, 10 µF. 
 
2.5.7 Site-directed mutagenesis 
For site-directed mutagenesis (SDM) QuikChange Multi Site-Directed 
Mutagenesis Kit (Agilent Technologies) was used according to the manufacturer’s 
instructions. Multiple primers can be used in a single reaction to generate 
mutations, so long as the primers do not overlap. Briefly, primers were designed to 
incorporate single or multiple base pair changes according to the manufacturer’s 
guidelines (see Table 2.5). These primers were used for production of circular PCR 
products using an enzyme mix containing high fidelity PfuTurbo DNA polymerase 
and nick-sealing ‘components’. See below for PCR mix and cycle. Following PCR, 
the template (un-mutated) plasmid was degraded by incubation with Dpn I for 1 
hour at 37oC, and the remaining DNA mix was used to transform XL10-GOLD 
ultracompetent cells (see Chapter 2.5.8). The obtained colonies were used for 
miniprep plasmid DNA purification, verification by sequencing and then used for 
maxiprep DNA production. 
 
Site-directed mutagenesis PCR mix: 
 
Note, half of the manufacturer’s recommended volumes work well. Half reactions 
are shown below: 
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Reagent Amount 
10X QuikChange Multi reaction buffer 1.25 µL 
QuikSolution 0.38 µL 
Template DNA 50 ng 
Mutagenic primer(s) 50 ng each 
dNTP mix 0.5 µL 
QuikChange Multi enzyme blend 0.5 µL 
dH2O Make up to 12.5 µL 
 
PCR cycle: 
Segment 
 
Cycles 
 
Temperature (ºC) 
 
Time 
 1 
 
1 
 
95 
 
1 min 
 2 
 
30 
 
95 
 
1 min 
 55 
 
1 min 
 65 
 
2 min/kb 
 3 
 
1 
 
4 
 
∞ 
  
2.5.8 Bacterial transformation 
Chemically competent DH5α E. coli (Life Technologies), stored at -80 ºC, 
were thawed on ice. 50 µL of DH5α was used per transformation. DNA added to 
and gently mixed with the bacteria, before incubation for 30 minutes on ice. For 
transformation of ligation products, 10 µl of ligation mixture was added to the 
bacteria, and for transformation of plasmid for the preparation of maxiprep DNA, 
0.5 µg of DNA was added to the bacteria. Following incubation on ice, the bacteria 
were heat shocked at 42 ºC for 45 seconds in a water bath before incubating on ice 
for 2 minutes. 250 µL of SOC (2% trypton (w/v), 0.5% yeast extract (w/v), 10.0 mM 
NaCl, 2.7 mM KCl, 21.0 mM MgCl2, 20.8 mM MgSO4, 20 mM D-glucose, The 
Francis Crick Institute) was added to the bacteria and the bacteria were recovered 
by incubating at 37 ºC in a. Eppendorf ThermoMixer for 45 minutes to 1 hour. 
Bacteria were plated onto LB-agar plates (1% Bacto-Tryptone (w/v), 0.5% yeast 
extract, 1.7 M NaCl, 1.5% agar, The Francis Crick Institute) containing the 
appropriate antibiotic (either ampicillin at 100 µg/µL or kanamycin at 50 µg/µL). For 
transformation of ligation products, the whole 250 µL of recovered bacteria was 
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plated, whereas 50 µL of plasmid transformation was plated for maxiprep. Bacteria 
were incubated overnight at 37 ºC to allow the formation of colonies. 
XL10-Gold Ultracompetent Cells (Agilent) were used for transformation of 
site-directed mutagenesis (SDM) products. The transformation protocol for these 
bacteria is the same as for DH5α, except that prior to transformation 1 µL of β-
Mercaptoethanol (provided in kit) is gently mixed with the chilled bacteria by 
tapping, and the mixture incubated on ice for 10 minutes before addition of DNA. 
2.5 µL of SDM reaction was used for each transformation. Bacteria on plates 
supplemented with the appropriate antibiotic were incubated overnight to allow 
colonies to form. 
 
2.5.9 Purification of plasmid DNA 
Colonies from bacterial plates were picked over a flame and inoculated into 
5 mL LB starter culture (1% Bacto-Tryptone (w/v), 0.5% yeast extract, 1.7 M NaCl, 
The Francis Crick Institute) supplemented with the appropriate antibiotic. These 
cultures were grown in a shaking incubator at 37 ºC overnight. Bacteria were 
pelleted at 4000 rpm for 4 minutes at 4ºC and the supernatant discarded. When a 
large number of minipreps were being processed the miniprep service at the 
Francis Crick Institute equipment park was used. For small numbers of minipreps, 
QIAprep Spin Miniprep Kit (Qiagen) was used according to the manufacturer’s 
instructions. DNA was eluted in 50 µL EB buffer. Miniprep DNA was then subjected 
to restriction digest as specified above and reaction products were analysed by 
agarose gel electrophoresis as described above. Plasmids harbouring inserts of the 
correct size (when cloning) were taken forward to sequencing verification as below. 
For SDM, plasmids were taken for sequencing without restriction digest. 
For the production of larger quantities of plasmids (after sequence 
verification), maxipreps were performed using the Qiagen Plasmid Maxi Kit. 
Colonies from bacterial plates were picked over a flame and inoculated into 5 mL 
LB starter culture supplemented with the appropriate antibiotic. These cultures 
were grown in a shaking incubator at 37 ºC overnight. The next morning, these 5 
mL starter cultures were added to 200 mL of LB medium with added antibiotic and 
incubated for 24 hours while swirling at 37 ºC. Bacterial cultures were pelleted at 
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6000 rpm for 30 minutes at 4 ºC and the supernatant discarded. Qiagen Plasmid 
Maxi Kit was then used according to the manufacturer’s instructions for purification 
of plasmid DNA. After precipitation and washing, DNA was dissolved in 500 µL TE 
(Tris-EDTA) buffer. The concentration of DNA was subsequently measured using a 
spectrophotometer (NanoDrop, Thermo Scientific) and the DNA made up to 1 µg/µL 
with TE. Aliquots were stored at -20 ºC for long-term storage, or at 4 ºC if the 
aliquot was in regular use.  
2.5.10 Primers 
All primers were purchased from Sigma. 
Table 2.5 Primers used in this thesis 
Primer Name Sequence (5' - 3') Used for: To make: 
EcoRVNtermMycW
AC Forward 
TAGAGATATCACCACCATGGAGCAAAAGCTC
ATTTCTGAGGAAGATCTCAATGGTGTAATGT
ATGCGAGGAAA 
Ligation Cloning 
Myc-WAC 
constructs from 
WAC start 
WAC BamHI 
Reverse TCTAGGATCCTCACACCATGAAGGAATT Ligation Cloning 
WAC constructs 
from WAC Stop 
EcoRVNtermMycW
AC aa320 For 
TAGAGATATCACCACCATGGAGCAAAAGCTC
ATTTCTGAGGAAGATCTCAATGGTACAACTC
CTTCCACGTCT 
Ligation Cloning Myc-WAC 320- 
WAC BamHI rev 
aa490 
TCTAGGATCCTCACACTGGTCCTTGCTTAAC
TA Ligation Cloning Myc-WAC 320-490 
EcoRVNtermMycW
AC For aa542 
TAGAGATATCACCACCATGGAGCAAAAGCTC
ATTTCTGAGGAAGATCTCAATGGTGTTGTAC
CACAGAATTCTTCTGC 
Ligation Cloning Myc-WAC 542-647 
WAC BamHI Rev 
aa319 TCTAGGATCCTCAGCAAGAATGTGATACGGG Ligation Cloning Myc-WAC 1-319 
EcoRVNtermMycW
AC aa163 For 
TAGAGATATCACCACCATGGAGCAAAAGCTC
ATTTCTGAGGAAGATCTCAATGGTTGGCTTG
AAAGAGAACAGAG 
Ligation Cloning Myc-WAC 163-647 
WAC BamHI rev 
aa610 
TCTAGGATCCTCAAGATCTTAAATTTTTTAAT
TCAGTACAAAT Ligation Cloning Myc-WAC 1-610 
In Fusion pEGFP-
C2, XhoI, WAC Iso1 
Forward 
GGACTCAGATCTCGAGCATGGTAATGTATGC
GAGGAAACAG In Fusion cloning 
EGFP-WAC 
constructs from 
WAC Stop 
In Fusion pEGFP-
C2, Sal I, WAC Iso1 
Reverse 
CCGCGGTACCGTCGACTTCACACCATGAAG
GAATTCTG In Fusion cloning 
EGFP-WAC 
constructs from 
WAC start 
In Fusion pEGFP-
C2, Sal I, 610aa 
Rev STOP 
CCGCGGTACCGTCGACTTCAAGATCTTAAAT
TTTTTAATTCAGTACAAAT In Fusion cloning EGFP-WAC 1-610 
In Fusion pEGFP-
C2, XhoI, 163aa For 
GGACTCAGATCTCGAGCTGGCTTGAAAGAG
AACAGAG In Fusion cloning 
EGFP-WAC 163-
647 
In Fusion pEGFP-
C2, Sal1, 319aa 
Rev 
CCGCGGTACCGTCGACTTCAGCAAGAATGT
GATACGGG In Fusion cloning EGFP-WAC 1-319 
In Fusion pEGFP-
C2, Xho1, 320aa 
For 
GGACTCAGATCTCGAGCACAACTCCTTCCAC
GTCT In Fusion cloning 
EGFP-WAC 320-
647 
In Fusion pEGFP-
C2, XhoI, 611 For 
GGACTCAGATCTCGAGCTTAGTCCGAGTATG
TGAAATTCAAG In Fusion cloning 
EGFP-WAC 611-
647 
In Fusion pEGFP-
C2, Sal I, 630 
Reverse 
CCGCGGTACCGTCGACTTCATCTCAAAAATA
GTATCCTTTGCTCT In Fusion cloning EGFP-WAC 1-630 
In Fusion pEGFP-
C2, Sal I, 620 
Reverse 
CCGCGGTACCGTCGACTTCAAGTTGCTTGAA
TTTCACATACTCG In Fusion cloning EGFP-WAC 1-620 
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Primer Name Sequence (5' - 3') Used for: To make: 
In Fusion pEGFP-
C2, XhoI, 580aa For 
GGACTCAGATCTCGAGCGAGAAGCAGGCAT
CAAGATTAC In Fusion cloning 
EGFP-WAC 580-
647 
-612-618 for TGTACTGAATTAAAAAATTTAAGATCTTTAGCAACTTTGCGAGAGCAAAGG PCR SOEing 
WAC aa619-647 
Fragment, SOE with 
below 
-612-618 rev CCTTTGCTCTCGCAAAGTTGCTAAAGATCTTAAATTTTTTAATTCAGTACA PCR SOEing 
WAC aa1-611 
fragment, SOE with 
above 
5'p for aa621 
inverse (P)TTGCGAGAGCAAAGGATACTA Inverse PCR 
EGFP-WAC Δ611-
620 
5'p Rev aa610 
inverse (P)AGATCTTAAATTTTTTAATTCAGTACAAAT Inverse PCR 
EGFP-WAC Δ611-
620 
pcDNA 3.1 + NheI 
infu Strep tag For 
aa13 
ACCCAAGCTGGCTAGCGCCACCATGTGGTC
CCACCCCCAGTTCGAGAAGGGCGGCATGTC
GGAAGAAACCAGGC 
In Fusion cloning Strep-tag II-GM130 
pcDNA 3.1 + XhoI 
infu Stop Rev aa998 
GCCCTCTAGACTCGAGTTATATAACCATGAT
TTTCACCTCGTCG In Fusion cloning Strep-tag II-GM130 
In Fusion pGEX 
4T2, SmaI, WAC 
Iso1 Forward 
ATCCCCGGAATTCCCGGGATGGTAATGTATG
CGAGGAAACAG In Fusion cloning GST-WAC 
In Fusion pGEX 
4T2, NotI, WAC 
Iso1 Reverse 
AGTCACGATGCGGCCGCTCACACCATGAAG
GAATTCTG In Fusion cloning GST-WAC 1-647 
In Fusion pGEX 
4T2, NotI, WAC 
Iso1 Reverse aa610 
AGTCACGATGCGGCCGCTCAAGATCTTAAAT
TTTTTAATTCAGTACAAAT In Fusion cloning GST-WAC 1-610 
NheI In Fu EosFP 
For Kozak 
ACCCAAGCTGGCTAGCGCCACCATGAGTGC
GATTAAGCCAGACATG 
PCR SOEing, In 
Fusion EosFP-GABARAP 
In Fu EosFP REV 
5xGly linker 
GCCTCCTCCACCACCTCGTCTGGCATTGTCA
GGC 
PCR SOEing, In 
Fusion EosFP-GABARAP 
In Fu huGABARAP 
For 5xGly linker 
GGTGGTGGAGGAGGCAAGTTCGTGTACAAA
GAAGAGCATC 
PCR SOEing, In 
Fusion EosFP-GABARAP 
In Fu huGABARAP 
REV STOP XhoI 
GCCCTCTAGACTCGAGTCACAGACCGTAGA
CACTTTCGT 
PCR SOEing, In 
Fusion EosFP-GABARAP 
WAC SDM Primer 1 GAAAAGAATCTACATCAGGTGATAAACCCGTATCACATTC SDM 
Silent mutations To 
make WAC 
(Q9BTA9-1) 
resistant to WAC-03 
siRNA 
WAC SDM Primer 2 CTACATCAGGTGATAAGCCGGTATCGCATTCTTGCACAACTCCTTC SDM 
Silent mutations To 
make WAC 
(Q9BTA9-1) 
resistant to WAC-03 
siRNA 
WAC SDM I626S 
L629S 
TTGCGAGAGCAAAGGAGCCTATTTTCGAGAC
AACAAATTAAG SDM 
Mutations of 
hydrophobic ‘a’ and 
‘d’ positions in WAC 
CC domain to 
remove RNF40 
binding 
GABARAP SDM 
primer 
GACGAAAGTGTCTACGCTCTGTGAAGCTGCT
CG SDM 
To make human 
GABARAP G116A 
mutation 
(p), 5’ phosphorylated primer 
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2.5.11 Plasmids 
All Myc-WAC and EGFP-WAC constructs are resistant to WAC-03 siRNA by site-
directed mutagenesis (see Chapter 2.5.7). 
 
Table 2.6 Plasmids used in this thesis 
Name 
 
Insert 
 
Vector 
 
Resistance 
 
Source 
 pEGFP-C2 
 
GFP 
 
pEGFP-C2 
 
Kanamycin 
 
Clontech 
 pcDNA3.1 (+) Empty pcDNA3.1 (+) Ampicillin 
Myc-WAC Human WAC isoform 
1 full length (1-647) 
pcDNA3.1 (-) Ampicillin N. McKnight 
Myc-WAC ΔCC WAC aa1-610 pcDNA3.1 (-) Ampicillin J. Joachim 
Myc-WAC ΔN WAC aa163-647 pcDNA3.1 (-) Ampicillin J. Joachim 
Myc-WAC NT WAC aa1-319 pcDNA3.1 (-) Ampicillin J. Joachim 
Myc-WAC CT WAC aa320-647 pcDNA3.1 (-) Ampicillin J. Joachim 
Myc-WAC 320-490 WAC aa320-490 pcDNA3.1 (-) Ampicillin J. Joachim 
Myc-WAC 542-647 WAC aa542-647 pcDNA3.1 (-) Ampicillin J. Joachim 
GFP-WAC Human WAC isoform 
1 full length (1-647) 
pEGFP-C2 
 
Kanamycin 
 
J. Joachim 
GFP-WAC ISLS WAC I626S & L629S 
double mutation 
pEGFP-C2 
 
Kanamycin 
 
J. Joachim 
GFP-WAC ΔCC WAC aa1-610 pEGFP-C2 
 
Kanamycin 
 
J. Joachim 
GFP-WAC 1-620 WAC aa1-620 pEGFP-C2 
 
Kanamycin 
 
J. Joachim 
GFP-WAC 1-630 WAC aa1-630 pEGFP-C2 
 
Kanamycin 
 
J. Joachim 
GFP-WAC 611-647 WAC aa611-647 pEGFP-C2 
 
Kanamycin 
 
J. Joachim 
GFP-WAC Δ611-620 WAC with aa611-620 
deleted inclusive 
pEGFP-C2 
 
Kanamycin 
 
J. Joachim 
GFP-WAC Δ612-618 WAC with aa612-618 
deleted inclusive 
pEGFP-C2 
 
Kanamycin 
 
J. Joachim 
GFP-WAC 580-647 WAC aa580-647 pEGFP-C2 
 
Kanamycin 
 
J. Joachim 
GFP-WAC ΔN WAC aa163-647 pEGFP-C2 
 
Kanamycin 
 
J. Joachim 
GFP-WAC NT WAC aa1-319 pEGFP-C2 
 
Kanamycin 
 
J. Joachim 
GFP-WAC CT WAC aa320-647 pEGFP-C2 
 
Kanamycin 
 
J. Joachim 
GST-WAC Human WAC isoform 
1 full length (1-647) 
pGEX-4T-2 Ampicillin J. Joachim 
GST-WAC ΔCC WAC aa1-610 pGEX-4T-2 Ampicillin J. Joachim 
GST-GABARAP Human GABARAP pGEX-5X-1 Ampicillin Z. Elazar 
GST GST pGEX-4T-2 Ampicillin GE life sciences 
pSC101-BAD-gbaAtet Red/ET 
recombinases 
pSC101-BAD-
gbaAtet 
Tetracycline Gene Bridges 
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Name 
 
Insert 
 
Vector 
 
Resistance 
 
Source 
 R6Kamp-FLAP C-terminal FLAP R6Kamp-FLAP Ampicillin T. Hyman 
WAC-BAC Human WAC gene 
14 exons and 
promoter 
pBAC Chloramphenicol Life Technologies 
3xHA-GM130 Rat GM130 pcDNA3.1 (+) Ampicillin J. Seemann 
Strep-tag II-GM130 Rat GM130 pcDNA3.1 (+) Ampicillin J. Joachim 
HA-GM130 aa383-1002 Human GM130 
isoform 1 aa381-
1002 
pSV-SPORT Ampicillin A. Barnekow 
HA-GM130 aa446-1002 Human GM130 
aa446-1002 
pSV-SPORT Ampicillin A. Barnekow 
HA-GM130 aa692-1002 Human GM130 
aa692-1002 
pSV-SPORT Ampicillin A. Barnekow 
HA-GM130 aa774-1002 Human GM130 
aa774-1002 
pSV-SPORT Ampicillin A. Barnekow 
GM130-ΔCterm-HA-MAO Rat GM130 aa1-879 
and MAO-A TMD 
aa481-528 
 
pcDNA3.1 (+) Ampicillin S. Munro 
GFP-LC3A Human LC3A pDEST-EGFP Ampicillin T. Johansen 
GFP-LC3B Human LC3B pDEST-EGFP Ampicillin T. Johansen 
GFP-LC3C Human LC3C pDEST-EGFP Ampicillin T. Johansen 
GFP-GABARAP Human GABARAP pDEST-EGFP Ampicillin T. Johansen 
GFP-GABARAP G116A GABARAP G116A 
mutation 
pDEST-EGFP Ampicillin H. Jefferies 
Myc-GABARAP Human GABARAP pDEST Ampicillin T. Johansen 
Myc-GABARAP GABARAP G116A 
mutation 
pDEST Ampicillin H. Jefferies 
GFP-GABARAPL1 Human GABARAPL1 pDEST-EGFP Ampicillin T. Johansen 
GFP-GATE-16 Human GATE-16 pDEST-EGFP Ampicillin T. Johansen 
mCherry-GFP-p62 Human p62 pDEST-CMV Ampicillin T. Johansen 
EosFP-GABARAP Human GABARAP pcDNA3.1 (+) Ampicillin J. Joachim 
Atg13-FLAG Atg13 pcDNA3.1 (-) Ampicillin N. McKnight 
HA-ULK1 WT Full length human 
ULK1 
pcDNA3.1 (+) Ampicillin A. Longatti 
HA-ULK1 ΔLIR ULK1 D356A, F357A, 
P361A triple mutant  
pcDNA3.1 (+) Ampicillin F. McAlpine 
HA-ULK1 ΔLIR/KI ULK1 K46I, D356A, 
F357A, P361A 
quadruple mutant  
pcDNA3.1 (+) Ampicillin F. McAlpine 
2.5.12 Sequencing 
Sequencing was performed with BigDye Terminator v3.1 (BDT) (The Francis Crick 
Institute) sequencing reactions. 
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Reaction mix: 
BDT Mix (provided by the equipment park, The Francis Crick Institute) 8 µL 
Sequencing primer 1 µL of 3.2 pmol / µL 
Plasmid DNA 200 ng or linear PCR product (>2000bp, 40-100 ng, 1000-2000bp 10-
40 ng) 
Made to 20 µL final volume in dH2O 
 
Sequencing reaction PCR cycle: 
Segment 
 
Cycles 
 
Temperature (ºC) 
 
Time 
 1 
 
1 
 
96 
 
3 min 
 2 
 
25 
 
96 
 
10 sec 
 50 
 
5 sec 
 60 
 
4 min 
 3 
 
1 
 
4 
 
∞ 
  
Sequencing reactions were cleaned up using the DyeEx 2.0 Spin Kit (Qiagen) 
according to the manufacturer’s instructions. Cleaned reactions were dried using a 
vacuum centrifuge at 45oC for 20 minutes. Sequencing was performed using 
capillary sequencing on an Applied Biosystems 3730Xl DNA analyser by The 
Francis Crick Institute equipment park. DNA sequences were analysed and aligned 
using MegAlign (DNASTAR) software. 
 
2.6 Data analysis 
2.6.1 Imaris image analysis software 
LC3 and WIPI2 puncta and centrosomal GABARAP intensity was quantified 
using Imaris 7 X64 software (Bitplane). The thresholds for detection limits based on 
the size and intensity of puncta, were set manually by comparing puncta detection 
in starved (+ Bafilomycin) vs fed cells. The same image analysis settings were 
used for each condition of an experiment for comparability. Cells were counted 
manually, or a mask was created in Imaris to measure cell area. For quantification 
purposes, the enlarged GABARAP positive structure was designated as 
centrosomal GABARAP. 
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2.6.2 ImageJ densitometry 
ImageJ (National Institute of Health) was used for quantification of western 
blots by measuring the density of film exposure. Microsoft excel was used to 
tabulate and normalise the data and statistics were performed as below. Live cell 
imaging data was analysed by image J, regions of interest were designated on 
movies to obtain intensity over time data. The Maximum intensity projection 
function was used to flatten Z-stacks (where indicated) and individual projections 
combined into a time-lapse. 
 
2.6.3 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6 software as 
indicated in figure legends. Asterisk(s) indicate significance: *, p ≤ 0.05, **, p ≤ 0.01, 
***, p ≤ 0.001, ****, p ≤ 0.0001. Data shown is the mean of the indicated number of 
experiments. Error bars display the standard error of the mean (SEM) for 3 or more 
experiments or the standard deviation (SD) for less than 3 experiments. 
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Chapter 3. Analysis of WAC nuclear function 
3.1 Introduction and aim 
3.1.1 Introduction 
WAC performs functions on the Golgi and in the nucleus (Totsukawa et al., 
2011, Zhang and Yu, 2011), as well as promoting starvation-induced autophagy 
(McKnight et al., 2012). It is not known whether WAC’s nuclear function is related 
to its role in autophagy regulation. In the nucleus WAC promotes 
monoubiquitination of histone 2B (H2B) at lysine 120, an epigenetic modification 
that is associated with maintenance of active transcription (Bonnet et al., 2014). I 
hypothesised that WAC may control autophagy gene regulation via its epigenetic 
function rather than its Golgi localised function. In this manner WAC may be a 
potent regulator of autophagy gene transcription in a similar way to TFEB and 
ZKSCAN3 (Martina et al., 2012, Roczniak-Ferguson et al., 2012, Settembre et al., 
2011, Chauhan et al., 2013). ZKSCAN3 functions as a transcriptional repressor of 
autophagy gene expression such as LC3B and WIPI2 as well as a repressor of 
lysosomal biogenesis genes. Upon nutrient starvation or Torin 1 treatment, which 
both stimulate autophagy, ZKSCAN3 relocalises from the nucleus to the cytoplasm. 
On the other hand, transcriptional factor EB (TFEB) functions as an activator of 
autophagic and lysosomal gene expression. Under nutrient rich conditions TFEB is 
phosphorylated by kinases such as mTOR, binds 14-3-3 proteins and is retained in 
the cytoplasm. Upon starvation, TFEB is dephosphorylated and it translocates to 
the cell nucleus. 
 
3.1.2 Aim 
In order to understand more about WAC’s role in the nucleus I began by 
cloning a series of truncations of the WAC protein, to understand how WAC 
localises to the nucleus versus cytoplasm. These truncations were designed to 
remove the highly conserved WW or CC domains of WAC, separate the two halves 
of WAC or to isolate folded regions of the WAC protein. A full explanation of the 
rationale behind these truncations is given is (Chapter 4.4.2) and a map of the 
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truncations is shown in Figure 3.1. I next investigated WAC’s effects on the 
regulation of autophagy gene transcription by knockdown experiments coupled with 
qRT-PCR. A more comprehensive, unbiased analysis of WAC’s effect on 
transcription was gleaned by transcriptome-wide microarray analysis of WAC 
knockdown samples as well as knockdown of the entire WAC/RNF20/RNF40 
complex. After bioinformatic analysis of the datasets hits were validated by qRT-
PCR experiments. Finally I began investigating the role of the interaction between 
WAC and RNF20/40 in epigenetic modification. 
 
3.2 Analysis of WAC nuclear localisation 
3.2.1 Amino acids 1-162 are required for WAC nuclear retention whereas 
aa320-647 direct membrane association 
WAC has no canonical nuclear localisation signal (data not shown) and it is 
unknown which domain(s) of the WAC protein direct its residency in the nucleus. 
WAC binds RNA polymerase II (RNAP) via its WW domain and also RNF20/40 via 
its coiled-coil (CC) domain. As RNAP and RNF20/40 are both nuclear proteins, 
both the WW and CC domains of WAC are candidates for nuclear localisation. I 
cloned a series of WAC truncations to determine the region of WAC that controls its 
subcellular localisation (Figure 3.1). Full length Myc-WAC human isoform 1, aa1-
647, localised primarily to the nucleus in most cells, and was also detected in the 
cytoplasm occasionally (Figure 3.2a). Myc-WAC was excluded from regions of the 
nucleus, which could be nucleoli. This was confirmed by subcellular fractionation, 
whereby most of Myc-WAC was found in the nuclear pellet whereas a small 
amount was found associating with membranes (Figure 3.2b). WAC’s association 
with membranes has been shown before by subcellular fractionation (Totsukawa et 
al., 2011). Removal of the CC domain of WAC (aa1-610) resulted in a similar 
localisation to the full-length protein (Figure 3.2a). However, removal of a large 
section of the N-terminus of WAC, aa163-647, including the WW domain of WAC, 
resulted in accumulation of WAC in the cytoplasm, although WAC was still able to 
localise to the nucleus. This suggests that the first 162 amino acids of WAC are 
required for its nuclear retention. In support of this, the N-terminal half of WAC aa1-
319, was primarily localised to the nucleus and sometimes to the cytoplasm, 
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similarly to the full-length protein. In contrast the C-terminal half of WAC localised 
primarily to punctate structures in the cytoplasm, reminiscent of membranous 
structures, and also to a minor extent in the nucleus. This was confirmed by 
subcellular fractionation (Figure 3.2b), whereby the C-terminal half of WAC was 
enriched on membranes compared with the full-length protein. The final two pieces 
of the WAC protein cloned were two regions that are predicted to be folded (Figure 
4.8). WAC aa320-490 was found in the nucleus and in the cytoplasm as was 
aa542-647. However aa542-647 exhibited a more cytosolic localisation than 
aa320-647, which associates with membranes. Taken together, these data suggest 
that the first 162aa of WAC are required for concentration in the nucleus, perhaps 
by interaction with RNAP. Whereas the C-terminal half of WAC directs its 
association with membranes, perhaps including the Golgi. 
 
 
Figure 3.1 Schematic showing human Myc-WAC isoform 1 truncation constructs 
Primary structure map of Myc-WAC isoform 1 constructs used for localisation 
studies. The conserved WW domain and coiled-coil (CC) domains are shown 
boxed as well as the putative nuclear export signal (NES). The dashed lines 
indicate the positions of WW or CC domains in the constructs.  
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Figure 3.2 WAC nuclear versus membrane localisation is encoded by different 
amino acid regions 
(a) HEK293A cells expressing the indicated construct were analysed by confocal 
microscopy. Scale bars 20 µm. Experiment was performed once for aa320-490 and 
aa542-647 fragments and three times for other truncations. For interpreting WAC 
staining, WAC antibody epitope is within the first 163 amino acids of WAC. (b) 
HEK293A cells expressing the indicated construct were subjected to subcellular 
fractionation followed by western blotting. Experiment was performed once. 
 
3.3 Investigating the role of WAC in transcriptional regulation 
3.3.1 WAC depletion reduces LC3B mRNA levels and p53 mRNA and protein 
levels 
I next wanted to understand if WAC controls the transcription of autophagy 
genes and began by analysing mRNA levels of mAtg8 proteins after WAC 
knockdown, under basal or starvation conditions. WAC knockdown was confirmed 
by western blot (Figure 3.3a). qRT-PCR revealed that LC3B mRNA levels were 
modestly reduced after WAC knockdown under both basal and starvation  
conditions (Figure 3.3b). There was little effect of WAC knockdown on GABARAP 
mRNA levels under basal conditions however a reduction was observed during 
starvation. Unlike LC3B, GATE-16 (GABARAPL2), was barely affected by WAC 
knockdown. These data suggest that WAC may be a regulator of LC3B mRNA 
expression but not of Atg8 mRNA expression as a whole; further repeat 
experiments are necessary to confirm this (see Figure 3.6). 
WAC is known to regulate target genes of the p53 transcription factor 
(Zhang and Yu, 2011). Furthermore, RNF20 regulates p53 gene expression 
(Shema et al., 2008). Thus it is also possible that WAC regulates p53 gene 
expression itself. Indeed WAC depletion reduced p53 transcript levels as well as 
reduced p53 protein expression levels (Figure 3.3b, c and d). p53 is also known as 
a regulator of autophagy; in the nucleus p53 is promotes the expression of genes 
that positively regulate autophagy such as TSC2, DRAM, and AMPK subunits, 
whereas in the cytoplasm it appears to repress autophagy (Maiuri et al., 2010). 
One of the targets of p53 that promotes autophagy is sestrin-2, which promotes 
autophagy by activating AMP-activated protein kinase (AMPK) to phosphorylate 
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and activate TSC2 and thereby inhibit mTOR (Budanov and Karin, 2008). Sestrin2 
also inhibits mTOR in an AMPK-independent fashion (Parmigiani et al., 2014). 
However, in contrast to the reduction of p53 mRNA levels after WAC knockdown, 
only small changes in sestrin2 transcript levels were detected (Figure 3.3b). Thus it 
is unlikely that changes in Sestrin2 expression explains WAC’s effect on 
autophagy. It could be that a greater reduction in p53 levels is required to see 
effects on Sestrin2. 
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Figure 3.3 WAC depletion affects LC3B mRNA and p53 mRNA and protein 
expression 
(a) HEK293A cells were treated with the indicated siRNA for 72 hours followed by 
incubation in full medium (FM) or EBSS (ES) for 2 hours prior to analysis by 
immunoblot. (b) Triplicate samples set up the same day as (a) were taken for qRT-
PCR analysis of the indicated genes. Mean ± SD. (a and b) were performed once. 
(c) HEK293A cells were treated with the indicated siRNA for 72 hours followed by 
incubation in full medium (Fed) or EBSS (Starved) for 2 hours prior to analysis by 
immunoblot. (d) Quantification of (c) from 2 independent experiments. Mean ± SD. 
 
3.3.2 RNF40 knockdown does not reduce LC3B mRNA levels or affect 
autophagy flux 
In the nucleus WAC functions as a heterohexameric complex with the E3 
ligases RNF20 and RNF40 with a 2:2:2 stoichiometry and each of these complex 
members is required for H2B monoubiquitination at lysine 120 (Zhang and Yu, 
2011). Thus, genes regulated by WAC should also be regulated by RNF20 and 
RNF40, according to the canonical model of WAC nuclear function. Efficient 
knockdown of RNF40 mRNA was obtained with 4 different siRNA duplexes (Figure 
3.4). To my surprise, although depletion of WAC again modestly reduced LC3B 
mRNA levels, RNF40 knockdown did not. There may even be an increase of LC3B 
transcript levels upon RNF40 depletion, although this was not observed with every 
siRNA duplex. This suggests that there may be genes that are regulated 
specifically by WAC independently of RNF20/40, and perhaps independently of 
WAC’s function in H2B monoubiquitination. Of course it is also possible that the 
reduction of LC3B transcript upon WAC knockdown is an off-target effect of the 
WAC-03 siRNA and future studies should aim to rescue this effect. Again there was 
a reduction of p53 mRNA levels after WAC knockdown and there was a small 
reduction of p53 transcript after knockdown with all 4 RNF40 siRNAs (Figure 3.4). 
This suggests that WAC and RNF40 both regulate p53 transcription, and therefore 
one may predict that the WAC/RNF20/40 complex as a whole controls p53 
expression. 
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Figure 3.4 Depletion of RNF40 may affect p53 mRNA expression 
(a) HEK293A cells were treated with the indicated siRNA for 72 hours followed by 
analysis by qRT-PCR for the indicated gene targets. Mean ± SD biological 
duplicates. Experiment was performed once. 
 
I next wanted to investigate if knockdown of RNF40 affected autophagic flux. 
Knockdown of WAC reduced LC3 lipidation under conditions of starvation and 
Bafilomycin A1 treatment (Figure 3.5) as expected (McKnight et al., 2012). 
Moreover, ULK1 activity, as measured by phosphorylation by ULK1 on its complex 
member Atg13 at Serine 318 (Joo et al., 2011) was slightly reduced after WAC 
knockdown (Figure 3.5 and see also Figure 5.5a), further suggesting that 
autophagy flux is reduced after WAC knockdown. Depletion of RNF40 showed no 
reduction in LC3 lipidation and ULK1 activity. Efficacy of RNF40 siRNAs was 
assessed in a separate experiment (Figure 3.4). As expected, depletion of RNF40 
reduced WAC protein levels, as the complex members stabilised one another 
(Karpiuk et al., 2012, Zhang and Yu, 2011). The effects of WAC on autophagy flux 
and different stages of the pathway are studied in greater detail in Chapter 5. 
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Figure 3.5 Knockdown of RNF40 did not affect autophagy flux 
HEK293A cells were treated with the indicated siRNA for 72 hours followed by 
incubation for 2 hours in full medium (Fed), EBSS or EBSS + BafA and then 
immunoblot. Experiment was performed once. Shorter film exposure of LC3II, LC3II 
(Short). 
 
3.3.3 Design and optimisation of siRNA knockdown for transcriptomic 
analysis  
The data presented so far suggests that WAC modestly regulates the 
expression of at least 2 genes involved in autophagy: LC3B and p53. However, 
many proteins directly participate as members of the autophagic machinery and 
many other proteins functions as regulators of the autophagic process (Chapter 1). 
I next decided to take an unbiased approach to analyse WAC’s effects on 
autophagy gene expression by performing a transcriptome-wide microarray 
analysis. This has obvious throughput advantages versus qRT-PCR. It is worth 
noting that qRT-PCR arrays targeting a set of genes involved in autophagy are 
available (e.g. Qiagen, 84 gene array) and although these offer a cost advantage 
versus a microarray the resultant dataset is limited. 
To prepare RNA samples for microarray analysis I designed the following 
experiment to optimise the sample preparation (Figure 3.6). HEK293A cells were 
subjected to knockdown by reverse transfection method as usual (see Materials 
and Methods), however this was done in 6-well plates as opposed to my normal 
knockdown in 24-well plates. Using a larger plate size allows enough RNA material 
to be available for qRT-PCR hit validation after microarray analysis within the same 
samples. 3 independent experiments were carried out with cells treated with RISC 
Free or WAC siRNAs for 72 hours with a 2 hour incubation in starvation medium 
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(EBSS) or full medium prior to RNA extraction. RNA quality (purity and 
degradation) was assessed as discussed in the Materials and Methods. After this, I 
assessed knockdown efficacy by qRT-PCR, and assessed changes in genes 
previously shown to be affected by WAC knockdown. As expected WAC 
knockdown resulted in significant reductions in LC3B and p53 mRNA levels, 
whereas no effect on the GAPDH ‘housekeeping’ gene was observed. One 
concern I had was that I was only able to achieve a ~70% knockdown in WAC 
mRNA levels, whereas before at the protein level (Figure 3.3a) I obtained a more 
impressive knockdown. For the purposes of the microarray submission I wanted to 
ensure that I provided samples with the best possible WAC knockdown, in order to 
reduce false negatives from the analysis. With this in mind I decided to repeat the 
knockdowns and also to redesign the experiment as explained below. 
 
 
Figure 3.6 Optimisation of WAC depleted samples for microarray analysis  
HEK293A cells were treated with the indicated siRNA for 72 hours followed by 
analysis by qRT-PCR for the indicated gene targets. Mean ± SEM 3 independent 
experiments. Unpaired Student’s t test, *, p ≤ 0.05. 
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HEK293A cells were treated with siRNAs, this time in 24-well format (Figure 
3.7), as I have previously done (Figure 3.3a). The experiment was designed for 
samples to be hybridised to an Illumina HT-12 v4 BeadArray. This array consists of 
50mer probes on immobilised beads that probe to exon regions. Some genes are 
covered by multiple probes, which improves the confidence of expression changes. 
However, some genes are only covered by a single probe sequence. The 
advantage of this system is that it is cheaper than competing technologies whilst 
still providing transcriptome-wide data. Furthermore, we have bioinformatic 
processes (e.g. scripts) in place at the Francis Crick Institute that allow the rapid 
analysis of the resultant dataset. Other options for analysing transcriptomic 
changes include exome arrays and RNA-seq technology. These methods have the 
advantage of being able to detect changes in individual isoform expression and 
splicing.  
The Illumina chip that holds the BeadArray has space for 12 samples to be 
hybridised and thus my experiment was designed with the submission of 12 
samples in mind. I designed the experiment with triplicate samples from the same 
experiment, with RISC Free, WAC, RNF20 and RNF40 siRNA treatments making 
up the 12 samples (Figure 3.7). This meant I could not do a comparison of basal 
versus starvation conditions. However, I reasoned that WAC affects basal 
autophagy as p62 accumulates upon WAC knockdown under basal conditions 
(McKnight et al., 2012). The advantage of including RNF20/40 knockdowns as well 
as WAC, meant that I could investigate genes regulated by the entire complex, as 
well as genes regulated by WAC independently perhaps by a non-canonical 
mechanism. By using biological replicates from the same experiment, rather than 
separate experiments, I could reduce sample variability to reduce the possibility of 
false negatives in the microarray, especially when dealing with modest gene 
changes. Reproducibility of hits could then be further confirmed during the 
validation stage. 
The final alteration to experimental design was to use pools of siRNAs 
against WAC, RNF20 or RNF40 rather than individual duplexes (Figure 3.7). This 
should in theory dilute any off-target effects whilst maintaining the on-target effects. 
As can be seen in Figure 3.7 knockdown of WAC with 2 different siRNAs (3+4) 
resulted in >85% knockdown of WAC message. This was a good improvement over 
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the knockdown previously achieved in the 6-well format (Figure 3.6). This could be 
due to the scalability of the reverse transfection knockdown protocol or perhaps the 
aliquot/batch of siRNA used. A good knockdown of RNF40 was also achieved 
using a pool of 2 siRNAs (1+2) (Figure 3.7) which individually work well (Figure 3.4). 
Four individual RNF20 siRNAs and a pool of all four produced a robust depletion of 
RNF20 message. Triplicate RNA samples of the pooled siRNA treatments for WAC, 
RNF20, RNF40 as well as RISC free, were submitted to the Genome Centre at 
Barts and The London School of Medicine and Dentistry, London. Samples were 
processed as briefly described in the Materials and Methods.  
 
 
Figure 3.7 Preparation of knockdown samples for Illumina BeadArray™ analysis 
HEK293A cells were treated with the specified siRNA or siRNA pools for 72 hours 
followed by analysis by qRT-PCR for the indicated gene targets. Mean ± SD 
biological triplicates from one experiment. The following samples were used in 
Illumina BeadArray™ analysis: RISC Free (RF) siRNA and siRNA pools of WAC 
(siRNAs 3+4), RNF40 (siRNAs 1+2) and RNF20 (siRNAs 1-4). 
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3.3.4 WAC regulates gene expression independently and as part of the 
WAC/RNF20/40 complex 
The microarray data was analysed by Probir Chakravarty in the 
Bioinformatics service at the Francis Crick Institute after discussions about how 
best to probe the dataset. An explanation of the analysis is provided in the 
Materials and Methods. Knockdown of WAC significantly affected (up or 
downregulated) the mRNA expression levels of 1,925 genes versus the RISC Free 
control (Figure 3.8). It is worth noting that the numbers displayed (Figure 3.8) show 
genes that are significantly affected (p ≤ 0.05) however no cut-off for fold change 
has been applied, therefore mild effects are also displayed.  
Out of the 1,925 genes regulated by WAC knockdown, 961 were uniquely 
affected by WAC knockdown alone (Figure 3.8 and Table 7.1). Some of these will 
likely be due to off-target effects but some are likely to be genuinely regulated by 
WAC. These genes are listed in Table 7.1 and ranked by fold change, negative to 
positive order. The most decreased gene after WAC knockdown was reassuringly 
WAC. It is worthwhile to note that this change was around -3.7 fold, whereas by 
qRT-PCR I was able to detect a stronger decrease of WAC from the same samples 
(Figure 3.7). This may be due to some difference between the two techniques. The 
majority of significantly affected genes showed modest changes, with a change in 
either direction of < 1.5 fold (Table 7.1). Out of these 961 genes uniquely regulated 
by WAC, 551 were downregulated after WAC knockdown, whereas 410 were 
upregulated. The up and downregulated genes were separated and taken for gene 
set enrichment analysis. Specifically, I was looking for biological pathways which 
were, as a whole, significantly affected by WAC knockdown. Importantly, 
autophagy, membrane trafficking and lysosomal pathways were included in this 
analysis. In the 410 genes upregulated after WAC knockdown, no biological 
pathways were significantly affected. However, in the 551 genes downregulated by 
WAC knockdown, pathways involved in the immune response and in inflammation 
were significantly enriched (Table 7.2). Autophagy was not a significantly affected 
pathway. Of note, genes involved in MHC class I antigen presentation were 
downregulated upon WAC knockdown (Table 7.2); these were the HLA genes and 
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beta-2 microglobulin (B2M) (Table 7.1), which are components of the MHC class I 
complex (Neefjes et al., 2011). 
Some genes involved in autophagy were regulated by WAC knockdown 
alone. However, there was no consistent trend of up or down regulation. For 
example WIPI1, VAMP3 and LC3B were downregulated upon WAC depletion, 
whereas VMP1 and WIPI2 were upregulated. It was good to see that LC3B came 
out as specifically regulated by WAC as predicted by my qRT-PCR data (Figure 3.4 
and Figure 3.6). The unpredictable effects on autophagy genes highlights the 
importance of statistical analysis of the dataset rather than hand-picking favourite 
genes. Nonetheless, it was still possible that WAC modulates autophagy by 
affecting the expression of a cluster of genes that regulate autophagy, that are not 
well known autophagy proteins. With this in mind the 551 genes downregulated 
specifically by WAC knockdown were cross-referenced with Nicole McKnight’s 
genome-wide screen for novel autophagy regulators (Table 7.1) (McKnight et al., 
2012). Genes that were downregulated after WAC knockdown, and in the top 
quarter of the genome-wide screen, i.e. those that had a tendency to decrease 
GFP-LC3 spot formation after knockdown, were given a ‘Yes’ value in Table 7.1. 
This was used for a further validation of the microarray results, which will be 
described in Chapter 3.3.5. 
Interestingly, 319 genes were commonly affected by knockdown of WAC, 
RNF20 or RNF40 versus RISC free control (Figure 3.8 and Table 7.3). Of these 
319 genes, 18 were differentially regulated by knockdown of WAC, RNF20 or 
RNF40 (highlighted red in Table 7.3). For example the target may be increased in 
knockdown of WAC and RNF20 but be decreased in knockdown of RNF40. 
Reassuringly, 301 out of the 319 genes moved in the same direction (up or 
downregulated) upon knockdown of the 3 complex members (shown in black in 
Table 7.3). These 301 genes likely provide a high-confidence list of transcripts 
regulated by the WAC/RNF20/40 complex as a whole. It is unlikely that these 
common genes are due to an off-target effect of any one siRNA. Whether these 
genes are directly regulated by the WAC/RNF20/40 complex, or are secondary 
effects of knockdown of the complex, would need to be determined by another 
technique such as chromatin immunoprecipitation followed by DNA sequencing 
(ChIP-seq). 
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Of these 301 genes, 183 were downregulated after knockdown and 118 
were upregulated. These groups were taken for pathway analysis. Genes involved 
in mitosis were significantly downregulated (data not shown). However, no other 
pathways were significantly affected. To gain more information from the gene lists, 
they were taken for transcription factor pathway analysis. This was to ascertain 
whether genes that are controlled by particular transcription factors were 
significantly enriched in the 118 up (Table 7.4) or 183 downregulated (Table 7.5) 
gene lists. This analysis has its limitations, for example c-Myc targets were both 
significantly enriched in the up and downregulated gene lists. Some target groups 
appeared specific though. For example, genes regulated by SMAD proteins were 
significantly upregulated after knockdown of WAC/RNF20/40. Whereas targets of 
the Glucocorticoid receptor alpha were significantly decreased. It was reassuring to 
see that p53 target genes and p53 itself, were significantly reduced after 
knockdown of WAC/RNF20/40 as expected (Table 7.3 and Table 7.5). 
 
Figure 3.8 Number of genes significantly up or down regulated upon depletion of 
WAC, RNF20 or RNF40 
Venn diagram showing genes that are significantly (p ≤ 0.05) affected (either 
upregulated or downregulated) upon knockdown of WAC (blue), RNF20 (green) or 
RNF40 (yellow) for 72 hr versus the RISC free control in HEK293A cells. 1,925, 
1,095 and 1,783 genes were significantly affected (either upregulated or 
downregulated) upon depletion of WAC, RNF40 or RNF20 respectively. 319 genes 
were commonly affected by knockdown of WAC, RNF20 or RNF40. For more 
information, (including direction of regulation, fold change and p-values) about 
genes uniquely affected by WAC knockdown (961 genes) and those commonly 
affected by knockdown of WAC, RNF20 or RNF40 (319 genes) see Table 7.1 and 
Table 7.3 respectively. 
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3.3.5 Validation of microarray data 
As mentioned above, it was still possible that WAC modulates autophagy by 
affecting the expression of autophagy regulating genes that are not well 
characterised. Furthermore, a subset of autophagy regulating genes, rather than 
the pathway in general may be affected. Thus, I began validating hits from the 
microarray dataset by qRT-PCR. I focused on the 551 genes uniquely 
downregulated after WAC knockdown (Table 7.1). This is because RNF40 
knockdown did not affect autophagic flux (Figure 3.5). The first gene I investigated 
was VAMP3, which was one of the most potently downregulated genes (-1.9 fold 
versus RISC free) after WAC knockdown and it is involved in autophagosome 
formation (Puri et al., 2013). Puri et al. showed VAMP3 is involved in the fusion of 
Atg16L1 and Atg9 membrane carriers which may form precursor membranes for 
autophagosome formation. Knockdown with siRNA WAC-03 resulted in a decrease 
VAMP3 message in both basal and starvation conditions (Figure 3.9a). As 
expected knockdown of WAC with 3 different siRNAs, -02, -03 and -04 reduced 
WAC protein levels (Figure 3.9b). However only WAC-03 siRNA reduced VAMP3 
protein levels. Therefore VAMP3 is likely to be an off-target effect of the WAC-03 
siRNA and regulation of VAMP3 by WAC does not explain WAC’s effect on 
autophagy. 
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Figure 3.9 VAMP3 depletion is an off-target effect of WAC siRNA treatment 
(a) HEK293A cells were treated with the specified siRNA for 72 hours, maintained 
in full medium or incubated in EBSS or 40 or 130 minutes followed by analysis by 
qRT-PCR for the indicated gene targets. Mean ± SEM from 3 independent 
experiments. (b) HEK293A cells were treated with the specified siRNA for 72 hours 
followed by immunoblot. Experiment performed once. 
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For further validation I decided to take a different approach. 551 genes 
downregulated after WAC knockdown were too numerous to validate by qRT-PCR 
and so I had to filter the dataset in some rational way. These 551 genes were 
cross-referenced against Nicole McKnight’s siGenome screen as explained above 
(Table 7.1). This resulted in 145 genes which were both downregulated by WAC 
knockdown in my microarray and were putative positive regulators of autophagy 
based on the genome-wide screen. 44 of these 145 genes were highly significantly 
downregulated (p ≤ 0.005) after WAC knockdown. LC3B did not remain after this 
filtering process. From this list of 44 genes, genes which were unlikely to be directly 
involved in autophagy were removed. This was done in a biased manner manually 
based first on UniProt annotations. For example if a gene was involved in 
translation or transcription, and thus may have affected expression of the GFP-LC3 
readout in the genome-wide screen, this was removed. The list of 44 genes were 
then referenced against the autophagy interaction network (Behrends et al., 2010), 
to see if they were putative interactors of autophagy proteins. Genes which also 
caused cell death in the genome-wide screen were also removed, as these may 
indirectly stimulate the autophagy stress response. After this process 22 genes 
were taken for qRT-PCR analysis (Figure 3.10). mRNA expression was measured 
in HEK293A cells treated with WAC-02 or WAC-03 siRNA (Figure 3.10), whereas 
in the microarray a pool of WAC-03 and -04 siRNAs were used. As expected 
knockdown of WAC message had no effect on GAPDH expression levels (Figure 
3.10a). 6 genes were not reduced by WAC depletion with either WAC-02 or -03 
siRNAs (Figure 3.10b), suggesting that these may be off-target effects of WAC-04 
siRNA from the microarray. 8 genes were likely off-target effects of the WAC-03 
siRNA (Figure 3.10c). 8 genes were reduced after knockdown with both WAC 
siRNAs (Figure 3.10d) suggesting that these are on-target effects of WAC 
knockdown and genes that are specifically controlled by WAC independently of 
RNF20/40. A description of these on-target genes is given in Table 3.1. 
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Figure 3.10 qRT-PCR validation of candidates from microarray 
(a-d) HEK293A cells were treated with the specified siRNA for 72 hours followed by 
analysis by qRT-PCR for the indicated gene targets. Mean ± SD, biological 
triplicates from one experiment. (a) Efficacy of WAC siRNAs for WAC knockdown 
and effects on the ‘housekeeping’ gene GAPDH. (b) 6 transcripts did not 
recapitulate the results of the microarray analysis. (c) 8 transcripts were affected by 
WAC siRNA -03 only. (d) 8 transcripts were affected by both WAC-02 and -03 
siRNAs and may be ‘on-target’ effects of WAC knockdown. 
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Gene Description (UniProt annotation) Published role in autophagy? 
SLC30A7 Golgi membrane protein. Zinc transporter.  
RAPGEF5 GEF for RAP1A, RAP2A and MRAS.  
ZSWIM5 Uncharacterised.  
NFKB1 Pleiotropic transcription factor. Activating and repressing functions. 
Yes. Inducer of BECN1 and p62 
expresison. But also repressive 
function. (Fullgrabe et al., 2014) 
LITAF Lysosomal.  Colocalises with LC3. Positive regulator. (Bertolo et al., 2013)  
FAM69A ER transmembrane protein. Uncharacterised.  
BEX2 Positive regulator of BCL-2 BCL-2 inhibits Beclin1 in autophagy (Pattingre et al., 2005) 
HSPA1A Also known as HSP70. Protein chaperone. Interacts with TSC2. 
Binds Beclin1-VPS34 complex 
and (indirectly) mediates 
SUMOylation of Vps34. Positive 
Role. (Yang et al., 2013) 
Table 3.1 Putative autophagy regulating genes positively regulated by WAC 
independently of RNF20/40 
Genes from Figure 3.10d are shown. 
 
3.3.6 WAC function in histone ubiquitination does not require interaction 
with RNF40 
The microarray analysis and qRT-PCR validation demonstrates that WAC 
regulates the expression of genes independently of RNF20/40. This could be 
through a direct function of WAC or a secondary effect of WAC depletion. This 
leads to the hypothesis that these WAC specific effects are also independent of the 
physical interaction between WAC and RNF20/40. To probe this, I made and used 
a double point mutant of WAC (I626S and L629S) that does not bind to RNF40, in 
rescue experiments. An explanation of the design of this mutant, along with 
evidence that it does not bind RNF40 is shown in Chapter 4.4.3. 
Overexpression of EGFP-WAC was not sufficient to drive H2B 
monoubiquitination at lysine 120 in one experiment (Figure 3.11a), although 
expression of the ISLS mutant may increase it. The specificity of H2B ubiquitination 
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was shown by treatment with the drug 5,6-dichloro-1-β-D-ribofuranosyl-1H-
benzimidazole (DRB) which inhibits CDK9 activity and therefore is thought to 
prevent phosphorylation of RNAP, recruitment of the WAC/RNF20/40 complex and 
H2B ubiquitination (Zhang and Yu, 2011). Depletion of WAC severely impaired 
H2B ubiquitination as expected (Figure 3.11b and c) and this was fully rescued by 
expression of siRNA resistant EGFP-WAC full length (aa1-647). However removal 
of the WAC C-terminal coiled-coil domain (EGFP-WAC aa1-610), ablated the 
rescue activity of WAC, suggesting that the coiled-coil domain is required for 
WAC’s epigenetic function. However, surprisingly, the ISLS mutant, which does not 
bind RNF40, was able to fully rescue H2B ubiquitination. This is unlikely to be 
explained by RNF20, as RNF20/40 function as an obligate heterodimer (they 
stabilise one another) and knockdown of one member prevents H2B 
monoubiquitination (Shema et al., 2011, Karpiuk et al., 2012) (Zhang and Yu, 
2011). This goes against the published model of WAC’s function in the nucleus 
(Figure 1.10). These data suggest that WAC can promote epigenetic modification, 
and presumably activate transcription, without interacting with RNF20/40 but by 
promoting H2B monoubiquitination via another mechanism. 
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Figure 3.11 The interaction of WAC with RNF20/40 is not required for WAC-
mediated H2B monoubiquitination at lysine 120 
(a) HEK293A cells expressing the indicated construct were treated with 50 µM DRB 
for 4 hours or an equivalent volume of DMSO prior to immunoblot. Experiment was 
performed once. (b) HEK293A cells treated for 72 hours with the indicated siRNA 
were transfected with the specified constructs prior to immunoblot. (c) 
Quantification of (b) mean ± SD from 2 independent experiments. 
 
3.4 Discussion 
The majority of WAC present in the cell is localised to the nucleus, with only a 
small amount of WAC likely to be on the Golgi (Figure 3.2). Thus, an investigation 
of how WAC could affect autophagy cannot ignore the nuclear function of the WAC 
protein. The data presented in this chapter suggest that the first 162 amino acids of 
WAC control localisation to the nucleus, whereas the C-terminal half of WAC, 
which also contains a putative nuclear export signal (NES) (Figure 3.1), directs 
WAC’s cytoplasmic localisation and association with membranes. Perhaps removal 
of the nuclear localising region of the WAC protein allows the NES to dominate, 
and shifts the equilibrium between nuclear import and export. How WAC associates 
with membranes is unknown, but as WAC has no transmembrane domain, some 
associated factor may recruit WAC to membranes. WAC has no nuclear 
localisation signal, however it may be that binding of WAC to RNA polymerase II 
facilitates its localisation to the nucleus. Binding of WAC to RNF20/40 is not 
required for WAC’s nuclear retention, as removal of the C-terminal coiled-coil 
domain has no effect on nuclear localisation.  
The qRT-PCR and microarray data presented here confirms that WAC controls 
the expression of genes, as previously demonstrated (Zhang and Yu, 2011). WAC, 
RNF20 and RNF40, which form a complex together with Rad6 that drives H2B 
monoubiquitination, also regulate a set of genes together, which could be direct 
targets of the complex. For example this complex promotes the expression of p53 
and also of p53 target genes. It would be interesting to see if WAC, via modulation 
of p53, could act as a tumour suppressor gene. Of note, RNF20 may function as a 
tumour suppressor gene (Shema et al., 2008). This dataset provides for the first 
time a genome-wide list of transcripts regulated by the complex as a whole and by 
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WAC alone. However, most of the changes observed were quite modest, and 
effects on protein expression would also have to be validated separately in future 
studies. Perhaps surprisingly, there was a paucity of genes clustered into biological 
processes regulated by the WAC/RNF20/40 complex. However, bioinformatic 
analysis suggests that the complex may be involved in regulating transcription 
factor pathways such as SMAD or glucocorticoid receptor targets. Future studies 
could probe the functional relevance of this. Interestingly, almost as many genes 
were upregulated after knockdown of the complex members, as were 
downregulated (Shema et al., 2008). On first glance this may be surprising as H2B 
monoubiquitination is an epigenetic mark that is generally associated with active 
transcription, and is thought to promote transcriptional elongation by RNA 
polymerase II after the transcription start (Zhang and Yu, 2011). However, previous 
microarray analysis after RNF20 knockdown revealed a significant number of 
genes that were upregulated (Shema et al., 2008). These RNF20-suppressed 
genes were associated with increased H2B monoubiquitination. Thus it may not be 
surprising that some genes are repressed by the WAC/RNF20/40 complex and this 
could be due to its function in H2B monoubiquitination.  
A large number of genes (961) may be regulated (551 positively, 410 
negatively) by WAC independently of RNF20 and RNF40. This is in line what has 
been published for RNF20, where knockdown reduced the expression of ~3% of 
genes in HeLa cells and a similar percentage was upregulated (Shiloh et al., 2011, 
Shema et al., 2008). It should be mentioned though, that the WAC unique/specific 
gene set is less reliable then the gene set common to the whole complex. This may 
be because there are a significant number of hits that are off-target effects, which 
can only be discerned by further validation. Nevertheless, this suggests that WAC 
could regulate gene expression (e.g. LC3B) through some non-canonical, i.e. 
RNF20/40 independent, mechanism. The observation that WAC may promote the 
expression of antigen presentation genes is worthy of further investigation. Here I 
have focused more on the genes activated by WAC, in the search of autophagy 
promoting genes. However, it is also possible that WAC suppresses a negative 
regulator of autophagy, and therefore functions as a positive regulator. A non-
canonical mechanism for WAC function in transcriptional regulation is supported by 
the discovery that the interaction of WAC with RNF40 is somehow not required for 
its role in H2B ubiquitination. It could be that the interaction of WAC with RNF20/40 
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per se is not required for H2B ubiquitination, but the function of the E3 ligase can 
be stimulated by WAC in an indirect manner by affecting another factor such as the 
E2 Rad6. Whether the ISLS WAC mutant interacts with Rad6 has not been 
determined. Alternatively, WAC may also activate some other E3 ligase that 
mediates H2B monoubiquitination at Lysine 120, which has yet to be identified. It 
would be interesting to see if the genes regulated by WAC independently of 
RNF20/40 also require WAC’s RNF20/40 binding-independent function in H2B 
ubiquitination. 
WAC’s effect on autophagy is likely to be independent of RNF40, and is 
therefore unlikely to be explained by effects on p53 expression. WAC affected 
LC3B expression but none of the other Atg8 proteins were identified in the 
microarray. This specific effect on LC3B is unlikely to explain WAC’s effect on 
autophagy due to the redundancy of the Atg8s (Weidberg et al., 2010). WAC does 
not simply effect LC3B expression but is required for autophagy flux in general 
(McKnight et al., 2012), this is investigated in greater detail in Chapter 5. The 
transcriptomic analysis reveals that WAC is not a broad or master regulator of 
autophagy gene expression, and is not a regulator of related processes such as 
lysosome function. Genes related to autophagy were affected in an unpredictable 
manner. Thus I would hypothesise that WAC’s effect on autophagy may be due to 
its cytoplasmic function, rather than its control of gene expression. I cannot 
however completely rule out some effect of WAC on autophagy from its nuclear 
localisation. For example, WAC promotes the expression of at least 3 genes that 
promote autophagy (NFKB1, LITAF and HSPA1A) and 5 other genes which are 
possible autophagy regulators. The next steps in future studies addressing this 
would be to confirm similar effects on protein expression levels, effects on 
functional readouts of those proteins and that WAC is resident on those genetic 
loci. 
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Chapter 4. Identification of GM130 as a WAC binding 
partner and mapping the WAC-GM130 interaction 
4.1 Introduction and aim 
4.1.1 Introduction 
The mechanisms by which WAC and GM130 exert their effects on 
autophagy are unknown. Although WAC promotes transcription through its nuclear 
function (Zhang and Yu, 2011), transcriptomic analysis (Chapter 3) suggests that 
WAC is neither a potent nor a broad regulator of autophagy gene expression. 
WAC’s other known subcellular location is the Golgi where it interacts with 
VCP/p97, via the deubiquitinase VCIP135, to mediate Golgi complex reassembly 
post-mitosis (Totsukawa et al., 2011). VCP is a hexameric AAA ATPase that 
functions as a chaperone with unfoldase or segregase activity (the disassembly of 
protein complexes) and has been implicated in pathologies such as inclusion body 
myopathy with Paget’s disease of bone and frontotemporal dementia (IBMPFD) 
and amyotrophic lateral sclerosis (ALS) (Yamanaka et al., 2012, Meyer et al., 2012). 
Through binding cofactors, VCP controls various cellular functions such as 
endoplasmic reticulum (ER), Golgi and nuclear envelope reassembly and ER-
associated protein degradation (ERAD). VCP and its yeast homologue Cdc48 both 
positively regulate autophagy (Krick et al., 2010, Tresse et al., 2010), and VCP has 
been shown to mediate the selective degradation of depolarised mitochondria by 
autophagy, induced by the E3 ubiquitin ligase Parkin (Tanaka et al., 2010). Yeast 
Cdc48 is thought to promote phagophore elongation and autophagosome formation 
(Krick et al., 2010). In light of this, it is possible that WAC affects autophagy via 
modulation of VCP function. However, unlike its yeast homologue Cdc48, 
mammalian VCP promotes autophagosome maturation under basal conditions. In 
VCP depleted cells, or cells overexpressing a dominant-negative mutant of VCP, 
there was an accumulation of immature autophagosomes with ubiquitinated 
contents (Tresse et al., 2010). In contrast, WAC promotes autophagy initiation 
(McKnight et al., 2012) and ULK1 activation (Chapter 5); this phenotypic disconnect 
suggests a mode of action of WAC that is independent of VCP.  
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A number of autophagy machinery proteins are regulated at the Golgi 
complex (see Chapter 1.1.3). Thus, I postulated that WAC could affect autophagy 
through undiscovered interactions at the Golgi. In addition, the Golgi is also thought 
to directly contribute membranes to the forming phagophore (Biazik et al., 2015) 
and because WAC affects Golgi membrane fusion, it is possible that membrane 
flow from the Golgi to the phagophore could be altered in WAC depleted cells. This 
remains to be investigated and has not been addressed in my study.  
Depletion of GM130 was found to induce autophagy (Chang et al., 2012). It 
was suggested that this was due to a loss of ER-to-Golgi transport and protein 
glycosylation. However, treatment with the drug Brefeldin A, which results in the 
disassembly of the Golgi complex and loss of protein secretion and glycosylation 
(Misumi et al., 1986), is thought not to affect autophagic flux (Weidberg et al., 2010, 
Nishida et al., 2009, Zoppino et al., 2010). Therefore, there may be an alternative 
outstanding explanation for GM130’s effects on autophagy. 
 
4.1.2 Aim 
In order to further characterise the function of WAC in autophagy I began by 
carrying out an immunoprecipitation (IP) approach coupled with mass spectrometry 
to identify novel WAC interactors. To this end, I generated a HeLa stable cell line 
carrying a bacterial artificial chromosome (BAC) containing the human WAC gene 
(CTD-2309l17, Life Technologies) tagged at the C-terminus with a FLAP tag (WAC-
FLAP) (Figure 4.3). The FLAP tag consists of FLAG-TEV site-S-peptide-3C site-
EGFP (Figure 4.3a). It is named the FLAP tag because it is a localisation and 
affinity purification (LAP) tag with FLAG. The FLAP tag was added onto the C-
terminus of WAC by homologous recombination (Figure 4.1), as the construct is too 
large to engineer by traditional cut-and-paste cloning. This was carried out using a 
previously described method (Poser et al., 2008) and the Quick & Easy BAC 
Modification Kit from Gene Bridges. I also attempted to generate N-terminally 
tagged FLAP-WAC, however this resulted in a truncated protein product. The WAC 
BAC contained the entire WAC gene (91 kb, UCSC Genome Browser) including 
introns and exons as well as large upstream and downstream regions, more than 
10 kb either side. This means that the WAC-FLAP should be expressed under the 
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control of the WAC promoter and (short-range) regulatory elements and spliced 
into isoforms. As BACs normally integrate in the host genome as single or low copy 
number (Poser et al., 2008), this should mean that WAC-FLAP is spliced as 
different isoforms and expressed at near or below endogenous levels. Thus, this 
system circumvents problems associated with protein overexpression, such as 
mislocalisation and aberrant interactions, and provides a tractable way to modify 
genes with large tags. One disadvantage of BACs versus other technologies such 
as CRISPR is that protein expression levels are subject to the locus of integration 
of the BAC in the host genome, this can be somewhat ameliorated by screening 
multiple clones to identify the ‘normal’ expression level independent of integration 
locus (Figure 4.2).  
The experimental design was to IP endogenous WAC from HEK293A cells 
and to also IP WAC-FLAP using GFP-Trap® (Chromotek) from HeLa cells, 
followed by analysis of protein complexes by mass spectrometry (Figure 4.4). The 
resulting datasets were then intersected to find proteins that bound to WAC and 
also to WAC-FLAP but not to the control (beads and lysate). One advantage of this 
approach is that it is high stringency, in the sense that proteins that non-specifically 
cross-react with either the WAC or the GFP antibody should be filtered out. This 
strategy proved to be fruitful, as I had attempted to validate endogenous WAC 
interactors only to conclude that they non-specifically bound to the WAC-antibody 
(data not shown). Another advantage of this strategy is that cell type specific 
interaction partners should be reduced, in order to focus on interactions with a 
broader biological meaning. It is also worth noting that a disadvantage to this 
technique is the possibility of false negatives, for example if fusion of the FLAP tag 
to the WAC C-terminus inhibits some subset of interactions, or if there are 
interactions specific to particular WAC isoforms.  
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4.2 Generation of a WAC-FLAP cell line 
4.2.1 Modification of WAC BAC with a FLAP tag by homologous 
recombination 
E. coli harbouring a BAC that contains your genomic locus of interest can be 
obtained commercially from Life Technologies. The UCSC genome browser can be 
used to map BACs to your genomic region of interest before ordering. In this case 
the BAC (clone identification: CTD-2309l17) contains the WAC gene (Figure 4.1). 
These bacteria are then transformed with a plasmid (pRed/ET) that encodes for 
recombinases. At 30oC the pRed/ET plasmid can replicate. Concurrently, the FLAP 
tag should be prepared. A number of BAC tagging vectors are available, designed 
by the Tony Hyman Lab in Dresden, Germany. To tag the C-terminus of a gene 
with the FLAP tag, the R6Kamp-FLAP plasmid can be used as a template for PCR 
amplification. In order to target the FLAP tag to the C-terminus of your gene, 
regions of homology must be incorporated into your PCR product. Both the forward 
and reverse primers, designed to amplify the FLAP tag, contain 50 bp of homology 
to the WAC gene as shown by overhangs in Figure 4.1. This allows for precision in 
the site of integration. The primers are designed so that the FLAP tag is inserted 
before the stop codon of the WAC gene in exon 14 (the last exon of WAC isoform 1, 
UCSC genome browser and Ensembl). This is true in the case of WAC isoforms 1, 
2 and 4 (UniProt nomenclature), which should therefore become tagged. However 
WAC isoform 3 uses a different stop codon and therefore should not be tagged. It 
is not clear if isoform 3 is even stable as it is predicted to be degraded by nonsense 
mediated decay (Ensembl). 
E. coli transformed with pRed/ET and containing your BAC can now be 
induced to express recombinases by the addition of L-arabinose to the growth 
medium and by shifting the temperature from 30oC to 37oC. Although pRed/ET 
stops replicating at this temperature, because each cell should have multiple 
copies, it will be retained for at least a few division cycles. After this, the FLAP tag 
PCR product is electroporated into these bacteria to allow the recombination 
reaction to occur. The FLAP tag itself contains a neomycin/kanamycin resistance 
gene for selection in mammalian/bacterial cells respectively. Thus recombined 
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BACs can be selected for and subsequently screened. The design of the FLAP tag 
is quite elegant. The EGFP sequence within the FLAP tag has been split into 2 
exons, with the intervening intron containing the antibiotic resistance gene 
(Neo/Kan) under the control of a PGK promoter and gb2 promoter for eukaryotic 
and bacterial expression respectively. In my experience it was very difficult to 
sequence directly from the BAC as a template, perhaps due to the DNA secondary 
structure of the large construct. Therefore it was necessary to sequence PCR 
products of the recombination region to identify the final modified WAC-FLAP BAC. 
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Figure 4.1 Recombineering of bacterial artificial chromosomes 
Flow diagram showing steps to modify a BAC by homologous recombination. Left 
homology region, LHR; right homology region, RHR. 
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4.2.2 Generation of HeLa WAC-FLAP BAC cell line 
After generation of the modified BAC, I then produced a stable cell line. 
HeLa, MEF and HEK293A cells were transfected with the WAC-FLAP BAC using 
Effectene transfection reagent (Qiagen) and the protocol developed by Ina Poser 
(Poser et al., 2008) (Figure 4.2). I was unable to isolate cells expressing full length 
WAC-FLAP in the case of MEFs and HEK293A cells. With HEK293A cells, 
spontaneous resistance to G418 developed during selection, even with control 
transfected cells. This is a problem that has been encountered in other labs 
(personal communication, Mark Petalcorin). However, I was successful in the case 
of HeLa cells. I also transfected HeLa cells with N-terminally tagged FLAP-WAC 
BAC. 
After transfection, cells were selected in a high concentration of G418, the 
surviving colonies were pooled together and taken for FACs sorting. Forward and 
side scatter was first used to gate out doublet cells and cells with unusually high 
granularity. Analysis of fluorescence in two different channels, as shown in Figure 
4.2, allows the exclusion of autofluorescent cells, which would lie on a gradient of 1 
on the graphs shown. Cells with detectable EGFP were single-cell sorted into 96-
well plates and kept under selection with a low concentration of G418. Clones were 
analysed by confocal microscopy. Some of these clones were unsuitable for 
generation of a cell line. These ‘bad’ clones had undesirable features such as high 
expression and/or heterogeneous expression. This could be due to genetic 
instability or the incorrect sorting of more than one cell into a well. ‘Good’ clones 
had low and homogenous expression and in addition these cells had similar 
morphological characteristics to wild-type HeLa cells. 
Next, it was necessary to check that the expressed tagged protein was 
translated at the expected size and not truncated or degraded. HeLa cells 
expressing N-terminally tagged FLAP-WAC or C-terminally tagged WAC-FLAP 
were used for FLAG immunoprecipitation followed by western blotting with anti-
GFP (Figure 4.2). Endogenous WAC (isoform 1) migrates with a molecular weight 
of around 80 kDa by SDS-PAGE (Figure 4.3d). However, FLAP-WAC was only 
expressed as a truncated product of around 55 kDa. This is unlikely to be due to 
instability induced by tagging because EGFP-WAC expresses at full length (Figure 
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4.6e). Instead this could be due to some recombination event within the BAC itself. 
Clearly FLAP-WAC was unsuitable for cell line generation. However, FLAP-WAC 
localised to the nucleus just like WAC-FLAP (data not shown). This suggests that 
the first 200aa (estimated) of the WAC protein (647aa) is sufficient to target WAC 
to the nucleus as expected (Figure 3.2).  
WAC-FLAP was expressed as four bands all approximately the right size to 
be full-length protein (Figure 4.2). The largest 3 of these bands can be accounted 
for by tagged versions of the WAC isoforms 1, 2 and 4 as explained above. 
However, the presence of a smaller fourth band is interesting; this could be a post-
translationally modified form of one of the isoforms. Alternatively, this could be 
evidence of expression of another WAC isoform (UniProt accession A0A0A0MRT2). 
There is currently no experimental evidence of expression of this isoform (mRNA or 
expressed sequence tag) but it is nonetheless predicted. A0A0A0MRT2 is 
predicted to be protein coding (Ensembl), is of the correct size to account for the 
lowest of the four bands and should also be tagged as it contains exon 14.  
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Figure 4.2 Transfection, selection and cloning of HeLa WAC-FLAP cell line 
Schematic depicting stable cell line generation. FACS plots show 10,000 events 
per cell line. FACS sorting was carried out by Andy Filby. Fluorescence units are 
arbitrary. Confocal microscopy, immunoprecipitation and SDS-PAGE analysis was 
used to screen clones. 
  
4.2.3 Validation of HeLa WAC-FLAP BAC stable cell line 
Before using the WAC-FLAP cell line as a tool to identify novel WAC 
interactors, it was necessary to establish that WAC-FLAP behaved similarly to the 
endogenous WAC protein. Immunoblot analysis revealed that WAC-FLAP HeLa 
cells expressed tagged WAC isoforms 1 and 4 near to endogenous WAC protein 
levels (Figure 4.3b). Because BACs integrate in the host genome at usually single 
copy number (Poser et al., 2008) I expected to see expression of WAC-FLAP at a 
lower level than the endogenous WAC protein and indeed this was the case. The 
epitope used to generate the anti-WAC antibody is present only in isoforms 1 and 4, 
therefore only these can be detected.  
Staining HeLa WAC-FLAP cells with anti-GFP and anti-GM130 antibodies, 
and comparing against wild-type control HeLa cells, revealed that WAC-FLAP 
localised both to the nucleus and to the Golgi apparatus as previously described for 
endogenous WAC (Totsukawa et al., 2011) (Figure 4.3c). Because WAC-FLAP is 
expressed at low levels under the control of the WAC promoter, I could not observe 
Golgi localised WAC by assessing EGFP fluorescence alone, thus it was 
necessary to stain WAC-FLAP cells with anti-GFP antibody. Even after staining, 
the signal was too low to detect by confocal microscopy and so the thicker z-
sectioning of epifluorescence microscopy was required to enhance the signal.  
Complementary to microscopy analysis, subcellular fractionation showed 
that WAC-FLAP isoforms 1 and 4 associated with a crude membrane extract and 
with a nuclear fraction, to a similar extent as the endogenous isoforms 1 and 4 
(Figure 4.3d). Cytosolic WAC was not detected. These results were expected as 
membrane association of WAC has also been shown before by subcellular 
fractionation (Totsukawa et al., 2011). The transmembrane autophagy protein Atg9, 
which localises to the trans-Golgi network and endosomal system (Young et al., 
2006), was used a marker for the membrane fraction. Superoxide dismutase 
(SOD1) was used as a marker for the cytosol, and a component of the nuclear 
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lamina, Lamin B, was used to identify the nuclear pellet. Only a small percentage 
(an estimated ≤ 10%) of WAC isoforms 1 and 4 localise to membranes both in 
WAC-FLAP HeLa and HEK293A cells (Figure 4.3d and e), with the majority of 
WAC being within the nucleus. This may explain why nuclear WAC-FLAP but not 
Golgi WAC-FLAP, could be detected without staining with anti-GFP antibody 
(Figure 4.2). One limitation of this fractionation technique is the presence of 
residual intact cells in the nuclear pellet as seen by Atg9 and SOD1 in this fraction. 
This is because a balance must be made during homogenisation of whole cells, too 
little results in insufficient plasma membrane breakage, too much risks damaging 
the nuclei and releasing nucleoplasmic proteins. 
Immunoprecipitation of WAC-FLAP using GFP-Trap beads followed by 
western blotting with anti-GFP showed that WAC-FLAP interacted with the known 
WAC interaction partner RNF40 (Zhang and Yu, 2011) (Figure 4.3f). RNF40 binds 
the WAC C-terminal coiled-coil domain. Thus, at least in this instance, the C-
terminal FLAP tag does not interfere with interactions at the C-terminal WAC 
coiled-coil domain. In conclusion, using a range of assays WAC-FLAP behaves 
similarly to the endogenous WAC protein and could be used to investigate WAC 
interactions and other biological functions of the WAC protein. 
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Figure 4.3 Validation of HeLa WAC-FLAP cell line 
(a) Schematic of the WAC-FLAP BAC. TEV protease cleavage site, TEV; 
PreScission protease cleavage site, 3C. (b) WAC-FLAP HeLa lysate was analysed 
by SDS-PAGE and western blot. WAC antibody recognises isoforms 1 and 4 due to 
epitope position. (c) WT HeLa and WAC-FLAP HeLa cells were analysed by 
epifluorescence microscopy after staining with the indicated antibodies. (d) WAC-
FLAP HeLa cells were homogenised before subcellular fractionation by differential 
centrifugation and analysis by SDS-PAGE and western blot. Membranes were 
loaded as a 10x concentrate compared to other fractions. Nuclear pellet, NP; 
cytosol, Cyt; membrane, Mem. (e) HEK293A cells were incubated in full medium 
(FM) or starvation medium EBSS (ES) for 2 hours prior to subcellular fractionation 
and western blotting. Nuclear pellet, NP; membrane, Mem. (f) Lysates from WAC-
FLAP HeLa cells were subjected to GFP-Trap followed by SDS-PAGE and western 
blotting. Blocked agarose beads with lysate was used as a control (Ctrl). Markers 
indicate molecular weight in kilodaltons. Experiments shown were performed once. 
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4.3 Identification of GM130 as a novel WAC interactor by mass 
spectrometry 
4.3.1 Experimental design of co-immunoprecipitation coupled with mass 
spectrometry  
As outlined in the aims section of this chapter, my experimental plan was to 
immunoprecipitate WAC from HEK293A cells and compare these protein 
complexes with those from WAC-FLAP HeLa cells (Figure 4.4). The relative 
advantages/disadvantages of this approach have also been discussed. 
 
 
Figure 4.4 Experimental design of immunoprecipitation coupled to mass 
spectrometry 
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4.3.2 Analysis of mass spectrometry datasets to reveal high stringency 
WAC interactors 
HEK293A cells or HeLa WAC-FLAP cells (not shown) were maintained in 
full medium or starved in EBSS for 2 hours prior to lysis and anti-WAC or anti-GFP 
immunoprecipitation (Figure 4.5a and b). Protein complexes were ran on SDS-
PAGE gels before MeOH and glacial acetic acid fixation and staining with colloidal 
Coomassie. The gels were only ran for a short time and each lane was cut into 
bands and submitted for LC-MS mass spectrometry analysis (by David Frith and 
Bram Snijders, see Chapter 2.3.9 for method). The bands predicted to be WAC and 
the known interacting proteins RNF20 and RNF40, which are of similar size, are 
indicated (Figure 4.5a). The efficacy of immunoprecipitation was confirmed by 
Western blot analysis of supernatants after pull-down (Figure 4.5b). 
After mass spectrometry the datasets were analysed as follows (Figure 4.5c, 
d and e). There were only small differences in the proteins identified between fed 
and starved samples (data not shown), and so the comparison was carried out 
between fed samples (HEK293A versus WAC-FLAP HeLa). Intensity based 
absolute quantification (iBAQ) was used as a label-free quantitative method to 
analyse WAC interactors (Schwanhausser et al., 2011, Fabre et al., 2014). The 
advantage of iBAQ is that I could distinguish between high abundance and low 
abundance WAC interactions, without the need for generating a labelled cell line 
such as with SILAC (Stable Isotope Labelling by Amino acids in Cell culture). The 
drawback with iBAQ quantification is that you cannot prove a true negative. If your 
protein of interest is missing in one sample, it may be that by chance the peptide 
was not detected in that particular case. With SILAC, heavy and light labelled 
samples are mixed, injected and compared together, which means true negatives 
can be established. More specifically, the atomic weight of the amino acid per se 
does not affect the hydrophobicity or therefore retention time during high-
performance liquid chromatography (HPLC). So identical heavy and light peptides 
should fly together during mass spectrometry. The absence of either the heavy or 
light peptide will be apparent from mass. Nonetheless, iBAQ is still a useful 
technique. During iBAQ the sum of the all the observed peptide intensities is 
normalised to the number of observable peptides of a protein. This means that if 1 
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peptide is found from a very small protein this is scored much more highly than 1 
peptide identified from a very large protein. This is a simplification though as the 
analysis is influenced by the tryptic digest pattern of a particular protein, not just the 
size. 
The table in Figure 4.5 shows that 19 proteins, including WAC, were pulled 
down from both HEK293A and HeLa WAC-FLAP cells. These 19 proteins were 
filtered from the original list of 1,536 identified proteins. The 18 interactors identified 
were only in the experiment (both WAC and WAC-FLAP immunoprecipitation) but 
not the control. Extra information is given in the table to aid interpretation of the 
data. The posterior error probably (PEP) is a measurement of how reliable the 
peptide identification is: the smaller the number the smaller the possible error. The 
intensity column shows the sum of the observed signal intensities from the two 
datasets. As a further quality parameter, CRAPome frequencies are displayed 
http://www.crapome.org/ (Mellacheruvu et al., 2013). The CRAPome is a database 
of common contaminating proteins found in affinity purification mass spectrometry 
experiments. Where multiple gene names are given in the same row, these are 
either alternative names for the same gene, or the genes may be so similar that the 
identified peptides may belong to any of them. 
As expected, nuclear and Golgi proteins, as described by UniProt 
annotations, were identified as WAC interactors: RNF20, RNF40, UBE2A, 
PRPF40A, WTAP, RBM15, MCM4, THOC2 (nuclear) and GOLGA2, ERC1, RAB1 
and MYO18A (Golgi). As a validation of the technique known WAC interactors were 
identified, these were RNF20, RNF40 and UBE2A. UBE2A (Rad6) is the E2 
ubiquitin-conjugating enzyme that acts in conjunction with the RNF20/40 E3 
ubiquitin ligase complex (Zhang and Yu, 2011). 
In particular, I chose to focus on GM130 (GOLGA2) as a novel WAC 
interactor, because GM130 affects autophagy via an unknown mechanism (Chang 
et al., 2012). Furthermore, multiple GM130 peptides were identified in both 
experiments. The iBAQ values (Figure 4.5d and e) suggest that WAC-RNF20-
RNF40 exists as a stoichiometric complex. This supports the suggestion that WAC-
RNF20-RNF40 exists as a 2:2:2 heterohexameric complex (Zhang and Yu, 2011). 
The WAC-GM130 interaction is likely to be substoichiometric. 
It should be mentioned that Golgi-localised WAC interactors VCIP135 
(direct) and VCP/p97 (indirect) were not identified as WAC interactors in my hands, 
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even in the individual datasets (IP WAC or IP WAC-FLAP) before intersection. This 
may be because I did not have exogenous ATP in my buffer, whereas these 
interactions were originally studied in the presence of ATP (Totsukawa et al., 2011). 
As VCP is an ATPase, this could possibly affect conformation and interactions. 
Alternatively, WAC-VCIP135-VCP may occur at a very low incidence. 
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Figure 4.5 Immunoprecipitation of WAC complexes and mass spectrometry 
peptide identification 
(a) HEK293A cells were incubated with full medium (FM) or starved in EBSS (ES) 
for 2 hours. Lysates were incubated with protein G beads or with protein G beads 
plus anti-WAC antibody. Immunoprecipitated complexes were eluted followed by 
SDS-PAGE and colloidal Coomassie staining. Fixed gel slices were processed for 
mass spectrometry analysis by David Frith. Markers (M) shown in kilodaltons. (b) 
Western blot of lysates from (a) before and after immunoprecipitation. (c) Table 
displaying high stringency WAC interactors after filtering mass spectrometry 
datasets from HEK293A cells and HeLa WAC-FLAP cells. WAC and previously 
published interactors are highlighted in blue, GM130 (GOLGA2) is highlighted in 
orange. Posterior error probability, PEP. Data analysis performed by Bram 
Snijders. (d, e) Intensity based absolute quantification (iBAQ) values of identified 
proteins after immunoprecipitation of WAC from HEK293A cells (d) or 
immunoprecipitation of WAC-FLAP from HeLa cells (e). 19 proteins from table (c) 
are shown as blue or orange dots. WAC, published interactors and GM130 are 
shown as blue dots. Experiments shown were performed once. 
 
4.4 Validation of mass spectrometry data and mapping the 
WAC-GM130 interaction 
4.4.1 WAC interacts with COPI and with GM130 
After analysis of the mass spectrometry datasets I wanted to validate 
interactions by co-immunoprecipitation and western blotting. When analysing the 
unfiltered mass spectrometry data I noticed that a COPI coatomer subunit, alpha-
COP, was clearly enriched in pull-downs from HEK293A and HeLa WAC-FLAP 
cells (Table 4.1). The alpha-COP peptides did not meet the mass spectrometry 
filtering criteria in Figure 4.5c, as there was some background binding of alpha-
COP in the control samples. Nevertheless, I questioned whether WAC could 
interact with the COPI complex. This relevant because COPI was shown to 
regulate autophagy by maintaining endosome function and hence is important in 
the maturation stages of autophagy (Razi et al., 2009). COPI is a vesicle coat 
protein complex involved in retrograde trafficking (Golgi-to-ER) (Letourneur et al., 
1994, Cosson and Letourneur, 1994) and also in bidirectional intra-Golgi transport 
(Orci et al., 1997, Malhotra et al., 1989). COPI has also been implicated in 
anterograde transport (Bednarek et al., 1995) and is involved in maintaining the 
structure of the Golgi apparatus (Guo et al., 1994). I also sought to validate the 
WAC-GM130 interaction as highlighted before. 
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Table 4.1 alpha COP peptides are enriched in WAC or WAC-FLAP 
immunoprecipitates 
 
Immunoprecipitation of endogenous WAC from HEK293A cells indicated that 
WAC interacts with GM130 and with COPI, as shown by detection of another COPI 
subunit, beta’-COP (Figure 4.6a). In my hands and with our reagents western blot 
detection of co-immunoprecipitated alpha-COP was unsuccessful. A small amount 
of beta’-COP was found sticking to the control, whereas GM130 had little 
background binding. Thus, this experiment essentially replicates the findings of 
mass spectrometry. It should be noted that WAC interacts only with a very small 
percentage (estimated at < 5%) of GM130 and beta’-COP, even when the 
immunoprecipitation of the target (WAC) is efficient. 
At this stage I decided to study in greater detail WAC-GM130 interactions, 
rather than COPI. This was because of the reduced background binding of GM130 
versus COPI. More importantly perhaps, was that COPI depletion elicits a 
maturation defect in autophagy (Tooze and Razi, 2009), and hence is 
phenotypically dissimilar to WAC (Chapter 5 and (McKnight et al., 2012)). 
After starvation of HEK293A cells in EBSS to induce autophagy, I saw a small 
increase in the amount of co-immunoprecipitated GM130 in WAC pull-downs 
(Figure 4.6b and c). However, the interaction of WAC with RNF40 did not appear to 
be regulated by starvation. Densitometry and quantification of 3 experiments 
revealed that the increase in the WAC-GM130 interaction upon nutrient starvation 
was statistically significant (Figure 4.6c). In the HeLa WAC-FLAP cells I saw a 
similar effect from one experiment (Figure 4.6d): the amount of GM130 pulled-
down with WAC-FLAP increased upon starvation whereas RNF40 was unaffected.  
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Figure 4.6 WAC interacts with GM130 through its coiled-coil domain in a 
starvation regulated manner 
(a) WAC was immunoprecipitated using an anti-WAC antibody from HEK293A cells 
incubated in full medium before immunoblotting. Anti-GFP was used as control 
(Ctrl). HC, heavy chain. (b) WAC was immunoprecipitated from HEK293A cells 
before immunoblotting. Anti-GFP was used as control (Ctrl). Cells were maintained 
in full medium (FM) or EBSS (ES) for 2 hr prior to lysis. (c) Quantification of (b), co-
immunoprecipitated GM130 was normalised to amount of WAC 
immunoprecipitated. Statistics were performed using an unpaired Student’s t test, *, 
p ≤ 0.05. Mean ± SEM from 3 independent experiments. (d) Lysates from HeLa 
cells stably expressing WAC-FLAP were used for GFP-Trap pull-down before 
immunoblot. Cells were maintained in full medium (FM) or EBSS (ES) for 2 hr prior 
to lysis. Blocked agarose beads (the same matrix as GFP-TRAP beads) incubated 
with lysate were used as control. The two WAC bands visible are WAC-FLAP 
isoforms 1 and 4. Experiment was performed once (e) Lysates from HEK293A cells 
co-transfected with 3xHA-GM130 (rat) and EGFP-WAC (human) full length (FL), 
aa1-319 (NT), aa320-647 (CT), aa163-647 (ΔN) or aa1-610 (ΔCC) were used for 
HA immunoprecipitation followed by immunoblot. Experiment was performed once. 
(f) Lysates from HEK293A cells co-transfected with 3xHA-GM130 (rat) and EGFP, 
EGFP-WAC human full length aa1-647 (FL) or aa1-610 (ΔCC) were used for GFP-
Trap pull-down followed by immunoblot. Experiment was performed once. 
 
4.4.2 The WAC coiled-coil domain is required for the interaction with GM130 
I next wanted to see which domain(s) of WAC were required for its interaction 
with GM130. I cloned a series of truncated EGFP-WAC constructs in pEGFP C2 
and these are shown in Figure 4.7. These were: EGFP-WAC full length aa1-647 
(FL), N-terminal half aa1-319 (NT), C-terminal half aa320-647 (CT), aa163-647 
(ΔN) and aa1-610 (ΔCC). The ΔCC truncation removes the highly conserved 
coiled-coil domain of WAC. The ΔN truncation removes a large section of the WAC 
N-terminus, up to and including the conserved WW domain of WAC. The rest of the 
WAC protein is not predicted to contain any known domains and there is no three 
dimensional structure of WAC (Protein Data Bank). So to make some sort of 
informed decision on my truncation strategy I used the FoldIndex© tool (Prilusky et 
al., 2005) (Figure 4.8). The first half of the WAC protein is predicted to be unfolded. 
Although, presumably incorrectly, the WW domain (aa130-168, InterPro) is 
predicted to be unfolded, this is probably because the FoldIndex tool does not take 
into account domains but rather uses hydrophobicity and charge of amino acids. 
The C-terminal half of WAC is predicted to possess more structure than the first 
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half and may constitute some sort of functional module. This is why I decided to 
clone the two halves of WAC.  
After immunoprecipitation of 3xHA-GM130 (rat, gift from Joachim Seemann) 
(Figure 4.6e) I saw that WAC pieces FL, CT and ΔN were all co-
immunoprecipitated. Proportionately, in this experiment at least, the CT and ΔN 
truncation of EGFP-WAC interacted more with 3xHA-GM130 than FL WAC. This 
may be related to the enhanced ability of these truncations to exit the nucleus 
(Figure 3.2). NT and ΔCC did not interact with 3xHA-GM130. This suggests that 
the coiled-coil domain of WAC is required to interact with GM130. In support of this, 
a reciprocal assay where EGFP-WAC or ΔCC WAC was immunoprecipitated also 
suggested that the coiled-coil domain of WAC was crucial for interaction with 3xHA-
GM130 (Figure 4.6f). 
 
 
Figure 4.7 Human WAC isoform 1 primary structure and truncation constructs 
Boxed regions indicate the highly conserved WW and coiled-coil (CC) domains of 
WAC. The putative nuclear export signal (NES) of WAC is also shown. The dashed 
lines in the truncation constructs indicate the positions of the WW and CC domains. 
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Figure 4.8 FoldIndex© analysis of human WAC isoform 1 
(a) Probability plot of ability of the WAC protein to fold. 1=folded, -1=unfolded. (b) 
Primary structure of WAC isoform 1 with predicted ordered (green) and disordered 
regions (red) highlighted. 
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4.4.3 Amino acids 611-620 in the WAC coiled-coil domain are necessary but 
not sufficient for GM130 binding 
GM130 and RNF20/40 interact with the WAC coiled-coil domain. RNF20 
and RNF40 both contain coiled-coil domains, which bind WAC. Removal of the C-
terminal region aa559-647 of WAC resulted in the loss of both RNF20 and RNF40 
binding (Zhang and Yu, 2011). I wanted to investigate if GM130 and RNF20/40 
bound WAC at the same or different regions and if binding of one required or 
inhibits the binding of the other. With this aim in mind I designed a series of finer 
truncations, deletions and mutations of the WAC coiled-coil domain (Figure 4.9c). 
In addition to the EGFP-WAC aa1-160 (ΔCC) truncation, I cloned aa1-620 and 
aa1-630. To probe the contribution of the structure of the coiled-coil domain I made 
the double point mutant I626S and L629S (ISLS mutant). These two residues are 
conserved from Drosophila and reside in the ‘a’ and ‘d’ positions of the WAC 
coiled-coiled domain, in the centre of the predicted coiled-coil region (Figure 4.9d). 
The ‘a’ and ‘d’ positions of a coiled-coil domain are especially important for the 
structure of coiled-coils. Amino acids at these positions are usually hydrophobic 
and are buried at the interface between the alpha-helices that form the coiled-coil 
structure (Burkhard et al., 2001). By mutating these residues to polar serines I 
hoped to disrupt the structure of the WAC coiled-coil domain, with my functional 
readout being interactions with RNF40 or GM130. 
EGFP-WAC aa1-610 does not bind GM130 (or binds very weakly) but aa1-
620 restores the interaction, suggesting that the highly conserved 10 amino acids 
611-620 are required for GM130 binding (Figure 4.9a, b and d). However, aa611-
647, which includes the entire predicted coiled-coil domain, did not bind GM130. 
Thus amino acids 611-620 are necessary but not alone sufficient to bind GM130. 
The ISLS mutation completely ablated WAC binding to RNF40, however binding of 
GM130 was unaffected. As RNF20/40 directly binds WAC in the nucleus (Zhang 
and Yu, 2011), this suggests that the WAC-GM130 interaction (presumably on the 
Golgi), can occur independently of RNF20/40. As a proportion of the input, WAC 
interacts with much more RNF40 than GM130, as predicted by mass spectrometry 
(Figure 4.5d and e). All of my coiled-coil domain truncations resulted in the 
complete loss of RNF40 binding to WAC. This indicates that in addition to I626 and 
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L629, the adjacent sequence is critical for RNF40 binding. Interestingly, WAC 
aa611-647 did not bind RNF40 at all.  
When taking a closer look at the coiled-coil domain of WAC (Figure 4.9d), I 
noticed that the domain may actually extend past the predicted region in the N-
terminal direction, because amino acids at the ‘a’ and ‘d’ positions of heptads still 
remain hydrophobic. Thus it was suspected that aa611-647 did not contain all of 
the information to encode for the WAC coiled-coil domain and might not adopt the 
native conformation. In support of this hypothesis, aa580-647, which includes all 
possible residues encoding for the WAC coiled-coil domain, binds RNF40 (Figure 
4.9b). No binding to GM130 was detected suggesting that RNF40 binding to WAC 
occurs independently of WAC-GM130 interaction.  
One concern I had was that maybe the WAC truncation aa1-610 does not 
interact with GM130 because too many amino acids have been removed, leading 
to misfolding of the protein. To help address this, I made more precise deletions of 
the WAC coiled-coil domain using inverse PCR and PCR SOEing (Splicing by 
Overlap Extension) (Ho et al., 1989). Inverse PCR uses primers pointing away from 
each other, in my case on a plasmid template. These primers are designed to 
exclude the region to be deleted. The resulting linear amplicon is then subjected to 
intramolecular ligation to restore a circular plasmid with the targeted region 
removed. In PCR SOEing two PCR products are made of the two halves you want 
to join together, these are designed to flank the region to be deleted. The primers 
used to amplify one fragment contain an overhang, which is homologous to the end 
region of the other fragment, and vice versa. Thus the two PCR products from the 
first two PCR reactions are now mixed and used as both the primers and template 
in a third PCR reaction. The resulting amplicon contains the two halves spliced 
together with the original intervening sequence removed. Using these techniques I 
removed a 10 amino acid region (Δ611-620) as well as one heptad (Δ612-618) 
(Figure 4.9b). Removal of one heptad in WAC reduced binding to GM130 and 
removed binding to RNF40. Deletion of aa611-620 reduced WAC-GM130 binding 
to greater extent, where only very little binding was observed. Again the RNF40 
interaction was lost. These results further confirm the essential 10aa region for 
GM130 interaction. Although I saw degradation products of GFP-WAC (degraded 
from the C-terminus) in my GFP-Trap experiments (Figure 4.9a and b) even in the 
presence of the protease inhibitors (Roche), this does not seem to have altered the 
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results of the experiment.
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Figure 4.9 10 amino acids in the WAC coiled-coil domain are crucial for GM130 
interaction 
(a) Lysates from HEK293A cells transiently expressing EGFP or EGFP-WAC 
constructs FL, ISLS, ΔCC, aa1-620, aa1-630 or aa611-647 were used for GFP-
Trap pull-down followed by Western blotting. Endogenous GM130 and RNF40 
interaction was analysed by immunoblot. (b) Lysates from HEK293A cells 
transiently expressing EGFP, EGFP-WAC FL, ΔCC, aa1-620, aa1-630, Δ611-620, 
Δ612-618 or aa580-647 were used for GFP-Trap pull-down followed by immunoblot 
analysis. (c) Scheme of human WAC isoform 1 and deletion mutants used for 
mapping experiments, showing the WW domain, putative nuclear export signal 
(NES) and C-terminal coiled-coil (CC) domain, which includes the required 
sequence for GM130 binding. Domains are indicated by dashed lines. GM130 
binding ability is summarised on right. Deletion of 10aa region or 7aa heptad is 
indicated by a black square. Grey circles show ISLS mutations. (d) Alignment of 
protein sequence of human WAC (coiled-coil region) and its orthologues using 
UniProt. Alignment is using described algorithm (Soding, 2005). Sequences aligned 
were: Q9BTA9-1 Homo sapiens, G3XEV5 Rattus norvegicus, Q924H7-1 Mus 
musculus, E1C6W1 Gallus gallus, Q5U4Q0 Xenopus tropicalis, Q7ZUK7 Danio 
rerio, Q9VX88 (CG8949 isoform A) Drosophila melanogaster. Conserved amino 
acid sequence (*), conservative change (:), semi-conservative change (.), non-
conservative change ( ). Coiled-coil region is denoted by heptads assigned abcdefg 
positions. Green letters show predicted coiled-coil region using the COILS tool 
(Lupas et al., 1991) a 4-heptad window and a probably of > 0.5. Blue letters show 
extended heptads that are not predicted by bioinformatics to be coiled-coil but 
nevertheless possess some of the characteristics of a coiled-coil. Mutated residues 
for mapping experiments are shown in red. 
 
4.4.4 The WAC coiled-coil domain is required for direct interaction with 
GM130 in vitro 
Coiled-coils are protein interaction domains that form direct interactions with 
coiled-coil domains on other polypeptide chains (Burkhard et al., 2001). The 
majority of GM130 has predicted coiled-coil structure (Nakamura et al., 1995) and 
thus it is possible that the predicted WAC coiled-coil domain interacts directly with 
GM130. In order to test this I sought to purify both WAC and GM130 and 
investigate if they bound each other in vitro directly (Figure 4.10). Firstly I tested 
expression of GST-WAC and GST-1-610 (ΔCC) in E. coli (Figure 4.10a). WAC has 
no homologue in E. coli (BLASTP, data not shown). By assaying fusion protein 
expression in different colonies I could detect IPTG-induced proteins of the correct 
size to be GST-WAC or GST-1-610, as marked by asterisks. Although most of 
GST-WAC was insoluble (Figure 4.10b), enough of the protein was soluble to use 
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for purification purposes. Removal of the WAC coiled-coil domain greatly enhanced 
the solubility of GST-1-610.  
To purify GM130 my strategy was to express the protein in HEK293A cells. 
Although it is possible to express full length GM130 in bacterial cells (Ishida et al., 
2015), I was informed that this was difficult because GM130 often becomes 
insoluble (personal communication, Joachim Seemann). The advantage of 
expressing GM130 in HEK293A cells is that I know it is soluble (Figure 4.6), and it 
should be post-translationally modified. These modifications could be important for 
GM130 interaction; for example, it is known that phosphorylation of GM130 on 
Ser25 by Cdc2 disrupts interaction with p115 (Lowe et al., 1998). The disadvantage 
is that known GM130 interactors may contaminate my purification procedure. I tried 
to ameliorate this problem in two ways. Firstly, I cloned full-length rat GM130 with 
an N-terminal Strep-II tag (WSHPQFEK) with a 2xGly linker. The Strep-II tag binds 
with high affinity and selectivity to Strep-Tactin (a modified form of streptavidin) 
(Schmidt and Skerra, 2007). This is useful because I can wash the immobilised 
StrepII-GM130 with a high salt buffer to remove interaction partners. StrepII-
GM130 can then be specifically eluted with biotin to separate proteins that non-
specifically bind to the matrix. Biotin binds to Strep-Tactin thereby competing off 
StrepII-GM130. Most of StrepII-GM130 was eluted off Strep-Tactin after 5 minutes 
with biotin (Figure 4.10c). Secondly, I co-expressed StrepII-GM130 with HA-VP35. 
VP35 (virus protein 35) is an Ebola virus protein that antagonises the protein 
kinase R (PKR)-mediated repression of translation (Feng et al., 2007), which is 
triggered in HEK293 cells in response to transfection with plasmid DNA (Schumann 
et al., 2009). Thus co-expression of VP35 with your protein of interest can boost 
recombinant protein levels (Gantke et al., 2013). This is useful not just to improve 
yield, but also for stoichiometric reasons. In theory I should be able to saturate 
interactions with binding partners of GM130 to maximise the amount of 
uncomplexed protein. As seen in Figure 4.10c and d, expression of HA-VP35 
improved the yield of StrepII-GM130 and in conjunction with the Strep-II tag-Strep-
Tactin purification system, allowed for GM130 purification from human cells without 
detectable contaminants. 
GST-WAC and GST-1-610 (ΔCC) were immobilised on glutathione 
sepharose resin (Figure 4.10e), washed multiple times in a high salt buffer and 
then incubated with equal volumes of StrepII-GM130 in vitro. After binding, the 
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beads were washed and boiled before SDS-PAGE and western blotting. The levels 
of GST-WAC and ΔCC were monitored by Ponceau S staining. StrepII-GM130 was 
detected by Western blotting. This experiment was repeated three times and 
suggests that GM130 binds directly to the C-terminal coiled-coil domain of WAC. It 
should be noted that I had degradation problems with full length GST-WAC (data 
not shown), and that future investigations into the direct binding could make use of 
smaller more stable domains of WAC. 
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Figure 4.10 In vitro binding of GST-WAC and StrepII-GM130 requires the WAC 
coiled-coil domain 
(a) E. coli BL21-CodonPlus(DE3)-RIL cells were transformed with pGEX-4T-2 
GST-WAC or GST-1-610 (ΔCC), individual colonies were picked and cultured 
followed by protein expression induction with 1mM IPTG at OD600 = 0.6. Whole cell 
lysates of bacterial cultures were analysed by SDS-PAGE and Coomassie Blue 
staining. GST-WAC and GST-1-610 are indicated (*). (b) Solubility of GST-WAC 
and GST-1-610 from colonies picked in (a) was assessed by SDS-PAGE and 
Coomassie Blue staining. Bacterial cultures were lysed by sonication and subjected 
to centrifugation to separate soluble supernatant (S) and insoluble pellet (P) 
fractions. GST-WAC and GST-1-610 are indicated (*). (c) HEK293A cells were 
transiently transfected with empty vector (pcDNA 3.1 (+)), StrepII-GM130 (rat) or 
StrepII-GM130 and HA-VP35. Cells were lysed and incubated with Strep-Tactin 
beads (Qiagen) before stringent washing in buffer containing 1% Triton X-100 and 
1M NaCl. StrepII-GM130 was eluted by the addition of 10mM biotin to the buffer 
and incubation at 4oC. Purification procedure was monitored by SDS-PAGE and 
colloidal Coomassie staining. (d) Purity of StrepII-GM130 used in in vitro binding 
assays (e) was confirmed by SDS-PAGE and colloidal Coomassie staining. (e) 
GST-WAC and GST-1-610 (ΔCC) were immobilised on glutathione sepharose 
beads. Equal volumes of soluble StrepII-GM130 were incubated with GST-WAC or 
GST-1-610 beads before washing. Bound proteins were eluted by boiling and ran 
on SDS-PAGE gels followed by western blotting. Protein levels of GST fusions 
were assessed by Ponceau S staining. In vitro binding experiment was repeated 
three times in total. Molecular weights in kilodaltons are indicated. 
 
4.4.5 WAC binds to a C-terminal region of GM130 that encompasses the 5th 
and 6th coiled-coil domains 
After identifying a 10 amino acid region of WAC that is required for GM130 
binding (Figure 4.9), I wanted see which region of GM130 was sufficient to bind to 
WAC. The majority of GM130 is predicted to adopt a coiled-coil structure, and 
interaction partners have been mapped to different regions of the protein, both 
within and outside of the coiled-coil domains (Figure 4.11c). I used truncations of 
human GM130 (gift from Angelika Barnekow) to map where WAC bound. 
Unfortunately, at this point I did not have full-length human GM130, so I had to use 
full-length rat GM130 as my positive control for EGFP-WAC binding (Figure 4.11a). 
Although, rat and human GM130 have high similarity as out of 1002 amino acids in 
human GM130, 748 are identical in the rat protein (UniProt alignment tool). This 
initial experiment suggested the first 445 amino acids of human GM130 isoform 1 
are dispensable for interaction with EGFP-WAC. Moreover, removal of these amino 
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acids did not seem to positively or negative regulate the interaction, at least from 
this one experiment. One caveat to keep in mind, is the rat full-length GM130 has 3 
HA tags, whereas the human truncations only have one HA tag each. This could 
affect IP efficiency and Western blot signal. To further extend these results, I used 
smaller truncations of human GM130 (Figure 4.11b). Full-length EGFP-WAC, but 
as expected not ΔCC, interacted with both aa692-1002 and aa774-1002. This 
suggests that WAC interacts with the C-terminal region of GM130, which includes 
the binding sites for ZFPL1, syntaxin 5 and GRASP65 (Chiu et al., 2008, Diao et 
al., 2008, Barr et al., 1998). This experiment was repeated twice with the same 
result. These smaller pieces of GM130 had more variable expression, especially 
when co-expressed with EGFP-WAC (data not shown). Thus I had to express 
these constructs separately, mix the lysates and then perform the IP, this gave me 
more control over the ectopic protein levels. It would be interesting to see in future 
studies if the interaction of WAC with GM130 is in competition with other GM130 
protein interactions. 
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Figure 4.11 EGFP-WAC interacts with the last 227 amino acids of HA-GM130 
(a) HEK293A cells were transiently transfected with EGFP-WAC and GM130 
constructs: 3xHA-GM130 full length (rat), HA-383-1002 (human), HA-446-1002 
(human) or pGADT7 (vector control). Cell lysates were subjected to anti-HA 
immunoprecipitation before SDS-PAGE and Western blotting. Experiment was 
performed once. (b) HEK293A cells were transfected separately with EGFP-WAC 
full length (FL), ΔCC or GM130 constructs HA-692-1002 or HA-774-1002. Lysates 
were mixed followed by anti-HA immunoprecipitation, SDS-PAGE and Western 
blotting. This experiment was repeated twice. (c) Schematic showing primary 
structure of human GM130 isoform 1. The six coiled-coil domains are indicated as 
well as interaction regions with known binding partners. 
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4.5 GM130 tethers WAC to the Golgi apparatus and this 
requires export of WAC from the nucleus 
4.5.1 WAC localisation to the Golgi and ERGIC requires the expression of 
GM130 
WAC colocalises with the cis-Golgi marker GM130 (Totsukawa et al., 2011). 
How this subcellular localisation occurs is unknown. After co-staining WAC with 
different markers of the secretory pathway, I saw that WAC colocalised with 
GM130 as expected, and also with another Golgi marker beta-COP (Duden et al., 
1991) (Figure 4.12a). This was predicted, as WAC likely interacts with the COPI 
coatomer, of which beta-COP is a component (Figure 4.6a). In addition to this, 
WAC colocalised with the ER-Golgi intermediate compartment (ERGIC) as marked 
by ERGIC-53. The ERGIC is a membrane compartment of the secretory pathway 
that mediates trafficking between the endoplasmic reticulum and the Golgi 
(Appenzeller-Herzog and Hauri, 2006). More colocalisation of WAC was seen with 
the juxtanuclear ERGIC, which is likely to be juxta-Golgi also, than with the 
peripheral ERGIC puncta that closely are apposed to ER-exit sites (Figure 4.12a). 
In contrast, there was less colocalisation of WAC with the trans-Golgi network 
(TGN) markers p230 and TGN46. In conclusion, WAC localises to membrane 
compartments of the secretory pathway, namely the ERGIC and the cis-Golgi, but 
minimally with the TGN. 
WAC interacts and colocalises with GM130. GM130 functions as a tethering 
molecule and has multiple interaction partners. This leads to the question: does 
GM130 tether WAC to the Golgi apparatus? To begin answering this I knocked 
down GM130 in HEK293A cells (Figure 4.12c). In cells with little or no detectable 
GM130 expression (see asterisked cell Figure 4.12c) I never observed juxtanuclear 
WAC localisation, even if the TGN remained intact, as judged by TGN46 staining. 
This experiment is supportive of GM130-mediated tethering of WAC to the Golgi. 
This experiment was performed once and would need to be repeated, but I provide 
additional evidence for GM130 tethering of WAC to the Golgi in (Figure 4.13).  
I next investigated whether GM130 was required to recruit WAC to a crude 
membrane isolate by subcellular fractionation. Surprisingly, knockdown of GM130 
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did not alter the amount of WAC recovered from the membrane pellet (Figure 
4.12d). Although this experiment was performed once, it suggests that a significant 
population of WAC may also localise to GM130-negative membrane compartments.  
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Figure 4.12 WAC localises to the cis-Golgi and the ERGIC and this requires 
GM130 expression 
(a) HeLa cells or HEK293A cells were fixed and labelled with antibodies to WAC, β-
COP, GM130 (HeLa) or ERGIC-53 (HEK293A) and analysed by indirect 
immunofluorescence and confocal microscopy. Scale bars, 10 µm. (b) HeLa cells 
were fixed and labelled with antibodies against p230 and TGN46 before analysis by 
indirect immunofluorescence and confocal microscopy. Scale bars, 10 µm. (c) 
HEK293A cells were treated with GM130 siRNA (01) for 72 hr before analysis by 
confocal microscopy using the indicated antibodies. (*) Cell expressing very low 
levels of GM130. Scale bars, 25 µm. Experiment performed once. (d) HEK293A 
cells were treated with RISC free (RF) or GM130 (GM) siRNA (01) for 72 hr before 
subcellular fractionation by differential centrifugation and SDS-PAGE followed by 
Western blotting. Nuclear pellet, Nuc; post-nuclear supernatant , PNS; cytosol, Cyt; 
membrane pellet, Mem. Experiment performed once. (a-c) Cells display variable 
nuclear WAC signal because of variable nuclear envelope permeabilisation by 
saponin.  
 
4.5.2 GM130 tethers WAC to the Golgi 
There is evidence that GM130 controls the structural organisation of the 
Golgi complex (see Chapter 1.4 for details). If GM130 knockdown does disrupt the 
cis-Golgi, this may indirectly affect WAC Golgi localisation. To address this concern 
I carried out additional experiments (Figure 4.13). 
Firstly, I depleted the endogenous WAC protein by siRNA knockdown in 
HEK293A cells. Knockdown efficacy was assessed by confocal microscopy (Figure 
4.13a). After knockdown there was a reduction of nuclear and Golgi WAC signal, 
indicating that the antibody is specific. This antibody, from Hisao Kondo, has 
previously been validated in HeLa cells, where WAC knockdown also reduced anti-
WAC signal in the nucleus and Golgi (Totsukawa et al., 2011). It is worth noting 
that Golgi-localised WAC is a heterogeneous phenotype, in that I do not see this in 
every cell. After knockdown of WAC, I attempted to rescue Golgi WAC localisation 
by expression of siRNA resistant EGFP-WAC or ΔCC, which binds GM130 very 
poorly or not at all (Figure 4.13b). In cells expressing EGFP-WAC full-length, I 
could detect Golgi-localised WAC by staining with the WAC antibody. However, in 
cells expressing EGFP-ΔCC I never detected Golgi-localised WAC. The EGFP 
signal was not detectable on the Golgi, but only in the nucleus, even for full-length 
EGFP-WAC. This is probably because the amount of total WAC on the Golgi is too 
low to be detected by EGFP fluorescence alone and therefore indirect 
immunofluorescence is required, as with the HeLa WAC-FLAP cells (Figure 4.2 
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and Figure 4.3c). This experiment supports my data that WAC is tethered to the 
Golgi via its interaction with GM130 mediated via its C-terminal coiled-coil domain. 
Finally, I made use of a recently developed tool from the Sean Munro lab 
(Wong and Munro, 2014). To explain, GM130 is truncated at the C-terminus in 
order to remove its Golgi localisation ability, which is directed by Grasp65 binding 
(Barr et al., 1998), and fused to the trans-membrane domain of mono amine 
oxidase, allowing localisation of GM130 to the outer membrane of the mitochondria. 
Mitochondrial localisation of this construct was confirmed in my hands by treatment 
of cells with MitoTracker Red (Figure 4.13c). This construct was originally used to 
determine the trafficking itinerary of vesicular secretory cargo, encoded by golgin 
specific tethering events. However, this tool could also be used to study protein 
interaction-partners of GM130. With this goal in mind, I saw that co-expression of 
EGFP-WAC with GM130-ΔCterm-HA-MAO drove the relocalisation of EGFP-WAC 
to the mitochondria, mitochondrially tethered WAC was enriched to the extent that 
antibody staining of WAC was not required (Figure 4.13d). In contrast EGFP-WAC 
aa1-319 (NT), which does not bind GM130 (Figure 4.6e), always remained 
exclusively nuclear, and no mitochondrial relocalisation was induced with GM130-
ΔCterm-HA-MAO co-expression. This experiment was repeated twice with the 
same result.  
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Figure 4.13 WAC localisation to the Golgi requires the WAC coiled-coil domain 
(a) HEK293A cells were treated with WAC siRNA (03) and analysed after 72 hr by 
indirect immunofluorescence and confocal microscopy using the indicated 
antibodies. Scale bars, 50 µm. (b) siRNA resistant EGFP-WAC FL or ΔCC were 
expressed in HEK293A cells treated with WAC siRNA (03) for 72 hr before analysis 
by confocal microscopy using the indicated antibodies. Scale bars, 20 µm. 
Experiment performed once. (c) HEK293A cells expressing GM130-ΔCterm-HA-
MAO were incubated in full medium with MitoTracker Red for 2 hr before staining 
with anti-HA antibody and analysis by confocal microscopy. Scale bars, 10 µm. (d) 
EGFP-WAC (FL) or aa1-319 (NT) were co-expressed with GM130-ΔCterm-HA-
MAO (monoamine oxidase (MAO) aa481-528) in HEK293A cells before labelling 
with anti-HA, and confocal microscopy. Scale bars, 10 µm. This experiment was 
repeated twice. 
 
4.5.3 Exportin1-dependent nuclear export is required to maintain the WAC-
GM130 interacting pool 
I wanted to gain some understanding of the relationship between the 
nuclear and cytoplasmic pools of the WAC protein. I noticed that WAC contains a 
putative nuclear export signal (NES) in the middle of the protein starting at aa367 
LPALQATLQL (Figure 4.9c). This was predicted using the NetNES tool (la Cour et 
al., 2004). NESs are hydrophobic leucine-rich sequences that are recognised by 
CRM1 (exportin1) to facilitate nuclear export (Fornerod et al., 1997). CRM1-
dependent nuclear export can be inhibited using the compound Leptomycin B 
(Wolff et al., 1997). I wanted to see if nuclear export affect recruitment of EGFP-
WAC to mitochondrially targeted GM130 (Figure 4.14). I used the autophagy cargo 
receptor p62 as a control readout, because p62 has a NES and rapidly 
accumulates in the nucleus upon Leptomycin B (LMB) treatment (Pankiv et al., 
2010). In fed control cells, EGFP-WAC could be targeted to the mitochondria when 
GM130-ΔCterm-HA-MAO was expressed and I could also detect some cytoplasmic 
p62 puncta. Two hours treatment with LMB was sufficient to robustly retain p62 in 
the nucleus, however I still found EGFP-WAC retained on the mitochondria. When I 
incubated cells with LMB for 24 hours, despite some toxicity, under these 
conditions there was even more accumulation of p62 in the nucleus, however WAC 
was not detected on mitochondrially localised GM130, suggesting that the NES in 
the WAC protein is functional. This experiment was repeated twice with the same 
result. It suggests that unlike cytosolic p62, WAC tethered to the Golgi (or in this 
case the mitochondria) is not free to diffuse. In fact the dissociation rate of WAC-
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GM130 would be predicted to be quite slow from this experiment. However, during 
extended inhibition of CRM1-dependent nuclear export, EGFP-WAC eventually 
dissociates from GM130 and relocalises to the nucleus. Thus, the cytoplasmic pool 
of WAC is predicted to exchange with nuclear WAC and vice versa, and this 
exchange is predicted to maintain Golgi WAC.  
 
 
Figure 4.14 Nuclear export of EGFP-WAC is required to maintain interaction with 
cytoplasmic GM130 
HEK293A cells expressing EGFP-WAC and GM130-ΔCterm-HA-MAO were 
incubated in full medium without or with Leptomycin B (LMB) for the indicated time 
before staining with anti-HA and anti-p62 antibodies and analysis by confocal 
microscopy. Scale bars, 10 µm. This experiment was repeated twice in total. 
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4.6 Discussion 
In this chapter I have developed a strategy for identifying novel WAC 
interactors, by intersecting mass spectrometry datasets from immunoprecipitation 
experiments from different cell lines. Modification of a bacterial artificial 
chromosome by homologous recombination permitted the benefits of tagging and 
the use of the high affinity GFP-Trap® system (Chromotek), as well as protein 
expression at low levels. A COPI subunit (beta’-COP) and GM130 were both 
validated as novel WAC interactors. alpha-COP was also suggested as a WAC 
interactor by mass spectrometry. Interestingly, ɑ-cop and β’-cop are both part of the 
same coatomer subcomplex and interact directly with each other (Eugster et al., 
2000). I assumed that this suggested WAC interacts with the COPI complex 
because COPI is stable with a half-life of around 28 hours and free subunits are 
scarce in interphase cells (Lowe and Kreis, 1996), but I concede this may not 
necessarily be the case without confirmation of other COPI subunits interacting 
with WAC. GM130 is thought to tether COPI vesicles to the Golgi (Sonnichsen et 
al., 1998). More specifically, GM130 binds the vesicle tethering protein p115, which 
in turn binds to Giantin on COPI vesicles. Docking of COPI vesicles to the Golgi 
can be inhibited by pre-treatment of the Golgi with GM130 antibodies. This 
functional link between GM130 and COPI offers the exciting possibility that WAC 
may also affect tethering of COPI. Knockdown of WAC results in vesiculation of the 
Golgi at the ultrastructural level (Totsukawa et al., 2011). It may be that this 
phenotype is related to WAC interactions with GM130 and/or COPI. Interestingly, 
Rab1, which interacts with GM130 to regulate COPII tethering (Moyer et al., 2001, 
Weide et al., 2001), may also interact with WAC (Figure 4.5c).  
The WAC-GM130 interaction is slightly enhanced upon starvation. How this 
occurs is unknown. However as both WAC and GM130 are modified by post-
translational modifications (Xu and Arnaout, 2002, Lowe et al., 1998), this could 
provide a way for nutrient status to signal to WAC-GM130. Although this effect is 
statistically significant, the biological significance of this finding remains to be 
proven.  
I have mapped the WAC-GM130 interaction on both sides, with more 
resolution on WAC, identifying a 10 amino acid region (aa611-620) in the coiled-
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coil domain required to bind GM130. This 10 amino acid region is highly conserved 
back to Drosophila (Figure 4.9d). It is worth mentioning that WAC and GM130 both 
have homologues in Drosophila, however only GM130 has an identified homologue 
in yeast (Bug1) (Behnia et al., 2007, Xu and Arnaout, 2002). It would be interesting 
to see if the WAC binding region on GM130 was conserved in yeast and if a 
functional WAC homologue does indeed exist in yeast. Finer mapping experiments 
would be needed to begin this.  
The interaction between WAC and GM130 appears to be direct. With this in 
mind, the 5th and/or 6th coiled-coil domains of GM130 are the best candidates for 
the WAC interaction site because coiled-coil domains often associate with one 
another (Burkhard et al., 2001). In contrast to the WAC-GM130 interaction, any 
perturbation of the WAC coiled-coil domain completely disrupted the WAC-RNF40 
interaction, suggesting the whole domain is required for interaction with RNF40. In 
fact, the WAC coiled-coil domain may be larger than previously predicted by 
bioinformatics (Xu and Arnaout, 2002). It may be that WAC-RNF40 is especially 
sensitive to any changes in the coiled-coil structure as probed by the I626S, L629S 
mutations, whereas WAC-GM130 may be more tolerant of changes in structure. 
Alternatively, the WAC-GM130 interaction may not be dictated by the structure of 
the coiled-coil per se, but other factors may be important such as ionic interactions. 
These binding assays suggest that WAC-GM130 and WAC-RNF40 can bind in a 
mutually exclusive manner and one might infer that they possess separate 
functions too. GM130 did not bind to the WAC region aa580-647, which suggests 
that a secondary region of WAC is required to bind GM130 in addition to the 10 
amino acid region (aa611-620). In support of this, I sometimes observed residual 
binding of GM130 to WAC even in the absence of the WAC coiled-coil domain 
(Figure 4.9a and b). As WAC aa320-647 does bind to GM130 (Figure 4.6e), this 
suggests that aa320-579 are also required for binding to GM130. This region of the 
protein is predicted to be folded (Figure 4.8). The presence of two regions on WAC 
that are required to interact with GM130 may suggest a multivalent interaction or 
perhaps some cooperativity between interaction sites. Ultimately, understanding 
these interactions at the three dimensional level would be crucial in unravelling this. 
How WAC is localised to the Golgi was unknown (Totsukawa et al., 2011). 
WAC localises to and co-purifies with the Golgi complex, purified from rat liver, and 
like GM130, WAC is stably associated with the Golgi, remaining on the Golgi after 
Chapter 4. Results 
 
162 
 
1M KCl wash (Totsukawa et al., 2011, Nakamura et al., 1995). A number of 
experiments suggest that GM130 tethers WAC to the Golgi, however WAC appears 
to also associate with (presumably non-Golgi) membranes in a manner not 
dependent on GM130 (Figure 4.12d). Peptides of the epidermal growth factor 
receptor (EGFR) were detected by mass spectrometry for WAC interactors (Figure 
4.5c), it could be that WAC localises to EGFR-positive GM130-negative membrane 
compartments such as endosomes or the plasma membrane (Tomas et al., 2014). 
WAC localisation to the Juxtanuclear region, which included the ERGIC and Golgi, 
required GM130 expression (Figure 4.12). GM130 is known to cycle between the 
ERGIC and Golgi (Marra et al., 2001), and this could be why depletion of GM130 
resulted in loss of WAC from both the Golgi and the ERGIC. Experiments with the 
drug Leptomycin B suggest that the GM130-binding and nuclear pools of the WAC 
protein exchange with one another. How WAC nucleocytoplasmic translocation is 
regulated still remains a mystery.  
No autophagy machinery components were identified as WAC interactors, 
which would have been a more straightforward path. However, as GM130 
regulates autophagy (Chang et al., 2012), it makes sense to further investigate this 
as a mechanism for how WAC could modulate autophagy. 
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Chapter 5. Elucidation of WAC function in the 
autophagy pathway 
5.1 Introduction and aim 
5.1.1 Introduction 
As described previously (Chapter 1) WAC and GM130 both regulate 
autophagy. Depletion of WAC by siRNA reduced LC3 lipidation and impaired p62 
degradation (McKnight et al., 2012). Conversely, depletion of GM130 by shRNA 
resulted in an increase in lipidated LC3 and an accumulation of autophagosomes 
(Chang et al., 2012). Thus WAC and GM130 appear to be positive and negative 
regulators of autophagy respectively. The data presented in Chapter 4 suggests 
that WAC interacts with GM130. This leads to the hypothesis that WAC may act to 
repress some negative function of GM130 on autophagy, in order to regulate and 
maintain high autophagic flux during starvation. I predict this function to be 
regulatory rather than absolutely required for autophagy. The question is therefore: 
how does this occur? One explanation could be that WAC and/or GM130 exert 
some direct effect on the autophagy machinery. Although no core autophagy 
proteins were identified as WAC interactors by mass spectrometry (Chapter 4), 
there is the possibility of false negatives as discussed, and it may be that WAC 
interactions with the autophagy machinery could be detected by other methods.  
Interestingly, GM130 interacts with both Rab1b and Rab33b specifically in their 
GTP-bound states, and therefore could be an effector of these Rabs (Moyer et al., 
2001, Weide et al., 2001, Valsdottir et al., 2001). Both Rab1b and Rab33b have 
been implicated in autophagy (Itoh et al., 2008, Itoh et al., 2011, Doring and Prange, 
2015, Mochizuki et al., 2013, Zoppino et al., 2010, Huang et al., 2011). Rab 
proteins are small GTPases that control specificity in membrane trafficking 
pathways by regulating vesicle tethering and fusion events through interactions 
with effector molecules (Barr, 2013). Effectors bind to the Rabs in their active GTP-
bound state. Active GTP-bound Rabs are targeted to membranes to exert their 
function, whereas GDP bound Rab proteins can be sequestered in the cytosol by 
binding to guanine nucleotide displacement inhibitor (GDI). Rab activation and 
deactivation is promoted by guanine nucleotide exchange factors (GEFs) and 
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GTPase activating proteins (GAPs), respectively. Although the GM130-Rab1 
interaction is likely to be involved in the secretory pathway (Moyer et al., 2001), the 
involvement of Rab1 in autophagy is thought to be independent of its function in 
secretion (Huang et al., 2011). Rab1 exerts its effect on the autophagy at a very 
early stage during omegasome formation (Mochizuki et al., 2013). Rab33b on the 
other hand, interacts with Atg16L1 this is thought to modulate both autophagosome 
formation and maturation (Itoh et al., 2011, Itoh et al., 2008). Additionally, like 
Rab1b, Rab33b also appears to have a role in the secretory pathway (Valsdottir et 
al., 2001). One hypothesis I had was that GM130 may bind Rab1b and or Rab33b 
as an effector, to direct their function in secretion. WAC may be able to redirect 
these Rabs away from GM130 towards their autophagy specific function. Although 
this hypothesis was attractive to me, I could find no conclusive evidence that WAC 
regulated GM130-Rab interactions through the use of immunoprecipitation and 
immunofluorescence approaches (data not shown). 
 
5.1.2 Aim 
With this background in mind, I aimed to address WAC-GM130 function in the 
autophagy pathway in two stages. Firstly, I decided to characterise in more detail 
the effects of WAC and GM130 on autophagy. In the case of WAC I aimed to carry 
out a comprehensive analysis of WAC’s effect on the autophagy pathway, which 
can be simplified as a hierarchy of signal transduction and protein recruitment 
events. With GM130, I aimed to reproduce and extend the published data that 
GM130 is a negative regulator of autophagy. This phenotypic approach, I hoped, 
could give insights into the mechanism by which WAC and GM130 affect 
autophagosome formation. Secondly, In order to elucidate how WAC-GM130 could 
impact on autophagy it is necessary to identify if any interactions with the 
autophagy machinery exist. After I stopped working on GM130-Rab interactions I 
decided to change strategy. A former student in the lab Nicole McKnight, reported 
in her thesis that WAC colocalised with GABARAP. This led me to investigate 
WAC-GM130 interactions with GABARAP, by overexpression and co-
immunoprecipitation studies combined with indirect immunofluorescence of 
endogenous protein staining. This was combined with siRNA knockdown 
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experiments that allowed me to dissect further WAC and GM130 effects on the 
GABARAP protein in terms of subcellular localisation and protein interactions. 
 
5.2 WAC is required for maximal ULK1 kinase activation 
downstream of mTORC1 deactivation 
5.2.1 WAC is required for efficient LC3 lipidation and p62 degradation 
As stated in the aims above, I began by further investigating the impact of 
WAC on the autophagy hierarchy. It has been shown that WAC is a positive 
regulator of autophagy (McKnight et al., 2012) (see Chapter 1.3). WAC depletion 
resulted in impaired p62 degradation and reduced LC3 lipidation and GFP-LC3 
puncta formation. I began by trying to reproduce and extend these data, using 
lipidation of LC3 and autophagic clearance of p62 as my readout for WAC’s impact 
on autophagy. Depletion of WAC reduced the formation of LC3-II upon starvation 
and treatment with BafA (Figure 5.1a and b). Less effect on LC3-II levels was 
observed in fed/basal conditions, as seen previously (McKnight et al., 2012). 
Furthermore, introduction of siRNA resistant EGFP-WAC into WAC depleted cells 
reversed the reduction in LC3 lipidation, at least from one experiment (Figure 5.1c). 
This suggests that WAC’s effect on LC3 lipidation is not a result of an off-target 
effect of the siRNA used. In support of this suggestion, a reduction of GFP-LC3 
puncta and LC3 lipidation was seen with multiple WAC siRNA duplexes, previously 
described (McKnight et al., 2012) and Nicole McKnight, (“A Genome-wide Screen 
for Starvation-induced Autophagy Identifies New Modulators of Autophagy”, 2010). 
Knockdown of WAC increased basal p62 protein levels in both HEK293A cells and 
mouse embryonic fibroblasts (MEFs) (Figure 5.1d, e and f) supporting the 
published data. Human WAC isoform 1 is 95% identical to the mouse protein at the 
amino acid level ((Xu and Arnaout, 2002) and UniProt), so one would expect the 
proteins to be functionally similar in MEFs and HEK293A cells. 
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Figure 5.1 Depletion of WAC reduces LC3 lipidation and degradation of p62 
(a) HEK293A cells were treated for 72 hr with RISC Free (RF) or WAC siRNA (03) 
and then incubated in full medium (Fed), EBSS or EBSS + Bafilomycin A1 (Baf) for 
2 hr before immunoblot analysis. (b) Quantification of (A), mean ± SD from 2 
independent experiments. Full medium, FM; EBSS, ES; EBSS + BafA1, EB. (c) 
siRNA-resistant EGFP-WAC or empty vector were expressed in HEK293A cells 
treated for 72 hr with either RISC free (RF) or WAC siRNA. After 2hr starvation with 
EBSS and BafA1, cells were analysed by immunoblot. Experiment performed once. 
(d-f) HEK293A or MEF cells were treated for 72 hr with RF or WAC siRNA before 
immunoblot analysis. Graph shows quantification from HEK293A cells, mean ± SD 
from 2 independent experiments. 
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5.2.2 WAC isoform 1 promotes LC3B puncta formation and this requires the 
GM130-interacting coiled-coil domain 
Knockdown of WAC with different siRNA duplexes reduces the formation of 
GFP-LC3B spots in HEK293 cells (McKnight et al., 2012). In light of this, I wanted 
to investigate whether WAC regulated the formation of endogenous LC3B positive 
autophagosomes. In control HEK293A cells, LC3B positive puncta were formed 
after 2 hours starvation with EBSS, however fewer puncta were seen in cells 
treated with WAC siRNA (Figure 5.2a and b). This reduction in autophagosome 
formation was rescued by the expression of siRNA resistant Myc-WAC isoform 1 in 
WAC depleted cells. Cells expressing Myc-WAC were identified by nuclear Myc 
staining. However, introduction of truncated Myc-WAC aa1-610 (ΔC), which does 
not interact with GM130 (Figure 4.6e and f) did not rescue LC3B spot formation to 
control levels. This suggests that the coiled-coil domain of WAC is required for 
maximal autophagosome formation during starvation and that the interaction with 
GM130 may also be required. 
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Figure 5.2 The WAC coiled-coil domain is required for maximal LC3B puncta 
formation during starvation 
(a and b) RISC Free or WAC (siWAC) siRNA treated HEK293A cells for 72 hr 
transfected with empty vector (a), siRNA resistant Myc-WAC (WT) or siRNA 
resistant Myc-WAC aa1-610 (ΔC) (b), starved for 2 hr with EBSS. LC3B puncta 
were analysed by confocal microscopy. (c) LC3B puncta from (a and b) Mean ± 
SEM of 3 independent experiments, a total of >400 cells counted per condition, 
unpaired Student’s t test, ****, p ≤ 0.0001. 
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5.2.3 WAC promotes WIPI2 spot formation upon nutrient deprivation 
WIPI2 binds to the pool of phosphatidylinositol 3-phosphate (PI3P) lipid 
formed by the Vps34-containing Beclin1 complex upon starvation (Polson et al., 
2010). WIPI2 marks early autophagic structures such as phagophores rather than 
more mature structures like autolysosomes, and functions downstream of 
omegasomes. Thus, WIPI2 can be used as a specific marker for early autophagic 
structures. Furthermore, because WIPI2 functions to recruit the Atg12–5-16L1 
complex to phagophores, thereby allowing LC3 lipidation (Dooley et al., 2014), 
WIPI2 is considered upstream of LC3 lipidation. I wanted to investigate whether 
WAC also affects autophagy upstream of LC3 lipidation. 
Treatment of HEK293A cells with siRNA targeting WAC reduced WIPI2 
puncta formation upon starvation, without affecting total WIPI2 protein levels 
(Figure 5.3a, b and c). Furthermore this reduction could be rescued by the 
transfection of siRNA resistant Myc-WAC (isoform 1) (Figure 5.3d). I saw a similar 
effect from one experiment in HeLa cells, using two different WAC siRNAs (Figure 
5.4). In the HeLa cell experiment, I normalised the number of WIPI2 spots to the 
cell area (Figure 5.4b), rather than the cell number. This was in case WAC had 
some effect on cell size and thus an indirect effect on WIPI2 spot number. However 
normalisation to cell area did not change the phenotype observed. These data 
suggest that in the absence of WAC, there is less PI3P being produced by Vps34 
and thus less recruitment of WIPI2 to cytoplasmic puncta. There are alternative 
interpretations of this data; for example in the absence of WAC, WIPI2 is tethered 
at some other compartment and unable to be recruited, or that PI3P phosphatase 
activity is enhanced upon WAC knockdown. Both of these conclusions are less 
likely given the additional data I will discuss. 
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Figure 5.3 Knockdown of WAC attenuates starvation-induced WIPI2 puncta 
formation in HEK293A cells 
(a) HEK293A cells were treated with RISC Free (RF) or WAC siRNA for 72 hr 
before starvation for 2 hr in EBSS, followed by fixation and labelling with WIPI2 
antibody and confocal microscopy analysis. Scale bars, 50 µm. (b) WIPI2 puncta in 
(a) were counted, normalised to cell number. Mean ± SD from 2 independent 
experiments, >150 cells counted per condition in total. RISC Free, RF; Full 
medium, FM; EBSS, ES. (c) HEK293A cells were treated with RF or WAC (03) 
siRNA for 72 hr, at the same time as experiment shown in (a) before 
immunoblotting. (d) Empty vector (Vec) or Myc-WAC were expressed in HEK293A 
cells that were treated with RF or WAC (siW) siRNA for 72 hr followed by starvation 
in EBSS for 2 hr prior to WIPI2 staining and confocal microscopy. Statistics were 
performed using an unpaired Student’s t test, ****, p ≤ 0.0001. Mean ± SEM from 3 
independent experiments, >300 cells were counted per condition in total. 
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Figure 5.4 WAC depletion reduces WIPI2 spot formation in HeLa cells 
(a) HeLa cells were treated for 72 hr with RISC Free or WAC siRNA (03 or 04, 03 is 
displayed only) and then incubated in full medium (Fed) or EBSS (Starved) for 2 hr 
prior to analysis by either confocal microscopy (a) or immunoblot (c, fed). (b) 
Quantification of (a), mean ± SD from at least 120 cells per condition. Full medium, 
FM; EBSS, ES. Number of WIPI2 spots were normalised to cell area. 
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5.2.4 WAC regulates ULK1 kinase activity downstream of mTORC1 
In the presence of amino acids the autophagy-initiating protein kinase, ULK1, 
is phosphorylated and inhibited by mTORC1. mTORC1 is a master inhibitor of 
canonical ULK-dependent autophagy and this is reviewed in greater detail in 
Chapter 1. Phosphorylation of ULK1 at serine 757 by mTORC1 antagonises the 
pro-autophagic interaction between ULK1 and AMPK (Kim et al., 2011). This 
phosphorylation site should thus provide a functional readout of the autophagy 
specific arm of mTORC1 signalling, as opposed to translational control for example 
(Laplante and Sabatini, 2012). Upon amino acid starvation mTORC1 is deactivated, 
resulting in dephosphorylation of ULK1, ULK1 activation, autophosphorylation and 
phosphorylation of ULK1 substrates. The ULK complex member, Atg13, is 
phosphorylated at serine 318 by active ULK1 (Joo et al., 2011). However, Ser318 
phosphorylation of Atg13 by ULK1 is thought to be involved in mitophagy, in a 
mechanism whereby Atg13 can dissociate from the ULK1 complex and localise to 
damaged mitochondria. The Atg13 S318A mutation has a dominant-negative effect 
on mitophagy, but does not inhibit basal or starvation-induced autophagy. This 
means that phosphorylation at Ser318 on Atg13 should in theory be a readout for 
active ULK1, but not necessarily a functional readout of starvation-induced 
autophagy.  
In order to investigate if Atg13 phosphorylation at Ser318 responds as 
expected to nutrient starvation, I performed a starvation time course (Figure 5.5a 
and b). At the time I did the experiment it was unknown whether this 
phosphorylation event would be stimulated by EBSS starvation, but it was pleasing 
to see that Atg13 Ser318 phosphorylation was recently validated as a readout for 
ULK1 activity and nutrient status (Petherick et al., 2015). This was facilitated by the 
development of small molecule inhibitors of ULK1. This modification is now used as 
a readout in screens and biochemical assays (Rosenberg et al., 2015, Popovic and 
Dikic, 2014). After starving HEK293A cells for 15, 30 or 60 minutes there was a 
loss of phosphorylation of ULK1 at Ser757 that correlated with an increase of 
phosphorylation at Ser318 on Atg13, as expected (Figure 5.5a). In cells depleted of 
WAC the profile of mTORC1 deactivation upon starvation (ULK1 p-Ser757) was 
similar to control cells, however activation of the ULK1 complex (Atg13 p-Ser318) 
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was significantly reduced after 15 minutes and remained reduced after 1 hour 
(Figure 5.5b). This result suggests that knockdown of WAC does not affect 
starvation-induced deactivation of mTORC1, but does reduce activation of the 
ULK1 complex.  
In order to strengthen this conclusion I performed immunofluorescence for 
WIPI2 after treating control HEK293A cells or WAC knockdown cells with Torin1 for 
2 hours (Figure 5.5c). Torin1 is a potent ATP-competitive inhibitor of the both 
mTORC1 and mTORC2 that inhibits mTORC1 more completely than rapamycin 
(Thoreen et al., 2009). Thus Torin1 treatment induces autophagy and results in 
WIPI2 puncta formation (Polson et al., 2010). Knockdown of WAC reduced Torin1-
induced WIPI2 puncta formation, to a similar extent as was seen during nutrient 
starvation (Figure 5.3b and Figure 5.4b). This further suggests that WAC exerts its 
effect on autophagy downstream of mTOR.  
Another function of mTORC1 is to control protein synthesis (Laplante and 
Sabatini, 2012). One way this occurs is through the phosphorylation of S6 kinase 1 
(S6K1) by active mTORC1 in the presence of nutrients. S6K1 in turn 
phosphorylates its substrate, ribosomal protein S6. Thus signalling to the 
translational arm of the mTORC1 pathway can also be monitored. Upon siRNA 
targeting of WAC I again saw a reduction of starvation-induced ULK1 activation as 
measured by Atg13 Ser318 phosphorylation, this time after 2 hours (Figure 5.5d). 
This reduction was modest suggesting WAC is a regulator of autophagy as I 
proposed before. mTORC1 deactivation during starvation, as measured by S6 
phosphorylation at Ser240 and Ser244, was identical after 2 hours in both control 
and WAC knockdown cells. Taken together these data suggest that WAC is not 
involved in the signalling events of mTORC1 deactivation, but rather promotes 
activation of the ULK1 complex. 
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Figure 5.5 WAC is required for maximal ULK1 activation but not mTORC1 
deactivation upon starvation 
(a) HEK293A cells treated with RISC free (RF) or WAC siRNA (03) for 72 hr were 
incubated in full medium (FM) or EBSS (ES) for 15, 30 and 60 min prior to 
immunoblot analysis. (b) Quantification of (a), statistical analysis unpaired 
Student’s t test, Mean ± SEM from 3 independent experiments, *, p ≤ 0.05. (c) 
HEK293A cells were treated for 72 hr with RF or WAC siRNA (03) and then 
incubated in full medium or full medium + Torin1 for 2 hr before analysis by 
confocal microscopy and quantification of WIPI2 puncta. Mean ± SD from at least 
80 cells per condition. (d) HEK293A cells were treated for 72 hr with RF or WAC 
siRNA and then incubated in full medium (Fed) or EBSS for 2 hr before immunoblot 
analysis. Experiment performed once. 
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5.2.5 Depletion of WAC prevents redistribution of Atg9 away from the Golgi 
region during starvation 
Atg9 is a transmembrane protein that is essential for autophagy and in 
mammals Atg9 is localised to a pool at the trans-Golgi network (TGN) in nutrient 
replete conditions (Young et al., 2006). A population of Atg9 has also been 
identified at the plasma membrane (Puri et al., 2013, Popovic and Dikic, 2014). 
During starvation, Atg9 relocalises from the TGN to endosomes, and this requires 
ULK1. Given that WAC knockdown reduces ULK1 activity, I reasoned that 
depletion of WAC should also affect relocalisation of Atg9 during starvation. This 
was important as a modest reduction in ULK1 signalling upon WAC knockdown 
may not necessarily be of biological significance. In HEK293A cells maintained in 
full medium Atg9 was concentrated in a juxtanuclear pool marked by GM130 
(Figure 5.6). This was not necessarily colocalisation, as I had to open the pinhole of 
the confocal microscope to detect Atg9 signal. Upon starvation many cells lost this 
juxtanuclear concentration of Atg9, suggesting Atg9 had relocalised to another 
membrane compartment as previously published (Young et al., 2006). During 
starvation of ULK1 or WAC knockdown cells, Atg9 was retained at the Golgi region 
in many cases. This experiment was performed only once, and so it would be 
important to reproduce and quantify this effect for future studies.  
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Figure 5.6 WAC knockdown prevented starvation-induced mAtg9 redistribution 
HEK293A cells were treated with RISC free, ULK1 (04) or WAC (03) siRNA for 72 
hr followed by treatment with full medium (Fed) or EBSS (Starved) for 2 hr, fixation 
and analysis by confocal microscopy. Scale bars, 50 µm. Experiment performed 
once. 
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5.3 GM130 is a negative regulator of autophagosome formation 
5.3.1 Depletion of GM130 enhances LC3 Lipidation, p62 degradation and 
WIPI2 spot formation 
It was previously published that GM130 is a negative regulator of autophagy 
based on the following observations (Chang et al., 2012): In A549 cells treatment 
with a shRNA targeted against GM130 increased the amount of lipidated LC3 
under basal conditions as well endogenous LC3 puncta formation under basal 
conditions. In the K-rasLA1 lung cancer mouse model, aerosolised delivery of 
shRNA targeting GM130 to the lungs increased the levels of lipidated LC3, LC3 
histopathological staining and autophagosome number by electron microscopy. 
However, despite these results, done without the use of tools to inhibit autophagic 
flux such as Bafilomycin A1 it is not clear whether depletion of GM130 blocks 
autophagic degradation or increases the levels of autophagy (as described in the 
guidelines (Klionsky et al., 2012)). In light of this, I sought to reproduce and extend 
the published findings that GM130 is a negative regulator of autophagy in our 
model HEK293A cell line, and to investigate the effects of GM130 on the early 
autophagy pathway, if any.  
siRNA depletion of GM130 with two different duplexes showed a small 
increase of LC3II levels in both basal and starvation conditions, whereas no effect 
was seen on LC3I levels (Figure 5.7a and c). However, under conditions of 
starvation in the presence of BafA, LC3II levels were unaffected by GM130 
knockdown. p62 protein levels relative to actin were also decreased to a small 
extent upon GM130 depletion with 2 different siRNAs, in both basal and starvation 
conditions (Figure 5.7b and d). However no effect was seen during BafA treatment. 
These results suggest that depletion of GM130 increases LC3 lipidation and p62 
degradation and thus GM130 is negative regulator of basal and starvation induced 
autophagy. I proceeded to investigate markers of the early autophagy pathway 
after knockdown of GM130. WIPI2 puncta formation during starvation was 
significantly enhanced upon GM130 depletion, but no effect was seen on basal 
WIPI2 spot number (Figure 5.7e). ULK1 activity, as measured by phosphorylation 
of Atg13 on Ser318, was significantly increased in nutrient replete conditions with 
GM130-03 siRNA only but not with GM130-01 siRNA (Figure 5.7f and g). During 
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starvation, knockdown of GM130 had no effect on ULK1 activity. It may be that 
under starvation conditions Ser318 of Atg13 is maximally phosphorylated and 
further increases are not possible or detectable. The fact that only one siRNA to 
GM130 affected ULK1 activity suggest that this may be an off-target effect of the 
siRNA, or that the effect is very small and hard to reproduce. Nonetheless, these 
data suggest that like WAC, GM130 affects the early autophagy pathway. 
However, unlike WAC, GM130 appears to modestly inhibit the formation of 
autophagosomes. 
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Figure 5.7 Knockdown of GM130 enhances autophagy at an early stage of the 
pathway  
(a and b) HEK293A cells treated with RISC Free (RF) or GM130 siRNA-01 or -03 
incubated in full medium (fed), or EBSS with or without Bafilomycin A1 for 2 hrs, 
followed by immunoblot. (c) LC3-II levels from (a) mean ± SEM of 4 independent 
experiments, Mann-Whitney test, *, p ≤ 0.05. (d) p62 degradation from (b) mean ± 
SEM of 5 independent experiments, Mann-Whitney test, *, p ≤ 0.05. (e) HEK293A 
cells treated with RF or GM130 siRNA (-01) incubated in full medium (FM), or 
EBSS (ES) for 2 hrs and fixed for labelling. Statistical analysis unpaired Student’s t 
test, Mean ± SEM 4 independent experiments. **, p ≤ 0.01. >30 fields of cells were 
analysed per condition in total. Spot counting and analysis was performed by 
Minoo Razi. (f) HEK293A cells treated with RF or GM130 siRNA-01 or -03 
incubated in full medium (fed), or EBSS for 2 hrs and immunoblotted. (g) 
Quantification of (f), statistical analysis unpaired Student’s t test, Mean ± SEM 5 
independent experiments, **, p ≤ 0.01 
 
5.3.2 Overexpression of GM130 inhibits LC3 lipidation 
If knockdown of GM130 increases autophagy, overexpression of GM130 
should in theory block autophagy at an early stage, assuming that the 
overexpressed protein in some way functionally replicates the endogenous protein. 
Overexpression of rat 3xHA-GM130 resulted in a robust decrease of LC3II 
accumulation during starvation and BafA treatment (Figure 5.8a and b), similar to 
knockdown of WAC (Figure 5.1a and b). This suggests that GM130 overexpression 
blocks the formation of lipidated LC3 during starvation. However, puzzlingly other 
markers of autophagy were unaffected by GM130 overexpression. The profile of 
p62 degradation was similar between vector transfected and GM130 
overexpressing cells. WIPI2 spot formation was also unaffected after GM130 
overexpression, in both basal and starvation conditions. In summary, although 
there is some evidence that GM130 overexpression blocks autophagy, this is not 
conclusive based on an investigation of multiple autophagic readouts. It has 
recently been published that overexpressed GM130 translocates to the nucleus 
(Wei et al., 2015), and it may be that GM130 overexpression may not be a good 
functional opposite of GM130 depletion.  
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Figure 5.8 Overexpression of HA-GM130 suppresses LC3 lipidation but does not 
affect p62 degradation or WIPI2 spot formation 
(a) HEK293A cells expressing empty vector or 3xHA-GM130 were incubated in full 
medium (FM), full medium with BafA (FB), EBSS (ES), or EBSS with BafA (EB) for 
2 hr prior to immunoblot. Shorter and longer film exposures of LC3 immunoblot are 
denoted with (short) and (long) respectively. (b) Quantification of (a) statistics were 
performed using an unpaired Student’s t test, *, p ≤ 0.05. Mean ± SEM from 3 
independent experiments. (c) Quantification of (a) statistics were performed using 
an unpaired Student’s t test, *, p ≤ 0.05. Mean ± SEM from 5 independent 
experiments. (d) HEK293A cells expressing empty vector or 3xHA-GM130 were 
incubated in full medium (FM) or EBSS (ES) for 2 hr prior to fixation, confocal 
microscopy and spot counting (performed by Minoo Razi). 
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5.4 GM130 directly interacts with GABARAP and WAC 
indirectly interacts with GABARAP 
5.4.1 GM130 binds to GABARAP 
After investigating the effects of WAC and GM130 on the hierarchy of the 
autophagy pathway, I wanted to understand how WAC and GM130 could regulate 
autophagy at a more molecular level. I decided to investigate GABARAP because 
Nicole Mcknight (“A Genome-wide Screen for Starvation-induced Autophagy 
Identifies New Modulators of Autophagy”, 2010) had previously reported a 
colocalisation of GABARAP with WAC on punctate structures, although no 
colocalisation of WAC with GFP-LC3 was observed. I noticed that there was minor 
colocalisation between GM130 and GABARAP under both basal and starvation 
conditions (Figure 5.9a). Interestingly, GM130 was arranged around or juxtaposed 
to enlarged GABARAP structures that appeared larger than autophagosomes. As 
GM130 and GABARAP exhibited some colocalisation I tested if they could interact. 
After overexpressing the EGFP-tagged human Atg8 family of proteins in HEK293A 
cells followed by GFP-TRAP immunoprecipitations, I could show that out of the 
mAtg8 proteins tested endogenous GM130 interacted most abundantly with EGFP-
GABARAP (Figure 5.9b). Myc-WAC was also detected as binding EGFP-
GABARAP, but did not prefer GABARAP unlike GM130. Importantly, WAC and 
GM130 both interacted with GABARAP at the endogenous level, after 
immunoprecipitation of GABARAP (Figure 5.9c). The interaction between GM130 
and GABARAP appears to be direct (Figure 5.9d). After incubation of two different 
concentrations (by volume) of soluble Strep II-GM130 (purified as per Figure 4.10d) 
with immobilised recombinant GST or GST-GABARAP on glutathione sepharose 
beads, more GM130 was seen binding to GST-GABARAP than to the GST alone 
control. This also suggests that the GM1130-GABARAP interaction is independent 
of lipidation. 
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Figure 5.9 WAC and GM130 interact with GABARAP 
(a) HEK293A cells in full medium (FM) or EBSS (ES) for 2 hrs. Arrows indicate 
colocalisation. Scale bars, 20 µm. (b) Myc-WAC and EGFP, EGFP-LC3A, LC3B, 
LC3C, GABARAP, GABARAPL1 or GATE-16 co-expressed followed by GFP-Trap 
and immunoblot. Experiment performed twice. (c) Immunoprecipitation of 
GABARAP from fed or starved cells and immunoblot analysis. B, beads; Ctrl, Anti-
GFP; GABA, Anti-GABARAP. Experiment performed twice. (d) Recombinant GST 
or GST-GABARAP beads were incubated with purified Strep II-GM130 before 
immunoblot. Purified GST proteins were provided by Harold Jefferies. Experiment 
performed once. 
 
5.4.2 Mitochondrially targeted GM130 can recruit GABARAP, and WAC 
interacts with GABARAP indirectly  
Expression of mitochondrially targeted GM130 was able to recruit EGFP-
WAC to mitochondria (Figure 4.13d). I wanted to see if the same was true for 
GABARAP as it also interacts directly with GM130. After the expression of GM130-
ΔCterm-HA-MAO, EGFP-GABARAP was also seen concentrated on the 
mitochondria (Figure 5.10a). In HEK293A cells transfected with empty control 
vector, GABARAP was found in puncta during starvation conditions that are likely 
to be autophagosomes (Figure 5.10b). I also observed an enlarged GABARAP 
structure as mentioned above. However after expression of GM130-ΔCterm-HA-
MAO I noticed endogenous GABARAP concentrated around the mitochondria with 
some colocalisation with mitochondrially targeted GM130. This colocalisation was 
not complete and not to the extent of EGFP-tagged GABARAP. It may be that 
overexpressed GABARAP localises better with mitochondrial GM130 because of 
stoichiometric reasons or perhaps because of some dysregulation. The minor 
colocalisation of endogenous GABARAP with mitochondrially targeted GM130 is 
perhaps expected as only minor colocalisation between endogenous GABARAP 
and GM130 is observed.  
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Figure 5.10 Mitochondrially localised GM130 can recruit GABARAP 
(a) Co-expressed EGFP-GABARAP and GM130-ΔCterm-HA-MAO labelled with 
anti-HA. Scale bars, 10 µm. Experiment performed once. (b) Empty vector or 
GM130-ΔCterm-HA-MAO were expressed in HEK293A cells followed by 2 hr 
incubation with EBSS, anti-HA and anti-GABARAP labelling and analysis by 
confocal microscopy. Arrows indicate co-localization. Scale bars, 20 µm. 
Experiment performed twice. 
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I next wanted to further probe the WAC-GABARAP interaction. As shown 
(Figure 5.9b and c) both the overexpressed and endogenous forms of WAC and 
GABARAP interact. To investigate if this interaction occurred directly I used 
recombinant purified untagged human GABARAP, produced from E. coli (Figure 
5.11a). In addition, I separately expressed EGFP-WAC in HEK293A cells and 
immunoprecipitated EGFP-WAC using GFP-TRAP (Figure 5.11b). Immobilised 
EGFP-WAC on beads was washed 5 times in 1M NaCl, followed by washing into a 
low salt buffer (Figure 5.11b). This was to help dissociate protein complexes 
immunoprecipitated from HEK293A cells, in support of this, endogenous 
GABARAP was not detected binding to its interactor mCherry-GFP-p62 (Pankiv et 
al., 2007), after 1M NaCl washes (Figure 5.11b). However, it is possible that 
interacting proteins may remain bound to EGFP-WAC after 1M NaCl washes, on 
the other hand the advantage of expressing EGFP-WAC in mammalian cells is that 
post-translational modifications on WAC that may influence protein-protein 
interactions should be maintained. mCherry-GFP-p62 was used as a control that 
directly interacts with GABARAP. It has previously been shown that p62 interacts 
directly with GABARAP and other Atg8 proteins (Pankiv et al., 2007). After the 
addition of purified recombinant untagged GABARAP (Figure 5.11a) to the salt 
washed GFP-Traps I could detect enhanced binding of GABARAP to mCherry-
GFP-p62 over the EGFP alone control (Figure 5.11b and c), as would be expected 
(Pankiv et al., 2007). However no binding to EGFP-WAC was observed above the 
EGFP control levels (Figure 5.11b and c). Unfortunately, there was some 
background binding of GABARAP to the EGFP control (Figure 5.11b) and it may be 
possible that reduction of this background may reveal some low level binding of 
WAC and GABARAP. Nevertheless, under these conditions there was no evidence 
of direct binding of GABARAP to WAC. It is likely that WAC interacts with 
GABARAP in an indirect fashion, possibly by binding through GM130. 
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Figure 5.11 Recombinant GABARAP did not interact with GFP-WAC 
(a) Colloidal Coomassie stained SDS-PAGE gel showing purified untagged human 
GABARAP from E. coli. Purified GABARAP was provided by Stephane Mouilleron. 
(b) Lysates from HEK293A cells expressing the indicated GFP constructs were 
used for GFP-TRAP followed by salt washes and incubation with purified 
recombinant GABARAP from (a) and immunoblot. mCherry-GFP-p62 was used as 
a positive control for GABARAP binding. GFP immunoblot shows the same gel and 
exposure for GFP, GFP-WAC and mCherry-GFP-p62. The intervening space 
between the faster migrating GFP band and the slower migrating GFP-WAC and 
mCherry-GFP-p62 bands has been removed, as indicated by an empty space. (c) 
Quantification of (b) from 2 independent experiments, mean ± SD. 
 
5.5 Centrosomal GABARAP traffics to autophagosomes during 
starvation 
5.5.1 GABARAP colocalises with γ-tubulin 
The enlarged GABARAP structure that was juxtaposed to GM130 (Figure 
5.9a and Figure 5.10b) did not appear to be an autophagosome because it was too 
large and was present under basal conditions. This structure was observed not in 
every cell but in many. The question remained as to what this structure 
represented. To my mind there were a few candidates of singular rounded 
structures that reside next to the cell nucleus such as the, endocytic recycling 
compartment, the aggresome, and the centrosome. GABARAP, via binding of p62, 
may be connected with aggresomes, which are enlarged aggregates of 
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ubiquitinated proteins (Pankiv et al., 2007). Furthermore, GABARAP has been 
seen at the basal body of the primary cilium (Pampliega et al., 2013), which is 
somewhat analogous to the centrosome. The primary cilium is a sensory organelle 
that grows from a mother centriole and is induced by serum starvation. After 
labelling for GABARAP with two different GABARAP antibodies under basal 
conditions I could observe GABARAP colocalising with γ-tubulin (Figure 5.12a and 
b), a marker for the pericentriolar material of the centrosome (Woodruff et al., 
2014). The centrosome is comprised of two centrioles made of tubulin that are 
embedded in a matrix of coiled-coil proteins called the pericentriolar material 
(PCM). γ-tubulin ring complexes that nucleate microtubules are embedded in this 
matrix. The localisation of GABARAP to the centrosome was observed in cell lines 
derived from different tissues and species suggesting that it is not unique to the 
HEK293A model cell line (Figure 5.12a). However, the centrosome in HEK293A 
cells appeared enlarged and much more obvious than in the other cell lines tested. 
These enlarged γ-tubulin positive structures have been demonstrated before in 
HEK293A cells (Zhao et al., 2003). Low level expression of GFP-GABARAP using 
tetracycline-inducible HEK293 cells indicated that GFP-GABARAP could also 
localise to the centrosome (Figure 5.12c). This suggests that the GABARAP 
observed at the centrosome is unlikely to be due to an artefact of the antibody 
staining. 
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Figure 5.12 A population of GABARAP localises to the centrosome 
(a) HEK293A, HeLa, U2OS, RPE-1, HCT116 and MEF cells were labelled as 
indicated. Scale bars, 5 µm. Rabbit anti-GABARAP was used. (b) HEK293A cells 
were stained with sheep anti-GABARAP antibody and mouse anti-γ-tubulin before 
analysis by confocal microscopy. Scale bars, 20 µm. (c) GFP-GABARAP 
expression in HEK293 Flp-In T-Rex cells after tetracycline treatment for 24 hr. 
Scale bars, 20 µm. Experiments performed once. 
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5.5.2 Non-lipidated GABARAP resides on the pericentriolar material of the 
centrosome 
I wanted to further confirm the specificity of endogenous GABARAP staining 
at the centrosome. After treatment of HEK293A cells with siRNAs targeting 
GABARAP there was less GABARAP staining at the centrosome (Figure 5.13a), 
suggesting that the centrosomal GABARAP staining is indeed specific. By co-
staining for GABARAP and Centrin-3 (Figure 5.13b), a marker for the centrioles 
(Middendorp et al., 2000), I noticed that the enlarged GABARAP structure was 
localised in a ring around Centrin-3, or sometimes juxtaposed to Centrin-3 (not 
shown). This further suggests that GABARAP localises to the pericentriolar 
material of the centrosome and not to the centrioles. I supposed enlarged 
GABARAP structures may be aggresomes and also because γ-tubulin marks 
aggresomes as well as centrosomes (Tanaka et al., 2004). I thus wanted to 
exclude the possibility that the enlarged GABARAP structure I observed was an 
aggresome. After nutrient starvation GABARAP puncta were observed that 
colocalised with p62 as expected (Figure 5.13c), these are likely to be 
autophagosomes, however the enlarged GABARAP structure was not positive for 
p62. Furthermore the enlarged GABARAP structure was negative for ubiquitin 
staining (Figure 5.13d), even after proteasomal inhibition with MG132 or 
epoxomycin (not shown). Thus, I conclude that GABARAP is present at the 
centrosome and that this population of GABARAP is distinct from the aggresome.  
Finally, I wanted to see if GABARAP at the centrosome required lipidation 
for its localisation. In order to show this I transfected HEK293A cells with a G116A 
mutant of myc-GABARAP. This mutant of GABARAP cannot be processed into the 
lipidated form of GABARAP and thus remains non-lipidated (Chen et al., 2007). 
More specifically, the Atg8 proteins are produced as pro-proteins that are cleaved, 
exposing a C-terminal glycine that can be attached to phosphatidylethanolamine 
through an amide bond between the glycine and the amino group of 
phosphatidylethanolamine (Ichimura et al., 2000). Mutation of this Glycine to an 
Alanine prevents lipidation (Kirisako et al., 2000). Like the wild-type Myc-
GABARAP, the G116A mutant could also localise at the centrosome (Figure 
5.13e). This suggests that the pool of GABARAP at the centrosome is not lipidated. 
It is possible that G116A GABARAP may interact with the endogenous GABARAP 
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present on the centrosome, as GABARAP interacts with itself by crystal structure 
(Nymann-Andersen et al., 2002). To exclude this possibility, it would be interesting 
to repeat this experiment in the future with GABARAP knockout cells. 
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Figure 5.13 Non-aggresomal and non-lipidated GABARAP localises to the 
pericentriolar material of the centrosome 
(a) HEK293A cells were treated for 72 hr with RISC Free or GABARAP siRNAs, 
labelled with the indicated antibodies and analysed by confocal microscopy. Scale 
bars, 50 µm. Inset, line scan. Experiment performed twice. (b) HEK293A cells 
labelled as indicated. Scale bars, 10 µm. (c) HEK293A cells incubated in EBSS for 
2 hr or (d) DMSO or MG132 for 2 hr and assessed using the indicated antibodies. 
Scale bars, 10 µm (c), 20 µm (d). (e) HEK293A cells expressing Myc-GABARAP or 
G116A mutant labelled as indicated. Scale bars 20 µm. Staining and microscopy 
was perfroemd by Minoo Razi. (b-e) Experiments performed once. 
 
5.5.3 Centrosomal GABARAP localisation is regulated by the cell cycle but 
not by secretory membrane trafficking 
In order to elucidate if centrosomal GABARAP had some function I began 
by investigating its dynamics, and if its localisation to the centrosome could be 
perturbed in some way. Surprisingly, in metaphase cells I noticed that the enlarged 
GABARAP structure was completely dissociated from the γ-tubulin positive spindle 
poles (Figure 5.14a). Although the mechanism or significance of this phenomenon 
is unknown, it suggests that centrosomal GABARAP is regulated by the cell cycle 
and is dynamically associated with the centrosome. 
I next wanted to see if centrosomal GABARAP was regulated by membrane 
trafficking. To test this HEK293A cells were treated with Brefeldin A (BFA), a drug 
that causes the disassembly of the Golgi complex, and Golgi proteins relocalise to 
ER-exit sites (Ward et al., 2001). Glycosylation and protein secretion are inhibited 
after BFA treatment (Misumi et al., 1986). After BFA treatment the Golgi was 
indeed disassembled (Figure 5.14b). However, GABARAP positive puncta likely to 
be autophagosomes, were still formed upon starvation with BFA, and enlarged 
GABARAP structures (centrosomal GABARAP) were still observed. These data 
suggest that recruitment of GABRAP to the centrosome or to autophagosomes 
does not require secretion and agrees with previous findings that BFA treatment 
does not affect autophagic flux (Weidberg et al., 2010, Nishida et al., 2009, 
Zoppino et al., 2010). 
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Figure 5.14 GABARAP dissociates from γ-tubulin during metaphase but not after 
Brefeldin A treatment 
(a) Asynchronous HEK293A cells were incubated in full medium and metaphase 
cells were analysed by confocal microscopy. A single mitotic cell is shown at two 
different positions in the Z-axis. Scale bars, 5 µm. This phenotype was observed in 
metaphase cells from 3 independent experiments, (b) HEK293A cells were 
incubated in full medium (FM) or EBSS (ES) with or without Brefeldin A (BFA) for 2 
hr and assessed by confocal microscopy using the indicated antibodies. Scale 
bars, 50 µm. Experiment performed once. 
 
5.5.4 Microtubules are required to concentrate non-lipidated GABARAP at 
the centrosome and away from the Golgi 
GABARAP at the centrosome is not lipidated and does not require post-
Golgi membrane secretion (Figure 5.13 and Figure 5.14). The centrosome 
functions as a microtubule organising centre. GABARAP is known to bind 
microtubules directly (Wang and Olsen, 2000) and thus the question arose as to 
whether centrosomal GABARAP was regulated by microtubules. Nocodazole is a 
compound that causes the disassembly of microtubules in cells and an 
accompanied fragmentation of the Golgi complex (Cole et al., 1996). The resultant 
Golgi mini stacks are relocalised adjacent to ER-exit sites. After treatment of 
HEK293A cells with a concentration of nocodazole that was sufficient to completely 
disassemble microtubules (Figure 5.15a), I saw the formation of GABARAP puncta 
under basal conditions (Figure 5.15b). Unlike autophagosomes, these puncta 
readily colocalised with GM130, on the Golgi ministacks. There was also a small 
but highly significant decrease of centrosomal GABARAP (Figure 5.15c), although 
GABARAP remained on the centrosome in many cells (data not shown). Golgi-
localised GABARAP after microtubule depolymerisation was also observed in the 
presence of Wortmannin, a PI3 kinase inhibitor that also inhibits the Beclin 1 
containing class III PI(3)K complex and thus prevents lipidation of Atg8 proteins 
(Kihara et al., 2001). These data suggest that in the absence of microtubules 
GABARAP relocalises from the centrosome to the Golgi, not as lipidated 
GABARAP but perhaps tethered by a protein such as GM130.  
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Figure 5.15 Nocodazole treatment reduces the amount of GABARAP at the 
centrosome and results in relocalisation of GABARAP to Golgi mini-stacks 
(a) HEK293A cells were incubated in full medium with DMSO or nocodazole for 5 
hr and assessed by confocal microscopy using the indicated antibodies. Scale 
bars, 20 µm. (b) HEK293A cells were incubated in full medium (FM), FM with 
nocodazole or FM with nocodazole and wortmannin for 5 hr and assessed by 
confocal microscopy using the indicated antibodies. Scale bars, 20 µm. (c) 
Quantification of centrosomal GABARAP intensity after nocodazole treatment. 
Mean ± SEM of 3 independent experiments, >300 cells in total were counted per 
condition, unpaired Student’s t test, ****, p ≤ 0.0001. Full medium plus nocodazole, 
FM + N. Enlarged GABARAP structures were taken as centrosomal GABARAP and 
their signal intensities were measured. 
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5.5.5 Nutrient starvation regulates the amount of GABARAP at the 
centrosome 
GABARAP is recruited to autophagosomes upon nutrient starvation where it 
is lipidated and may function in driving closure of the forming autophagosome, as 
well as later functions in maturation (Weidberg et al., 2010, Wang et al., 2015). I 
hypothesised that the pool of non-lipidated GABARAP at the centrosome may 
provide a reservoir of GABARAP that could be used when autophagy is acutely 
induced. During starvation I saw the formation of GABARAP puncta 
(autophagosomes) as before (Figure 5.16a), which was completely inhibited by 
wortmannin treatment. I noticed a small reduction of GABARAP at the centrosome 
during starvation. After quantifying GABARAP signal intensity at the centrosome in 
hundreds of cells (Figure 5.16b), it was apparent that upon nutrient starvation there 
is a small but significant reduction in the amount of GABARAP at the centrosome 
that accompanies the formation of autophagosomes. This suggests that during 
starvation GABARAP could relocalise from a centrosomal reservoir to forming 
autophagosomes. 
Chapter 5. Results 
 
198 
 
 
Chapter 5. Results 
 
199 
 
 
Figure 5.16 Less GABARAP localises to the centrosome after 2 hr starvation, 
accompanied by GABARAP puncta formation 
(a) HEK293A cells incubated in full medium (FM), EBSS (ES) or EBSS with 
wortmannin for 2 hr. Scale bars, 20 µm. (b) Quantification of centrosomal 
GABARAP after 2 hr with full medium (FM) or EBSS (ES). Mean ± SEM of 3 
independent experiments, >420 cells were counted in total per condition, unpaired 
Student’s t test, ****, p ≤ 0.0001. 
 
5.5.6 Photoactivatable GABARAP transports from the centrosome to 
forming autophagosomes during starvation 
Although my experiments in fixed cells suggested that centrosomal 
GABARAP could contribute to autophagosomes (Figure 5.16), these were only 
suggestive. Hence I wanted to gather more evidence to support this hypothesis. In 
order to study the dynamics of specifically the centrosomal GABARAP pool, I 
attached a photoconvertible fusion protein, EosFP, to the N-terminus of GABARAP. 
EosFP is a fluorescent protein from coral that is constitutively green, but is 
converted from green fluorescence to red upon excitation with UV light 
(Wiedenmann et al., 2004). EosFP-GABARAP colocalised with γ-tubulin and WIPI2 
in starved HEK293A cells (Figure 5.17a), thus suggesting that EosFP-GABARAP 
replicated endogenous GABARAP by localising to the centrosome and 
autophagosomes. EosFP-GABARAP formed rings around γ-tubulin, these were 
easily identifiable in live cells and were targeted in photoconversion experiments 
(Figure 5.17a, b and c). EosFP-GABARAP that was more homogenously 
distributed at the centrosome was hard to identify in live cells in the absence of a 
centrosomal marker. This is because these structures were confused with 
autophagosomes or aggregates of the overexpressed protein. 
In starved live HEK293A cells, centrosomal EosFP-GABARAP was targeted 
for photoconversion, by irradiation with the 405nm laser. After photoconversion of 
the centrosomal green EosFP-GABARAP to red, GABARAP-positive red spots 
formed, which correlated with a decrease in the intensity of red centrosomal 
EosFP-GABARAP (Figure 5.17b, Figure 5.18a and Movie 1, see CD for movie and 
appendix for movie legend). Within minutes photoconverted centrosomal EosFP-
GABARAP translocated to distal regions which were monitored by quantifying 
fluorescence intensities (Figure 5.18b). Like autophagosomes, EosFP-GABARAP 
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puncta were highly mobile (Kochl et al., 2006, Kimura et al., 2008) and additionally 
made transient interactions with centrosomal EosFP-GABARAP (Movie 2, see CD 
for movie and appendix for legend). Strikingly, peripheral green EosFP-GABARAP 
spots (that existed prior to photoconversion), acquired centrosomally-derived red 
photoactivated EosFP-GABARAP (Figure 5.17b, Figure 5.18a). After the live cell 
time-lapse microscopy the cells were fixed and stained with LC3 and γ-tubulin 
(Figure 5.17 and Figure 5.18). As the cells were seeded on gridded MatTek dishes 
during time-lapse imaging, I was able to find the same cells by correlative confocal 
microscopy. This technique confirmed that the photoconverted pool of GABARAP 
was at the centrosomal area, and that photoconverted centrosomal GABARAP had 
moved to peripheral puncta, many of which were LC3 positive, although some were 
LC3 negative (Figure 5.18c). Taken together these data suggest that forming and 
expanding autophagosomes acquire GABARAP derived from the PCM. It is also 
possible however that GABARAP is delivered to fully formed autophagosomes  
 
Chapter 5. Results 
 
201 
 
 
Chapter 5. Results 
 
202 
 
 
Figure 5.17 EosFP-GABARAP localises to the centrosome and WIPI2 puncta and 
forms puncta derived from the centrosomal region 
(a) HEK293A cells expressing EosFP-GABARAP were incubated in EBSS for 2 hr 
before labelling with γ-tubulin and WIPI2 and analysis by confocal microscopy. 
Scale Bars, 10 µm. (b) Live HEK293A cells expressing EosFP-GABARAP were 
starved in EBSS and imaged every 5 s using a swept field confocal microscope. 
Photoconversion (PC) was performed with localised pulses of 405nm light. PC 
moment is set to 0 s. Yellow arrow indicates photoconverted region. Blue arrow 
shows defined punctum. To reduce noise, 6 sequential images, equal to 30 s 
timeframe, were averaged for each time period shown. Scale bar, 20 µm. Inset has 
been contrast adjusted for clarity. Experiment was performed 3 times on separate 
days, see also Figure 5.18. (c) Confocal microscopy performed on same cell from 
(b). After time-lapse imaging, cells were fixed and stained for γ-tubulin. Yellow 
arrow indicates the same structure as in (b). Scale bar, 20 µm. 
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Figure 5.18  Photoconverted GABARAP translocates from the centrosomal area 
to LC3 positive puncta during starvation 
(a) EosFP-GABARAP in starved HEK293A cells was imaged every 30 s using a 
swept field confocal microscope. 5 x 1 s images were captured prior to 
photoconversion (PC). PC moment is set to 0 s. Yellow arrow, photoconverted 
region. Magenta arrowhead, distal region. White and blue arrows track defined 
puncta. Scale bars, 10 µm. (b) Quantification of fluorescence intensity from video in 
(a). PC region marked by yellow arrow and distal region marked by magenta 
arrowhead in (a). Intensity 5 s prior to PC moment is set to 1 for normalisation. (c) 
Confocal microscopy performed on same cell from video in (a). After imaging, cells 
were fixed and stained for LC3 and γ-tubulin. Arrows and arrowheads correspond 
to structures shown in (a). Scale bars, 10 µm. 
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5.5.7 Cytosolic GABARAP translocates faster than centrosomal GABARAP 
In contrast to the centrosomal pool, cytosolic EosFP-GABARAP diffused 
within seconds across the cell, rather than translocating in the timescale of minutes 
(compare Figure 5.18b and Figure 5.19b). This was measured by either assessing 
the movement of photoconverted EosFP-GABARAP across the cell (Figure 5.19a 
and b), or by looking at the diffusion of non-photoconverted (green) EosFP-
GABARAP into a photoconverted (red) area (Figure 5.19c and d). Within seconds, 
this cytosolic photoconverted EosFP-GABARAP was recruited to punctate 
structures in the cell (Figure 5.19a). These puncta already had green non-
photoconverted EosFP-GABARAP (data not shown). Perhaps this recruitment of 
cytosolic GABARAP to pre-existing GABARAP puncta occurred by lipidation or 
perhaps by homotypic interactions with other GABARAP molecules. Thus, given 
the kinetics of cytosolic diffusion versus translocation from the centrosomal area, it 
is likely that the red EosFP-GABARAP-puncta in Figure 5.17b and Figure 5.18a are 
derived from a centrosomal pool and not from unintentional photoconversion of the 
cytosolic pool.  
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Figure 5.19 Diffusion of cytosolic GABARAP occurs much more rapidly than 
movement of GABARAP from the centrosome 
(a) HEK293A cell expressing EosFP-GABARAP, only red channel shown. 
Photoconversion (PC) moment is set to 0 s. Yellow box (top), photoconverted 
region. Yellow box (bottom), distal region. Scale bar, 10 µm. Experiment performed 
on multiple cells. (b) Quantification of intensities from boxed regions in (a). Intensity 
60 s prior to PC moment is set to 1 for normalisation. (c) HEK293A cell expressing 
high levels of cytosolic EosFP-GABARAP starved in EBSS and imaged every 0.35 
s using a swept field confocal microscope. PC was performed with 405nm light. PC 
moment is set to 0 s. Scale bar, 10 µm. (d) Graph shows quantification of 
fluorescence intensity from yellow circle in images (c), for green channel only. 
Intensity 6 s prior to PA moment is set to 1 for normalisation. 
 
5.5.8 Golgi-localised GABARAP after nocodazole treatment is relatively 
immobile and does not contribute to de novo puncta formation 
In order to further investigate the effect of depolymerising microtubules on 
GABARAP (Figure 5.15), I pre-treated live HEK293A cells expressing EosFP-
GABARAP with nocodazole followed by incubation in EBSS with nocodazole 
(Figure 5.20). I wanted to ask if microtubules are required to translocate GABARAP 
from the centrosome to forming autophagosomes. However, in these cells I could 
never find the distinct ring-shaped structures of EosFP-GABARAP around the 
centrosome (not shown) I previously described (Figure 5.17a). Thus I could not 
target these for photoconversion experiments. This is perhaps reassuring though, 
as there is less endogenous GABARAP at the centrosome after nocodazole 
treatment (Figure 5.15c). After nocodazole treatment (Figure 5.20a) I noticed an 
accumulation of dispersed or peripherally distributed EosFP-GABARAP puncta. I 
targeted these puncta individually for photoconversion and performed time-lapse 
microscopy. These structures were relatively immobile over a 20 minute period 
after photoconversion. Furthermore, unlike with centrosomal EosFP-GABARAP, I 
did not observe translocation of photoconverted EosFP-GABARAP from these 
nocodazole-dispersed structures to other puncta. Correlative confocal microscopy 
revealed that similar to endogenous GABARAP (Figure 5.15b), EosFP-GABARAP 
was retained on Golgi mini-stacks (Figure 5.20b). This is another indicator that 
EosFP-GABARAP simulates the endogenous protein. This suggests that without 
microtubules centrosomal GABARAP relocalises to the Golgi where it becomes 
immobile. This population is unlikely to contribute to autophagosome formation. It 
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should be noted that I was only able to obtain one good video for the nocodazole 
experiment (Figure 5.20), and thus my observations may not be representative of 
variation in a heterogeneous cell population and should be repeated in future 
studies. 
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Figure 5.20 EosFP-GABARAP disperses after nocodazole treatment and 
relocalises to relatively immobile Golgi mini-stacks 
(a) EosFP-GABARAP expressing HEK293A cells in full medium with nocodazole 
for 2 hr, then incubated in EBSS with nocodazole and imaged. Discrete structures 
were targeted for photoconversion and Images were captured every 3 s. All visible 
red structures after photoconversion were targeted individually for photoconversion. 
Blue arrows track a subset of these puncta. Scale bars, 20 µm. (b) Confocal 
microscopy performed on same cells from video in (a). After imaging, cells were 
fixed and stained for GM130. Arrows correspond to structures shown in (a). Scale 
bars, 20 µm. Experiment was performed once. 
 
5.6 WAC inhibits binding of GABARAP to GM130 to promote 
centrosomal GABARAP localisation 
5.6.1 WAC regulates GABARAP localisation 
Since WAC and GM130 interact with GABARAP (Figure 5.9b and c), I next 
investigated if WAC and GM130 regulated the localisation of GABARAP to the 
centrosome or forming autophagosomes. Centrosomal GABARAP that colocalised 
with γ-tubulin, was seen in both fed and starved cells (Figure 5.22a), and in starved 
cells GABARAP-positive autophagosomes appeared (Figure 5.21). In starvation, 
WAC knockdown resulted in an accumulation of GABARAP on the Golgi (Figure 
5.21) and ERGIC (Figure 5.22b) as marked by GM130 and ERGIC-53 respectively. 
This phenotype was characterised by an accumulation of GABARAP staining in the 
juxtanuclear region that exhibited a fragmented or dispersed pattern, and a 
reduction or loss of GABARAP contained within the enlarged GABARAP structure, 
the centrosome (Figure 5.21 and Figure 5.22a). It should be noted that not all WAC 
knockdown cells displayed this phenotype, and that this may be due to efficacy of 
the siRNA treatment or another heterogeneous property of the cell population such 
as cell cycle stage. The accumulation of GABARAP on the Golgi after WAC 
knockdown may be explained by an increase in the interaction of GABARAP with 
GM130 after WAC depletion (Figure 5.22c and d). This may also explain the 
accumulation of GABARAP on the ERGIC after WAC knockdown as GM130 is also 
known to traffic through the intermediate compartment (Marra et al., 2001).  
Chapter 5. Results 
 
209 
 
GM130 can regulate centrosome morphology and function (Kodani and 
Sutterlin, 2008a) and after GM130 knockdown, I noticed that generally there was a 
small increase in the size and intensity of the centrosomal GABARAP pool Figure 
5.21 and Figure 5.22a). These data suggest that WAC and GM130 control the 
localisation of centrosomal GABARAP in a reciprocal manner. WAC may promote 
GABARAP retention at a centrosomal reservoir, whereas GM130 may limit the pool 
of centrosomal GABARAP. Furthermore, WAC appears to negatively regulate 
GABARAP-GM130 binding. Future work should aim to further describe these 
phenotypes in a more quantitative manner. 
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Figure 5.21 Depletion of WAC increases the amount of GABARAP at the Golgi 
HEK293A cells were treated with RISC Free (RF), WAC or GM130 siRNAs for 72 
hr and incubated with full medium (Fed) or EBSS (Starved) for 2 hr. Scale bars, 50 
µm. Experiment was performed twice. 
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Figure 5.22 WAC knockdown increases the amount of GABARAP on the ERGIC 
and increases GM130-GABARAP binding 
(a) HEK293A cells were treated with RISC Free (RF), WAC or GM130 siRNAs for 
72 hr, incubated with full medium (FM) or EBSS (ES) for 2 hr and analysed by 
confocal microscopy. Scale bars, 20 µm. Yellow arrows show GABARAP on the 
centrosome, white arrows show centrosomes without GABARAP. (b) HEK293A 
cells were treated with RISC Free, WAC or GM130 siRNAs for 72 hr, incubated 
with EBSS for 2 hr and analysed by confocal microscopy. Scale bars, 20 µm. (a – 
b) experiment performed once. (c) HEK293A cells were treated with RISC Free or 
WAC siRNAs for 72 hr and incubated with full medium (F) or EBSS (S) for 2 hr 
followed by GABARAP immunoprecipitation and immunoblotting. B, beads; Ab, 
GABARAP antibody; Lys, lysate. (d) Quantification of (c), Student’s t test, **, p ≤ 
0.001. Mean ± SEM of 3 independent experiments. 
 
5.6.2 Golgi-localised GABARAP after WAC depletion is relatively immobile 
and does not contribute to de novo puncta formation 
To investigate GABARAP dynamics in WAC depleted cells, I employed 
EosFP-GABARAP and photoconversion. After transfection of EosFP-GABARAP 
into HEK293A cells depleted of WAC (Figure 5.23a) I noticed an accumulation of 
EosFP-GABARAP in the juxtanuclear region. Photoconversion and time-lapse 
microscopy of the juxtanuclear-accumulated EosFP-GABARAP revealed that this 
pool of GABARAP is relatively immobile and did not form cytoplasmic GABARAP 
spots during starvation (Figure 5.23a and Movie 3, see CD for movie and appendix 
for legend). Fixation and correlative confocal microscopy of time-lapse imaged cells 
(Figure 5.23b) confirmed that juxtanuclear EosFP-GABARAP was localised on and 
around the Golgi, and that regions targeted for photoconversion were GM130 
positive. This is similar to the accumulation of endogenous GABARAP at the Golgi 
upon WAC depletion (Figure 5.21). Thus, in the absence of WAC, GABARAP 
accumulates on the Golgi and this population is unlikely to contribute to 
autophagosome formation. In general WAC knockdown leads to reduced 
autophagosome formation. 
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Figure 5.23 EosFP-GABARAP is retained on the Golgi after WAC knockdown and 
this population does not contribute to puncta formation during starvation 
(a) EosFP-GABARAP expressed in HEK293A cells treated with WAC siRNA for 72 
hr. Live cell imaging under starvation conditions. During photoconversion (PC), 
images from a single z-slice were acquired every 0.4 s. After PC z-stacks were 
acquired every 13 s. Shown are a selection of frames acquired at indicated times. 
Yellow arrows denote PC regions. Scale bars, 20 µm. Experiment was performed 
twice on separate days. (b) After time-lapse imaging, same cells shown in (a) were 
fixed and stained for GM130. Scale bars, 20 µm. 
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5.7 Non-lipidated GABARAP promotes ULK1 activity  
5.7.1 GABARAP specifically promotes ULK1 activation likely by binding 
through the ULK1 LIR motif and independently of lipidation. 
WAC depletion reduces activation of the ULK1 complex (Figure 5.5) but also 
likely inhibits GABARAP trafficking from the Golgi region to the centrosome (Figure 
5.21). The question arises whether these two observations are independent or 
interconnected. GABARAP is thought to promote autophagosome closure and also 
fusion with lysosomes (Weidberg et al., 2010, Wang et al., 2015). I wanted to 
elucidate if knockdown of GABARAP could also attenuate ULK1 activation, thereby 
indicating a novel role of GABARAP in the early signalling events of 
autophagosome formation and demonstrating a phenotypic similarity between 
WAC and GABARAP. The clue that this could be the case is that GABARAP 
directly binds ULK1 complex members (Kraft et al., 2012, Alemu et al., 2012) 
(Okazaki et al., 2000). Atg13 p-Ser318 levels were significantly decreased after 
depletion of GABARAP, but not LC3B, GABARAPL1 or GATE-16 (Figure 5.24a, b, 
c and d). The efficacy of knockdown was confirmed at the mRNA level by qRT-
PCR (Figure 5.24e), although I was only able to obtain a weak knockdown (< 50% 
reduction) of LC3A and LC3C (data not shown). By comparing the relative mRNA 
levels of the mAtg8 homologues to GAPDH (Figure 5.24f), my results suggested 
that in HEK293A cells, GABARAP is the most abundant mAtg8 protein followed by 
GATE-16, LC3B, GABARAPL1, LC3C and lastly by LC3A. This is similar to what 
has recently been published for the prostate cancer cell line LNCaP (Szalai et al., 
2015), although in these cells LC3A was more abundant than LC3C. Thus 
GABARAP, the most abundant mAtg8 (at least in LNCaP cells and possibly in 
HEK293A cells) specifically promotes activation of ULK1. I should add that 
although I followed the published method (Szalai et al., 2015) to compare the 
expression of the mAtg8s, strictly speaking it could be problematic to compare the 
expression of different genes, unless it is demonstrated that the qRT-PCR 
amplification efficiencies for each gene target are similar, which I have not done. 
Future studies into mATG8 expression in HEK293A cells should address this. 
However, it is nonetheless interesting that I obtained very similar results to (Szalai 
et al., 2015), even when using independently-designed qRT-PCR primers. 
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I next wanted to see if overexpression of GABARAP could modulate ULK1 
activity and if this depended on the ULK1 LIR motif. Overexpression of HA-ULK1 in 
fed HEK293 cells was sufficient to drive Atg13-FLAG phosphorylation even under 
basal conditions when ULK1 should not be active (as seen before (Chan et al., 
2009)) and also when the ULK1 LIR was mutated (ΔLIR) (Figure 5.24g). As a 
negative control, expression of HA-ULK1 K46I ΔLIR, which has a kinase 
inactivating mutation (Chan et al., 2009), did not result in phosphorylation of Atg13-
FLAG. The ULK1 LIR mutation used was generated in the Tooze lab (Kraft et al., 
2012).These data suggest that the LIR motif of ULK1 per se is not required for the 
kinase activity of ULK1. In fact, there was a trend towards enhanced ULK1 activity 
upon mutation of the LIR motif, although this was not significant (Figure 5.24j). I 
next asked whether the LIR motif of ULK1 could regulate ULK1 activity in the 
presence of other overexpressed proteins. In the presence of EGFP-GABARAP 
and the non-lipidated G116A GABARAP mutant (Figure 5.24h), the ULK1 LIR was 
required for maximal phosphorylation of Atg13-FLAG (Figure 5.24g, i and j). 
However, when EGFP-LC3B was overexpressed in the presence of HA-ULK1 and 
Atg13-FLAG, mutation of the ULK1 LIR does not reduce ULK1 activity, similarly to 
transfection with an empty vector control.  
These data suggest that overexpression of ULK1 leads to dysregulated 
phosphorylation of Atg13 under basal conditions when ULK1 should be turned off; 
this is used as a readout for ULK1 activity. ULK1 activity in this scenario is 
independent of the LIR motif of ULK1. However in the presence of GABARAP, 
which binds ULK1 and its complex members directly, the LIR motif of ULK1 is 
required for its full activity. This is independent of lipidation of GABARAP and may 
indicate that direct binding of GABARAP to ULK1 maintains ULK1 activity. This 
effect is specific because unlike GABARAP, LC3B does not affect the kinase 
activity of the ULK1 LIR mutant. 
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Figure 5.24 Knockdown of GABARAP, but not other mAtg8s, attenuates ULK1 
activity  
(a) HEK293A cells treated with RISC Free (RF) or GABARAP siRNA for 72 hr, 
incubated in EBSS for 2 hr followed by immunoblot. p-Atg13, pSer318. (b) 
Quantification of (a), Student’s t test, ***, p ≤ 0.001. Mean ± SEM of 3 independent 
experiments. (c) HEK293A cells treated with RF, LC3B, GABARAP, GABARAPL1 
or GATE-16 siRNAs for 72 hr before 2 hr incubation in EBSS and immunoblot. p-
Atg13, pSer318. (d) Quantification of (c) student’s t test, ****, p ≤ 0.0001. Mean ± 
SEM of 3 independent experiments. Not significant versus RF control, NS. (e) 
HEK293A cells were treated with RF, LC3B, GABARAP, GABARAPL1 or GATE-16 
siRNA for 72 hr prior to analysis by qRT-PCR. Expression of each gene is 
normalised to the RISC Free sample. 3 independent experiments that are date 
matched with 3 experiments from (d). (f) HEK293A cells were maintained in fed 
medium before analysis by qRT-PCR. 2 independent experiments; mean ± SD. (g) 
HEK293A cells expressing indicated proteins analysed by immunoblot. Full 
medium. *, non-specific band. KI, kinase inactive ULK1. (h) HEK293A cells 
expressing EGFP-GABARAP wild-type or the G116A mutant were incubated in full 
medium with BafA (FB) or EBSS with BafA (EB) for 2 hr prior to electrophoresis on 
an 8% SDS-PAGE gel and immunoblot. *, non-specific band. SDS-PAGE and 
western blotting were performed by Minoo Razi. (i) HEK293A cells expressing 
indicated proteins analysed by immunoblot. Full medium. *, non-specific band. KI, 
kinase inactive ULK1. (j) Quantifications of (g and i), overexpressed vector, n=4 
experiments; overexpressed LC3B, n=3 experiments; overexpressed GABARAP, 
n=5 experiments; overexpressed G116A, n=2 experiments. Statistics were 
performed using an unpaired Student’s t test, ***, p ≤ 0.001. 
 
5.8 Discussion 
WAC and GM130 are two regulators of autophagy, whose mechanism of 
action was unresolved and previously unconnected (McKnight et al., 2012, Chang 
et al., 2012). In this chapter I provide further evidence that WAC is a positive 
regulator of autophagosome formation and that GM130 functions as a negative 
regulator, using multiple readouts of the autophagic pathway. WAC drives 
autophagy initiation by maintaining ULK1 activation downstream of mTORC1. 
Another important autophagy regulator is AMP-activated protein kinase (AMPK), 
which is activated and activates ULK1 and autophagy in response to glucose 
starvation (Kim et al., 2011). Whether WAC regulates AMPK activity upstream of 
ULK1 is a possibility that has not been thoroughly investigated to date. In the model 
system I have used in my work to study autophagy, namely EBSS starvation of 
HEK293A cells, I did not see evidence of AMPK activation as measured by ULK1 
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phosphorylation at serine 555 (data not shown). However a study of glucose 
starvation has not been undertaken. 
GM130 knockdown enhances WIPI2 puncta formation and thus GM130 may 
regulate autophagy at an early stage like WAC. There is some phenotypic 
disconnect between GM130 and WAC however, as it was not conclusive whether 
GM130 also regulates ULK1 activity. It may be that WAC has a more specific role 
in autophagy regulation, whereas GM130 may simply act to sequester GABARAP, 
perhaps for some unknown Golgi-localised function. Importantly though, the C-
terminal GM130-interacting coiled-coil domain of WAC was required to rescue 
LC3B puncta formation after WAC depletion. This suggests that the WAC-GM130 
interaction is indeed important for autophagy regulation. Although RNF20/40 also 
interacts with WAC through its coiled-coil domain it is less likely that this interaction 
is required for autophagosome formation, as RNF40 knockdown did not affect LC3 
lipidation (Chapter 3.3.2). 
In Chapter 4 I demonstrated that WAC and GM130 interacted with one 
another, although how this impacted on the autophagy machinery was unknown. 
Here I show that GM130 interacts with GABARAP directly and that WAC may 
interact with GABARAP via GM130. It may be that the GM130-GABARAP 
interaction is facilitated by a LIR motif in GM130, and this remains to be 
investigated. WAC appears to suppress GM130 binding to GABARAP and this 
could promote the maintenance of a centrosomal GABARAP ‘reservoir’ versus 
Golgi or ERGIC localised GABARAP. How this occurs is unknown. It may be that 
WAC could affect GABARAP binding to GM130 sterically, or by inducing some 
conformational change. The centrosomal GABARAP reservoir correlates with 
autophagic activity, as GM130 depletion resulted in a small increase in centrosomal 
GABARAP levels and also an increase in autophagy. How GABARAP translocates 
between the centrosome and the Golgi is not fully understood either. GABARAP 
binds microtubules directly (Wang and Olsen, 2000) and microtubules facilitate the 
concentration of GABARAP on the centrosome versus the Golgi. Under basal 
conditions GABARAP may continually traffic from the Golgi to the centrosome via 
microtubules, explaining why much greater colocalisation between GABARAP and 
GM130 is seen after nocodazole treatment to depolymerise the microtubule 
cytoskeleton. However, regulated GABARAP translocation likely involves motor 
proteins that impart directional control, analogous to the JIP1/Dynein mediated 
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translocation of LC3 positive autophagosomes in neurons (Fu et al., 2014). 
Whether GABARAP has a specific non-autophagosomal function at the 
centrosome is a question that remains unanswered. This would not be surprising 
as much of the centrosomal non-lipidated GABARAP remains localised there 
during starvation and indeed, many core autophagy proteins have non-autophagic 
functions (Subramani and Malhotra, 2013). Moreover, the factor that anchors non-
lipidated GABARAP at the pericentriolar material also remains to be identified.  
In more general terms, the Golgi acts as a hub for autophagy proteins under 
basal conditions as discussed in Chapter 1.1.3. Moreover, the Golgi complex is 
intimately linked with the centrosome and GM130 controls centrosome morphology 
and function (Kodani et al., 2009, Kodani and Sutterlin, 2008b). Golgi proteins such 
as AKAP450, which bind GM130 (and possibly WAC (Rolland et al., 2014)), 
GMAP-210 and HOOK3 connect the Golgi ribbon to the microtubule network and 
centrosome (Walenta et al., 2001, Hurtado et al., 2011, Rios et al., 2004, Rivero et 
al., 2009). Interestingly, Atg4D which processes GABARAPL1 is localised to the 
centrosome (Betin and Lane, 2009), and multiple autophagy proteins are localised 
around the centrioles at the basal body of the primary cilium (Pampliega et al., 
2013). It will be interesting to see if other autophagy proteins localise to the PCM. 
Of special interest would be members of the ULK1 complex, which GABARAP 
directly binds. 
The photoconversion data I present in this chapter suggests that non-
lipidated centrosomal GABARAP is transported to autophagosomal structures. 
Presumably this pool of GABARAP becomes lipidated at some stage, this could be 
further elucidated by photoconversion of centrosomal GABARAP in the presence of 
wortmannin, which has not be done to date. It could be that this mobilised 
GABARAP performs some function in autophagosome closure, fusion or ULK1 
activation or even a mixture of these. However, I hypothesise that in the absence of 
centrosomal GABARAP, cytosolic GABARAP can adequately contribute to 
autophagosome formation. Centrosomal GABARAP likely functions as an 
additional reservoir or provides some specialised role. This is because nocodazole 
treatment does not prevent autophagosome formation nor GABARAP puncta 
formation during starvation, (Kochl et al., 2006) and data not shown. 
The ULK complex members ULK1/2, FIP200 and Atg13 bind GABARAP 
preferentially via LC3-interacting regions (LIRs) (Alemu et al., 2012, Kraft et al., 
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2012, Okazaki et al., 2000). The identification of LIRs in the ULK complex 
suggested that the LC3 and GABARAP subfamilies act as a scaffold for recruitment 
of the ULK complex. However, in addition to this I show that knockdown of 
GABARAP specifically attenuates ULK1 activation whereas LC3B, GABARAPL1 
and GATE-16 did not regulate ULK1 activity. In contrast, in yeast (Kraft et al., 2012), 
the Atg1 kinase is delivered to the vacuole via Atg8 to act as a brake on autophagy 
and the Atg8-Atg1 interaction does not modulate Atg1 kinase activity. The non-
lipidated pool of GABARAP at the centrosome may somehow prime ULK1 activity. 
In support of this, ULK1 activation by GABARAP, but not LC3B, requires the ULK1 
LIR motif but does not require GABARAP lipidation. Thus, LIR motifs could be 
functional regulatory elements rather than simply for recruitment of cargo or 
scaffolding. Data in the Tooze lab suggest that the interaction between GFP-
GABARAP and endogenous ULK1 is not affected by starvation (data not shown). 
One important question arises though: how is the GABARAP-mediated activation of 
ULK1 regulated if not by lipidation or recruitment to the phagophore-localised pool 
of ULK? Presumably spatially uncontrolled activation of ULK1 would be 
unproductive. In the absence of WAC, aberrant GABARAP interaction with GM130 
likely disrupts the centrosomal GABARAP reservoir, GABARAP retained on the 
Golgi is unlikely to contribute to autophagosome formation and this may impede 
GABARAP-mediated ULK1 activation. Hence GABARAP-mediated positive 
regulation of ULK1 provides an explanation for WAC’s effect on ULK1 signalling. 
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Chapter 6. Discussion 
In this thesis I have carried out an investigation of the mechanism by which 
WAC promotes the early stages of starvation-induced autophagy. This has involved 
studying WAC’s role in the nucleus and in the cytoplasm. By assessing WAC’s 
effect on the transcriptome it was apparent that WAC is not a master regulator of 
autophagy gene expression or of the expression of autophagy related processes. 
However, some individual autophagy genes were significantly affected by WAC 
depletion and I cannot rule out some nuclear effect of WAC on autophagy 
regulation. This analysis led to the surprising realisation that WAC may regulate 
gene expression independently of RNF20/40. This is surprising as 
WAC/RNF20/RNF40 are supposedly a stable complex involved in the same 
epigenetic mechanism (Zhang and Yu, 2011). WAC is thought to mediate H2B 
monoubiquitination by recruiting and activating the RNF20/40 E3 ligase complex by 
direct interaction. However, I found that a WAC mutant unable to bind RNF40 was 
able to rescue H2B monoubiquitination. These data point to a non-canonical 
mechanism of WAC-mediated gene regulation perhaps driven by H2B 
monoubiquitination independently of the RNF20/40 E3 ligase complex. The 
regulation of MHC class I-mediated antigen presentation genes is a candidate for 
further studying this possibility. In addition, the microarray data provides the first 
repository of genes regulated by all three members of the WAC/RNF20/40 complex 
and suggests novel pathways regulated by the complex as a whole, for example 
SMAD targets. Whether these genes are regulated directly or through secondary 
mechanisms would have to be further validated. There has been no direct proof of 
WAC’s effect on splicing, however there are indications that WAC could be 
involved in splicing (Xu and Arnaout, 2002), although I was not able to investigate 
this with the tools used in my study  
In the absence of clear indications that WAC regulated autophagy from the 
nucleus, I began by investigating its role in the cytoplasm and especially from the 
Golgi, an organelle implicated in autophagy. From mass spectrometry I could not 
detect members of the autophagy machinery as WAC interactors, however the 
negative autophagy regulator GM130 was identified as a novel WAC interactor. 
GM130 appeared to be a negative regulator of the early stages of autophagy from 
the literature (Chang et al., 2012). The WAC-GM130 interaction was validated and 
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delineated. In addition it appears that WAC interacts with COPI subunits. It would 
be fascinating to know if WAC affects GM130 mediated tethering of COPI vesicles 
or COPI-mediated retrograde or intra-Golgi transport. Moreover, WAC’s 
maintenance of Golgi structure is thought to be through a mechanism involving p97 
(Totsukawa et al., 2011) but it may be that WAC additionally modulates GM130-
COPI to affect Golgi architecture. I did not find VCIP135 or p97 as WAC interactors 
from the mass spectrometry data, however RNF20/40 was confirmed. Other novel 
candidate WAC interactors from the mass spectrometry were less promising as 
they did not validate or appeared to be very low abundance interactions. It may be 
that to study and discover additional WAC interactions techniques to preserve 
transient or weak interactions, such as chemical crosslinking, should be used in the 
future. 
The WAC-GM130 interaction is responsible for WAC’s tethering to the Golgi 
and appears to be direct. WAC affects autophagy at the early ULK1 activation 
stage and GM130 affects autophagy at least at the WIPI2 spot formation stages, 
although effects on ULK1 activity were not clear. How WAC-GM130 could link to 
and affect the autophagy machinery was not clear until the discovery of the direct 
GM130-GABARAP and indirect WAC-GABARAP interactions. Surprisingly, I found 
a novel pool of non-lipidated GABARAP enriched at the pericentrosomal material of 
the centrosome. How this pool of GABARAP is anchored to the centrosome is 
unknown, but the biochemical purification of centrosomes and electron microscopy 
could determine the participating factors and whether membranes are involved. 
This structure was enlarged, and therefore tractable to study, in the HEK293A cell 
line that I used, but centrosomal GABARAP was present in a range of cell lines 
from different originating tissues. Moreover, this is a genuine localisation of the 
GABARAP protein as it is detected by different antibodies, the staining is sensitive 
to GABARAP siRNA, and three different tagged forms of GABARAP localise to the 
centrosome. The centrosomal-Golgi trafficking of GABARAP appears to be 
regulated by WAC and by microtubules (Figure 6.1). How this occurs is not known, 
but depletion of WAC results in increased binding of GM130 to GABARAP, 
GABARAP accumulation at the Golgi and ERGIC and less GABARAP at the 
centrosome, suggesting a competition by WAC for GABARAP-GM130 binding. 
Disassembly of the microtubule cytoskeleton also results in GABARAP 
accumulation at the Golgi and reduction at the centrosome. As GM130 binds 
Chapter 6. Discussion 
 
223 
 
microtubules directly and controls microtubule nucleation (Wei et al., 2015) (Rivero 
et al., 2009), and GABARAP binds microtubules directly (Wang and Olsen, 2000), it 
could be that WAC alters microtubule mediated trafficking of GABARAP through an 
interaction with GM130. Interestingly, WAC interacts with AKAP450 by yeast two-
hybrid (Rolland et al., 2014) and as AKAP450 binds GM130, centrosomal 
components and nucleates microtubules (Rivero et al., 2009), this could be another 
link to how WAC affects GABARAP localisation.  
In addition, the role of motors in the centrosome-Golgi transport of GABARAP 
is not known, although my preliminary data suggest that cytoplasmic dynein could 
be involved in regulating this (data not shown). Importantly, centrosomally localised 
GABARAP can be transported to peripheral LC3-positive structures upon starvation, 
suggesting that the centrosomal pool of GABARAP may function in 
autophagosome formation. This likely requires microtubule mediated transport, 
however the centrosomal pool of GABARAP is probably not absolutely required for 
GABARAP targeting to the autophagosome, as microtubule disassembly did not 
prevent WIPI2-positive GABARAP puncta from forming (data not shown). This 
centrosome-to-autophagosome transport requires the action of WAC, perhaps by 
preventing the excessive tethering of GABARAP to GM130. The factors that 
mediate this transport are also unknown and remain to be investigated. A 
candidate for this could be kinesin motors, which mediate plus-end directed 
microtubule transport. In general the role of the centrosome in regulating 
autophagy proteins is a new idea, and how this relates to the concentration of 
autophagy proteins at the basal body of the primary cilium (Pampliega et al., 2013) 
is also an interesting consideration. The function of GABARAP at the centrosome, 
and on the Golgi, is also something that remains to be further explored and 
understood. 
A trafficking route of GABARAP from Golgi to centrosome and from 
centrosome to autophagosome suggests a complicated relationship between 
GABARAP subcellular localisation and GABARAP function. I would tentatively 
predict that the centrosome-Golgi trafficking route of GABARAP may have some 
non-autophagic function and would be in competition with the centrosome-
autophagosome transport of GABARAP. Perhaps analogous to this idea is the 
Golgi-mediated repression of Beclin1 autophagy function (Shoji-Kawata et al., 
2013) and the autophagy-independent role of Beclin1 in maintaining centrosome 
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stability (Park et al., 2014). Disruption of the Golgi-centrosome axis of GABARAP 
trafficking may indirectly affect autophagy by depleting/increasing the centrosomal 
reservoir of GABARAP. I would speculate that under basal conditions of low 
autophagy, GABARAP may have some membrane trafficking function centred on 
the Golgi or could modulate some function of GM130. Thus it could be interesting 
to investigate the role of GABARAP in Golgi structural maintenance, vesicle 
tethering or protein secretion for example. Pertinent to this, GABARAP has been 
localised to the rims of Golgi cisternae by electron microscopy (Kittler et al., 2001). 
WAC could act as a switch to regulate the Golgi versus centrosome localisation of 
GABARAP, perhaps to toggle between GABARAP-mediated functions at those 
subcellular compartments and to maintain a centrosomal GABARAP reservoir that 
could be mobilised for autophagy. However, my data suggests that the WAC-
mediated repression of GABARAP-GM130 interaction occurs constitutively (under 
basal and starvation conditions) and further work would be needed to elucidate if 
WAC’s function is regulated by specific signals. 
The role of GABARAP at the centrosome is poorly understood, but I would 
hypothesise that GABARAP has some non-autophagic constitutive function at the 
centrosome, as most of centrosomal GABARAP remains on the centrosome during 
starvation. Perhaps GABARAP could take part in centrosome-organised functions 
such as spindle assembly and cell polarity, or perhaps GABARAP mobilisation from 
the centrosome is more potently induced by other autophagy stimuli such as 
glucose starvation for example. Moreover, autophagy proteins including GABARAP 
localise to the basal body (mother centriole) and axoneme of the primary cilium, a 
sensory organelle that forms during G1 and G0 phases of the cell cycle (Pampliega 
et al., 2013). During long term (24 hour) serum starvation, a stimulus that drives the 
formation of autophagosomes and primary cilia, autophagy functions to degrade a 
centrosomally-localised inhibitor of ciliogenesis OFD1, to allow primary cilia 
formation (Tang et al., 2013). In addition, signalling to the primary cilium activates 
autophagy in the region of the plasma membrane/basal body (Pampliega et al., 
2013). However, during nutrient replete conditions basal autophagy is involved in 
inhibiting the formation of the primary cilium through degrading IFT20 involved in 
ciliogenesis (Pampliega et al., 2013). Thus, it is plausible that GABARAP remains 
on the centrosome to coordinate the interlinked autophagosome and cilia formation 
pathways. The GABARAP reservoir at the centrosome may be co-opted for the 
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rapid and extensive formation of autophagosomes during acute 2 hour amino acid 
and serum starvation (EBSS starvation). However, a sufficient quantity of 
GABARAP may simultaneously need to remain at the centrosome to be able to 
function in cilia formation during the appropriate stage of the cell cycle, or during 
longer starvation periods. This could involve the GABARAP-mediated autophagic 
targeting of a ciliogenesis regulator such as OFD1, although this is unknown. One 
clue for a possible cell cycle regulation of GABARAP function is that I observed 
GABARAP dissociation from the spindle poles (centrosomes) during metaphase. 
Interestingly, this is a stage of the cell cycle where ciliogenesis is prevented, as 
centrosomes must be used for spindle formation (Ishikawa and Marshall, 2011). 
Whether GABARAP localisation at the centrosome is functionally linked to 
ciliogenesis is not understood. On the other hand, GABARAP at the basal body 
and axoneme of the primary cilium may be involved in converting extracellular cues 
to cytoplasmic autophagosome formation. Under these circumstances, GABARAP 
may also traffic from the basal body (mother centriole region) to forming 
autophagosomes. This remains to be investigated. In summary, I postulate that 
during starvation, the acute requirement for large-scale autophagosome formation 
would recruit a portion of the centrosomal pool of GABARAP. The remaining 
GABARAP pool could provide some centrosomally-localised function, such as in 
ciliogenesis. 
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Figure 6.1 A model for WAC regulation of the centrosomal GABARAP reservoir 
WAC inhibits the GM130-GABARAP interaction, which may maintain a pool of non-
lipidated GABARAP at the centrosome. Microtubules control the Golgi-centrosome 
localisation of GABARAP. GABARAP at the centrosome can relocalise to LC3 
positive structures and this likely requires microtubules. The role of motor proteins 
or membrane carriers in this process is not understood. At the phagophore, 
GABARAP may interact with ULK1 to keep it in an active state (see Figure 6.2). 
 
 
The interactions between GABARAP and GM130 and WAC certainly pointed to 
the mechanism of autophagy regulation. However there was a problem in my 
hypothesis, in that WAC affects ULK1 regulation (initiation) whereas GABARAP is 
thought to act at a later stage (elongation). GABARAP is known to directly bind the 
ULK1 complex and it was hypothesised that ULK1 drives the function of GABARAP 
in elongation. However I hypothesised that GABARAP regulates ULK1 activity. In 
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the presence of GABARAP or G116A non-lipidated GABARAP, but not in the 
presence of LC3B or in the absence of GABARAP, maximal ULK1 activation 
requires the ULK1 LIR motif. Moreover depletion of GABARAP, but not other LC3 
family members, results in reduced endogenous ULK1 activity. Thus it could be 
that binding of GABARAP to ULK1 maintains its activation, and this is independent 
of lipidation of GABARAP (Figure 6.2). Thus the WAC-GM130 interaction, which is 
likely involved in regulating the localisation of GABARAP, may in turn affect the 
activation of ULK1. However the fact remains that the LIR motif of ULK1 per se is 
not required for its kinase activity, but is only sensitised in the presence of 
GABARAP. Hence when the ULK1 LIR is mutated and GABARAP is present, it 
may be that GABARAP can bind to the LIRs on FIP200 and Atg13, and this 
intermediate complex may be semi-active. 
Based on the presented data and existing literature, I would like to discuss a 
hypothetical model to explain the non-hierarchical GABARAP-ULK1 function 
(Figure 6.2). It is non-hierarchical in the sense that a protein that is downstream in 
the autophagy pathway (GABARAP) may regulate an upstream factor (ULK1). In 
summary, starvation activates the ULK complex leading to its recruitment to 
phagophore formation sites on the ER (Itakura and Mizushima, 2010). ULK1 is able 
to phosphorylate and activate the Beclin-1 complex (Russell et al., 2013), which 
creates a pool of PtdIns(3)P at the omegasome (Axe et al., 2008). PtdIns(3)P 
recruits WIPI2, which recruits the Atg12–5-16L1 complex (Dooley et al., 2014). 
Atg16L1 can simultaneously bind WIPI2b and FIP200, but FIP200 binding is 
downstream of WIPI2b and not required for LC3 lipidation (Dooley et al., 2014). 
Thus, recruitment of FIP200 (the ULK complex) to the phagophore by Atg16L1 is 
downstream of PtdIns(3)P, WIPI2, and Atg12–5-16L1 driven mAtg8 lipidation, see 
Figure 6.2. This hypothesis would provide an explanation for the PI3P mediated 
reinforcement of the ULK1 complex at the phagophore (Karanasios et al., 2013). 
The ULK complex bound to the Atg12–5-16L1 on the phagophore could then be 
activated by unlipidated GABARAP coming from the centrosome (or perhaps also 
the cytosol) or lipidated GABARAP on the phagophore membrane. GABARAP 
association then maintains ULK1 activation via a LIR interaction and ULK1 
substrate phosphorylation during the final stages of phagophore formation, until the 
ULK1 complex dissociates prior to closure as shown previously (Karanasios et al., 
2013). 
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Figure 6.2 A hypothetical model for GABARAP-mediated maintenance of ULK1 
activation at the phagophore 
See main text for discussion. 
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Chapter 7. Appendix 
7.1 Live cell imaging movies 
Movies from photoconversion experiments of EosFP-GABARAP are on the CD 
found in the cover of this thesis. Legends are described below. 
 
Movie 1) Related to Figure 5.18. Centrosomal GABARAP transports to 
forming autophagosomes.  
Live cell imaging of a HEK293A cell expressing EosFP-GABARAP. Cells were 
washed into EBSS, imaged and photoconverted at 37oC with 10% CO2 using a 
Nikon Eclipse Ti Swept Field Confocal microscope. Arrows mark the structures 
shown in Figure 5.18a. Yellow arrow shows photoconverted centrosomal 
GABARAP. Blue arrow shows GABARAP punctum acquiring centrosomal 
GABARAP. Movie spans 25 mins played at 5 fps with 1 frame equal to 30 s. Note: 
first 5 frames are equal to 5 x 1 s images before photoconversion. 
 
Movie 2). Related to Figure 5.18. GABARAP positive puncta are highly mobile 
and make transient interactions with the enlarged GABARAP structure. 
Live cell imaging of a HEK293A cell expressing EosFP-GABARAP. Cells were 
washed into EBSS, imaged and photoconverted at 37oC with 10% CO2 using a 
Nikon Eclipse Ti Swept Field Confocal microscope. Enlarged EosFP-GABARAP 
structure in the centre of the cell is targeted for photoconversion and is assumed to 
be centrosomal GABARAP. Blue arrow shows GABARAP punctum making contact 
with centrosomal GABARAP before leaving in a different direction. Movie spans 26 
mins played at 10 fps with 1 frame equal to 5 s. Note: first 12 frames span the 60 s 
before photoconversion. 
 
Movie 3). Related to Figure 5.23. Depletion of WAC retains GABARAP on the 
Golgi where it becomes relatively immobile and does not make puncta 
Live cell imaging of HEK293A cells depleted of WAC expressing EosFP-
GABARAP. Cells were washed into EBSS, imaged and photoconverted at 37oC 
with 10% CO2 using a Nikon Eclipse Ti Swept Field Confocal microscope. Arrows 
mark the structures shown in Figure 5.23a. Golgi-localised GABARAP (yellow 
arrows) was targeted for photoconversion. Movie spans 25 mins played at 11.5 fps 
with 1 frame equal to 13.1 s. Maximum intensity projections of z-stacks are shown. 
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7.2 Microarray data 
Table 7.1 961 genes significantly (p ≤ 0.05) up or downregulated after WAC 
knockdown only versus RISC Free control 
Fold change versus RISC Free, FC. Adjusted p-value, adj. p-value. Top quarter-
positive regulator: in the top quarter of genome-wide screen for novel positive 
regulators of starvation-induced autophagy (McKnight et al., 2012).  
Gene symbol Protein name FC adj. p-value 
Top quarter 
-positive 
regulator 
WAC WW domain containing adaptor with coiled-coil -3.719 2.4E-07 YES 
SLC35B2 solute carrier family 35, member B2 -2.524 3.6E-07 NO 
LYN v-yes-1 Yamaguchi sarcoma viral related oncogene homolog -2.354 9.3E-06 NO 
DUSP3 dual specificity phosphatase 3 -2.264 1.4E-06 YES 
ACOT7 acyl-CoA thioesterase 7 -2.184 1.2E-05 NO 
MIS18A MIS18 kinetochore protein homolog A (S. pombe) -2.067 2.2E-05 NO 
VAMP3 vesicle-associated membrane protein 3 -1.919 1.6E-05 NO 
PLCB1 phospholipase C, beta 1 (phosphoinositide-specific) -1.908 8.3E-06 NO 
WDR12 WD repeat domain 12 -1.879 3.8E-05 YES 
DENND5B DENN/MADD domain containing 5B -1.843 1.4E-04 YES 
DHX40 DEAH (Asp-Glu-Ala-His) box polypeptide 40 -1.842 7.4E-04 NO 
IMPDH1 IMP (inosine 5'-monophosphate) dehydrogenase 1 -1.815 1.4E-03 NO 
CYP20A1 cytochrome P450, family 20, subfamily A, polypeptide 1 -1.799 2.7E-07 NO 
CALD1 caldesmon 1 -1.798 6.3E-05 NO 
CBR4 carbonyl reductase 4 -1.746 6.2E-04 NO 
SHISA2 shisa homolog 2 (Xenopus laevis) -1.745 2.9E-03 NO 
AP3M1 adaptor-related protein complex 3, mu 1 subunit -1.739 3.2E-04 NO 
ZMAT3 zinc finger, matrin-type 3 -1.714 1.3E-03 NO 
NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 -1.695 3.2E-04 YES 
LINC00152 long intergenic non-protein coding RNA 152 -1.690 2.1E-04 YES 
HSPB8 heat shock 22kDa protein 8 -1.667 1.2E-04 NO 
TTF2 transcription termination factor, RNA polymerase II -1.654 1.1E-04 YES 
TAF7L 
TAF7-like RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 50kDa -1.642 4.2E-04 NO 
MCM3 minichromosome maintenance complex component 3 -1.629 6.7E-06 NO 
ERAP2 endoplasmic reticulum aminopeptidase 2 -1.626 1.3E-03 NO 
LTBR lymphotoxin beta receptor (TNFR superfamily, member 3) -1.625 4.1E-03 NO 
FNDC3A fibronectin type III domain containing 3A -1.621 4.4E-05 NO 
EIF3J eukaryotic translation initiation factor 3, subunit J -1.620 5.4E-04 NO 
FAM69A family with sequence similarity 69, member A -1.615 3.9E-05 YES 
KIAA0430 KIAA0430 -1.613 1.8E-03 NO 
DDT D-dopachrome tautomerase -1.610 3.8E-05 NO 
HLA-A major histocompatibility complex, class I, A -1.610 1.5E-05 NO 
MAP2K4 mitogen-activated protein kinase kinase 4 -1.597 1.0E-04 NO 
COMTD1 catechol-O-methyltransferase domain containing 1 -1.586 1.7E-03 NO 
AKAP12 A kinase (PRKA) anchor protein 12 -1.586 3.7E-03 NO 
SH3PXD2A SH3 and PX domains 2A -1.581 2.7E-04 YES 
RPL29 ribosomal protein L29 -1.574 1.8E-03 NO 
ACADVL acyl-CoA dehydrogenase, very long chain -1.545 7.3E-04 NO 
OSTC oligosaccharyltransferase complex subunit -1.543 7.4E-04 NO 
INTS2 integrator complex subunit 2 -1.538 4.4E-04 NO 
AFF4 AF4/FMR2 family, member 4 -1.537 1.4E-02 YES 
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OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa -1.521 1.0E-03 YES 
CMSS1 cms1 ribosomal small subunit homolog (yeast) -1.515 1.7E-03 YES 
ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) -1.514 2.0E-03 NO 
BEX2 brain expressed X-linked 2 -1.510 3.1E-04 YES 
MFSD3 major facilitator superfamily domain containing 3 -1.505 9.1E-03 NO 
GPX3 glutathione peroxidase 3 (plasma) -1.498 3.6E-03 YES 
IMPAD1 inositol monophosphatase domain containing 1 -1.491 7.4E-04 NO 
RAB21 RAB21, member RAS oncogene family -1.489 3.7E-03 NO 
MAPK13 mitogen-activated protein kinase 13 -1.486 5.6E-03 NO 
MATN2 matrilin 2 -1.478 4.9E-03 NO 
FHL1 four and a half LIM domains 1 -1.472 2.2E-04 YES 
FBXO6 F-box protein 6 -1.471 1.9E-04 NO 
TM7SF2 transmembrane 7 superfamily member 2 -1.467 9.6E-03 NO 
SCARB2 scavenger receptor class B, member 2 -1.463 8.4E-03 NO 
CWF19L2 CWF19-like 2, cell cycle control (S. pombe) -1.463 5.8E-03 NO 
CARD10 caspase recruitment domain family, member 10 -1.459 1.3E-03 YES 
MBTPS1 membrane-bound transcription factor peptidase, site 1 -1.455 6.3E-05 YES 
MTHFS 
5,10-methenyltetrahydrofolate synthetase (5-formyltetrahydrofolate 
cyclo-ligase) -1.454 3.3E-03 NO 
NCR3LG1 natural killer cell cytotoxicity receptor 3 ligand 1 -1.451 1.9E-04 NO 
TXNDC9 thioredoxin domain containing 9 -1.451 2.3E-03 NO 
HLA-H major histocompatibility complex, class I, H (pseudogene) -1.447 3.8E-05 YES 
AMZ2 archaelysin family metallopeptidase 2 -1.446 3.9E-04 NO 
ADH5 alcohol dehydrogenase 5 (class III), chi polypeptide -1.440 1.1E-03 NO 
NPC2 Niemann-Pick disease, type C2 -1.437 6.9E-05 NO 
SLC30A7 solute carrier family 30 (zinc transporter), member 7 -1.426 2.5E-03 YES 
C17ORF80 chromosome 17 open reading frame 80 -1.423 1.2E-03 NO 
SIL1 SIL1 homolog, endoplasmic reticulum chaperone (S. cerevisiae) -1.422 2.5E-03 NO 
NME4 NME/NM23 nucleoside diphosphate kinase 4 -1.422 5.9E-03 NO 
LITAF lipopolysaccharide-induced TNF factor -1.419 1.5E-03 YES 
PKMYT1 protein kinase, membrane associated tyrosine/threonine 1 -1.414 5.9E-03 NO 
OCRL oculocerebrorenal syndrome of Lowe -1.411 3.5E-03 NO 
LAMB2 laminin, beta 2 (laminin S) -1.411 1.4E-03 YES 
LINC00478 long intergenic non-protein coding RNA 478 -1.410 1.8E-04 NO 
JAZF1 JAZF zinc finger 1 -1.409 2.1E-03 NO 
HLA-E major histocompatibility complex, class I, E -1.406 2.9E-03 YES 
XK X-linked Kx blood group (McLeod syndrome) -1.403 8.7E-03 YES 
SULF2 sulfatase 2 -1.403 2.0E-03 NO 
FHL2 four and a half LIM domains 2 -1.401 7.8E-03 NO 
APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B -1.400 4.7E-04 NO 
PRKAG1 protein kinase, AMP-activated, gamma 1 non-catalytic subunit -1.399 1.6E-03 NO 
LAMA5 laminin, alpha 5 -1.398 1.2E-02 NO 
GLG1 golgi glycoprotein 1 -1.395 1.3E-03 NO 
SPATS2 spermatogenesis associated, serine-rich 2 -1.395 3.1E-04 NO 
FAS Fas (TNF receptor superfamily, member 6) -1.393 3.0E-03 NO 
CST3 cystatin C -1.393 4.4E-03 NO 
MEA1 male-enhanced antigen 1 -1.391 7.3E-04 NO 
C11ORF54 chromosome 11 open reading frame 54 -1.389 3.1E-03 NO 
SP110 SP110 nuclear body protein -1.388 2.7E-03 YES 
FAM83H family with sequence similarity 83, member H -1.388 2.7E-03 NO 
RAB11FIP2 RAB11 family interacting protein 2 (class I) -1.385 2.5E-03 NO 
ITGB5 integrin, beta 5 -1.384 3.4E-04 NO 
FIS1 fission 1 (mitochondrial outer membrane) homolog (S. cerevisiae) -1.384 5.5E-03 NO 
SMPDL3A sphingomyelin phosphodiesterase, acid-like 3A -1.384 4.6E-03 NO 
FAM213A family with sequence similarity 213, member A -1.383 1.1E-02 NO 
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RRM2 ribonucleotide reductase M2 -1.383 2.2E-02 NO 
NSF N-ethylmaleimide-sensitive factor -1.382 5.2E-03 NO 
ZNF239 zinc finger protein 239 -1.381 2.8E-04 YES 
HLA-B major histocompatibility complex, class I, B -1.380 4.1E-03 NO 
C12ORF5 chromosome 12 open reading frame 5 -1.378 1.8E-03 YES 
TMEM106B transmembrane protein 106B -1.378 8.5E-03 YES 
NUCB1 nucleobindin 1 -1.375 1.5E-02 YES 
RUNDC1 RUN domain containing 1 -1.371 1.5E-03 NO 
CMTM6 CKLF-like MARVEL transmembrane domain containing 6 -1.368 5.2E-03 NO 
MYCBP2 MYC binding protein 2, E3 ubiquitin protein ligase -1.368 1.3E-02 YES 
LRRCC1 leucine rich repeat and coiled-coil centrosomal protein 1 -1.363 1.9E-03 NO 
CYCSP55 cytochrome c, somatic pseudogene 55 -1.360 2.9E-03 YES 
VANGL2 vang-like 2 (van gogh, Drosophila) -1.358 3.4E-03 NO 
ITPRIPL2 inositol 1,4,5-trisphosphate receptor interacting protein-like 2 -1.356 8.8E-03 NO 
SAMD9 sterile alpha motif domain containing 9 -1.356 1.2E-04 YES 
MAP1LC3B microtubule-associated protein 1 light chain 3 beta -1.353 2.4E-02 YES 
MOCS1 molybdenum cofactor synthesis 1 -1.353 5.8E-03 NO 
CORO2A coronin, actin binding protein, 2A -1.352 1.5E-02 NO 
GYPC glycophorin C (Gerbich blood group) -1.352 8.3E-04 NO 
AVEN apoptosis, caspase activation inhibitor -1.350 3.5E-02 NO 
XBP1 X-box binding protein 1 -1.347 1.6E-03 YES 
ZNF219 zinc finger protein 219 -1.347 6.1E-03 NO 
HMGA1 high mobility group AT-hook 1 -1.346 8.7E-03 NO 
CEP55 centrosomal protein 55kDa -1.345 7.8E-03 NO 
GCDH glutaryl-CoA dehydrogenase -1.344 3.1E-03 NO 
CAP2 CAP, adenylate cyclase-associated protein, 2 (yeast) -1.344 5.0E-03 NO 
ADAM23 ADAM metallopeptidase domain 23 -1.344 1.1E-03 NO 
P4HA2 prolyl 4-hydroxylase, alpha polypeptide II -1.343 3.8E-04 NO 
P4HA1 prolyl 4-hydroxylase, alpha polypeptide I -1.343 5.8E-04 YES 
PRAME preferentially expressed antigen in melanoma -1.342 2.4E-03 NO 
SUMF1 sulfatase modifying factor 1 -1.340 5.3E-04 NO 
PITPNM1 phosphatidylinositol transfer protein, membrane-associated 1 -1.339 3.5E-02 NO 
IRAK1 interleukin-1 receptor-associated kinase 1 -1.337 1.6E-03 NO 
ITFG1 integrin alpha FG-GAP repeat containing 1 -1.336 2.0E-03 NO 
RCOR3 REST corepressor 3 -1.336 1.2E-02 NO 
CARD8 caspase recruitment domain family, member 8 -1.335 2.4E-02 YES 
SSR4 signal sequence receptor, delta -1.334 2.3E-03 NO 
YOD1 YOD1 OTU deubiquinating enzyme 1 homolog (S. cerevisiae) -1.332 4.0E-03 YES 
LEPREL2 leprecan-like 2 -1.332 1.6E-02 NO 
PFKP phosphofructokinase, platelet -1.331 1.5E-04 NO 
VAMP2 vesicle-associated membrane protein 2 (synaptobrevin 2) -1.330 6.1E-04 YES 
RAB8B RAB8B, member RAS oncogene family -1.328 4.5E-03 NO 
LGALS3BP lectin, galactoside-binding, soluble, 3 binding protein -1.326 3.1E-02 NO 
ZSWIM5 zinc finger, SWIM-type containing 5 -1.326 1.0E-03 YES 
SERPINH1 
serpin peptidase inhibitor, clade H (heat shock protein 47), member 1, 
(collagen binding protein 1) -1.326 1.1E-02 YES 
ENPP4 ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative) -1.323 4.9E-03 NO 
PGLS 6-phosphogluconolactonase -1.323 7.0E-03 YES 
ERO1L ERO1-like (S. cerevisiae) -1.323 7.3E-04 NO 
RRM2B ribonucleotide reductase M2 B (TP53 inducible) -1.322 1.5E-03 NO 
PNKP polynucleotide kinase 3'-phosphatase -1.321 3.7E-02 YES 
CXCL16 chemokine (C-X-C motif) ligand 16 -1.320 1.5E-03 NO 
PNMA2 paraneoplastic Ma antigen 2 -1.319 1.4E-03 NO 
RAPGEF5 Rap guanine nucleotide exchange factor (GEF) 5 -1.319 5.0E-04 YES 
KBTBD2 kelch repeat and BTB (POZ) domain containing 2 -1.318 9.8E-03 NO 
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LIG1 ligase I, DNA, ATP-dependent -1.317 1.3E-02 NO 
RBM4B RNA binding motif protein 4B -1.316 6.4E-04 NO 
UFC1 ubiquitin-fold modifier conjugating enzyme 1 -1.316 4.3E-04 YES 
WWOX WW domain containing oxidoreductase -1.315 7.3E-03 NO 
RAP1B RAP1B, member of RAS oncogene family -1.315 4.2E-03 NO 
CDK5RAP3 CDK5 regulatory subunit associated protein 3 -1.314 1.6E-02 NO 
ZNF618 zinc finger protein 618 -1.313 6.8E-04 NO 
SYK spleen tyrosine kinase -1.312 1.4E-03 YES 
VPS35 vacuolar protein sorting 35 homolog (S. cerevisiae) -1.311 7.3E-03 YES 
KEAP1 kelch-like ECH-associated protein 1 -1.310 6.3E-03 NO 
ITFG2 integrin alpha FG-GAP repeat containing 2 -1.307 1.3E-02 NO 
MCM5 minichromosome maintenance complex component 5 -1.307 4.4E-02 NO 
YEATS2 YEATS domain containing 2 -1.305 7.9E-03 YES 
MIDN midnolin -1.304 7.3E-03 NO 
NUP210 nucleoporin 210kDa -1.302 4.9E-03 NO 
SNX16 sorting nexin 16 -1.302 2.8E-03 NO 
FAM45A family with sequence similarity 45, member A -1.302 1.9E-03 NO 
PRNP prion protein -1.302 4.8E-03 NO 
GALT galactose-1-phosphate uridylyltransferase -1.301 2.2E-02 NO 
HSD17B7P2 hydroxysteroid (17-beta) dehydrogenase 7 pseudogene 2 -1.300 2.6E-03 YES 
INSIG2 insulin induced gene 2 -1.298 4.0E-02 NO 
KIAA1147 KIAA1147 -1.296 1.8E-02 YES 
GOLIM4 golgi integral membrane protein 4 -1.296 4.2E-02 NO 
DDR1 discoidin domain receptor tyrosine kinase 1 -1.295 1.3E-02 NO 
ZDHHC8 zinc finger, DHHC-type containing 8 -1.294 4.0E-03 NO 
PHF19 PHD finger protein 19 -1.294 6.7E-04 NO 
NUFIP2 nuclear fragile X mental retardation protein interacting protein 2 -1.292 1.0E-02 NO 
LOXL1 lysyl oxidase-like 1 -1.292 6.4E-03 YES 
ZNF580 zinc finger protein 580 -1.291 4.9E-02 NO 
MRPL34 mitochondrial ribosomal protein L34 -1.291 3.6E-02 NO 
TRAK2 trafficking protein, kinesin binding 2 -1.289 3.7E-02 NO 
CTSH cathepsin H -1.287 1.4E-02 NO 
TP53I3 tumor protein p53 inducible protein 3 -1.286 2.5E-03 NO 
RPS27L ribosomal protein S27-like -1.285 9.8E-04 YES 
JMJD8 jumonji domain containing 8 -1.284 8.7E-03 NO 
RBM47 RNA binding motif protein 47 -1.284 5.4E-04 YES 
HSPA1A heat shock 70kDa protein 1A -1.283 1.5E-03 YES 
TMTC1 transmembrane and tetratricopeptide repeat containing 1 -1.282 7.0E-04 NO 
KLC3 kinesin light chain 3 -1.282 2.8E-02 NO 
SEPN1 selenoprotein N, 1 -1.282 9.7E-03 NO 
S100A13 S100 calcium binding protein A13 -1.281 2.4E-02 NO 
HMGN5 high mobility group nucleosome binding domain 5 -1.280 3.4E-02 NO 
IRF7 interferon regulatory factor 7 -1.280 1.1E-02 NO 
PRRG4 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) -1.279 6.2E-03 NO 
BBX bobby sox homolog (Drosophila) -1.279 2.6E-02 YES 
ZNF672 zinc finger protein 672 -1.278 2.0E-02 NO 
ARFGAP3 ADP-ribosylation factor GTPase activating protein 3 -1.278 2.7E-02 NO 
EFCAB14 EF-hand calcium binding domain 14 -1.277 2.0E-02 NO 
TMED1 transmembrane emp24 protein transport domain containing 1 -1.277 1.2E-02 NO 
AKIP1 A kinase (PRKA) interacting protein 1 -1.276 3.8E-02 NO 
TFPI 
tissue factor pathway inhibitor (lipoprotein-associated coagulation 
inhibitor) -1.276 3.3E-03 NO 
TMEM59 transmembrane protein 59 -1.276 1.6E-03 NO 
AKR1D1 aldo-keto reductase family 1, member D1 -1.275 2.4E-02 NO 
BCAP29 B-cell receptor-associated protein 29 -1.275 6.3E-03 NO 
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TCEAL7 transcription elongation factor A (SII)-like 7 -1.274 3.8E-02 NO 
CUTC cutC copper transporter homolog (E. coli) -1.274 1.2E-02 YES 
NAGLU N-acetylglucosaminidase, alpha -1.274 2.4E-02 NO 
PLAC9 placenta-specific 9 -1.272 4.2E-03 NO 
CHST14 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 14 -1.272 2.0E-02 NO 
SMAD6 SMAD family member 6 -1.271 1.5E-02 YES 
MGC72080 MGC72080 pseudogene -1.271 2.7E-02 NO 
CARD11 caspase recruitment domain family, member 11 -1.271 2.5E-02 YES 
OSTM1 osteopetrosis associated transmembrane protein 1 -1.270 1.7E-02 NO 
TBX18 T-box 18 -1.270 9.7E-03 NO 
ANXA5 annexin A5 -1.270 1.4E-02 NO 
CKB creatine kinase, brain -1.270 4.8E-03 NO 
CUEDC1 CUE domain containing 1 -1.269 4.9E-02 NO 
NPHP3 nephronophthisis 3 (adolescent) -1.269 2.1E-03 NO 
NXT2 nuclear transport factor 2-like export factor 2 -1.269 2.2E-03 YES 
CAT catalase -1.268 7.0E-03 NO 
DTNA dystrobrevin, alpha -1.268 2.8E-02 NO 
RINL Ras and Rab interactor-like -1.267 2.1E-02 NO 
SMAGP small cell adhesion glycoprotein -1.267 4.4E-03 NO 
TSPAN31 tetraspanin 31 -1.267 4.7E-02 NO 
FAAH fatty acid amide hydrolase -1.266 1.9E-02 NO 
GLB1 galactosidase, beta 1 -1.265 4.8E-03 NO 
C2CD5 C2 calcium-dependent domain containing 5 -1.263 4.6E-02 NO 
SUPT3H suppressor of Ty 3 homolog (S. cerevisiae) -1.263 4.5E-03 NO 
FAM111A family with sequence similarity 111, member A -1.261 7.3E-03 YES 
UBA3 ubiquitin-like modifier activating enzyme 3 -1.260 1.1E-02 NO 
ACVR1 activin A receptor, type I -1.259 1.2E-03 NO 
COMMD7 COMM domain containing 7 -1.259 5.0E-03 NO 
GFM2 G elongation factor, mitochondrial 2 -1.258 1.4E-03 YES 
HS3ST3A1 heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1 -1.258 1.2E-02 NO 
INPP1 inositol polyphosphate-1-phosphatase -1.257 1.1E-02 NO 
PMVK phosphomevalonate kinase -1.257 2.0E-02 NO 
TMEM132A transmembrane protein 132A -1.257 3.9E-02 YES 
PDCD4 programmed cell death 4 (neoplastic transformation inhibitor) -1.257 2.6E-03 NO 
PPARG peroxisome proliferator-activated receptor gamma -1.257 5.5E-03 NO 
SCARA3 scavenger receptor class A, member 3 -1.257 4.8E-03 NO 
BRD3 bromodomain containing 3 -1.257 1.1E-02 NO 
GBE1 glucan (1,4-alpha-), branching enzyme 1 -1.257 2.0E-02 YES 
DUS3L dihydrouridine synthase 3-like (S. cerevisiae) -1.256 1.3E-02 NO 
NLRX1 NLR family member X1 -1.256 1.7E-02 YES 
PRDX2 peroxiredoxin 2 -1.254 5.6E-03 NO 
EFEMP1 EGF containing fibulin-like extracellular matrix protein 1 -1.254 2.7E-02 NO 
DNAJC13 DnaJ (Hsp40) homolog, subfamily C, member 13 -1.253 8.7E-04 NO 
MFI2 
antigen p97 (melanoma associated) identified by monoclonal 
antibodies 133.2 and 96.5 -1.252 3.7E-02 YES 
SRXN1 sulfiredoxin 1 -1.252 4.6E-02 NO 
IFITM2 interferon induced transmembrane protein 2 -1.251 1.5E-02 NO 
TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) -1.251 1.2E-03 NO 
PSEN2 presenilin 2 (Alzheimer disease 4) -1.251 2.4E-03 NO 
MSRB3 methionine sulfoxide reductase B3 -1.250 2.3E-02 YES 
GBA glucosidase, beta, acid -1.249 2.5E-02 NO 
TAF10 
TAF10 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 30kDa -1.247 1.4E-02 YES 
ZNF318 zinc finger protein 318 -1.247 2.6E-03 NO 
AKR1B1 aldo-keto reductase family 1, member B1 (aldose reductase) -1.246 1.8E-02 NO 
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LRP5 low density lipoprotein receptor-related protein 5 -1.246 4.6E-03 NO 
BACE2 beta-site APP-cleaving enzyme 2 -1.246 1.6E-03 NO 
PCSK5 proprotein convertase subtilisin/kexin type 5 -1.246 1.6E-02 NO 
CYP2R1 cytochrome P450, family 2, subfamily R, polypeptide 1 -1.244 5.5E-03 NO 
PTGFRN prostaglandin F2 receptor inhibitor -1.244 1.9E-02 NO 
IVNS1ABP influenza virus NS1A binding protein -1.244 5.1E-03 YES 
NEU1 sialidase 1 (lysosomal sialidase) -1.243 3.8E-02 NO 
IFI27L2 interferon, alpha-inducible protein 27-like 2 -1.243 3.2E-02 NO 
CLDND1 claudin domain containing 1 -1.243 3.5E-02 NO 
NR2C1 nuclear receptor subfamily 2, group C, member 1 -1.242 9.1E-03 NO 
MEIS3P1 Meis homeobox 3 pseudogene 1 -1.241 2.3E-02 YES 
NUPR1 nuclear protein, transcriptional regulator, 1 -1.241 2.4E-03 NO 
KDM5A lysine (K)-specific demethylase 5A -1.240 1.5E-02 NO 
HLA-F major histocompatibility complex, class I, F -1.240 2.1E-02 NO 
CCNT1 cyclin T1 -1.240 2.3E-02 NO 
FERMT2 fermitin family member 2 -1.239 1.7E-02 NO 
VIM vimentin -1.239 2.0E-02 NO 
SESN1 sestrin 1 -1.238 2.8E-02 YES 
ELFN2 
extracellular leucine-rich repeat and fibronectin type III domain 
containing 2 -1.238 1.2E-02 YES 
P2RX4 purinergic receptor P2X, ligand-gated ion channel, 4 -1.238 1.7E-02 NO 
CKLF chemokine-like factor -1.238 8.2E-03 NO 
CCP110 centriolar coiled coil protein 110kDa -1.238 5.7E-03 NO 
C1ORF112 chromosome 1 open reading frame 112 -1.238 3.5E-02 YES 
GSTO2 glutathione S-transferase omega 2 -1.238 2.2E-02 NO 
PHYH phytanoyl-CoA 2-hydroxylase -1.235 8.1E-03 NO 
PRCP prolylcarboxypeptidase (angiotensinase C) -1.233 4.8E-03 NO 
C14ORF37 chromosome 14 open reading frame 37 -1.232 1.9E-02 NO 
PON2 paraoxonase 2 -1.232 9.3E-03 NO 
DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta -1.232 1.0E-02 NO 
DDAH1 dimethylarginine dimethylaminohydrolase 1 -1.231 1.0E-02 NO 
N6AMT1 N-6 adenine-specific DNA methyltransferase 1 (putative) -1.230 2.0E-03 NO 
ALG13 ALG13, UDP-N-acetylglucosaminyltransferase subunit -1.229 1.7E-02 NO 
OTUD4 OTU domain containing 4 -1.229 1.5E-03 NO 
CENPW centromere protein W -1.229 1.1E-02 YES 
PDLIM7 PDZ and LIM domain 7 (enigma) -1.228 3.0E-02 YES 
MUTYH mutY homolog (E. coli) -1.228 4.9E-02 NO 
ZFYVE16 zinc finger, FYVE domain containing 16 -1.228 2.3E-02 NO 
DZIP1 DAZ interacting protein 1 -1.227 4.1E-02 NO 
EHBP1L1 EH domain binding protein 1-like 1 -1.227 2.2E-02 NO 
CTSC cathepsin C -1.227 4.3E-02 YES 
RAD54L RAD54-like (S. cerevisiae) -1.227 1.1E-02 NO 
UAP1L1 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 -1.227 4.8E-02 NO 
C17ORF82 chromosome 17 open reading frame 82 -1.227 1.4E-03 NO 
TMEM173 transmembrane protein 173 -1.227 1.3E-02 NO 
SEMA4F 
sema domain, immunoglobulin domain (Ig), transmembrane domain 
(TM) and short cytoplasmic domain, (semaphorin) 4F -1.227 3.8E-02 YES 
C17ORF58 chromosome 17 open reading frame 58 -1.226 1.5E-02 NO 
TMEM237 transmembrane protein 237 -1.226 3.2E-03 YES 
DMRT2 doublesex and mab-3 related transcription factor 2 -1.226 2.1E-02 YES 
GGT1 gamma-glutamyltransferase 1 -1.226 1.3E-02 NO 
B2M beta-2-microglobulin -1.225 4.5E-02 YES 
SRSF5 serine/arginine-rich splicing factor 5 -1.224 1.9E-02 NO 
SLMAP sarcolemma associated protein -1.223 4.1E-02 NO 
PSMB5 proteasome (prosome, macropain) subunit, beta type, 5 -1.223 1.5E-03 YES 
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UBXN2A UBX domain protein 2A -1.222 2.5E-02 NO 
PSME1 proteasome (prosome, macropain) activator subunit 1 (PA28 alpha) -1.222 1.9E-02 NO 
SNORA12 small nucleolar RNA, H/ACA box 12 -1.221 1.3E-02 YES 
HAUS4 HAUS augmin-like complex, subunit 4 -1.221 4.7E-02 NO 
SERF1B small EDRK-rich factor 1B (centromeric) -1.220 1.1E-02 NO 
KIF13B kinesin family member 13B -1.220 3.2E-03 NO 
PLXNB1 plexin B1 -1.220 3.0E-02 YES 
C15ORF48 chromosome 15 open reading frame 48 -1.218 1.7E-02 NO 
SEL1L3 sel-1 suppressor of lin-12-like 3 (C. elegans) -1.218 2.0E-02 NO 
SPG20 spastic paraplegia 20 (Troyer syndrome) -1.218 5.9E-03 NO 
RABAC1 Rab acceptor 1 (prenylated) -1.217 3.1E-02 NO 
CCDC90B coiled-coil domain containing 90B -1.217 1.5E-02 NO 
ANGPTL2 angiopoietin-like 2 -1.217 1.0E-02 NO 
IL1RAP interleukin 1 receptor accessory protein -1.217 8.5E-03 NO 
DLG5-AS1 DLG5 antisense RNA 1 -1.216 2.7E-02 YES 
TRAK1 trafficking protein, kinesin binding 1 -1.216 1.7E-02 YES 
ZBTB8A zinc finger and BTB domain containing 8A -1.215 9.1E-03 YES 
HELZ2 helicase with zinc finger 2, transcriptional coactivator -1.215 6.2E-03 NO 
CNOT10 CCR4-NOT transcription complex, subunit 10 -1.214 2.2E-02 YES 
SLC2A12 solute carrier family 2 (facilitated glucose transporter), member 12 -1.214 8.5E-03 NO 
KCTD18 potassium channel tetramerisation domain containing 18 -1.214 2.9E-02 NO 
ZBTB4 zinc finger and BTB domain containing 4 -1.213 2.1E-03 YES 
BANP BTG3 associated nuclear protein -1.213 3.6E-02 NO 
TYMP thymidine phosphorylase -1.213 2.7E-02 NO 
BTG3 BTG family, member 3 -1.211 1.2E-02 NO 
WIPI1 WD repeat domain, phosphoinositide interacting 1 -1.211 3.1E-02 NO 
ZCCHC9 zinc finger, CCHC domain containing 9 -1.211 1.7E-02 NO 
SPCS3 signal peptidase complex subunit 3 homolog (S. cerevisiae) -1.209 1.1E-02 NO 
LRRK1 leucine-rich repeat kinase 1 -1.209 1.0E-02 NO 
E2F5 E2F transcription factor 5, p130-binding -1.207 7.9E-03 NO 
WDR6 WD repeat domain 6 -1.207 8.7E-03 NO 
RAMP1 receptor (G protein-coupled) activity modifying protein 1 -1.207 2.8E-03 NO 
RCAN3 RCAN family member 3 -1.206 1.4E-03 YES 
RRP7A ribosomal RNA processing 7 homolog A (S. cerevisiae) -1.206 4.9E-02 YES 
YIPF4 Yip1 domain family, member 4 -1.205 1.1E-02 YES 
CD58 CD58 molecule -1.205 8.3E-03 NO 
ILK integrin-linked kinase -1.204 4.7E-02 YES 
DHRS4L2 dehydrogenase/reductase (SDR family) member 4 like 2 -1.204 3.2E-02 NO 
NARS asparaginyl-tRNA synthetase -1.204 2.1E-02 NO 
TRIM5 tripartite motif containing 5 -1.204 1.1E-02 NO 
AQP11 aquaporin 11 -1.204 1.6E-02 YES 
PDE8B phosphodiesterase 8B -1.203 1.4E-03 NO 
TAX1BP3 Tax1 (human T-cell leukemia virus type I) binding protein 3 -1.202 3.8E-02 YES 
STAG3L2 stromal antigen 3-like 2 -1.202 4.6E-02 NO 
EPS8 epidermal growth factor receptor pathway substrate 8 -1.201 2.6E-02 NO 
NUDT3 nudix (nucleoside diphosphate linked moiety X)-type motif 3 -1.201 1.8E-02 NO 
TDRD7 tudor domain containing 7 -1.200 1.9E-02 YES 
GTF3C2 general transcription factor IIIC, polypeptide 2, beta 110kDa -1.200 1.7E-02 NO 
C17ORF96 chromosome 17 open reading frame 96 -1.200 4.6E-02 YES 
TERF2 telomeric repeat binding factor 2 -1.200 4.3E-02 NO 
GABPB1 GA binding protein transcription factor, beta subunit 1 -1.198 7.0E-03 NO 
TAGLN2 transgelin 2 -1.198 4.8E-02 NO 
FAXC failed axon connections homolog (Drosophila) -1.197 3.4E-02 YES 
SEPT10 septin 10 -1.197 2.0E-02 NO 
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ARSD arylsulfatase D -1.196 1.8E-02 NO 
ARPC1B actin related protein 2/3 complex, subunit 1B, 41kDa -1.196 1.8E-02 NO 
RIOK3 RIO kinase 3 -1.196 3.5E-02 YES 
CALHM2 calcium homeostasis modulator 2 -1.195 4.3E-02 NO 
ATL3 atlastin GTPase 3 -1.195 1.9E-02 NO 
LPL lipoprotein lipase -1.195 4.7E-02 NO 
GYG1 glycogenin 1 -1.194 1.9E-02 NO 
CDC7 cell division cycle 7 -1.194 1.1E-02 NO 
CCDC24 coiled-coil domain containing 24 -1.194 2.2E-02 NO 
FAM50B family with sequence similarity 50, member B -1.193 3.2E-02 NO 
MID2 midline 2 -1.192 6.2E-03 YES 
RAB3IL1 RAB3A interacting protein (rabin3)-like 1 -1.192 3.6E-02 NO 
AP1G2 adaptor-related protein complex 1, gamma 2 subunit -1.192 1.9E-02 NO 
ELOVL6 ELOVL fatty acid elongase 6 -1.192 5.8E-03 YES 
IFI30 interferon, gamma-inducible protein 30 -1.192 3.1E-02 YES 
BMP1 bone morphogenetic protein 1 -1.192 9.9E-03 NO 
NDUFA8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 19kDa -1.192 2.7E-02 YES 
VOPP1 vesicular, overexpressed in cancer, prosurvival protein 1 -1.191 4.2E-03 NO 
RTCA RNA 3'-terminal phosphate cyclase -1.191 4.8E-02 NO 
IKBIP IKBKB interacting protein -1.191 4.5E-03 NO 
PARP12 poly (ADP-ribose) polymerase family, member 12 -1.191 1.0E-02 NO 
DOCK8 dedicator of cytokinesis 8 -1.190 3.2E-02 YES 
TRIM56 tripartite motif containing 56 -1.190 3.2E-02 NO 
NUF2 
NUF2, NDC80 kinetochore complex component, homolog (S. 
cerevisiae) -1.189 2.2E-02 NO 
DNASE2 deoxyribonuclease II, lysosomal -1.189 1.5E-02 YES 
MYL6 myosin, light chain 6, alkali, smooth muscle and non-muscle -1.189 1.6E-02 YES 
FER fer (fps/fes related) tyrosine kinase -1.189 4.4E-02 YES 
TIA1 TIA1 cytotoxic granule-associated RNA binding protein -1.189 4.1E-02 YES 
FYCO1 FYVE and coiled-coil domain containing 1 -1.188 2.2E-02 YES 
BCDIN3D BCDIN3 domain containing -1.188 4.7E-02 YES 
ELMO2 engulfment and cell motility 2 -1.188 9.2E-03 NO 
ZNF462 zinc finger protein 462 -1.185 1.7E-02 NO 
HSD17B14 hydroxysteroid (17-beta) dehydrogenase 14 -1.185 4.0E-02 NO 
MANEA mannosidase, endo-alpha -1.185 4.9E-02 YES 
CHKB choline kinase beta -1.185 4.2E-02 YES 
UXT ubiquitously-expressed, prefoldin-like chaperone -1.185 4.9E-03 NO 
SCPEP1 serine carboxypeptidase 1 -1.184 2.0E-03 NO 
MRPL3 mitochondrial ribosomal protein L3 -1.184 2.0E-02 NO 
ZNF320 zinc finger protein 320 -1.183 3.2E-02 NO 
MAN1A2 mannosidase, alpha, class 1A, member 2 -1.183 3.1E-02 NO 
CELSR2 cadherin, EGF LAG seven-pass G-type receptor 2 -1.182 3.6E-02 NO 
MATN3 matrilin 3 -1.181 3.7E-02 YES 
CALML4 calmodulin-like 4 -1.181 8.2E-03 YES 
NDST1 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 -1.181 4.8E-02 NO 
NHLRC2 NHL repeat containing 2 -1.181 3.9E-02 NO 
TMEM56 transmembrane protein 56 -1.180 3.0E-03 NO 
BRSK1 BR serine/threonine kinase 1 -1.179 2.7E-02 NO 
NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9kDa -1.179 4.6E-02 NO 
ZNF641 zinc finger protein 641 -1.179 1.9E-02 NO 
LONRF2 LON peptidase N-terminal domain and ring finger 2 -1.179 3.0E-02 NO 
CYFIP2 cytoplasmic FMR1 interacting protein 2 -1.179 3.7E-02 NO 
BRWD3 bromodomain and WD repeat domain containing 3 -1.178 3.0E-02 NO 
LARGE like-glycosyltransferase -1.177 1.2E-02 NO 
HHAT hedgehog acyltransferase -1.177 2.4E-02 NO 
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TSHZ1 teashirt zinc finger homeobox 1 -1.177 1.4E-02 YES 
HOXD8 homeobox D8 -1.176 1.4E-02 YES 
ZNF544 zinc finger protein 544 -1.176 2.6E-02 NO 
SCMH1 sex comb on midleg homolog 1 (Drosophila) -1.175 5.7E-03 NO 
VLDLR very low density lipoprotein receptor -1.175 2.6E-02 YES 
MIF macrophage migration inhibitory factor (glycosylation-inhibiting factor) -1.175 3.0E-02 NO 
ARHGAP8 Rho GTPase activating protein 8 -1.174 1.1E-02 NO 
KHNYN KH and NYN domain containing -1.173 2.0E-02 YES 
TAPT1-AS1 TAPT1 antisense RNA 1 (head to head) -1.172 9.1E-03 NO 
PHLDB2 pleckstrin homology-like domain, family B, member 2 -1.171 3.9E-02 NO 
HK1 hexokinase 1 -1.171 2.3E-03 NO 
OSBPL10 oxysterol binding protein-like 10 -1.171 7.2E-03 NO 
PCK2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) -1.171 4.3E-02 NO 
SIGMAR1 sigma non-opioid intracellular receptor 1 -1.171 4.1E-02 NO 
TMPO thymopoietin -1.170 3.1E-02 NO 
PAQR7 progestin and adipoQ receptor family member VII -1.170 2.1E-02 NO 
CDH3 cadherin 3, type 1, P-cadherin (placental) -1.170 7.1E-03 NO 
CPQ carboxypeptidase Q -1.167 3.4E-02 NO 
KLHL17 kelch-like family member 17 -1.167 4.6E-02 NO 
C14ORF28 chromosome 14 open reading frame 28 -1.166 2.8E-02 NO 
CREBRF CREB3 regulatory factor -1.166 8.9E-03 NO 
PTPN4 protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte) -1.164 6.0E-03 NO 
ENOSF1 enolase superfamily member 1 -1.164 4.5E-02 YES 
RBM11 RNA binding motif protein 11 -1.163 2.8E-02 NO 
GK5 glycerol kinase 5 (putative) -1.163 3.0E-02 NO 
CHST13 carbohydrate (chondroitin 4) sulfotransferase 13 -1.162 1.1E-02 NO 
TMBIM1 transmembrane BAX inhibitor motif containing 1 -1.161 3.7E-02 NO 
HLA-C major histocompatibility complex, class I, C -1.161 3.1E-02 NO 
DNASE1L2 deoxyribonuclease I-like 2 -1.161 7.4E-03 YES 
CD83 CD83 molecule -1.161 3.5E-02 NO 
SH3KBP1 SH3-domain kinase binding protein 1 -1.160 2.1E-02 NO 
AADAT aminoadipate aminotransferase -1.160 3.1E-02 NO 
CCDC8 coiled-coil domain containing 8 -1.160 4.9E-02 NO 
FAM171A1 family with sequence similarity 171, member A1 -1.159 4.8E-02 NO 
MFSD6 major facilitator superfamily domain containing 6 -1.159 3.0E-02 YES 
ADCY10P1 adenylate cyclase 10 (soluble) pseudogene 1 -1.158 1.2E-02 NO 
NAAA N-acylethanolamine acid amidase -1.158 4.6E-02 NO 
TWF1 twinfilin, actin-binding protein, homolog 1 (Drosophila) -1.158 1.7E-02 YES 
PIGB phosphatidylinositol glycan anchor biosynthesis, class B -1.157 6.3E-03 NO 
INTU inturned planar cell polarity effector homolog (Drosophila) -1.157 4.3E-02 YES 
FAM129A family with sequence similarity 129, member A -1.156 4.4E-02 NO 
RNF217 ring finger protein 217 -1.156 3.2E-02 NO 
LOC550643 uncharacterized LOC550643 -1.156 2.5E-02 YES 
ZBED1 zinc finger, BED-type containing 1 -1.155 2.8E-02 NO 
CIB1 calcium and integrin binding 1 (calmyrin) -1.155 2.7E-02 NO 
CEP78 centrosomal protein 78kDa -1.155 2.2E-02 NO 
C21ORF67 chromosome 21 open reading frame 67 -1.154 4.3E-02 YES 
RPL19 ribosomal protein L19 -1.154 4.9E-02 YES 
BRE brain and reproductive organ-expressed (TNFRSF1A modulator) -1.153 9.0E-03 YES 
LSM4 LSM4 homolog, U6 small nuclear RNA associated (S. cerevisiae) -1.152 3.9E-02 NO 
METRNL meteorin, glial cell differentiation regulator-like -1.152 3.5E-02 NO 
SNORD52 small nucleolar RNA, C/D box 52 -1.152 1.3E-02 YES 
ZNF514 zinc finger protein 514 -1.152 1.1E-02 NO 
PDHB pyruvate dehydrogenase (lipoamide) beta -1.152 4.4E-02 NO 
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TP53I11 tumor protein p53 inducible protein 11 -1.151 2.1E-02 NO 
GABBR1 gamma-aminobutyric acid (GABA) B receptor, 1 -1.151 3.6E-02 NO 
ANKRD6 ankyrin repeat domain 6 -1.150 2.0E-02 YES 
RAB38 RAB38, member RAS oncogene family -1.150 4.4E-02 NO 
GNAS-AS1 GNAS antisense RNA 1 -1.149 3.0E-02 YES 
MCL1 myeloid cell leukemia sequence 1 (BCL2-related) -1.149 1.4E-02 NO 
AADACL4 arylacetamide deacetylase-like 4 -1.149 2.6E-02 NO 
NEDD4 
neural precursor cell expressed, developmentally down-regulated 4, 
E3 ubiquitin protein ligase -1.149 1.3E-02 NO 
SULT1A3 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 -1.149 3.7E-02 NO 
CD109 CD109 molecule -1.148 2.2E-02 NO 
U2SURP U2 snRNP-associated SURP domain containing -1.148 4.9E-02 NO 
EPHX2 epoxide hydrolase 2, cytoplasmic -1.148 4.3E-02 NO 
ACADL acyl-CoA dehydrogenase, long chain -1.147 2.1E-02 NO 
IL12A 
interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic 
lymphocyte maturation factor 1, p35) -1.147 3.9E-02 YES 
SPAG1 sperm associated antigen 1 -1.147 4.9E-02 NO 
FAIM Fas apoptotic inhibitory molecule -1.146 4.2E-02 NO 
TBC1D2B TBC1 domain family, member 2B -1.146 1.8E-02 YES 
DDX60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 -1.146 2.8E-02 YES 
TFDP2 transcription factor Dp-2 (E2F dimerization partner 2) -1.146 4.5E-02 YES 
SCARNA16 small Cajal body-specific RNA 16 -1.145 3.2E-02 YES 
NUP37 nucleoporin 37kDa -1.145 3.7E-02 NO 
DNAJC22 DnaJ (Hsp40) homolog, subfamily C, member 22 -1.145 3.5E-02 NO 
MCOLN3 mucolipin 3 -1.144 4.3E-02 NO 
TLX1 T-cell leukemia homeobox 1 -1.143 3.7E-02 YES 
GPER G protein-coupled estrogen receptor 1 -1.143 3.7E-02 YES 
C9ORF3 chromosome 9 open reading frame 3 -1.142 3.9E-02 NO 
MTX1 metaxin 1 -1.140 2.7E-02 NO 
PTPRM protein tyrosine phosphatase, receptor type, M -1.140 3.9E-02 NO 
BID BH3 interacting domain death agonist -1.140 4.8E-02 NO 
SORT1 sortilin 1 -1.139 3.9E-02 NO 
NT5DC1 5'-nucleotidase domain containing 1 -1.138 4.8E-02 NO 
ZNF226 zinc finger protein 226 -1.138 4.1E-02 YES 
UNC50 unc-50 homolog (C. elegans) -1.138 2.9E-02 NO 
MX1 
myxovirus (influenza virus) resistance 1, interferon-inducible protein 
p78 (mouse) -1.137 2.8E-02 NO 
KCNG3 potassium voltage-gated channel, subfamily G, member 3 -1.137 2.0E-02 NO 
AGXT2L2 alanine-glyoxylate aminotransferase 2-like 2 -1.137 2.3E-02 YES 
SLFN12 schlafen family member 12 -1.137 3.3E-02 YES 
TMCO4 transmembrane and coiled-coil domains 4 -1.136 3.5E-02 NO 
HVCN1 hydrogen voltage-gated channel 1 -1.136 9.1E-03 NO 
PANK3 pantothenate kinase 3 -1.136 4.4E-02 NO 
PJA2 praja ring finger 2, E3 ubiquitin protein ligase -1.134 3.0E-02 NO 
FNDC4 fibronectin type III domain containing 4 -1.133 2.5E-02 NO 
CD19 CD19 molecule -1.132 4.4E-02 NO 
CNPY4 canopy 4 homolog (zebrafish) -1.132 4.5E-02 NO 
NES nestin -1.131 2.8E-02 NO 
SLC12A6 solute carrier family 12 (potassium/chloride transporters), member 6 -1.131 4.1E-02 NO 
ANGEL1 angel homolog 1 (Drosophila) -1.131 4.2E-02 YES 
MPZL2 myelin protein zero-like 2 -1.131 2.0E-02 NO 
ECE1 endothelin converting enzyme 1 -1.131 4.1E-02 NO 
ABCA10 ATP-binding cassette, sub-family A (ABC1), member 10 -1.131 4.5E-02 NO 
POU6F1 POU class 6 homeobox 1 -1.130 1.6E-02 NO 
IRS1 insulin receptor substrate 1 -1.129 3.5E-02 YES 
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EMILIN3 elastin microfibril interfacer 3 -1.128 3.7E-02 NO 
MYL9 myosin, light chain 9, regulatory -1.128 3.2E-02 YES 
IL17RC interleukin 17 receptor C -1.127 1.2E-02 NO 
SMUG1 single-strand-selective monofunctional uracil-DNA glycosylase 1 -1.126 4.8E-02 NO 
ADAM19 ADAM metallopeptidase domain 19 -1.125 1.7E-02 YES 
LIMK2 LIM domain kinase 2 -1.125 4.6E-02 YES 
C17ORF98 chromosome 17 open reading frame 98 -1.125 2.7E-02 NO 
LRRC40 leucine rich repeat containing 40 -1.124 4.1E-02 NO 
TTC39B tetratricopeptide repeat domain 39B -1.124 3.5E-02 NO 
ICA1L islet cell autoantigen 1,69kDa-like -1.124 4.8E-02 NO 
TOB2P1 transducer of ERBB2, 2 pseudogene 1 -1.123 3.1E-02 NO 
UGT3A2 UDP glycosyltransferase 3 family, polypeptide A2 -1.122 2.3E-02 NO 
RBPMS RNA binding protein with multiple splicing -1.122 3.0E-02 NO 
STON1 stonin 1 -1.121 2.6E-02 NO 
C7ORF13 chromosome 7 open reading frame 13 -1.120 2.7E-02 NO 
EVA1A eva-1 homolog A (C. elegans) -1.120 3.6E-02 NO 
MAST4 microtubule associated serine/threonine kinase family member 4 -1.120 3.7E-02 NO 
CCDC91 coiled-coil domain containing 91 -1.119 3.9E-02 NO 
FES feline sarcoma oncogene -1.119 2.8E-02 NO 
CLPSL2 colipase-like 2 -1.118 3.2E-02 NO 
USF2 upstream transcription factor 2, c-fos interacting -1.118 3.1E-02 NO 
TMCO6 transmembrane and coiled-coil domains 6 -1.117 2.8E-02 YES 
DARS aspartyl-tRNA synthetase -1.115 4.3E-02 NO 
CDH23 cadherin-related 23 -1.115 3.2E-02 NO 
NLRP11 NLR family, pyrin domain containing 11 -1.110 4.9E-02 YES 
GPR56 G protein-coupled receptor 56 -1.110 4.1E-02 NO 
IRX6 iroquois homeobox 6 -1.105 4.8E-02 YES 
PMEPA1 prostate transmembrane protein, androgen induced 1 -1.094 4.8E-02 YES 
MTFR2 mitochondrial fission regulator 2 1.100 3.3E-02 
 PSG6 pregnancy specific beta-1-glycoprotein 6 1.110 4.9E-02 
 INHBB inhibin, beta B 1.113 3.3E-02 
 ZNF207 zinc finger protein 207 1.114 2.8E-02 
 PSMG1 proteasome (prosome, macropain) assembly chaperone 1 1.115 4.0E-02 
 HSD17B13 hydroxysteroid (17-beta) dehydrogenase 13 1.117 3.2E-02 
 MMGT1 membrane magnesium transporter 1 1.120 4.6E-02 
 SPANXA2 SPANX family, member A2 1.122 3.2E-02 
 CIDECP cell death-inducing DFFA-like effector c pseudogene 1.126 4.4E-02 
 GNG10 guanine nucleotide binding protein (G protein), gamma 10 1.128 4.4E-02 
 SNAP91 synaptosomal-associated protein, 91kDa 1.129 2.4E-02 
 CRSP8P mediator complex subunit 27 pseudogene 1.130 3.3E-02 
 RAE1 RAE1 RNA export 1 homolog (S. pombe) 1.131 2.0E-02 
 TIMM17A translocase of inner mitochondrial membrane 17 homolog A (yeast) 1.131 4.9E-02 
 SELRC1 Sel1 repeat containing 1 1.133 2.7E-02 
 
NDUFS3 
NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa (NADH-
coenzyme Q reductase) 1.133 1.7E-02 
 STK16 serine/threonine kinase 16 1.133 2.8E-02 
 RTFDC1 replication termination factor 2 domain containing 1 1.136 9.8E-03 
 RLF rearranged L-myc fusion 1.136 4.6E-02 
 CMC2 COX assembly mitochondrial protein 2 homolog (S. cerevisiae) 1.139 2.1E-02 
 SUCO SUN domain containing ossification factor 1.140 4.6E-02 
 WARS tryptophanyl-tRNA synthetase 1.142 3.1E-02 
 C17ORF76-
AS1 C17orf76 antisense RNA 1 1.143 4.7E-02 
 CDK8 cyclin-dependent kinase 8 1.143 3.0E-02 
 MT1H metallothionein 1H 1.144 2.5E-02 
 
Appendix 
 
241 
 
Gene symbol Protein name FC adj. p-value 
Top quarter 
-positive 
regulator 
CNOT8 CCR4-NOT transcription complex, subunit 8 1.144 3.9E-02 
 UBE2J2 ubiquitin-conjugating enzyme E2, J2 1.144 4.5E-02 
 RAP1A RAP1A, member of RAS oncogene family 1.144 8.5E-03 
 ARRDC2 arrestin domain containing 2 1.145 1.3E-02 
 ADPRM ADP-ribose/CDP-alcohol diphosphatase, manganese-dependent 1.145 2.4E-02 
 TBC1D10A TBC1 domain family, member 10A 1.145 1.3E-02 
 BCL7B B-cell CLL/lymphoma 7B 1.146 4.9E-02 
 ABHD12 abhydrolase domain containing 12 1.146 3.4E-02 
 OSGEP O-sialoglycoprotein endopeptidase 1.146 2.6E-02 
 PRUNE prune homolog (Drosophila) 1.147 4.8E-02 
 IFT46 intraflagellar transport 46 homolog (Chlamydomonas) 1.150 2.9E-02 
 ZC3H18 zinc finger CCCH-type containing 18 1.150 2.7E-02 
 SNORA18 small nucleolar RNA, H/ACA box 18 1.150 3.4E-02 
 NDUFAF2 NADH dehydrogenase (ubiquinone) complex I, assembly factor 2 1.151 2.7E-02 
 ETS2 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) 1.151 1.5E-02 
 RAB2A RAB2A, member RAS oncogene family 1.151 3.2E-02 
 TTC9C tetratricopeptide repeat domain 9C 1.152 1.3E-02 
 TBC1D13 TBC1 domain family, member 13 1.152 7.6E-03 
 REXO1 REX1, RNA exonuclease 1 homolog (S. cerevisiae) 1.152 3.9E-02 
 
SYS1 
SYS1 Golgi-localized integral membrane protein homolog (S. 
cerevisiae) 1.153 3.9E-02 
 GIGYF2 GRB10 interacting GYF protein 2 1.153 2.7E-02 
 GOLGA4 golgin A4 1.154 3.9E-02 
 RPS14 ribosomal protein S14 1.154 3.9E-02 
 ALKBH3 alkB, alkylation repair homolog 3 (E. coli) 1.154 4.4E-02 
 GLIPR2 GLI pathogenesis-related 2 1.155 4.8E-02 
 TIMM23 translocase of inner mitochondrial membrane 23 homolog (yeast) 1.156 4.6E-02 
 ZFP36L1 ZFP36 ring finger protein-like 1 1.156 2.7E-02 
 MC2R melanocortin 2 receptor (adrenocorticotropic hormone) 1.156 2.4E-02 
 ZBTB3 zinc finger and BTB domain containing 3 1.157 3.4E-02 
 PRDX1 peroxiredoxin 1 1.157 1.3E-02 
 PIP4K2B phosphatidylinositol-5-phosphate 4-kinase, type II, beta 1.158 2.2E-02 
 CEP72 centrosomal protein 72kDa 1.159 1.6E-02 
 AGAP10 ArfGAP with GTPase domain, ankyrin repeat and PH domain 10 1.159 3.9E-02 
 PIP4K2C phosphatidylinositol-5-phosphate 4-kinase, type II, gamma 1.159 4.7E-02 
 TMEM158 transmembrane protein 158 (gene/pseudogene) 1.159 1.9E-02 
 CSNK1A1 casein kinase 1, alpha 1 1.160 4.8E-02 
 BCS1L BC1 (ubiquinol-cytochrome c reductase) synthesis-like 1.160 4.1E-02 
 NFS1 NFS1 nitrogen fixation 1 homolog (S. cerevisiae) 1.161 9.2E-03 
 FGFR1OP2 FGFR1 oncogene partner 2 1.161 2.4E-02 
 SLC35C2 solute carrier family 35, member C2 1.161 4.8E-02 
 GNG7 guanine nucleotide binding protein (G protein), gamma 7 1.162 1.6E-02 
 DHDDS dehydrodolichyl diphosphate synthase 1.162 2.4E-02 
 C12ORF49 chromosome 12 open reading frame 49 1.162 4.8E-02 
 OPRM1 opioid receptor, mu 1 1.162 2.5E-02 
 EMC3 ER membrane protein complex subunit 3 1.162 1.5E-02 
 SAFB2 scaffold attachment factor B2 1.162 4.4E-02 
 SON SON DNA binding protein 1.162 1.7E-02 
 PPP2R5A protein phosphatase 2, regulatory subunit B', alpha 1.162 1.1E-02 
 ABCA11P ATP-binding cassette, sub-family A (ABC1), member 11, pseudogene 1.162 2.8E-02 
 
GGA3 
golgi-associated, gamma adaptin ear containing, ARF binding protein 
3 1.163 4.6E-02 
 SMYD3 SET and MYND domain containing 3 1.164 9.4E-03 
 GTSE1 G-2 and S-phase expressed 1 1.165 2.2E-02 
 C12ORF65 chromosome 12 open reading frame 65 1.165 7.3E-03 
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PGK1 phosphoglycerate kinase 1 1.165 2.7E-02 
 CDKN2A cyclin-dependent kinase inhibitor 2A 1.166 2.4E-02 
 CNOT7 CCR4-NOT transcription complex, subunit 7 1.167 3.2E-02 
 REEP6 receptor accessory protein 6 1.167 2.4E-02 
 GTF3C5 general transcription factor IIIC, polypeptide 5, 63kDa 1.168 3.1E-02 
 MAU2 MAU2 chromatid cohesion factor homolog (C. elegans) 1.168 3.5E-02 
 EIF3E eukaryotic translation initiation factor 3, subunit E 1.168 2.3E-02 
 ATXN2 ataxin 2 1.168 1.2E-02 
 EIF4EBP2 eukaryotic translation initiation factor 4E binding protein 2 1.168 2.2E-02 
 DDX39A DEAD (Asp-Glu-Ala-Asp) box polypeptide 39A 1.169 2.4E-02 
 ZNF35 zinc finger protein 35 1.169 1.1E-02 
 MARK1 MAP/microtubule affinity-regulating kinase 1 1.170 9.8E-03 
 DPH3 DPH3, KTI11 homolog (S. cerevisiae) 1.170 2.4E-02 
 MGP matrix Gla protein 1.170 3.2E-02 
 SPANXE SPANX family, member E 1.171 1.6E-02 
 ZNF668 zinc finger protein 668 1.171 1.7E-02 
 FXR1 fragile X mental retardation, autosomal homolog 1 1.171 3.0E-02 
 PRPS2 phosphoribosyl pyrophosphate synthetase 2 1.172 2.7E-02 
 FNTA farnesyltransferase, CAAX box, alpha 1.173 4.1E-02 
 SLC25A28 solute carrier family 25 (mitochondrial iron transporter), member 28 1.173 3.0E-02 
 
NACC1 
nucleus accumbens associated 1, BEN and BTB (POZ) domain 
containing 1.174 7.9E-03 
 FOXD1 forkhead box D1 1.174 5.5E-03 
 CA5B carbonic anhydrase VB, mitochondrial 1.174 2.8E-02 
 NFIA nuclear factor I/A 1.175 2.3E-02 
 MRPS17 mitochondrial ribosomal protein S17 1.175 3.8E-02 
 ATP6V1B2 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 1.175 5.1E-03 
 BBC3 BCL2 binding component 3 1.177 9.9E-03 
 OTUB1 OTU domain, ubiquitin aldehyde binding 1 1.177 2.1E-02 
 LOC730101 uncharacterized LOC730101 1.177 2.4E-02 
 PIBF1 progesterone immunomodulatory binding factor 1 1.178 2.1E-02 
 SETP3 septin 3 1.178 3.8E-02 
 RPL13 ribosomal protein L13 1.179 4.8E-02 
 RCL1 RNA terminal phosphate cyclase-like 1 1.179 3.1E-02 
 OTUD3 OTU domain containing 3 1.180 2.6E-02 
 INSIG1 insulin induced gene 1 1.181 2.0E-02 
 HPS5 Hermansky-Pudlak syndrome 5 1.181 4.1E-02 
 OLIG2 oligodendrocyte lineage transcription factor 2 1.181 2.2E-02 
 RPS15A ribosomal protein S15a 1.182 1.8E-02 
 LOC642980 uncharacterized LOC642980 1.182 3.2E-02 
 VAMP1 vesicle-associated membrane protein 1 (synaptobrevin 1) 1.182 2.9E-02 
 SRFBP1 serum response factor binding protein 1 1.183 1.3E-02 
 RNASEH1 ribonuclease H1 1.183 4.0E-02 
 SMN2 survival of motor neuron 2, centromeric 1.183 4.9E-02 
 WIPI2 WD repeat domain, phosphoinositide interacting 2 1.184 4.1E-02 
 ZCCHC17 zinc finger, CCHC domain containing 17 1.184 2.8E-02 
 PDCD6 programmed cell death 6 1.184 2.3E-03 
 RFXAP regulatory factor X-associated protein 1.185 2.7E-02 
 SMIM8 small integral membrane protein 8 1.185 5.5E-03 
 FBL fibrillarin 1.185 2.8E-02 
 
SVEP1 
sushi, von Willebrand factor type A, EGF and pentraxin domain 
containing 1 1.185 1.4E-02 
 MRPL32 mitochondrial ribosomal protein L32 1.185 3.8E-02 
 LARP4B La ribonucleoprotein domain family, member 4B 1.185 3.2E-02 
 UQCC ubiquinol-cytochrome c reductase complex chaperone 1.186 4.4E-02 
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TPD52 tumor protein D52 1.186 2.4E-02 
 VDAC1 voltage-dependent anion channel 1 1.186 3.3E-02 
 FBXW11 F-box and WD repeat domain containing 11 1.187 3.4E-02 
 NCBP2 nuclear cap binding protein subunit 2, 20kDa 1.187 2.0E-02 
 TMEM138 transmembrane protein 138 1.188 1.5E-02 
 BRCC3 BRCA1/BRCA2-containing complex, subunit 3 1.188 3.9E-02 
 
HIF1A 
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix 
transcription factor) 1.189 2.1E-02 
 PTP4A3 protein tyrosine phosphatase type IVA, member 3 1.189 1.4E-02 
 RUVBL1 RuvB-like 1 (E. coli) 1.189 4.9E-02 
 ATXN1L ataxin 1-like 1.189 1.3E-02 
 EP400 E1A binding protein p400 1.189 2.5E-02 
 SYNJ2BP synaptojanin 2 binding protein 1.190 6.6E-03 
 TMX2 thioredoxin-related transmembrane protein 2 1.190 2.4E-02 
 SF3B4 splicing factor 3b, subunit 4, 49kDa 1.190 7.6E-03 
 WDR20 WD repeat domain 20 1.190 2.8E-02 
 ZBTB8OS zinc finger and BTB domain containing 8 opposite strand 1.190 7.3E-03 
 TMEM97 transmembrane protein 97 1.190 4.0E-02 
 HSPD1 heat shock 60kDa protein 1 (chaperonin) 1.191 3.1E-02 
 TTC25 tetratricopeptide repeat domain 25 1.191 9.0E-04 
 KARS lysyl-tRNA synthetase 1.191 3.5E-02 
 CDX2 caudal type homeobox 2 1.192 4.1E-02 
 PPM1H protein phosphatase, Mg2+/Mn2+ dependent, 1H 1.192 4.8E-02 
 RAB18 RAB18, member RAS oncogene family 1.192 4.8E-02 
 MRPS31 mitochondrial ribosomal protein S31 1.194 8.1E-03 
 USPL1 ubiquitin specific peptidase like 1 1.194 3.5E-02 
 MTSS1 metastasis suppressor 1 1.194 5.8E-03 
 DHX37 DEAH (Asp-Glu-Ala-His) box polypeptide 37 1.194 2.9E-02 
 ANKRD10 ankyrin repeat domain 10 1.195 4.5E-02 
 ACACA acetyl-CoA carboxylase alpha 1.196 2.0E-02 
 ACYP1 acylphosphatase 1, erythrocyte (common) type 1.196 5.0E-02 
 MALSU1 mitochondrial assembly of ribosomal large subunit 1 1.198 3.1E-02 
 C9ORF123 chromosome 9 open reading frame 123 1.198 4.4E-03 
 L2HGDH L-2-hydroxyglutarate dehydrogenase 1.198 3.4E-03 
 HSPA14 heat shock 70kDa protein 14 1.199 3.2E-02 
 FDX1 ferredoxin 1 1.199 1.9E-02 
 ABL1 c-abl oncogene 1, non-receptor tyrosine kinase 1.200 4.8E-02 
 LEPROTL1 leptin receptor overlapping transcript-like 1 1.200 4.5E-02 
 TRMT6 tRNA methyltransferase 6 homolog (S. cerevisiae) 1.201 3.9E-02 
 NT5C3 5'-nucleotidase, cytosolic III 1.202 2.9E-02 
 PDPK1 3-phosphoinositide dependent protein kinase-1 1.202 2.7E-02 
 MMS19 MMS19 nucleotide excision repair homolog (S. cerevisiae) 1.202 1.9E-02 
 NXF1 nuclear RNA export factor 1 1.203 3.5E-03 
 XAGE1D X antigen family, member 1D 1.203 4.8E-02 
 TIFA TRAF-interacting protein with forkhead-associated domain 1.204 4.1E-02 
 RAP1GDS1 RAP1, GTP-GDP dissociation stimulator 1 1.204 2.8E-02 
 EIF1 eukaryotic translation initiation factor 1 1.204 4.7E-02 
 AKAP17A A kinase (PRKA) anchor protein 17A 1.205 4.2E-02 
 NAP1L4 nucleosome assembly protein 1-like 4 1.206 1.7E-02 
 SQLE squalene epoxidase 1.206 2.7E-02 
 BYSL bystin-like 1.207 4.9E-02 
 TDP1 tyrosyl-DNA phosphodiesterase 1 1.207 3.8E-02 
 
SLC25A17 
solute carrier family 25 (mitochondrial carrier; peroxisomal membrane 
protein, 34kDa), member 17 1.207 3.0E-02 
 ZNF322 zinc finger protein 322 1.207 2.1E-02 
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MVD mevalonate (diphospho) decarboxylase 1.208 2.2E-02 
 TXNL4A thioredoxin-like 4A 1.209 9.1E-03 
 PUS1 pseudouridylate synthase 1 1.210 2.2E-02 
 EDC3 enhancer of mRNA decapping 3 homolog (S. cerevisiae) 1.211 2.9E-02 
 FDFT1 farnesyl-diphosphate farnesyltransferase 1 1.211 6.3E-03 
 TRMT12 tRNA methyltransferase 12 homolog (S. cerevisiae) 1.211 1.2E-03 
 COA4 cytochrome c oxidase assembly factor 4 homolog (S. cerevisiae) 1.212 2.7E-02 
 GADD45G growth arrest and DNA-damage-inducible, gamma 1.213 9.1E-03 
 GGCX gamma-glutamyl carboxylase 1.213 4.0E-02 
 HTR3A 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic 1.213 1.5E-03 
 ELMO1 engulfment and cell motility 1 1.214 8.6E-03 
 PSMD13 proteasome (prosome, macropain) 26S subunit, non-ATPase, 13 1.214 4.7E-02 
 IFT27 intraflagellar transport 27 homolog (Chlamydomonas) 1.214 1.8E-02 
 NUDT2 nudix (nucleoside diphosphate linked moiety X)-type motif 2 1.215 4.2E-02 
 RDH11 retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 1.215 8.6E-03 
 ZDHHC7 zinc finger, DHHC-type containing 7 1.215 1.6E-02 
 TBL1X transducin (beta)-like 1X-linked 1.215 8.7E-03 
 GFOD2 glucose-fructose oxidoreductase domain containing 2 1.216 2.7E-02 
 NDUFB3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 12kDa 1.217 4.3E-03 
 FAM220A family with sequence similarity 220, member A 1.217 6.4E-03 
 ZNF296 zinc finger protein 296 1.218 5.5E-03 
 RAB1B RAB1B, member RAS oncogene family 1.218 2.0E-02 
 UBAP1 ubiquitin associated protein 1 1.219 1.0E-02 
 TRAPPC2P1 trafficking protein particle complex 2 pseudogene 1 1.220 1.5E-02 
 AXIN1 axin 1 1.222 3.5E-02 
 GAK cyclin G associated kinase 1.222 3.2E-02 
 TP53BP2 tumor protein p53 binding protein, 2 1.222 4.5E-02 
 FOXD4L1 forkhead box D4-like 1 1.223 1.5E-02 
 LPCAT1 lysophosphatidylcholine acyltransferase 1 1.223 4.6E-02 
 FARSA phenylalanyl-tRNA synthetase, alpha subunit 1.223 4.8E-02 
 PPME1 protein phosphatase methylesterase 1 1.224 4.6E-02 
 PTRHD1 peptidyl-tRNA hydrolase domain containing 1 1.224 3.3E-02 
 HSD17B10 hydroxysteroid (17-beta) dehydrogenase 10 1.224 2.9E-02 
 GATS GATS, stromal antigen 3 opposite strand 1.224 1.9E-03 
 SMG5 smg-5 homolog, nonsense mediated mRNA decay factor (C. elegans) 1.224 5.0E-02 
 DHX29 DEAH (Asp-Glu-Ala-His) box polypeptide 29 1.225 1.9E-02 
 
DPM2 
dolichyl-phosphate mannosyltransferase polypeptide 2, regulatory 
subunit 1.225 1.0E-02 
 ECHDC1 enoyl CoA hydratase domain containing 1 1.226 4.7E-02 
 MAPT microtubule-associated protein tau 1.226 8.5E-03 
 USP37 ubiquitin specific peptidase 37 1.226 4.3E-02 
 IQCK IQ motif containing K 1.226 2.2E-02 
 EDC4 enhancer of mRNA decapping 4 1.228 2.1E-02 
 NRBF2 nuclear receptor binding factor 2 1.228 4.6E-02 
 PRPF19 PRP19/PSO4 pre-mRNA processing factor 19 homolog (S. cerevisiae) 1.228 2.0E-02 
 
SRD5A1 
steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid 
delta 4-dehydrogenase alpha 1) 1.228 3.2E-02 
 ZNF446 zinc finger protein 446 1.228 2.5E-02 
 RNMTL1 RNA methyltransferase like 1 1.228 5.3E-03 
 ACSL3 acyl-CoA synthetase long-chain family member 3 1.228 1.3E-02 
 SLC35E1 solute carrier family 35, member E1 1.228 4.0E-02 
 CYP26A1 cytochrome P450, family 26, subfamily A, polypeptide 1 1.229 2.9E-03 
 NME7 NME/NM23 family member 7 1.229 6.2E-03 
 NOL11 nucleolar protein 11 1.229 2.1E-02 
 POP5 processing of precursor 5, ribonuclease P/MRP subunit (S. cerevisiae) 1.230 3.8E-02 
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GLRX5 glutaredoxin 5 1.230 4.6E-03 
 HNRNPA1 heterogeneous nuclear ribonucleoprotein A1 1.230 1.7E-02 
 PNO1 partner of NOB1 homolog (S. cerevisiae) 1.230 4.1E-03 
 CFDP1 craniofacial development protein 1 1.231 7.1E-03 
 NSMCE2 non-SMC element 2, MMS21 homolog (S. cerevisiae) 1.231 2.0E-02 
 ZNF770 zinc finger protein 770 1.231 4.8E-02 
 THADA thyroid adenoma associated 1.232 5.3E-03 
 ECSIT ECSIT homolog (Drosophila) 1.232 2.0E-02 
 
MARCH7 
membrane-associated ring finger (C3HC4) 7, E3 ubiquitin protein 
ligase 1.233 5.0E-02 
 RNU4ATAC RNA, U4atac small nuclear (U12-dependent splicing) 1.234 2.0E-02 
 EPN1 epsin 1 1.234 9.7E-03 
 BPGM 2,3-bisphosphoglycerate mutase 1.234 2.7E-02 
 STC2 stanniocalcin 2 1.236 3.6E-02 
 GNA11 guanine nucleotide binding protein (G protein), alpha 11 (Gq class) 1.236 9.3E-03 
 FGF9 fibroblast growth factor 9 (glia-activating factor) 1.237 1.6E-02 
 YDJC YdjC homolog (bacterial) 1.237 3.6E-02 
 ANKFY1 ankyrin repeat and FYVE domain containing 1 1.237 4.6E-02 
 SLC30A9 solute carrier family 30 (zinc transporter), member 9 1.237 1.2E-02 
 RNF167 ring finger protein 167 1.238 5.1E-03 
 TNRC6A trinucleotide repeat containing 6A 1.238 1.2E-02 
 SMC1A structural maintenance of chromosomes 1A 1.238 1.1E-02 
 SAR1A SAR1 homolog A (S. cerevisiae) 1.238 3.4E-02 
 HES6 hairy and enhancer of split 6 (Drosophila) 1.239 2.2E-02 
 PAG1 phosphoprotein associated with glycosphingolipid microdomains 1 1.239 3.3E-02 
 MEF2D myocyte enhancer factor 2D 1.239 1.3E-03 
 CCT8 chaperonin containing TCP1, subunit 8 (theta) 1.239 3.0E-02 
 RGS16 regulator of G-protein signaling 16 1.240 9.0E-03 
 RNU1-3 RNA, U1 small nuclear 3 1.240 1.3E-02 
 CHAF1A chromatin assembly factor 1, subunit A (p150) 1.240 1.8E-02 
 ACN9 ACN9 homolog (S. cerevisiae) 1.241 9.5E-03 
 RHOA ras homolog family member A 1.241 1.6E-02 
 COX16 COX16 cytochrome c oxidase assembly homolog (S. cerevisiae) 1.241 4.2E-03 
 SERP1 stress-associated endoplasmic reticulum protein 1 1.242 3.9E-02 
 DRD4 dopamine receptor D4 1.243 3.0E-02 
 BCYRN1 brain cytoplasmic RNA 1 1.243 2.8E-02 
 C14ORF132 chromosome 14 open reading frame 132 1.244 1.7E-03 
 MSMO1 methylsterol monooxygenase 1 1.245 2.3E-02 
 NT5DC3 5'-nucleotidase domain containing 3 1.245 1.0E-02 
 ILKAP integrin-linked kinase-associated serine/threonine phosphatase 1.246 6.9E-03 
 AP3D1 adaptor-related protein complex 3, delta 1 subunit 1.246 8.1E-03 
 EMD emerin 1.246 6.1E-03 
 C4ORF46 chromosome 4 open reading frame 46 1.246 1.3E-03 
 MED19 mediator complex subunit 19 1.246 2.4E-03 
 ONECUT2 one cut homeobox 2 1.246 6.4E-03 
 HDDC3 HD domain containing 3 1.247 2.0E-02 
 FAM53B family with sequence similarity 53, member B 1.251 1.3E-03 
 GPHN gephyrin 1.251 4.9E-02 
 PRMT2 protein arginine methyltransferase 2 1.251 3.3E-03 
 HILPDA hypoxia inducible lipid droplet-associated 1.252 1.2E-02 
 EBPL emopamil binding protein-like 1.252 4.6E-02 
 EIF2B2 eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa 1.252 2.2E-03 
 LCMT1 leucine carboxyl methyltransferase 1 1.252 1.4E-02 
 RRP8 ribosomal RNA processing 8, methyltransferase, homolog (yeast) 1.253 3.5E-02 
 ZMYM4 zinc finger, MYM-type 4 1.253 6.4E-03 
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RARS2 arginyl-tRNA synthetase 2, mitochondrial 1.253 4.6E-03 
 PLD3 phospholipase D family, member 3 1.253 1.4E-02 
 TCTN3 tectonic family member 3 1.254 1.1E-02 
 C12ORF44 chromosome 12 open reading frame 44 1.255 2.7E-02 
 DCAF6 DDB1 and CUL4 associated factor 6 1.255 8.1E-03 
 KIAA0556 KIAA0556 1.255 1.4E-02 
 ATP5J ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F6 1.255 6.4E-03 
 MED31 mediator complex subunit 31 1.256 1.1E-02 
 ZNF473 zinc finger protein 473 1.256 8.9E-03 
 NIPA2 non imprinted in Prader-Willi/Angelman syndrome 2 1.257 2.7E-02 
 USP7 ubiquitin specific peptidase 7 (herpes virus-associated) 1.257 2.9E-02 
 GCSH glycine cleavage system protein H (aminomethyl carrier) 1.257 1.9E-02 
 DGCR14 DiGeorge syndrome critical region gene 14 1.258 6.7E-03 
 MTPN myotrophin 1.258 4.4E-02 
 DHCR24 24-dehydrocholesterol reductase 1.259 1.2E-02 
 NAP1L1 nucleosome assembly protein 1-like 1 1.260 4.6E-02 
 AMOT angiomotin 1.260 3.1E-02 
 MRPL44 mitochondrial ribosomal protein L44 1.261 3.7E-03 
 ZSCAN32 zinc finger and SCAN domain containing 32 1.263 3.1E-03 
 KIF3B kinesin family member 3B 1.263 7.3E-03 
 TOMM20 translocase of outer mitochondrial membrane 20 homolog (yeast) 1.263 4.9E-02 
 EPT1 ethanolaminephosphotransferase 1 (CDP-ethanolamine-specific) 1.264 3.7E-03 
 EAF2 ELL associated factor 2 1.264 6.6E-03 
 KCTD10 potassium channel tetramerisation domain containing 10 1.266 2.1E-02 
 CA8 carbonic anhydrase VIII 1.266 2.4E-03 
 EIF2S1 eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa 1.267 2.7E-02 
 PPP1R7 protein phosphatase 1, regulatory subunit 7 1.268 1.0E-02 
 PKP4 plakophilin 4 1.268 3.4E-03 
 ZNF789 zinc finger protein 789 1.268 5.6E-04 
 EFHD2 EF-hand domain family, member D2 1.270 1.9E-03 
 C14ORF142 chromosome 14 open reading frame 142 1.270 2.1E-02 
 MED26 mediator complex subunit 26 1.271 2.3E-02 
 TOMM5 translocase of outer mitochondrial membrane 5 homolog (yeast) 1.273 1.2E-02 
 LOC100293704 uncharacterized LOC100293704 1.273 6.5E-03 
 MAPK1 mitogen-activated protein kinase 1 1.274 5.6E-03 
 VMP1 vacuole membrane protein 1 1.274 6.8E-03 
 ENOPH1 enolase-phosphatase 1 1.274 2.5E-02 
 STRA13 stimulated by retinoic acid 13 1.274 2.3E-03 
 PRADC1 protease-associated domain containing 1 1.277 1.2E-02 
 EMC6 ER membrane protein complex subunit 6 1.277 1.0E-02 
 MRPS12 mitochondrial ribosomal protein S12 1.279 3.1E-02 
 SERF2 small EDRK-rich factor 2 1.279 2.1E-02 
 RPL22 ribosomal protein L22 1.280 2.0E-02 
 CISD2 CDGSH iron sulfur domain 2 1.281 1.4E-02 
 PPP6R3 protein phosphatase 6, regulatory subunit 3 1.281 5.3E-03 
 LMCD1 LIM and cysteine-rich domains 1 1.283 6.3E-04 
 ARPC5L actin related protein 2/3 complex, subunit 5-like 1.285 1.1E-03 
 FAF1 Fas (TNFRSF6) associated factor 1 1.285 3.7E-03 
 SNRPD3 small nuclear ribonucleoprotein D3 polypeptide 18kDa 1.286 1.1E-02 
 PHF10 PHD finger protein 10 1.288 3.2E-02 
 GATC glutamyl-tRNA(Gln) amidotransferase, subunit C 1.288 3.4E-03 
 MMAB methylmalonic aciduria (cobalamin deficiency) cblB type 1.288 8.2E-04 
 PRPF38A PRP38 pre-mRNA processing factor 38 (yeast) domain containing A 1.288 3.8E-02 
 CANX calnexin 1.288 4.6E-02 
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SETD8 SET domain containing (lysine methyltransferase) 8 1.289 5.3E-03 
 AHCTF1 AT hook containing transcription factor 1 1.292 3.1E-02 
 TUSC2 tumor suppressor candidate 2 1.295 2.0E-02 
 TNFRSF19 tumor necrosis factor receptor superfamily, member 19 1.295 4.0E-02 
 PGAM4 phosphoglycerate mutase family member 4 1.297 8.2E-03 
 DIDO1 death inducer-obliterator 1 1.297 6.8E-03 
 TRAPPC3 trafficking protein particle complex 3 1.297 2.5E-03 
 RNF10 ring finger protein 10 1.298 4.4E-02 
 RAB7A RAB7A, member RAS oncogene family 1.298 2.1E-03 
 VTA1 Vps20-associated 1 homolog (S. cerevisiae) 1.298 1.6E-02 
 DACH1 dachshund homolog 1 (Drosophila) 1.298 8.9E-03 
 ERLIN1 ER lipid raft associated 1 1.301 9.9E-03 
 MPLKIP M-phase specific PLK1 interacting protein 1.301 1.8E-02 
 EBF2 early B-cell factor 2 1.302 2.2E-04 
 RNFT2 ring finger protein, transmembrane 2 1.308 2.2E-04 
 SS18L1 synovial sarcoma translocation gene on chromosome 18-like 1 1.308 3.6E-02 
 
GGA2 
golgi-associated, gamma adaptin ear containing, ARF binding protein 
2 1.308 2.1E-02 
 ACLY ATP citrate lyase 1.308 4.9E-02 
 YTHDF1 YTH domain family, member 1 1.308 4.6E-03 
 C9ORF37 chromosome 9 open reading frame 37 1.313 1.8E-02 
 RABL2B RAB, member of RAS oncogene family-like 2B 1.313 1.7E-02 
 HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) 1.315 2.3E-02 
 ILF3-AS1 ILF3 antisense RNA 1 (head to head) 1.320 3.8E-03 
 DAZAP1 DAZ associated protein 1 1.322 1.0E-02 
 HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase 1.324 1.9E-02 
 WRAP53 WD repeat containing, antisense to TP53 1.326 4.2E-02 
 CCDC85C coiled-coil domain containing 85C 1.326 1.6E-03 
 PSMA2 proteasome (prosome, macropain) subunit, alpha type, 2 1.327 1.3E-03 
 
YWHAG 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, gamma polypeptide 1.327 9.1E-03 
 RTN3 reticulon 3 1.331 6.4E-03 
 H3F3B H3 histone, family 3B (H3.3B) 1.332 2.0E-03 
 TRAP1 TNF receptor-associated protein 1 1.333 1.4E-02 
 STK3 serine/threonine kinase 3 1.335 2.5E-03 
 MAGOHB mago-nashi homolog B (Drosophila) 1.336 8.7E-03 
 FAM84B family with sequence similarity 84, member B 1.336 3.3E-02 
 HNRNPH3 heterogeneous nuclear ribonucleoprotein H3 (2H9) 1.337 3.4E-02 
 SGTA small glutamine-rich tetratricopeptide repeat (TPR)-containing, alpha 1.340 8.7E-03 
 ANKRD11 ankyrin repeat domain 11 1.341 6.4E-03 
 LDHC lactate dehydrogenase C 1.343 4.2E-04 
 SELT selenoprotein T 1.343 5.8E-03 
 
CITED1 
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-
terminal domain, 1 1.344 2.3E-03 
 ZDHHC11 zinc finger, DHHC-type containing 11 1.345 3.1E-03 
 RPRD1A regulation of nuclear pre-mRNA domain containing 1A 1.349 7.4E-03 
 RAB1A RAB1A, member RAS oncogene family 1.356 1.3E-02 
 NMT1 N-myristoyltransferase 1 1.358 5.9E-03 
 FOXA2 forkhead box A2 1.359 7.4E-03 
 CEBPG CCAAT/enhancer binding protein (C/EBP), gamma 1.377 3.9E-02 
 TMEM70 transmembrane protein 70 1.380 7.8E-04 
 FGFBP1 fibroblast growth factor binding protein 1 1.385 8.3E-04 
 LOC730020 uncharacterized LOC730020 1.389 3.6E-03 
 KIF1A kinesin family member 1A 1.402 1.3E-03 
 G3BP2 GTPase activating protein (SH3 domain) binding protein 2 1.409 1.2E-02 
 C12ORF76 chromosome 12 open reading frame 76 1.420 1.7E-04 
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RNF126 ring finger protein 126 1.428 3.9E-04 
 TRMT61B tRNA methyltransferase 61 homolog B (S. cerevisiae) 1.439 1.1E-04 
 TATDN1 TatD DNase domain containing 1 1.449 1.3E-03 
 IPO5 importin 5 1.449 1.1E-02 
 C2ORF68 chromosome 2 open reading frame 68 1.459 8.6E-05 
 TEX19 testis expressed 19 1.474 2.5E-05 
 SLC2A4RG SLC2A4 regulator 1.475 1.5E-03 
 RBBP4 retinoblastoma binding protein 4 1.480 4.1E-03 
 UBE2N ubiquitin-conjugating enzyme E2N 1.492 4.2E-03 
 SOX3 SRY (sex determining region Y)-box 3 1.496 2.6E-03 
 TKTL1 transketolase-like 1 1.730 1.8E-05 
 IGFBP5 insulin-like growth factor binding protein 5 1.926 1.9E-04 
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Table 7.2 Significantly (p ≤ 0.05) affected biological processes in 551 
downregulated genes after WAC knockdown only 
Analysis carried out using MetaCoreTM pathway analysis tool (Thomson Reuters). 
Adjusted p-value, adj. p-value. Ratio: number of genes in my list/number of genes 
in entire process in whole genome. 
 
# Process name adj. p-value Ratio 
1 Immune response_Antigen presentation 1.88E-06 26/188 
2 
Immune response_Phagosome in antigen 
presentation 9.48E-05 25/221 
3 Inflammation_Amphoterin signaling 4.19E-04 16/115 
4 Inflammation_NK cell cytotoxicity 3.23E-03 17/153 
5 Inflammation_IL-10 anti-inflammatory response 8.32E-03 11/81 
6 Inflammation_IgE signaling 1.43E-02 12/102 
7 Response to hypoxia and oxidative stress 1.89E-02 12/107 
8 Inflammation_Innate inflammatory response 3.87E-02 14/150 
9 Immune response_Phagocytosis 4.90E-02 16/190 
10 Inflammation_Protein C signaling 4.91E-02 10/94 
11 Inflammation_TREM1 signaling 4.91E-02 12/126 
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Table 7.3 319 genes significantly (p ≤ 0.05) up or downregulated, common to 
WAC, RNF20 and RNF40 knockdown versus RISC Free control 
Genes highlighted in red are not regulated in the same way (up or down) between 
the WAC, RNF20 and RNF40 knockdown samples. Fold change versus RISC free, 
FC. 
 
Gene symbol Protein name 
FC in 
siWAC 
FC in 
siRNF40 
FC in 
siRNF20 
TNFRSF12A tumor necrosis factor receptor superfamily, member 12A -2.0 -1.4 1.3 
TAGLN transgelin -1.5 -1.9 1.5 
DMKN dermokine -1.3 -1.3 1.3 
RAC1 
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding 
protein Rac1) -1.3 1.4 -1.2 
TCTEX1D2 Tctex1 domain containing 2 1.2 -1.2 -1.6 
MT1A metallothionein 1A 1.3 -1.2 -1.3 
HMGN2 high mobility group nucleosomal binding domain 2 1.3 -1.2 -1.3 
EIF2AK1 eukaryotic translation initiation factor 2-alpha kinase 1 1.3 -1.3 -1.2 
CTSL2 cathepsin L2 1.1 -1.1 -1.2 
AK4 adenylate kinase 4 1.3 -1.2 -1.2 
CD44 CD44 molecule (Indian blood group) -1.3 -1.6 1.4 
TUBB2B tubulin, beta 2B class IIb 1.5 1.2 -1.2 
POLR1D polymerase (RNA) I polypeptide D, 16kDa 1.3 -1.3 1.2 
HN1 hematological and neurological expressed 1 -1.5 1.3 1.3 
PPFIA1 
protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), 
interacting protein (liprin), alpha 1 1.3 -1.4 1.3 
PRSS23 protease, serine, 23 -1.3 1.4 1.3 
UBE2D2 ubiquitin-conjugating enzyme E2D 2 1.2 -1.2 1.3 
SDHC 
succinate dehydrogenase complex, subunit C, integral membrane protein, 
15kDa 1.1 -1.2 1.2 
TPM4 tropomyosin 4 -1.9 -1.5 -1.2 
COL5A1 collagen, type V, alpha 1 -2.3 -2.3 -1.4 
FBXO4 F-box protein 4 -1.6 -1.2 -1.3 
SLC2A10 solute carrier family 2 (facilitated glucose transporter), member 10 -1.9 -1.5 -1.6 
ACTA2 actin, alpha 2, smooth muscle, aorta -2.0 -1.4 -1.6 
DIRC2 disrupted in renal carcinoma 2 -1.6 -1.4 -1.2 
TCEAL3 transcription elongation factor A (SII)-like 3 -1.5 -1.2 -1.3 
LOXL4 lysyl oxidase-like 4 -2.1 -1.7 -2.1 
TEAD2 TEA domain family member 2 -1.6 -1.4 -1.5 
MDK midkine (neurite growth-promoting factor 2) -2.0 -1.1 -1.8 
NYNRIN NYN domain and retroviral integrase containing -1.6 -1.2 -1.4 
LINC00294 long intergenic non-protein coding RNA 294 -1.8 -1.5 -1.3 
TMBIM4 transmembrane BAX inhibitor motif containing 4 -1.6 -1.2 -1.6 
FEZ1 fasciculation and elongation protein zeta 1 (zygin I) -1.6 -1.2 -2.0 
LAMP2 lysosomal-associated membrane protein 2 -1.4 -1.6 -1.3 
TMSB15A thymosin beta 15a -1.4 -1.1 -1.3 
TRIP6 thyroid hormone receptor interactor 6 -1.7 -1.5 -1.4 
TSPO translocator protein (18kDa) -1.4 -1.2 -1.3 
EFEMP2 EGF containing fibulin-like extracellular matrix protein 2 -1.7 -1.7 -1.9 
TST thiosulfate sulfurtransferase (rhodanese) -1.8 -1.2 -1.8 
TRIOBP TRIO and F-actin binding protein -1.5 -1.3 -1.2 
HIST1H2BJ histone cluster 1, H2bj -1.5 -1.4 -1.6 
FTL ferritin, light polypeptide -1.4 -1.2 -1.2 
MGST2 microsomal glutathione S-transferase 2 -1.5 -1.2 -1.3 
FADS1 fatty acid desaturase 1 -1.5 -1.3 -1.5 
MSRB2 methionine sulfoxide reductase B2 -1.6 -1.7 -2.0 
PHPT1 phosphohistidine phosphatase 1 -1.4 -1.2 -1.2 
HIST2H2AC histone cluster 2, H2ac -1.5 -1.2 -1.8 
HSPB1 heat shock 27kDa protein 1 -1.4 -1.3 -1.5 
MAGED1 melanoma antigen family D, 1 -1.5 -1.4 -1.6 
FBLN1 fibulin 1 -1.4 -1.7 -1.8 
PKD2 polycystic kidney disease 2 (autosomal dominant) -1.4 -1.2 -1.2 
MAP2 microtubule-associated protein 2 -1.4 -1.2 -1.3 
BEX4 brain expressed, X-linked 4 -1.5 -1.4 -1.3 
PAPLN papilin, proteoglycan-like sulfated glycoprotein -1.5 -1.3 -1.4 
ABCB10 ATP-binding cassette, sub-family B (MDR/TAP), member 10 -2.1 -1.4 -1.7 
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Gene symbol Protein name 
FC in 
siWAC 
FC in 
siRNF40 
FC in 
siRNF20 
FZD2 frizzled family receptor 2 -1.5 -1.3 -1.4 
PHF11 PHD finger protein 11 -1.4 -1.2 -1.2 
HIST2H4A histone cluster 2, H4a -1.5 -1.4 -1.6 
MSRA methionine sulfoxide reductase A -1.3 -1.1 -1.2 
ARHGEF39 Rho guanine nucleotide exchange factor (GEF) 39 -1.3 -1.3 -1.3 
RNASE4 ribonuclease, RNase A family, 4 -1.4 -1.3 -1.2 
CDC25B cell division cycle 25B -1.4 -1.5 -1.4 
KLHL5 kelch-like family member 5 -1.3 -1.2 -1.1 
ATP6V1B1 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 -1.3 -1.2 -1.5 
FXYD5 FXYD domain containing ion transport regulator 5 -1.3 -1.2 -1.2 
HIST2H2AA3 histone cluster 2, H2aa3 -1.7 -1.4 -2.1 
MYADM myeloid-associated differentiation marker -1.5 -1.3 -1.4 
HIST2H2AA4 histone cluster 2, H2aa4 -1.5 -1.3 -2.3 
CDK19 cyclin-dependent kinase 19 -1.4 -1.3 -1.7 
BRD2 bromodomain containing 2 -1.7 -1.4 -1.4 
HIST2H4B histone cluster 2, H4b -1.3 -1.2 -1.3 
SULT1A4 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 4 -1.6 -1.3 -1.6 
CD2BP2 CD2 (cytoplasmic tail) binding protein 2 -1.4 -1.3 -1.3 
FAM120C family with sequence similarity 120C -1.3 -1.3 -1.4 
VEGFB vascular endothelial growth factor B -1.3 -1.3 -1.4 
PPA2 pyrophosphatase (inorganic) 2 -1.3 -1.5 -1.8 
SMIM14 small integral membrane protein 14 -1.3 -1.6 -1.6 
CPS1 carbamoyl-phosphate synthase 1, mitochondrial -1.4 -1.5 -1.4 
LPIN1 lipin 1 -1.3 -1.3 -1.4 
HIST1H2BK histone cluster 1, H2bk -1.5 -1.7 -2.1 
CCDC15 coiled-coil domain containing 15 -1.3 -1.2 -1.3 
HEBP1 heme binding protein 1 -1.3 -1.2 -1.4 
ARMCX1 armadillo repeat containing, X-linked 1 -1.3 -1.3 -1.2 
ZNF362 zinc finger protein 362 -1.3 -1.2 -1.3 
IL11RA interleukin 11 receptor, alpha -1.4 -1.2 -1.3 
SLC16A9 solute carrier family 16, member 9 (monocarboxylic acid transporter 9) -1.3 -1.3 -1.2 
UCHL1 ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) -1.3 -1.4 -1.1 
EPSTI1 epithelial stromal interaction 1 (breast) -1.2 -1.3 -1.1 
FGGY FGGY carbohydrate kinase domain containing -1.2 -1.3 -1.3 
THAP10 THAP domain containing 10 -1.3 -1.3 -1.6 
NGFRAP1 nerve growth factor receptor (TNFRSF16) associated protein 1 -1.3 -1.5 -1.6 
LSMD1 LSM domain containing 1 -1.4 -1.3 -1.6 
ATRAID all-trans retinoic acid-induced differentiation factor -1.2 -1.3 -1.3 
UBE2C ubiquitin-conjugating enzyme E2C -1.3 -1.3 -1.3 
LINC00085 long intergenic non-protein coding RNA 85 -1.5 -1.4 -1.7 
CPVL carboxypeptidase, vitellogenic-like -1.3 -1.2 -1.4 
NUCKS1 nuclear casein kinase and cyclin-dependent kinase substrate 1 -1.5 -1.6 -1.9 
ALDH7A1 aldehyde dehydrogenase 7 family, member A1 -1.3 -1.2 -1.2 
CGNL1 cingulin-like 1 -1.4 -1.3 -1.5 
ACSF2 acyl-CoA synthetase family member 2 -1.3 -1.2 -1.2 
SLC44A1 solute carrier family 44, member 1 -1.5 -1.6 -1.9 
HSPB1P1 heat shock 27kDa protein 1 pseudogene 1 -1.4 -1.4 -1.5 
COQ2 coenzyme Q2 homolog, prenyltransferase (yeast) -1.3 -1.2 -1.3 
ARL6IP6 ADP-ribosylation-like factor 6 interacting protein 6 -1.4 -1.8 -1.2 
AURKB aurora kinase B -1.3 -1.3 -1.2 
C15ORF52 chromosome 15 open reading frame 52 -1.3 -1.2 -1.3 
TNFAIP8L1 tumor necrosis factor, alpha-induced protein 8-like 1 -1.3 -1.3 -1.4 
PTTG3P pituitary tumor-transforming 3, pseudogene -1.2 -1.3 -1.2 
PTPLA 
protein tyrosine phosphatase-like (proline instead of catalytic arginine), 
member A -1.2 -1.3 -1.3 
MTL5 metallothionein-like 5, testis-specific (tesmin) -1.2 -1.1 -1.2 
COMT catechol-O-methyltransferase -1.4 -1.4 -1.5 
RLN2 relaxin 2 -1.2 -1.2 -1.4 
HIST1H1C histone cluster 1, H1c -1.3 -1.6 -2.1 
TMEM187 transmembrane protein 187 -1.3 -1.2 -1.3 
GPX8 glutathione peroxidase 8 (putative) -1.3 -1.2 -1.3 
PPP1R3F protein phosphatase 1, regulatory subunit 3F -1.3 -1.3 -1.4 
DECR2 2,4-dienoyl CoA reductase 2, peroxisomal -1.2 -1.2 -1.3 
CCT6B chaperonin containing TCP1, subunit 6B (zeta 2) -1.2 -1.2 -1.3 
HMMR hyaluronan-mediated motility receptor (RHAMM) -1.5 -1.6 -1.6 
SULT1A1 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 -1.4 -1.3 -1.5 
ATG10 autophagy related 10 -1.3 -1.4 -1.5 
IRX3 iroquois homeobox 3 -1.2 -1.2 -1.2 
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Gene symbol Protein name 
FC in 
siWAC 
FC in 
siRNF40 
FC in 
siRNF20 
SIRT5 sirtuin 5 -1.2 -1.3 -1.3 
MGMT O-6-methylguanine-DNA methyltransferase -1.3 -1.3 -1.4 
MRPS9 mitochondrial ribosomal protein S9 -1.2 -1.2 -1.3 
CALY calcyon neuron-specific vesicular protein -1.3 -1.2 -1.4 
STOX2 storkhead box 2 -1.2 -1.2 -1.3 
SULT1A2 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2 -1.3 -1.3 -1.4 
UCP2 uncoupling protein 2 (mitochondrial, proton carrier) -1.3 -1.6 -1.4 
BACE1 beta-site APP-cleaving enzyme 1 -1.2 -1.2 -1.3 
TRO trophinin -1.3 -1.2 -1.3 
N6AMT2 N-6 adenine-specific DNA methyltransferase 2 (putative) -1.2 -1.2 -1.2 
CD97 CD97 molecule -1.3 -1.4 -1.4 
NME3 NME/NM23 nucleoside diphosphate kinase 3 -1.3 -1.2 -1.3 
RGS12 regulator of G-protein signaling 12 -1.3 -1.3 -1.3 
B3GALT6 UDP-Gal:betaGal beta 1,3-galactosyltransferase polypeptide 6 -1.2 -1.2 -1.7 
LPXN leupaxin -1.2 -1.3 -1.4 
TGFB1I1 transforming growth factor beta 1 induced transcript 1 -1.2 -1.2 -1.3 
TCEAL8 transcription elongation factor A (SII)-like 8 -1.2 -1.3 -1.3 
RAD51C RAD51 homolog C (S. cerevisiae) -1.3 -1.2 -1.4 
ESPNL espin-like -1.3 -1.3 -1.3 
ALG9 ALG9, alpha-1,2-mannosyltransferase -1.3 -1.3 -1.2 
TP53 tumor protein p53 -1.4 -1.3 -1.3 
ALG10B ALG10B, alpha-1,2-glucosyltransferase -1.2 -1.2 -1.1 
HIST2H2BE histone cluster 2, H2be -1.2 -1.2 -1.3 
VIPR1 vasoactive intestinal peptide receptor 1 -1.1 -1.2 -1.1 
RBCK1 RanBP-type and C3HC4-type zinc finger containing 1 -1.2 -1.6 -1.5 
PLTP phospholipid transfer protein -1.3 -1.3 -1.3 
RPP25L ribonuclease P/MRP 25kDa subunit-like -1.3 -1.3 -1.4 
APOA1BP apolipoprotein A-I binding protein -1.2 -1.2 -1.2 
TCEAL1 transcription elongation factor A (SII)-like 1 -1.3 -1.6 -1.4 
PKIA protein kinase (cAMP-dependent, catalytic) inhibitor alpha -1.2 -1.3 -1.4 
MRPL35 mitochondrial ribosomal protein L35 -1.2 -1.2 -1.2 
ATP11C ATPase, class VI, type 11C -1.2 -1.2 -1.2 
SLC25A15 
solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 
15 -1.3 -1.2 -1.2 
CCDC92 coiled-coil domain containing 92 -1.2 -1.5 -1.5 
HIST1H2AG histone cluster 1, H2ag -1.2 -1.1 -1.1 
NUDT7 nudix (nucleoside diphosphate linked moiety X)-type motif 7 -1.2 -1.3 -1.3 
POLA2 polymerase (DNA directed), alpha 2, accessory subunit -1.2 -1.3 -1.2 
AHSA2 AHA1, activator of heat shock 90kDa protein ATPase homolog 2 (yeast) -1.4 -1.3 -1.5 
OLFML2A olfactomedin-like 2A -1.2 -1.2 -1.1 
ATP9A ATPase, class II, type 9A -1.3 -1.4 -1.4 
TNS3 tensin 3 -1.2 -1.2 -1.2 
SLX4IP SLX4 interacting protein -1.3 -1.3 -1.3 
MFSD8 major facilitator superfamily domain containing 8 -1.2 -1.2 -1.3 
ZWINT ZW10 interactor, kinetochore protein -1.3 -1.3 -1.3 
FAM86A family with sequence similarity 86, member A -1.2 -1.2 -1.2 
STEAP2 STEAP family member 2, metalloreductase -1.2 -1.3 -1.2 
CSTB cystatin B (stefin B) -1.2 -1.2 -1.1 
DCAKD dephospho-CoA kinase domain containing -1.3 -1.4 -1.7 
SLC2A6 solute carrier family 2 (facilitated glucose transporter), member 6 -1.2 -1.2 -1.2 
MST1 macrophage stimulating 1 (hepatocyte growth factor-like) -1.2 -1.2 -1.3 
RAN RAN, member RAS oncogene family -1.1 -1.1 -1.4 
GSTM2 glutathione S-transferase mu 2 (muscle) -1.3 -1.4 -1.5 
HMGB1P1 high mobility group box 1 pseudogene 1 -1.3 -1.3 -1.4 
TCEAL4 transcription elongation factor A (SII)-like 4 -1.2 -1.2 -1.2 
ARMCX6 armadillo repeat containing, X-linked 6 -1.2 -1.3 -1.1 
RND2 Rho family GTPase 2 -1.2 -1.3 -1.2 
TRMT5 tRNA methyltransferase 5 homolog (S. cerevisiae) -1.2 -1.3 -1.2 
EHHADH enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase -1.2 -1.3 -1.3 
POP4 processing of precursor 4, ribonuclease P/MRP subunit (S. cerevisiae) -1.3 -1.3 -1.2 
GCHFR GTP cyclohydrolase I feedback regulator -1.3 -1.3 -1.4 
PHIP pleckstrin homology domain interacting protein -1.2 -1.2 -1.2 
TACC1 transforming, acidic coiled-coil containing protein 1 -1.2 -1.3 -1.4 
USP11 ubiquitin specific peptidase 11 -1.2 -1.2 -1.3 
SPPL2A signal peptide peptidase like 2A -1.2 -1.2 -1.3 
NIT2 nitrilase family, member 2 -1.2 -1.3 -1.3 
MESP1 mesoderm posterior 1 homolog (mouse) -1.2 -1.3 -1.4 
MBLAC2 metallo-beta-lactamase domain containing 2 -1.2 -1.2 -1.3 
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FC in 
siWAC 
FC in 
siRNF40 
FC in 
siRNF20 
HIST1H2AC histone cluster 1, H2ac -1.2 -1.3 -1.3 
KHDC1 KH homology domain containing 1 -1.2 -1.4 -1.3 
SLMO1 slowmo homolog 1 (Drosophila) -1.2 -1.4 -1.5 
CXXC4 CXXC finger protein 4 -1.2 -1.2 -1.2 
TUBA1C tubulin, alpha 1c -1.1 -1.2 -1.1 
GSTM1 glutathione S-transferase mu 1 -1.3 -1.4 -1.5 
DARS2 aspartyl-tRNA synthetase 2, mitochondrial -1.2 -1.2 -1.2 
ALPK1 alpha-kinase 1 -1.1 -1.1 -1.2 
RCCD1 RCC1 domain containing 1 -1.2 -1.2 -1.2 
ANLN anillin, actin binding protein -1.3 -1.3 -1.3 
GNB1L guanine nucleotide binding protein (G protein), beta polypeptide 1-like -1.1 -1.4 -1.4 
XPC xeroderma pigmentosum, complementation group C -1.2 -1.5 -1.3 
UBA52 ubiquitin A-52 residue ribosomal protein fusion product 1 2.1 1.3 1.9 
BRK1 BRICK1, SCAR/WAVE actin-nucleating complex subunit 1.6 1.6 1.2 
NASP nuclear autoantigenic sperm protein (histone-binding) 1.8 1.4 1.9 
ENAH enabled homolog (Drosophila) 1.8 1.2 1.3 
TUBB3 tubulin, beta 3 class III 1.6 1.4 1.9 
BAMBI BMP and activin membrane-bound inhibitor homolog (Xenopus laevis) 1.5 1.5 1.4 
BCCIP BRCA2 and CDKN1A interacting protein 1.6 1.3 1.4 
HES5 hairy and enhancer of split 5 (Drosophila) 1.5 1.7 1.5 
TPMT thiopurine S-methyltransferase 1.3 1.1 1.2 
ELAVL1 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) 1.5 1.2 1.2 
EIF2S2 eukaryotic translation initiation factor 2, subunit 2 beta, 38kDa 1.5 1.2 1.4 
PIN4 protein (peptidylprolyl cis/trans isomerase) NIMA-interacting, 4 (parvulin) 1.3 1.3 1.2 
DYNLL2 dynein, light chain, LC8-type 2 1.3 1.3 1.4 
BMP2 bone morphogenetic protein 2 1.4 1.5 1.6 
CLTA clathrin, light chain A 1.3 1.2 1.2 
RBM12 RNA binding motif protein 12 1.4 1.2 1.3 
FKBP1A FK506 binding protein 1A, 12kDa 1.4 1.3 1.3 
RPL37 ribosomal protein L37 1.7 1.2 1.3 
C16ORF72 chromosome 16 open reading frame 72 1.3 1.2 1.3 
GCNT1 glucosaminyl (N-acetyl) transferase 1, core 2 1.4 1.4 1.2 
CSRP2BP CSRP2 binding protein 1.3 1.1 1.2 
RPRM reprimo, TP53 dependent G2 arrest mediator candidate 1.4 1.2 1.6 
EMC8 ER membrane protein complex subunit 8 1.3 1.1 1.3 
YRDC yrdC domain containing (E. coli) 1.3 1.2 1.2 
PTRH2 peptidyl-tRNA hydrolase 2 1.4 1.3 1.2 
BCL2L11 BCL2-like 11 (apoptosis facilitator) 1.2 1.2 1.2 
DUSP5 dual specificity phosphatase 5 1.5 1.6 1.5 
MARC2 mitochondrial amidoxime reducing component 2 -1.4 -1.2 -1.3 
UBE2L3 ubiquitin-conjugating enzyme E2L 3 1.6 1.3 1.6 
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 1.4 1.3 1.7 
DKK1 dickkopf 1 homolog (Xenopus laevis) 1.4 1.8 2.1 
VPS37B vacuolar protein sorting 37 homolog B (S. cerevisiae) 1.3 1.2 1.3 
PITPNB phosphatidylinositol transfer protein, beta 1.2 1.1 1.1 
C14ORF2 chromosome 14 open reading frame 2 1.5 1.3 1.3 
CITED2 
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal 
domain, 2 1.3 1.2 1.6 
RAPGEF1 Rap guanine nucleotide exchange factor (GEF) 1 1.5 1.6 1.5 
LBH limb bud and heart development 1.4 1.3 1.3 
CPLX1 complexin 1 1.2 1.2 2.6 
NKRF NFKB repressing factor 1.2 1.2 1.2 
SDHAP1 succinate dehydrogenase complex, subunit A, flavoprotein pseudogene 1 1.2 1.2 1.2 
ZCCHC12 zinc finger, CCHC domain containing 12 1.4 1.3 1.5 
C7ORF41 chromosome 7 open reading frame 41 1.4 1.3 1.3 
HEY1 hairy/enhancer-of-split related with YRPW motif 1 1.4 1.5 1.2 
PARM1 prostate androgen-regulated mucin-like protein 1 1.4 1.3 1.5 
CCDC25 coiled-coil domain containing 25 1.4 1.3 1.2 
NOP16 NOP16 nucleolar protein 1.5 1.4 1.3 
PITHD1 
PITH (C-terminal proteasome-interacting domain of thioredoxin-like) domain 
containing 1 1.3 1.3 1.5 
CRK v-crk sarcoma virus CT10 oncogene homolog (avian) 1.2 1.3 1.3 
FAM189A1 family with sequence similarity 189, member A1 1.2 1.2 1.4 
ZMYM5 zinc finger, MYM-type 5 1.2 1.1 1.2 
SLBP stem-loop binding protein 1.2 1.3 1.3 
SNHG15 small nucleolar RNA host gene 15 (non-protein coding) 1.3 1.3 1.3 
HBA2 hemoglobin, alpha 2 1.3 1.3 2.2 
SUPV3L1 suppressor of var1, 3-like 1 (S. cerevisiae) 1.3 1.2 1.2 
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FC in 
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JAG1 jagged 1 1.3 1.4 1.4 
FAM206A family with sequence similarity 206, member A 1.2 1.2 1.4 
COL12A1 collagen, type XII, alpha 1 1.3 1.4 2.0 
MRTO4 mRNA turnover 4 homolog (S. cerevisiae) 1.3 1.3 1.2 
SBK1 SH3-binding domain kinase 1 1.2 1.1 1.2 
SRI sorcin 1.2 1.2 1.4 
TRAFD1 TRAF-type zinc finger domain containing 1 1.2 1.2 1.2 
CKMT1A creatine kinase, mitochondrial 1A 1.4 1.3 2.9 
RBM4 RNA binding motif protein 4 1.3 1.3 1.3 
PDCD2 programmed cell death 2 1.2 1.3 1.2 
ZNF271 zinc finger protein 271 1.2 1.2 1.2 
PLAGL2 pleiomorphic adenoma gene-like 2 1.3 1.3 1.3 
C10ORF2 chromosome 10 open reading frame 2 1.2 1.2 1.2 
EIF4H eukaryotic translation initiation factor 4H 1.2 1.1 1.2 
PPP2R2A protein phosphatase 2, regulatory subunit B, alpha 1.3 1.3 1.4 
FASTKD5 FAST kinase domains 5 1.3 1.2 1.2 
TMEM150A transmembrane protein 150A 1.1 1.3 1.2 
EIF3B eukaryotic translation initiation factor 3, subunit B 1.2 1.2 1.2 
CD24 CD24 molecule 1.2 1.4 1.7 
F12 coagulation factor XII (Hageman factor) 1.2 1.4 1.3 
RNF114 ring finger protein 114 1.3 1.3 1.3 
PDCD2L programmed cell death 2-like 1.3 1.4 1.3 
SPRY2 sprouty homolog 2 (Drosophila) 1.2 1.2 1.7 
MMP12 matrix metallopeptidase 12 (macrophage elastase) 1.2 1.2 1.3 
MTHFD2 
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 1.2 1.2 1.3 
NEDD4L 
neural precursor cell expressed, developmentally down-regulated 4-like, E3 
ubiquitin protein ligase 1.2 1.3 1.3 
TXNDC12 thioredoxin domain containing 12 (endoplasmic reticulum) 1.2 1.3 1.2 
RNPS1 RNA binding protein S1, serine-rich domain 1.2 1.1 1.2 
RSL1D1 ribosomal L1 domain containing 1 1.2 1.3 1.3 
LLPH LLP homolog, long-term synaptic facilitation (Aplysia) 1.2 1.2 1.2 
NCLN nicalin 1.3 1.3 1.3 
PPRC1 peroxisome proliferator-activated receptor gamma, coactivator-related 1 1.2 1.2 1.2 
MAGOH mago-nashi homolog, proliferation-associated (Drosophila) 1.2 1.2 1.2 
EPAS1 endothelial PAS domain protein 1 1.2 1.3 1.2 
FARP1 
FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 (chondrocyte-
derived) 1.2 1.3 1.2 
CCDC12 coiled-coil domain containing 12 1.3 1.3 1.2 
ZMYND19 zinc finger, MYND-type containing 19 1.3 1.3 1.2 
POLR3F polymerase (RNA) III (DNA directed) polypeptide F, 39 kDa 1.2 1.2 1.2 
POLR1C polymerase (RNA) I polypeptide C, 30kDa 1.2 1.2 1.2 
C16ORF91 chromosome 16 open reading frame 91 1.2 1.2 1.2 
SURF2 surfeit 2 1.3 1.3 1.2 
CEBPZ CCAAT/enhancer binding protein (C/EBP), zeta 1.2 1.2 1.2 
DPF2 D4, zinc and double PHD fingers family 2 1.2 1.2 1.2 
SEC24C SEC24 family, member C (S. cerevisiae) 1.1 1.2 1.1 
ID1 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 1.3 1.3 1.3 
AFTPH aftiphilin 1.2 1.2 1.1 
PHLDA1 pleckstrin homology-like domain, family A, member 1 1.2 1.2 1.3 
ATP6V0B ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b 1.2 1.2 1.2 
PIGC phosphatidylinositol glycan anchor biosynthesis, class C 1.1 1.2 1.1 
ABCF2 ATP-binding cassette, sub-family F (GCN20), member 2 1.2 1.2 1.3 
NTMT1 N-terminal Xaa-Pro-Lys N-methyltransferase 1 1.2 1.3 1.3 
ID3 inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 1.2 1.3 1.3 
SEC23B Sec23 homolog B (S. cerevisiae) 1.2 1.2 1.2 
FLNB filamin B, beta 1.2 1.2 1.2 
EXOSC3 exosome component 3 1.1 1.2 1.2 
TNFRSF10D 
tumor necrosis factor receptor superfamily, member 10d, decoy with truncated 
death domain 1.2 1.2 1.6 
RIMS4 regulating synaptic membrane exocytosis 4 1.3 1.4 1.3 
NOP2 NOP2 nucleolar protein 1.2 1.2 1.2 
EXOSC5 exosome component 5 1.3 1.4 1.4 
GJA1 gap junction protein, alpha 1, 43kDa 1.3 1.4 1.6 
KIF5C kinesin family member 5C 1.3 1.4 2.0 
SYT7 synaptotagmin VII 1.2 1.4 1.2 
AEN apoptosis enhancing nuclease 1.2 1.2 1.2 
ZNF598 zinc finger protein 598 1.2 1.2 1.2 
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Gene symbol Protein name 
FC in 
siWAC 
FC in 
siRNF40 
FC in 
siRNF20 
PCBP2 poly(rC) binding protein 2 1.2 1.3 1.5 
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Table 7.4 Significantly enriched (p ≤ 0.05) transcription factor targets in 118 
genes commonly upregulated after WAC, RNF20 and RNF40 knockdown versus 
RISC free control 
TF target group No. found p-value 
CREB1  61 2.9E-10 
SMAD5  7 7.3E-08 
SMAD1  7 2.8E-06 
SMAD3  8 1.7E-05 
c-Myc  30 2.6E-05 
c-Jun  14 7.7E-05 
SMAD9 (SMAD8)  3 1.3E-04 
TBX3  4 1.4E-04 
b-Myb  5 1.6E-04 
MSX1  3 2.9E-04 
FOXO3A  6 4.5E-04 
ZNF238  2 4.7E-04 
NANOG  12 5.7E-04 
YY1  16 6.1E-04 
Lef-1  5 9.2E-04 
SP1  18 2.0E-03 
ATF-5  2 2.0E-03 
TCF7L2 (TCF4)  7 2.5E-03 
RUNX3  3 2.8E-03 
hASH1  3 3.3E-03 
E2F1  11 3.5E-03 
C/EBPalpha  7 3.5E-03 
c-Fos  6 3.8E-03 
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Table 7.5 Significantly enriched (p ≤ 0.05) transcription factor targets in 183 
genes commonly downregulated after WAC, RNF20 and RNF40 knockdown 
versus RISC free control 
TF target group No. found p-value 
c-Myc  37 5.3E-04 
GCR-alpha  22 5.8E-04 
CREB1  64 1.1E-03 
Androgen receptor  17 1.7E-03 
RREB1  2 2.6E-03 
p53  18 2.8E-03 
NOR1  2 6.5E-03 
SP1  23 6.5E-03 
Eomesodermin  2 7.4E-03 
b-Myb  4 8.1E-03 
FHL2  1 8.7E-03 
BTF  1 8.7E-03 
PHF20  1 8.7E-03 
hASH1  3 1.1E-02 
TEF-3  3 1.4E-02 
KLF4  6 1.5E-02 
E2F1  13 1.5E-02 
RBMS1  1 1.7E-02 
ZNF804A  1 1.7E-02 
Parkin  1 1.7E-02 
DP2  1 1.7E-02 
PPAR-alpha  5 1.8E-02 
NANOG  12 2.0E-02 
SALL4  4 2.4E-02 
NUP133  1 2.6E-02 
KILLIN  1 2.6E-02 
SP3  9 2.6E-02 
TFIIB  3 3.1E-02 
BARX2  2 3.2E-02 
NeuroD2  1 3.5E-02 
HOXB8  1 3.5E-02 
IRX1  1 3.5E-02 
PU.1  7 4.3E-02 
NF-AT4(NFATC3)  2 4.8E-02 
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